DRAFT RED HERRING PROSPECTUS

Dated July 4, 2016

The Draft Red Herring Prospectus shall be updated on filing with RoC.
Please refer to Section 32 of the Companies Act, 2013
Book Built Offer

GREENSIGNAL BIO PHARMA LIMITED

(Our Company was incorporated as Green Signal Bio Pharma Private Limited at Chennai on November 21, 2005 under the provisions of the Companies Act, 1956. Name of our Company was
changed to GreenSignal Bio Pharma Private Limited with effect from April 21, 2016. Subsequently, our Company was converted into a public limited company with effect from May 12, 2016
under the provisions of Companies Act, 2013 and its name was changed to GreenSignal Bio Pharma Limited . For further details, please refer to “History and Certain Corporate Matters”) on
page 106.
Corporate Identification Number of our Company is U24232TN2005PLC058068
Registered and Corporate Office: Old No. 5, New No. 13/A-3 Sai Niketan Circular Road, United India Colony Kodambakkam, Chennai 600 024 , Tamil Nadu, India,
Tel: +91 44 2472 2244; Facsimile+91 44 2472 2233; Website: http://www.gsbpl.com; Company Secretary and Compliance Officer: Ms. S. Rathna Prabha
Tel.: +91 44 2472 2244 Extn. 25; Facsimile: +91 44 2472 2233; Email: [email protected];
For further details in relation to the changes in our registered and corporate office, refer to section titled “History and Certain Corporate Matters” on page 106
PROMOTERS OF THE COMPANY: MR. P. SUNDARAPARIPOORANAN AND DR. P. MURALI
PUBLIC OFFER OF 1,45,79,560 EQUITY SHARES OF A FACE VALUE OF ` 10 EACH (THE “EQUITY SHARES”) OF GREENSIGNAL BIO PHARMA LIMITED (THE “COMPANY”)
FOR CASH AT A PRICE OF ` [●] PER EQUITY SHARE INCLUDING A PREMIUM OF ` [●] THROUGH AN OFFER FOR SALE BY THE SELLING SHAREHOLDERS (AS DEFINED
IN THE SECTION “DEFINITIONS AND ABBREVIATIONS”) AGGREGATING UP TO ` [●] LACS (THE “OFFER”). THE OFFER WILL CONSTITUTE 38% OF THE FULLY DILUTED
POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR THE DETAILS OF THE EQUITY SHARES OFFERED BY EACH SELLING SHAREHOLDER, PLEASE
SEE THE SECTION “DEFINITIONS AND ABBREVIATIONS – OFFER RELATED TERMS – OFFER” ON PAGE 1.

THE FACE VALUE OF EQUITY SHARES IS ` 10 EACH. THE PRICE BAND, THE MINIMUM BID LOT AND THE RUPEE AMOUNT OF THE RETAIL DISCOUNT WILL BE DECIDED
BY OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE GLOBAL CO-ORDINATOR AND BOOK RUNNING LEAD MANAGER AND WILL BE
ADVERTISED AT LEAST FIVE WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SUCH ADVERTISEMENT SHALL BE AVAILABLE ON THE WEBSITES OF
THE BSE LIMITED (“BSE”) AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“ NSE”)

IN CASE OF ANY REVISIONS IN THE PRICE BAND, THE BID/OFFER PERIOD WILL BE EXTENDED BY AT LEAST THREE ADDITIONAL WORKING DAYS AFTER SUCH
REVISION OF THE PRICE BAND, SUBJECT TO THE BID/OFFER PERIOD NOT EXCEEDING 10 WORKING DAYS. ANY REVISION IN THE PRICE BAND AND THE REVISED
BID/OFFER PERIOD, IF APPLICABLE, WILL BE WIDELY DISSEMINATED BY NOTIFICATION TO THE BSE AND THE NSE, BY ISSUING A PRESS RELEASE, AND ALSO BY
INDICATING THE CHANGE ON THE WEBSITES OF THE GLOBAL CO-ORDINATOR AND BRLM, REGISTRAR AND SHARE TRANSFER AGENT TO THE OFFER AND
DEPOSITORY PARTICIPANTS, AND AT THE TERMINALS OF THE SYNDICATE MEMBERS.

In terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), this is an Offer for at least 25 % of the post-Offer capital. The Offer is being made through the
Book Building Process wherein not less than 75% of the Offer shall be allotted on a proportionate basis to Qualified Institutional Buyers (“QIBs”), provided that our Company and the Selling
Shareholders may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation
on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors),
including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If 75% of the Offer cannot be Allotted to QIBs, then the entire application money shall be refunded
forthwith. Further, not more than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Offer shall be available for
allocation to Retail Individual Bidders in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (the “SEBI ICDR
Regulations”), subject to valid Bids being received at or above the Offer Price. For details in relation to allocation to Retail Individual Bidders, specific attention of the investors is invited to the section
“Offer Procedure – Basis of Allotment” on page 226. All potential investors, other than Anchor Investors, shall participate in this Offer through an Application Supported by Blocked Amount
(“ASBA”) process providing details of their respective bank account which will be blocked by the Self Certified Syndicate Banks (“SCSBs”). For details, see the section ‘Offer Procedure’ on page 193.
RISK IN RELATION TO FIRST ISSUE
This being the first public issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ` 10 each and the Offer Price is [•]
times of the face value. The Offer Price (determined and justified by our Company and the Selling Shareholders, in consultation with the Global Co-ordinator and BRLM, as stated under the section
“Basis for Offer Price” on page 58 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or
sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISKS
Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors
are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer,
including the risks involved. The Equity Shares offered in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or
adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” on page 14
COMPANY’S AND SELLING SHAREHOLDERS’ ABSOLUTE RESPONSIBILITY
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring Prospectus contains all information with regard to our Company and the Offer,
which is material in the context of the Offer, that the information contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that
the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which make this Draft Red Herring Prospectus as a whole or any of such information or the
expression of any such opinions or intentions misleading in any material respect. The Selling Shareholders accept responsibility that this Draft Red Herring Prospectus contains all information about them
as Selling Shareholders in the context of the Offer and each Selling Shareholder assumes responsibility for statements in relation to such Selling Shareholder included in this Draft Red Herring Prospectus.
LISTING
The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the BSE and the NSE. We have received an ‘in-principle’ approval from each of the BSE and the NSE for
the listing of the Equity Shares pursuant to the letters dated [●] and [●], respectively. For the purposes of the Offer, the Designated Stock Exchange shall be the [●].
GLOBAL CO-ORDINATOR AND BOOK RUNNING LEAD MANAGER TO THE OFFER REGISTRAR TO THE OFFER

INDIAN OVERSEAS BANK BIGSHARE SERVICES PRIVATE LIMITED

Merchant Banking Division, E2 Ansa Industrial Estate, Sakivihar Road, Sakinaka
763, Anna Salai, Andheri East,
Chennai-600 002 Mumbai – 400 072
Tel.: + 91 44 2851 9548/ 2888 9367; Tel: + 91 22 4043 0200;
Email: [email protected] Facsimile: + 91 22 2847 5207
Investor Grievance Email:[email protected] Email: [email protected];
Website: www.iob.in Investor Grievance Email: [email protected]
Contact Person: (i) Mrs. B. Gomathy/Mrs.S.Chandra, Merchant Banking Division, Chennai Website: bigshareonline.com
(ii) Mr.Muralidharan, Capital Market Services Branch, Mumbai, Contact Person: Mr. Ashok Shetty
Tel: + 91 22 226 22017/2262 2018 SEBI Registration No.: INR000001385
Compliance Officer: Mrs. B. Gomathy
SEBI Registration No: INM000001386
BID/OFFER PROGRAM*
BID OPENS ON: [•] BID CLOSES ON: [•]
* Our Company and the Selling Shareholders may, in consultation with the Global Co-ordinator and BRLM, consider participation by Anchor Investors in accordance with the SEBI ICDR
Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.
 TABLE OF CONTENTS
SECTION I : GENERAL ..............................................................................................................................1
1. Definitions and Abbreviations ...........................................................................................................1
2. Certain Conventions, Presentation of Financial, Industrial and Market Data ................................ 11
3. Forward Looking Statements ..........................................................................................................13
SECTION II : RISK FACTORS ................................................................................................................14
SECTION III : INTRODUCTION ............................................................................................................35
4. Summary of the Industry ................................................................................................................35
5. Summary of Business ......................................................................................................................36
6. Summary of Financial Information ................................................................................................37
7. The Offer .........................................................................................................................................40
8. General Information ........................................................................................................................41
9. Capital Structure ..............................................................................................................................48
10. Objects of the Offer ........................................................................................................................57
11. Basis of the Offer Price ...................................................................................................................58
12. Statement of Tax Benefits ...............................................................................................................60
SECTION IV : ABOUT THE COMPANY ...............................................................................................64
13. Industry Overview ...........................................................................................................................64
14. Our Business ...................................................................................................................................82
15. Regulations and Policies .................................................................................................................92
16. History and Certain Corporate Matters ......................................................................................... 106
17. Our Management ........................................................................................................................... 109
18. Our Promoter and Promoter Group ............................................................................................... 120
19. Related Party Transactions ...........................................................................................................122
20. Dividend Policy ............................................................................................................................. 123
SECTION V: FINANCIAL INFORMATION ......................................................................................124
21. Financial Statements ..................................................................................................................... 124
22. Management’s Discussion and Analysis of Financial Condition and Results of Operations ........149
23. Financial Indebtedness ..................................................................................................................166
SECTION VI: LEGAL AND OTHER INFORMATION ......................................................................167
24. Outstanding Litigations and Material Developments ....................................................................167
25. Government and Other Approvals.................................................................................................172
26. Other Regulatory and Statutory Disclosures .................................................................................175
SECTION VII : OFFER INFORMATION ............................................................................................. 185
27. Terms Of The Offer ....................................................................................................................... 185
28. Offer Structure............................................................................................................................... 190
29. Offer Procedure ............................................................................................................................. 193
30. Restriction on foreign ownership of Indian Securities .................................................................236
SECTION VIII : MAIN PROVISIONS OF ARTICLE OF ASSOCIATIONS....................................237
SECTION IX: OTHER INFORMATION ............................................................................................. 256
31. Material Contracts and documents for inspection ........................................................................256
32. Declaration ....................................................................................................................................257

2
 SECTION I- GENERAL

DEFINITIONS AND ABBREVIATIONS

This Draft Red Herring Prospectus uses certain definitions and abbreviations which, unless the context indicates
or implies otherwise, have the meaning as provided below. References to statutes, rules, regulations, guidelines
and policies will be deemed to include all amendments and modifications notified thereto.

COMPANY RELATED TERMS

Term Description
Articles/Articles of The articles of association of our Company, as amended.
Association/our Articles
Auditors/ Statutory The statutory auditor of our Company, being M/s. RAJ AND RAVI, Chartered
Auditors Accountants
Board/Board of Directors/ The board of directors of our Company.
our Board
Company/GSBL/our GreenSignal Bio Pharma Limited, a company incorporated under the provisions of
Company/the Company/ Companies Act, 1956 as a private company and subsequently converted to a public
the Corporation/we/us/ our company under the provisions of Companies Act, 2013
Director(s) The director(s) on our Board.
Memorandum/ The memorandum of association of our Company, as amended from time to time.
Memorandum of
Association/our
Memorandum/MoA
Registered and Corporate Old No. 5, New No. 13/A-3 Sai Niketan Circular Road, United India Colony
Office Kodambakkam, Chennai 600024 , Tamil Nadu, India
Promoters of the Company Mr. P. Sundaraparipooranan and Dr. P. Murali
Promoter Group Mrs. Mallika Murali
RoC Registrar of Companies, Chennai, Tamil Nadu

OFFER RELATED TERMS

Term Description
Acknowledgement Slip The slip or document issued by the Designated Intermediary to a Bidder as proof
of registration of the Bid
Allotment/ Allot/ Allotted The allotment of Equity Shares pursuant to the Offer to successful Bidders/
Applicants
Allottee An Bidder/ Applicant to whom the Equity Shares are Allotted
Allotment Advice Note or advice or intimation of Allotment sent to the Bidders/ Applicants who
have been allotted Equity Shares after the Basis of Allotment has been approved
by the designated Stock Exchanges
Anchor Investor A Qualified Institutional Buyer, applying under the Anchor Investor Portion in
accordance with the requirements specified in SEBI ICDR Regulations, 2009.
Anchor Investor The form used by an Anchor Investor to make a Bid in the Anchor Investor
Application Form Portion and which will be considered as an application for Allotment in terms of
the Red Herring Prospectus and Prospectus
Anchor Investor The final price at which Equity Shares will be Allotted to Anchor Investors in
Allocation Price terms of the Red Herring Prospectus and the Prospectus, which price will be equal
to or higher than the Offer Price, but not higher than the Cap Price. The Anchor
Investor Offer Price will be decided by our Company and the Selling Shareholders
in consultation with the BRLM
Anchor Investor Portion Up to 60% of the QIB Portion which may be allocated by the Company and the
Selling Shareholders in consultation with the Book Running Lead Manager, to
Anchor Investors on a discretionary basis. One-third of the Anchor Investor
Portion is reserved for domestic Mutual Funds, subject to valid Bids being

1
Term Description
received from domestic Mutual Funds at or above the price at which allocation is
being done to Anchor Investors
Anchor Investor Bid/ One Working Day prior to the Bid/Offer Opening Date, on which Bids by Anchor
Offer Period Investors shall be submitted and allocation to Anchor Investors shall be completed.
ASBA Bidders Bidders (other than Anchor Investors) in the Offer who intend to submit the Bid
Application Supported by An application, whether physical or electronic, used by Bidders/ Applicants to
Blocked Amount/ make a Bid authorising an SCSB to block the Bid Amount in the specified bank
(ASBA)/ ASBA account maintained with such SCSB
ASBA Bid A Bid made by an ASBA Bidder
ASBA Account Account maintained with an SCSB which may be blocked by such SCSB to the
extent of the Bid Amount of the ASBA Bidder/ Applicant
Bid An indication to make an offer during the Bid/Offer Period by a Bidder pursuant to
submission of the Bid cum Application Form, or during the Anchor Investor
Bid/Offer Period by the Anchor Investors, to purchase the Equity Shares from the
Selling Shareholders at a price within the Price Band, including all revisions and
modifications thereto as permitted under the SEBI ICDR Regulations
Bidder Any prospective investor who makes a Bid pursuant to the terms of the Red
Herring Prospectus and the Bid cum Application Form and unless otherwise stated
or implied, includes an Anchor Investor
ASBA Bidder/ Applicant Prospective Bidders/ Applicants in the Offer who Bid/ apply through ASBA
Banker(s) to the Offer/ The banks which are clearing members and registered with SEBI as Banker to the
Escrow Collection Bank(s)/ Offer with whom the Escrow Account(s) may be opened, and as disclosed in the
Collecting Banker RHP/ Prospectus and Bid cum Application Form of the Company
Basis of Allotment Basis on which the Equity Shares will be Allotted to successful Bidders under the
Offer and which is described in the section entitled “Offer Procedure” on page 193.
Bid/Offer Closing Date The date after which the Syndicate, Registered Brokers and the SCSBs may not
accept any Bids for the Offer, which may be notified in an English national daily, a
Hindi national daily and a regional language newspaper at the place where the
registered office of the Company is situated, each with wide circulation.
Applicants/ bidders may refer to the RHP/ Prospectus for the Bid/ Offer Closing
Date
Bid/Offer Opening Date The date on which the Syndicate and the SCSBs may start accepting Bids for the
Offer, which may be the date notified in an English national daily, a Hindi national
daily and a regional language newspaper at the place where the registered office of
the Company is situated, each with wide circulation. Applicants/ bidders may refer
to the RHP/ Prospectus for the Bid/ Offer Opening Date
Bid Offer Period/Offer Except in relation to any Bids received from Anchor Investors, the period between
Period the Bid/Offer Opening Date and the Bid/Offer Closing Date, inclusive of
both days, during which prospective Bidders can submit their Bids, including any
revisions thereof
Bid Amount The highest value of the optional Bids indicated in the Bid cum Application Form
and payable by the Bidder/ Applicant upon submission of the Bid (except for
Anchor Investors), less discounts (if applicable). In case of issues undertaken
through the fixed price process, all references to the Bid Amount should be
construed to mean the Application Amount
Bid cum Application The form in terms of which the Bidder/ Applicant should make an offer to
Form subscribe for or purchase the Equity Shares and which may be considered as the
application for Allotment for the purposes of the Prospectus, whether applying
through the ASBA or otherwise. In case of issues undertaken through the fixed
price process, all references to the Bid cum Application Form should be construed
to mean the Application Form
Bid Lot [•]
Book Built Process/ Book The book building process as provided under SEBI ICDR Regulations, 2009, in
Building Process/Book terms of which the Offer is being made

2
Term Description
Building Method
BRLM/ Book Running Global Co-ordinator and Book Running Lead Manger in this case being Indian
Lead Manager Overseas Bank
Broker Centres Broker centres notified by the Stock Exchanges, where Bidders/ Applicants can
submit the Bid cum Application Forms/ Application Form to a Registered Broker.
The details of such broker centres, along with the names and contact details of the
Registered Brokers are available on the websites of the Stock Exchanges.
Bidding Centres Centres at which the Designated Intermediaries shall accept the Bid cum
Application Forms, i.e., Designated SCSB Branch for SCSBs, Specified Locations
for Syndicate, Broker Centres for Registered Brokers, Designated RTA Locations
for RTAs and Designated CDP Locations for CDPs
Book Running Lead The Book Running Lead Manager to the Offer shall mean Indian Overseas Bank,
Manager Merchant Banking Division
CAN/ Confirmation of The note or advice or intimation sent to each successful Bidder/ Applicant
Allotment Note indicating the Equity Shares which may be Allotted, after approval of Basis of
Allotment by the Designated Stock Exchange
Cap Price Higher end of the Price Band, in this case being ₹ [●] per Equity Share, above
which the Offer Price will not be finalized and above which no Bids will be
accepted
Collecting Depository A depository participant as defined under the Depositories Act, 1996, registered
Participant or CDP with SEBI and who is eligible to procure Bids at the Designated CDP Locations
in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10,
2015 issued by SEBI
Client ID Client Identification Number maintained with one of the Depositories in relation to
demat account
Cut-off Price Offer Price, finalized by our Company and the Selling Shareholders in consultation
with BRLM.

Only Retail Individual Bidders are entitled to Bid at the Cut-off Price. QIBs and
Non-Institutional Bidders are not entitled to Bid at the Cut-off Price
Demat Escrow Agent The escrow agent appointed pursuant to the Share Escrow Agreement, namely,
[•]
DP Depository Participant
DP ID Depository Participant’s Identification Number
Depositories National Securities Depository Limited and Central Depository Services (India)
Limited
Demographic Details Details of the Bidders/ Applicants including the Bidder/ Applicant’s address, name of
the Applicant’s father/ husband, investor status, occupation and bank account details
Designated Intermediaries Syndicate Members, Sub-Syndicate/Agents, SCSBs, Registered Brokers, Brokers,
the CDPs and RTAs, who are authorized to collect Bid cum Application Forms
from the Bidders, in relation to the Offer.
Designated SCSB Such branches of the SCSBs which shall collect the Bid cum Application Forms, a
Branches list of which is available on the website of SEBI at
http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries or
at such other website as may be prescribed by SEBI from time to time
Designated Date The date on which funds are transferred by the Escrow Collection Bank(s) from
the Escrow Account or the amounts blocked by the SCSBs are transferred from the
ASBA Accounts, as the case may be, to the Public Issue Account or the Refund
Account, as appropriate, after the Prospectus is filed with the RoC, following
which the board of directors may Allot Equity Shares to successful Bidders/
Applicants in the fresh Issue may give delivery instructions for the transfer of the
Equity Shares constituting the Offer for Sale
Designated CDP Such locations of the CDPs where Bidders can submit the Bid cum Application

3
Term Description
Locations Forms to Collecting Depository Participants.

The details of such Designated CDP Locations, along with names and contact
details of the Collecting Depository Participants eligible to accept Bid cum
Application Forms are available on the respective websites of the Stock Exchanges
(www.bseindia.com and www.nseindia.com)
Designated RTA Location Such locations of the RTAs where Bidders can submit the Bid cum Application
Forms to RTAs.

The details of such Designated RTA Locations, along with names and contact
details of the RTAs eligible to accept Bid cum Application Forms are available on
the respective websites of the Stock Exchanges (www.bseindia.com and
www.nseindia.com)
Designated Stock The designated stock exchange as disclosed in the RHP/ Prospectus of the
Exchange Company
Discount Discount to the Offer Price that may be provided to Bidders/ Applicants in
accordance with the SEBI ICDR Regulations, 2009.
Draft Red Herring This Draft Red Herring Prospectus dated July 4, 2016 issued in accordance with
Prospectus the SEBI ICDR Regulations, which does not contain complete particulars of the
price at which the Equity Shares will be transferred and the size of the Offer,
including any addendum or corrigendum thereto.
Engagement Letter Engagement letter dated January 1, 2016 issued by Company to BRLM,
Eligible FPIs FPIs from such jurisdictions outside India where it is not unlawful to make an
offer/ invitation under the Offer and in relation to whom the Red Herring
Prospectus constitutes an invitation to purchase the Equity Shares offered thereby.
Eligible NRIs NRI(s) from jurisdictions outside India where it is not unlawful to make an offer or
invitation under the Offer and in relation to whom the Bid cum Application Form
and the Red Herring Prospectus will constitute an invitation to subscribe to or
purchase the Equity Shares
Escrow Account Account to be opened with the Escrow Collection Bank(s) and in whose favour
the Anchor Investors will issue cheques or drafts or transfer funds in respect of the
Bid Amount when submitting a Bid
Escrow Agreement The agreement to be entered into by our Company, the Selling Shareholders, the
Registrar and Share Transfer Agent to the Offer, the BRLM, the Escrow Collection
Bank(s) and the Refund Bank(s) for collection of the Bid Amounts from Anchor
Investors and where applicable, refunds of the amounts collected from the Anchor
Investors, on the terms and conditions thereof
Employees Employees of a Company as defined under SEBI ICDR Regulations, 2009 and
including, in case of a new company, persons in the permanent and full time
employment of the promoting companies excluding the promoters and immediate
relatives of the promoter. For further details Bidder/ Applicant may refer to the
RHP/ Prospectus
Equity Shares Equity shares of the Company
FCNR Account Foreign Currency Non-Resident Account
FIIs Foreign institutional investors as defined under the SEBI FPI Regulations

First Bidder Bidder whose name shall be mentioned in the Bid cum Application Form or the
Revision Form and in case of joint Bids, whose name shall also appear as the first
holder of the beneficiary account held in joint names
Floor Price The lower end of the Price Band, at or above which the Offer Price and the Anchor
Investor Offer price may be finalised and below which no Bids may be accepted,
subject to any revision thereto
FPIs Foreign Portfolio Investors as defined under the Securities and Exchange Board of
India (Foreign Portfolio Investors) Regulations, 2014

4
Term Description
Foreign Venture Capital Foreign Venture Capital Investors as defined and registered with SEBI under the
Investors or FVCIs SEBI (Foreign Venture Capital Investors) Regulations, 2000
General Information The General Information Document prepared and issued in accordance with the
Document/ GID circular (CIR/CFD/DIL/12/2013) dated October 23, 2013 notified by SEBI,
suitably modified and included in “Offer Procedure” on page 193
Maximum RII Allottees The maximum number of RIIs who can be allotted the minimum Bid Lot. This is
computed by dividing the total number of Equity Shares available for Allotment to
RIIs by the minimum Bid Lot.
MICR Magnetic Ink Character Recognition - nine-digit code as appearing on a cheque
leaf
Mutual Fund A mutual fund registered with SEBI under the SEBI (Mutual Funds) Regulations,
1996
Mutual Funds Portion 5% of the QIB Portion (excluding the Anchor Investor Portion) available for
allocation to Mutual Funds only, being such number of equity shares as disclosed
in the RHP/ Prospectus and Bid cum Application Form
NECS National Electronic Clearing Service
NEFT National Electronic Fund Transfer
NRE Account Non-Resident External Account
NRIs NRIs from such jurisdictions outside India where it is not unlawful to make an
offer or invitation under the Offer and in relation to whom the RHP/Prospectus
constitutes an invitation to subscribe to or purchase the Equity Shares
NRO Account Non-Resident Ordinary Account
Net Offer The Offer less reservation portion, if any.
Non-Institutional All Bidders, including, sub accounts of FIIs which are foreign corporate or foreign
Investors or NIIs individuals and Category III foreign portfolio investors that are not QIBs or Retail
Individual Bidders and who have Bid for the Equity Shares for an amount more
than ₹ 200,000 (but not including NRIs other than Eligible NRIs)
Non-Institutional The portion of the Offer being such number of Equity Shares available for
Category allocation to NIIs on a proportionate basis and as disclosed in the RHP/ Prospectus
and the Bid cum Application Form
Non-Resident A person resident outside India, as defined under FEMA and includes NRIs, FIIs,
FPIs and FVCIs
OCB/ Overseas Corporate A company, partnership, society or other corporate body owned directly or
Body indirectly to the extent of at least 60% by NRIs including overseas trusts, in which
not less than 60% of beneficial interest is irrevocably held by NRIs directly or
indirectly and which was in existence on October 3, 2003 and immediately before
such date had taken benefits under the general permission granted to OCBs under
FEMA
Offer/Offer for Sale The offer for sale of up to 1,45,79,560 Equity Shares comprising an offer for sale
of: (i) up to 8,169,430Equity Shares offered by P. Sundaraparipooranan; (ii) up to
3,391,980 Equity Shares offered by Dr. P. Murali (iii) up to 23,75,000 Equity
Shares offered by Avon Cycles Limited;, (iv) up to 19,000 Equity Shares offered
by R. Srinivasan , and (v) up to 624,150 Equity Shares offered by Mallika Murali
for cash at a price of ₹ 10 per Equity Share aggregating to ₹ 14,57,95,600 lacs, in
terms of the Red Herring Prospectus
Offer Agreement Agreement dated June 16, 2016 entered into between Company, Selling
Shareholders and the BRLM and Amendment to said Agreement dated June 29,
2016
Offer Price The final price at which the Equity Shares will be Allotted to Bidders other than
Anchor Investors. Equity Shares will be Allotted to Anchor Investors at or above
the Offer Price.
The Offer Price will be decided by our Company, in consultation with the Selling
Shareholders and the on the Pricing Date
Offer Proceeds Proceeds of the Offer. For details please refer to Section “Objects of the Offer” on

5
Term Description
page no. 57.
Other Investors Investors other than Retail Individual Investors in a Fixed Price Issue. These
include individual applicants other than retail individual investors and other
investors including corporate bodies or institutions irrespective of the number of
specified securities applied for.
PAN Permanent Account Number allotted under the Income Tax Act, 1961
Price Band Price Band with a minimum price, being the Floor Price and the maximum price,
being the Cap Price and includes revisions thereof. The Price Band and the
minimum Bid lot size for the Offer may be decided by the Company and the
Selling Shareholders in consultation with the Book Running Lead Manager(s) and
advertised, at least five working days in case of an IPO and one working day in
case of FPO, prior to the Bid/ Offer Opening Date, in an English national daily,
Hindi national daily and regional language at the place where the registered office
of the Company is situated, newspaper each with wide circulation
Pricing Date The date on which the Company and the Selling Shareholders in consultation with
the Book Running Lead Manager(s), finalise the Offer Price
Prospectus The prospectus to be filed with the RoC in accordance with section 26 and 32 of
the Companies Act, 2013and the SEBI ICDR Regulations containing, amongst
other things, the Offer Price that is determined at the end of the Book Building
Process, the size of the Offer and certain other information
Public Offer Account Account opened with the Bankers to the Offer to receive monies from the Escrow
Account(s) and from the ASBA Accounts on the Designated Date
QIB Portion The portion of the Offer being such number of Equity Shares to be Allotted to
QIBs in terms of SEBI ICDR Regulations
Qualified Institutional As defined under SEBI ICDR Regulations, 2009 except FIIs, FPIs or any other
Buyers or QIBs foreign investor covered in the definition of the same
RTGS Real Time Gross Settlement
Regulation S Regulation S under the U.S. Securities Act
Red Herring Prospectus/ The Red Herring Prospectus to be issued in accordance with Section 32 of the
RHP Companies Act, 2013 and the provisions of the SEBI ICDR Regulations, which
will not have complete particulars of the Offer Price at which the Equity Shares
will be offered and the size of the Offer.

The Red Herring Prospectus will be registered with the Registrar of Companies at
least three Working Days before the Bid/Offer Opening Date and will become the
Prospectus upon filing with the Registrar of Companies after the Pricing Date
Refund Account(s) Account opened with the Refund Bank(s), from which refunds, if any, of the whole
or part of the Bid Amount to the Anchor Investors shall be made
Refund Bank(s) Refund bank(s) as disclosed in the RHP/ Prospectus and Bid cum Application
Form of the Company
Refunds through electronic Refunds through NECS, Direct Credit, NEFT, RTGS or ASBA, as applicable
transfer of funds
Registered Broker Stock Brokers registered with the Stock Exchanges having nationwide terminals,
other than the members of the Syndicate
RTA Agreement Agreement dated May 27, 2016 between Company, Selling Shareholders, and
Registrar to the Offer and Amendment to said Agreement dated June 29, 2016
Registrar and Share Registrar and share transfer agents registered with SEBI and eligible to procure
Transfer Agents/ RTA Bids at the Designated RTA Locations in terms of circular no.
CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI
Registrar to the Offer/ Bigshare Services Private Limited
RTO
Reserved Category/ Categories of persons eligible for making application/ bidding under reservation
Categories portion
Reservation Portion The portion of the Offer reserved for category of eligible Bidders/ Applicants as

6
Term Description
provided under the SEBI ICDR Regulations, 2009, if any.
Retail Individual Investors Individual Bidders who have Bid for the Equity Shares for an amount not more
(RIIs) than ₹ 200,000 in any of the bidding options in the Offer (including HUFs
applying through their Karta and Eligible NRIs and does not include NRIs other
than Eligible NRIs)
Retail Individual Shareholders of a listed company who applies or bids for a value of not more than
Shareholders ` 2,00,000
Retail Portion The portion of the Offer being such number of Equity Shares available for
allocation to RIIs which shall not be less than the minimum bid lot, subject to
availability in RII category and the remaining shares to be allotted on
proportionate basis.
Revision Form Form used by the Bidders, including ASBA Bidders, to modify the quantity of the
Equity Shares or the Bid Amount in any of their Bid cum Application Forms or
any previous Revision form(s).

QIB Bidders and Non-Institutional Bidders are not allowed to lower their Bids (in
terms of quantity and of Equity Shares or the Bid Amount) at any stage. Retail
Individual Bidders cannot revise their Bids after the Bid/Offer Closing Date
SEBI The Securities and Exchange Board of India constituted under the Securities and
Exchange Board of India Act, 1992
SEBI Act Securities and Exchange Board of India Act, 1992
SEBI AIF Regulations Securities and Exchange Board of India (Alternative Investments Funds)
Regulations, 2012
SEBI FII Regulations Securities and Exchange Board of India (Foreign Institutional Investors)
Regulations, 1995, repealed pursuant to the SEBI FPI Regulations
SEBI FPI Regulations Securities and Exchange Board of India (Foreign Portfolio Investors)
Regulations, 2014
SEBI FVCI Regulations Securities and Exchange Board of India (Foreign Venture Capital Investor)
Regulations, 2000
SEBI ICDR Regulations, The Securities and Exchange Board of India (Issue of Capital and Disclosure
Requirements) Regulations, 2009
Share Escrow Agreement The agreement dated [•] to be entered into amongst the Selling Shareholders, our
Company, the BRLMs and the Demat Escrow Agent in connection with the
transfer of Equity Shares under the Offer by the Selling Shareholders and credit
of such Equity Shares to the demat accounts of the Allottees
Selling Shareholders (i) P. Sundaraparipooranan; (ii) Dr. P. Murali (iii) Avon Cycles Limited (iv) R.
Srinivasan and (v) Mallika Murali
Self-Certified Syndicate Banks registered with SEBI, offering services in relation to ASBA, a list of which
Bank(s) or SCSB(s) is available on the website of SEBI at
http://www.sebi.gov.in/cms/sebi_data/attachdocs/1365051213899.html
Specified Locations Bidding centres where the Syndicate shall accept Bid cum Application Forms, a
list of which is available on the website of SEBI at
www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries and
updated from time to time
Stock Exchanges The stock exchanges as disclosed in the RHP/ Prospectus of the Company where
the Equity Shares Allotted pursuant to the Offer are proposed to be listed
Syndicate The Book Running Lead Manager(s) and the Syndicate member(s)
Syndicate Agreement The agreement to be entered into among the Company, and the Syndicate in
relation to collection of the Bids in this Offer (excluding Bids from ASBA
Bidders/ Applicants)
Syndicate Member(s)/ SM The Syndicate Member(s) as disclosed in the RHP/ Prospectus
TRS/Transaction Slip or document issued by the Syndicate, or the Designated Intermediary (only

7
Term Description
Registration Slip on demand), as the case may be, to the Bidders as proof of registration of the Bid
Underwriters The Book Running Lead Manager(s) and the Syndicate Member(s)
Underwriting Agreement The agreement dated [●] amongst the Underwriters, our Company and the Selling
Shareholders to be entered into on or after the Pricing Date
Working Day Any day, other than 2nd and 4th Saturday of the month, Sundays or public
holidays, on which commercial banks in Mumbai and Chennai are open for
business, provided however, with reference to (a) announcement of Price Band;
and (b) Bid/Offer Period, “Working Days” shall mean all days, excluding
Saturdays, Sundays and public holidays, which are working days for commercial
banks in India.

BUSINESS RELATED TERMS

Term Description
BCG/BCG Vaccine/ BCG or Bacillus Calmette Guerin is a vaccine used for prevention of Tuberculosis
vaccine/ BCG Vaccine (TB) in humans since 1921. The BCG vaccine is prepared from a strain of attenuated,
(Freeze Dried) live tuberculosis bacilli' Mycobacterium Bovis that has lost its virulence in humans by
I.P/B.P/E.P/U.S.P being specially cultured in an artificial medium for years.
BCG ONCO for BCG ONCO for immunotherapy is a live freeze-dried preparation made from Bacillus
Immunotherapy Calmette-Guerin strain, which is an attenuated strain of Mycobacterium bovis.
GAVI The Global Alliance for Vaccines and Immunizations
GMP Good Manufacturing Practice of WHO
IIBAT International Institute of Bio Technology and Toxicology
MoH Ministry of Health and Family Welfare
PAHO Pan American Health Organization
UNICEF United Nations Children's Emergency Fund
UROVAC This is our registered trademark for BCG-ONCO-Immunotherapy
WHO World Health Organization

INDUSTRY RELATED TERMS

Term Description
DCGI Drug Controller General of India
DPCO Drugs Price Control Order
ICGEB International Centre for Genetic Engineering and Biotechnology
NIH National Institute of Health,
NPPA National Pharmaceutical Pricing Authority
PATH Program for Appropriate Technology in Health
UCPMP Uniform Code of Pharmaceutical Marketing Practices,
UNFPA United Nation Population Fund

CONVENTIONAL TERMS OR ABBREVIATIONS

Term Description
AGM Annual General Meeting
Alternative Alternative Investment Funds as defined in and registered under SEBI AIF Regulations
Investment Funds or
AIFs
AS/Accounting Accounting Standards issued by the Institute of Chartered Accountants of India
Standards

8
Term Description
BSE BSE Limited
CAGR Compounded Annual Growth Rate
CDSL Central Depository Services (India) Limited
CFO Chief Financial Officer
CIN Corporate Identity Number
Companies Act, 2013 Companies Act, 2013
Companies Act, 1956 Companies Act, 1956
CSR Corporate Social Responsibility
Depositories The Depositories Act, 1996
DIN Director Identification Number
DoT Department of Telecommunication, Ministry of Communications and Information
Technology, Government of India
DP Depository Participant
DP ID Depository Participant’s Identification
DP/Depository A depository participant as defined under the Depositories Act
Participant
EBITDA Earnings before Interest, Tax, Depreciation and Amortisation
EGM Extraordinary General Meeting
Earnings per share
EPS
ESIC Employees’ State Insurance Corporation
ESI Act Employees’ State Insurance Act, 1948
FCNR Foreign Currency Non-Resident
FDI Foreign Direct Investment
FDI Policy Consolidated FDI Policy issued vide Department of Industrial Policy and Promotion
FIR First Information Report
FEMA Foreign Exchange Management Act, 1999 read with rules and regulations thereunder
and amendments thereto
FEMA Regulations Foreign Exchange Management (Transfer or Issue of Security by a Person
Resident Outside India) Regulations, 2000 as amended time to time
FPO Further Public Offering
GAAR General Anti-Avoidance Rules
GID General Information Document
GIR General Index Register
GST Goods and Services Tax
GoI/Government/Cen Government of India
tral Government
HUF Hindu Undivided Family
ICAI Institute of Chartered Accountants of India
IPC Indian Penal Code, 1860
IFSC Indian Financial System Code
IEC Importer-Exporter Code
IFRS International Financial Reporting Standards
IPC Indian Penal Code, 1860
Income Tax Act The Income Tax Act, 1961
Indian GAAP Generally Accepted Accounting Principles in India
IPO Initial Public Offering
ISIN International Securities Identification Number
Listing Regulations Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015
MCX Multi Commodity Exchange of India Limited

9
Term Description
MICR Magnetic Ink Character Recognition
National Investment National Investment Fund set up by resolution no. F. No. 2/3/2005-DDII dated
Fund November 23, 2005 of the Government of India published in the Gazette of India
NAV Net Asset Value
NCT National Capital Territory
NECS National Electronic Clearing Service
NEFT National Electronic Fund Transfer
NRE Account Non Resident External Account
NRI A person resident outside India, who is a citizen of India or a person of Indian origin,
and shall have the meaning ascribed to such term in the Foreign Exchange
Management (Deposit) Regulations, 2000
NRO Account Non Resident Ordinary Account
NSDL National Securities Depository Limited
p.a. Per Annum
P/E Ratio Price/Earnings ratio
PAN Permanent Account Number
PAT Profit After Tax
RBI Reserve Bank of India
SCRA Securities Contracts (Regulation) Act, 1956
SCRR Securities Contracts (Regulation) Rules, 1957
U.S. GAAP Generally Accepted Accounting Principles in the United States of America
U.S. Securities Act U.S. Securities Act, 1933
VAT Value Added Tax
VCFs Venture capital funds as defined in and registered with SEBI under the SEBI
VCF Regulations or the SEBI AIF Regulations as the case may be
Year/ Calendar Year Unless context otherwise requires, shall refer to the twelve month period ending
December 31

10
CERTAIN CONVENTIONS, PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA

Certain Conventions

All references to “India” contained in this Draft Red Herring Prospectus are to the Republic of India.

Unless stated otherwise, all references to page numbers in this Draft Red Herring Prospectus are to the page
numbers of this Draft Red Herring Prospectus.

Financial Data

Unless the context provides otherwise or it is stated otherwise, financial data included in this Draft Red Herring
Prospectus is derived from our Restated Financial Statements.

In this Draft Red Herring Prospectus, any discrepancies in any table between the total and the sums of the
amounts listed are due to rounding off. All figures in decimals have been rounded off to the second decimal and
all percentage figures have been rounded off to two decimal places.

Our Company’s Financial Year or Fiscal commences on April 1 and ends on March 31 of the next year, so all
references to particular Financial Year or Fiscal, unless stated otherwise, are to the 12 months period ended on
March 31 of that year.

The degree to which the Indian GAAP financial statements included in this Draft Red Herring Prospectus will
provide meaningful information is entirely dependent on the reader‘s level of familiarity with Indian accounting
practices. Any reliance by persons not familiar with Indian accounting practices on the financial disclosures
presented in this Draft Red Herring Prospectus should accordingly be limited.

Currency and Unit of Presentation

In this Draft Red Herring Prospectus, references to “`”, “Rs.”, “Indian Rupees”, “INR” and “Rupees” are to the
legal currency of India and references to “US$”, “USD”, and “U.S. dollars” are to the legal currency of the
United States of America,. For the purposes of this Draft Red Herring Prospectus data pertaining to the
Company will be given in ` in lacs. In this Draft Red Herring Prospectus, any discrepancy in any table between
total and the sum of the amounts listed are due to rounding off.

Exchange Rates

This Draft Red Herring Prospectus contains conversions of certain other currency amounts into Indian Rupees
that have been presented solely to comply with the SEBI ICDR Regulations. These conversions should not be
construed as a representation that these currency amounts could have been, or can be converted into Rupees, at
any particular rate or at all.

The following table sets forth, for the periods indicated, information with respect to the exchange rate between
the Rupee and USD:

Currency As on June 30, Fiscal Year ended

2016 2016 2015 2014* 2013* 2012*
1 USD 67.6166 66.3329 62.5908 60.0998 54.3893 51.1565
(Source: RBI Website)
*last working day of the fiscal year

11
 INDUSTRY AND MARKET DATA

Unless stated otherwise, industry and market data used in this Draft Red Herring Prospectus has been obtained
or derived from publicly available information as well as various industry publications and sources. Unless
otherwise stated, industry information has been included from the report titled “PHARMACEUTICAL
VACCINE INDUSTRY” dated June 14, 2016 issued by IRR Advisory Services Private Limited (the “IRR
Report”). For details, please see the section entitled “Industry Overview” on page 64. Such data involves risks,
uncertainties and numerous assumptions and is subject to change based on various factors. Accordingly,
investment decisions should not be based solely on such information.

Industry publications generally state that the information contained in such publications has been obtained from
publicly available documents from various sources believed to be reliable but their accuracy and completeness
are not guaranteed and their reliability cannot be assured. Accordingly, no investment decisions should be made
based on such information. Although we believe the industry and market data used in this Draft Red Herring
Prospectus is reliable, it has not been independently verified by us, the Selling Shareholders or the BRLM or
any of their affiliates or advisors. The data used in these sources may have been re-classified by us for the
purposes of presentation. Data from these sources may also not be comparable.

The extent to which the market and industry data used in this Draft Red Herring Prospectus is meaningful
depends on the reader’s familiarity with and understanding of the methodologies used in compiling such data.
There are no standard data gathering methodologies in the industry in which the business of our Company is
conducted, and methodologies and assumptions may vary widely among different industry sources.

12
 FORWARD LOOKING STATEMENTS

This Draft Red Herring Prospectus contains certain “forward-looking statements”. These forward-looking
statements can generally be identified by words or phrases such as “aim”, “anticipate”, “believe”, “expect”,
“estimate”, “intend”, “objective”, “plan”, “project”, “will”, “will continue”, “will pursue”, “seek to” or other
words or phrases of similar import. Similarly, statements that describe our Company’s strategies, objectives,
plans, prospects or goals are also forward-looking statements. Forward-looking statements reflect the current
views of our Company as of the date of this Draft Red Herring Prospectus and are not a guarantee of future
performance. These statements are based on the management’s beliefs and assumptions, which is in turn based
on currently available information. Although we believe the assumptions upon which these forward-looking
statements are based to be reasonable, any of these assumptions could prove to be inaccurate, and the forward
looking statements based on these assumptions could be incorrect. Neither our Company, our Directors, BRLM
nor any of their respective affiliates or advisors have any obligation to update or otherwise revise any statements
reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if
the underlying assumptions do not come to fruition. Moreover, all forward-looking statements are subject to
risks, uncertainties and assumptions about us that could cause actual results to differ materially from those
contemplated by the relevant forward-looking statement.

Actual results may differ materially from those suggested by the forward-looking statements due to risks or
uncertainties associated with respect to, but not limited to, regulatory changes pertaining to the industry in India
in which our Company operates and our ability to respond to them, our ability to successfully implement our
strategy, our growth and expansion, technological changes, our Company’s exposure to market risks, general
economic and political conditions in India which have an impact on its business activities or investments, the
monetary and fiscal policies of India, inflation or deflation, unanticipated turbulence in any or all of interest
rates or foreign exchange rates or both, equity prices and other rates or prices, the performance of the financial
markets in India and globally, changes in domestic laws, regulations and taxes and changes in the competitive
environment.

Certain important factors that could cause actual results to differ materially from our Company’s expectations
include, but are not limited to, the following:

 limited number of our products;

 negative publicity or other harm to our reputation;
 disruption in operations of any our plant; and
 failure to win bids by governments

For further discussion on factors that could cause the actual results to differ from the expectations, please see
sections entitled “Risk Factors”, “Our Business” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” on pages 14, 82 and 149, respectively.

We cannot assure the Bidders that the expectation reflected in these forward-looking statements will prove to be
correct. Given these uncertainties, Bidders are cautioned not to place undue reliance on such forward-looking
statements and not to regard such statements as a guarantee of future performance.

In accordance with the SEBI ICDR Regulations, our Company and the BRLM will ensure that Bidders in India
are informed of material developments from the date of this Draft Red Herring Prospectus until the time of the
grant of listing and trading permission by the Stock Exchanges.

13
 SECTION II – RISK FACTORS

An investment in the Equity Shares involves a high degree of risk. You should carefully consider all information
in this Draft Red Herring Prospectus, including the risks and uncertainties described below, before making an
investment in the Equity Shares. If any or some combination of the following risks actually occur, our business,
prospects, results of operations and financial condition could suffer, the trading price of the Equity Shares
could decline and you may lose all or part of your investment. In addition, the risks set out in this section may
not be exhaustive and additional risks and uncertainties not presently known to us, or which we currently deem
to be immaterial, may arise or may become material in the future. Unless specified in the relevant risk factor
below, we are not in a position to quantify the financial implication of any of the risks mentioned below. Any
potential investor in the Equity Shares should pay particular attention to the fact that we are subject to an
extensive regulatory environment that may differ significantly from one jurisdiction to other. In making an
investment decision, prospective investors must rely on their own examination of us on a consolidated basis and
the terms of the Offer including the merits and the risks involved. To obtain a complete understanding of our
business, you should read the sections “Our Business” and “Management’s Discussion and Analysis of
Financial Condition and Result of Operations” on pages 82 and 149, respectively. If our business, result of
operations or financial condition suffers, the price of the Equity Shares and the value of your investments in the
Equity Shares could decline.

This Draft Red Herring Prospectus also contains forward looking statements, which refers to future events that
produce known and unknown risks, uncertainties and other factors, many of which are beyond our control,
which may cause the actual results to be materially different from those expressed or implied by the forward
looking statements. Please refer to the chapter “Forward Looking Statements” on page 13.

In this section, unless the context otherwise requires, a reference to our “Company”, “we”, “us” and “our”
refers to GreenSignal Bio Pharma Limited. Unless otherwise stated or the context otherwise requires, the
financial information used in this section is derived from our Restated Financial Information, as applicable.

INTERNAL RISK FACTORS:

Risks Relating to Business

1. We have only two products and if our production of the BCG vaccine, which is the major source of
our revenue is stalled or stopped or if there is any impediment in its domestic or overseas sales and
distribution it will materially adversely affect our business and profits.

We currently have two products, namely the BCG vaccine for preventing tuberculosis and the BCG-
ONCO for Immunotherapy which is used in the treatment of urinary bladder cancer. The major
contributor to our revenues is the BCG vaccine which contributes 82.73% of our revenues for the
period ended March 31, 2016. Vaccine production is a highly regulated sector and in the event we
suffer any regulatory drawback which impedes production of this vaccine or even stalls production for
a temporary period then we will materially adversely suffer from such an event. Secondly, it is
pertinent that our material agreements such as the UNICEF Long Term Arrangement to undergo
renewal, for us to sustain the revenue derived from the export of the BCG vaccine. If any material
contract for marketing, sale, distribution of the BCG vaccine either in India or globally ceases then the
decline in revenue will materially adversely affect our business and operations. Because we have only
two products out of which the BCG vaccine is the mainstay of our business and any adverse price
control legislation or export control legislation will materially adversely affect our business.

2. Currently, we are producing only two products. BCG Vaccine and BCG – ONCO for
Immunotherapy, an immuno therapeutic drug for Urinary Bladder Cancer. Our business, prospects,
results of operations and financial condition may be adversely affected if any of these two products
in our portfolio do not perform as expected or if competing products become available and gain
wider market acceptance.

We are heavily dependent on our two products – BCG Vaccine and BCG – ONCO for Immunotherapy.
In addition we generate a significant portion of our revenues in India.

Our revenues from these products may decline as a result of increased competition, regulatory action,
pricing pressures or fluctuations in the demand for or supply of our products. Similarly, in the event of
any breakthrough in the development of alternative drugs for these products, our products may become
obsolete or be substituted by such alternatives. Our failure to effectively react to these situations or to

14
 successfully introduce new products in these areas, could adversely affect our business, prospects,
results of operations and financial condition.

3. In India, our price is regulated for the BCG vaccine and hence it is imperative for us to solicit
markets overseas. Though we are in the process of procuring contracts from various governments
and countries there is a high risk that the eventual business may not materialize and we are not able
to procure newer overseas markets. In the event we are unable to do so it will materially adversely
affect our business.

The ceiling price of the BCG vaccine for each dose in India is ` 5.58 as per notification dated
September 15, 2014. There is no regulatory price ceiling for our other product BCG-ONCO for
Immunotherapy. We supply the BCG vaccine to the MoH, Government of India pursuant to the
tendering process, in which we have placed successful bids for the past 7 years except the years 2013-
14 and 2014-15. Given the price ceiling for BCG vaccine in India it is imperative that we solicit and
ensure overseas markets. Our revenue from exports has commenced from the year 2014-15. Prior to
this there was no export market or revenue. Addition of newer overseas markets for the BCG vaccine is
essential to make gains in light of price control restriction in the domestic Indian territory. In the event
we are unable to do so it will materially adversely affect our business and profits. Though we are
exploring opportunities with various overseas jurisdictions and governments there is a high risk that the
eventual business may not materialise and we are not able to procure newer overseas markets. For more
details please refer section “Our Business” on page 82.

4. Our Company is involved in certain litigation relating to trademark, any adverse decision in the said
proceedings may impact our Company.

Our Company is involved in a litigation pertaining to trademark of our product BCG ONCO for
Immunotherapy. In the said case M/s. Serum Institute of India Ltd. has objected to use of the name
BCG ONCO BP. If the said case is decided against us it may impact our Company. For details of the
said case,please refer to “Outstanding Litigation and Material Developments” Also, CBI has also
initiated certain proceedings against our company under Section 420 of the IPC, the said proceedings
were quashed by the High Court of Chennai vide its order dated April 30, 2009 Cr. OP number 4389
of 2009. Against the said order of Hon’ble High Court of Chennai, CBI filed a special leave petition
8555/2009 before Hon’ble Supreme Court, which was dismissed by Hon’ble Supreme Court vide its
order dated February 22, 2016. We cannot assure you that such proceeding will not be initiated against
our Company in the future. Also in the past CBI has also filed case against our Company under
Section 420 of IPC read with section 120B of IPC , proceedings in the said case were quashed by High
Court. Also, we cannot assure you that more legal proceedings will not be initiated against our
Company in the future. Any adverse decision against our company in such legal proceedings may
impact operations and financial position of our Company. A brief summary of the pending litigation is
provided below for ease.
Name of Entity Criminal Civil/ Tax Labour Consumer Complaints Aggregate
Proceedings Arbitration proceedings disputes Complaints under Section amount
Proceedings 138 of NI Act, involved (` In
1881 lacs)
Company
By the Company Nil Nil Nil Nil Nil Nil Nil
Against the Company Nil 1 Nil Nil Nil Nil N.A.
Promoters
By the promoters Nil Nil Nil Nil Nil Nil Nil
Against the Nil Nil Nil Nil Nil Nil Nil
promoters
Group companies
By Group Companies N.A. N.A. N.A. N.A. N.A. N.A. N.A.

Against Group N.A. N.A. N.A. N.A. N.A. N.A. N.A.

Companies
Directors other than promoters
By the Directors Nil Nil Nil Nil Nil Nil Nil
Against the Directors Nil Nil Nil Nil Nil Nil Nil
Subsidiaries
By the Subsidiary N.A. N.A. N.A. N.A. N.A. N.A. N.A.
Against the N.A. N.A. N.A. N.A. N.A. N.A. N.A.
Subsidiary

15
 For further details on the litigation please refer to chapter titled as “Outstanding Litigations and
Material Developments” on page 167.

5. Our main contract for overseas sales and distribution is with UNICEF which is valid till 2018 and
there is no assurance that the same will be renewed.

We are one of the four companies worldwide who have been WHO-prequalified to supply the BCG
vaccine to UNICEF. And we have secured a long term arrangement dated November 23, 2015 with
UNICEF to supply the BCG vaccine to UNICEF subject to the purchase orders placed with our
company. We also supply the BCG vaccine to Indonesia and Nepal which are countries outside the
UNICEF ambit. The sales under the UNICEF contract of BCG vaccine account for 8.40% of our
revenue for the year ended 2015-16. Thus it is clear that the long term arrangement is vital for growth
and sustenance of the company as well as profits. The UNICEF contract expires as on November 2018.
And there is no guarantee that it will be renewed on more favourable terms or on the same terms or at
all. In the event it is not renewed then we will need to find other jurisdictions and suppliers to secure
sales of the BCG vaccine. We are heavily dependent on this one major contract for the major source of
our revenue and in the event we are unable to secure renewal of the same our business and operations
will be materially affected.

6. For our immunotherapy drug, BCG –ONCO, in India our tie up is with Cadila Healthcare Ltd. and
this contract is expiring on June 29, 2016 there is no assurance that we will be able to distribute this
vaccine effectively under any new arrangement or by ourselves.

Our Company produces this drug under the registered name of ‘Urovac’ however there are other
manufacturers such as Cadila Healthcare Ltd. who manufacture the same immunotherapy drug under
the brand name Oncovac. This product is marketed through a partnership with Cadila Healthcare Ltd.
We have entered into a sales and distribution agreement with Cadila Healthcare Ltd. for five years and
the same is expiring in June 2016. Under this contract, Cadila Healthcare Ltd. shall market our product
BCG-ONCO for Immunotherapy under it’s own brand name namely ‘Oncovac’ in the domestic Indian
market on an exclusive basis. We have not taken any active steps for renewal of this contract and upon
expiry of this exclusive sale and distribution agreement the challenge will be to market our product
under our own registered brand name ‘Urovac’ in India. There is no assurance that we will be able to
distribute this vaccine effectively under any new arrangement or by ourselves. In the event we are
unable to do so this will adversely affect our profits and growth.

7. We have only one facility, which is on lease, and this exposes us to higher risks of disasters and
structural failures, further, this may hamper production of various other vaccines due to regulatory
controls for isolation such as those required for the BCG vaccine.

Our manufacturing facility is located at No.49, Pappankuppam Village, Gummidipoondi, Tiruvalluvar

Dist - 601 201. Apart from the Vaccine Manufacturing Facility, the campus also houses our Research
& Development Center. Our R&D Center is approved by Department of Scientific and Industrial
Research, Government of India. The land on which this facility is situated has been leased from Mr. P.
Sundaraparipooranan, Promoter of our company for a term of ten years commencing from February 23,
2016. Prior to this the said land was leased from Mr. P. Sundaraparipooranan as well as Ms. B.
Dakshayani, (former Director of the Company) whose 30% share in the land was subsequently
acquired by P. Sundaraparipooranan so as to become 100% owner of the same. Being the only facility
for production on our main product, the BCG vaccine, we have to exercise strict controls for production
of BCG vaccine and no other vaccine can be produced in the same facility as recommended by WHO
guidelines. If we are not able to maintain and exercise stringent production controls we may be not be
able to expand and develop into more vaccines. Further being only one facility it exposes us more to
any bio-hazardous breakdown, major structural damages and breakdown of plant and machinery. If any
of these events happen it will materially adversely affect our business and operations. Further as the
land appurtenant to our facility has been leased to us by our promoter Mr. P. Sundaraparipooranan,
there is always a risk that we may not be able to renew the lease for the same. Any non-renewal of the
lease in our favour will materially adversely affect our operations and profits. There is also the risk that
of the promoter in future disassociates from the Company his resources, namely the lease of land will
be unavailable for the Company. In this event our business and operations will be materially and
adversely affected.

16
8. For countries outside the UNICEF ambit we have to liaise with governments and agencies and
procure registrations and clearances which is a time consuming procedure and there is a risk that
such clearances and registrations may not even be obtained.

We are trying to expand supply of both our products overseas. For the BCG vaccine, in addition to
countries in the UNICEF fold we supply our vaccine to Indonesia and Nepal. For this we have to liaise
with governments and agencies and procure registrations and clearances which have a time consuming
procedure and there is a risk that such clearances and registrations may not even be obtained.
Inordinate delays in obtaining registrations coupled with an absence of assurance that they will be
obtained at all will deplete our resources and materially adversely affect our business.

9. Our Business is subject to extensive regulation. If we fail to comply with applicable regulations
prescribed by Governments and Regulatory Agencies, our Business, results of operations and
financial condition could be adversely affected.

We operate in a highly regulated industry and our operations are subject to extensive regulation in each
market in which we do business. Regulatory authorities in each of these markets must approve our
products before we or our distribution agents can market them. Applicable regulations have become
increasingly stringent, a trend which may continue in the future. The penalties for non-compliance with
these regulations can be severe, including the revocation or suspension of our business licence,
imposition of fines and criminal sanctions in those jurisdictions.

Regulatory agencies may at any time inspect our manufacturing facilities or the quality of our products
based on newly developed scientific knowledge and/or tools. If any inspection or quality assessment
results in observations/ alerts or sanctions, the relevant regulator may amend or withdraw our existing
approvals to manufacture and market our products in such jurisdiction, which could adversely affect
our business, financial condition and results of operations.

If we fail to comply with applicable statutory or regulatory requirements, there could be a delay in the
submission or grant of approval for the manufacturing and marketing new vaccines and drugs.
Moreover, if we fail to comply with the various conditions attached to such approvals, licenses,
registrations and permissions once received, the relevant regulatory body may suspend, curtail or
revoke our ability to market such products or impose fines upon us. In Indonesia, Nepal, India, and
many of the international markets in which we sell our products, the approval process for a new
product is complex, lengthy and expensive. The time taken to obtain approvals varies by country, but
generally takes between six to eighteen months from the date of application. If we fail to obtain such
approvals, licenses, registrations and permissions, in a timely manner or at all, our business, results of
operations and financial condition could be adversely affected.

We are also subject to a broad range of safety, health, environmental, labour, workplace and related
laws and regulations in the jurisdictions in which we operate. In addition, we may be required to incur
costs to remedy the damage caused by such discharges, pay fines or other penalties for non-
compliance. Complying with, and changes in, these laws and regulations may increase our compliance
costs and adversely affect our business, prospects, results of operations and financial condition.
Furthermore, non-compliance with the limits prescribed by the relevant laws and regulations may lead
to the suspension of our manufacturing licences, which will halt production and adversely affect our
business operations.

We are also subject to the laws and regulations governing relationships with employees in such areas as
minimum wage and maximum working hours, overtime, working conditions, hiring and termination of
employees, contract labour and work permits.

10. Our domestic revenues from BCG vaccine as well as BCG-ONCO for Immunotherapy showed a
steep decline in the years 2013-14 and 2014-15 due to us not obtaining the MoH tender for BCG and
reduced demand under the Cadila Healthcare marketing and distribution agreement. If such events
repeat themselves then it will reduce our revenues considerably and materially adversely affect
business operations and profit.

The years 2014 and 2015 saw a deep decline in our domestic sales of both BCG vaccine and BCG-
ONCO for Immunotherapy. The decline in the revenues for the BCG Vaccine was due to us not being
the lowest bidder in MoH tenders. The decline in the revenues from BCG ONCO for Immunotherapy
was due to price increase under the arrangement with Cadila Healthcare Limited and corresponding
lower quantity ordered by Cadila Healthcare Limited. Subsequently in fiscal 2016, our domestic

17
 revenue increased to more stable numbers and this was mainly due to us getting the tenders from MoH.
In the event we do not obtain MoH tenders it will adversely affect our domestic revenues and profits. In
the event we are unable to market our brand Urovac that will also materially adversely affect out
revenues and profits from business.

11. Our Company has made a Net loss for the preceding four out of five financial years and has made
profits only in the year ended March 31, 2016 (out of the past five years). Continual losses will
adversely affect our sustainability and business operations.

For the past five years, although our company has been earning positive profits on the operational front
owing to the fixed costs of finance and depreciation and the tax charges, the company has eventually
incurred losses as follows: For the year ended March 31, 2015 our loss was ` 21.33 lacs, for the year
ended March 31, 2014 our loss was ` 129.71 lacs, for the year ended March 31, 2013 our loss was `
50.01 lacs and for the year ended March 31, 2012 our loss was ` 48.11 lacs.

However, on account of the widening of the export market over the last two years, the profitability of
the company has improved over the earlier years. The Company registered a profit figure in the last
financial year 2015-16 of ` 530.95 lacs. There is no assurance that we will be able to secure sufficient
overseas markets in a timely manner or even assure renewal of the UNICEF long term agreement in
order to sustain the profits shown year ended March 31, 2016. In the event we are unable to do so it
will materially adversely affect our operations and business.

12. Our Company had negative cash flow in two out of last five financial years. We cannot assure that
our company will not have such negative cash flows again in the future.

Our cash flows were negative for financial year ended Financial Year ended 2014 and 2013
respectively and stood at ` (0.61 lacs) and ` (3.10 lacs) respectively due to increased capital
expenditure. Though, our cash flowagain turned positive since Financia Year 2015 and 2016. Also, for
period ended June 30, 2016 cash flow was negative and stood at ` (117.81 lacs) predominantly due
to reduction in working capital outstanding and increase in sundry debtors.

However, we cannot assure you that we will will not have negative cash flows in future. Negative
cash flows may hamper our business and opeartions.

13. The regulatory uncertainty associated with pharmaceutical pricing, reimbursement and related
matters could adversely affect the marketing, pricing and demand for our products.

In many countries in which we currently operate, including India, pharmaceutical prices are subject to
regulation. The existence of price controls can limit the revenues we earn from our products. India
enacted the National Pharmaceuticals Pricing Policy in 2012. As a result, a number of drug
formulations were identified as essential drugs and were added to India’s National List of Essential
Medicines and these drugs are subjected to price controls in India. On May 15, 2013, the Department of
Pharmaceuticals released the revised DPCO 2013 (which replaced the earlier Drugs (Prices Control)
Order, 1995). The Drugs (Price Control Order) 2013 (“hereinafter referred as “The DPCO 2013”
governs the price control mechanism for 509 formulations listed in the National List of Essential
Medicines. As per this order, the prices of each of the formulations are determined based on the
average of all drugs having an Indian market share of more than 1% by value. The individual drug
price notifications for a majority of the products have been released by the National Pharmaceutical
Pricing Authority. The DPCO 2013 also regulates the margin that can be offered to the trade channels
including the retailers. Ceiling Price for BCG. Vaccine for each dose is ` 5.58 as per notification dated
September 15, 2014. For details please refer to “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” beginning on page 149.

Under terms of the DPCO 2013 non-compliance with the notified ceiling price or breaching the ceiling
price would be tantamount to overcharging the consumer under the order, and the amount charged over
and above the ceiling price shall be recovered along with interest thereon from the date of
overcharging. Further, non-compliance with the price notification issued by National Pharmaceutical
Pricing Authority (“NPPA”), could also attract prosecution of the officers of the Company under the
Essential Commodities Act, 1955 including imprisonment for a term up to seven years and shall also be
liable for fine. Any action against us or our management for violation of the DPCO 2013 may divert
management attention and could adversely affect our business, prospects, results of operations and
financial condition.

18
14. We are susceptible to product liability claims that may not be covered by insurance which may
require substantial expenditure and may adversely affect our reputation and if successful, could
require us to pay substantial sums.

We may also be subject to claims resulting from manufacturing defects or negligence in storage or
handling which may lead to the deterioration of our products. For example, our distributors may
continue to sell our products beyond their expiry date or product recall. Even unsuccessful product
liability claims would likely require us to incur substantial amounts on litigation, divert management’s
time, adversely affect our goodwill and impair the marketability of our products. Moreover, a
deterioration in our quality controls could also result in product liability claims against us. The risk of
product liability suits is also likely to increase if we develop our own new patented products in addition
to making generic versions of drugs that have been in the market for some time.

We do not have any product liability insurance and hence our exposure to such liability is high.
Further, we may not have taken insurance or may not have vendor extension covers from our partners’
insurance policies in the countries into which we export our products. A successful product liability
claim that is may require us to pay substantial sums and may adversely affect our financial position and
results of operations. In addition, insurance coverage for product liability may become prohibitively
expensive in the future, though even at this stage we do not have the same. From time to time, the
pharmaceutical industry has experienced difficulty in obtaining desired product liability insurance
coverage. If any product liability claim is not covered by insurance or exceeding the policy limits were
sustained against us, it could adversely affect our business, financial condition and results of
operations. In any case in the absence of any product liability insurance as on date if we are found
liable under a claim that we are unable to meet, it will materially adversely affect our business and
operations.

15. If there is a change in policies related to tax, duties or other such levies applicable to us, it may
affect our results of operations.

We benefit from certain tax regulations and incentives that accord favourable treatment to certain of
our manufacturing facilities as well as for our research and development activities. For details
regarding income tax deductions, please refer to the chapter “Statement of Tax Benefits” on page 60.

New or revised accounting policies or policies related to tax, duties or other such levies promulgated
from time to time by the relevant authorities may significantly affect our results of operations. We
cannot assure you that we would continue to be eligible for such lower tax rates or any other benefits.
The reduction or termination of our tax incentives, or non-compliance with the conditions under which
such tax incentives are made available, will increase our tax liability and adversely affect our business,
prospects, results of operations and financial condition.

16. Any manufacturing or quality control problems may damage our reputation for high quality
products and expose us to litigation or other liabilities, which could adversely affect our financial
results.

Pharmaceutical manufacturers are subject to significant regulatory scrutiny. Our Manufacturing

Facility at Pappankulam Village, Gummidipoondi District must manufacture products in accordance
with Good Manufacturing Practices stipulated by WHO, state level food and drug administrations, the
DCGI and other regulatory agencies.

Furthermore, we are liable for the quality of our products for the entire duration of the shelf life of the
product. After our products reach the market, certain developments could adversely affect demand for
our products, including any contamination of our products by intermediaries, re-review of products that
are already marketed, new scientific information, greater scrutiny in advertising and promotion, the
discovery of previously unknown side effects or the recall or loss of approval of products that we
manufacture, market or sell.

Disputes over non-conformity of our products with such quality standards or specifications are
generally referred to independent government approved testing laboratories. If any such independent
laboratory confirms that our products do not conform to the prescribed or agreed standards and
specifications, we would bear the expenses of replacing and testing such products, which could
adversely affect our business, results of operations and financial condition.

19
 We also face the risk of loss resulting from, and the adverse publicity associated with, manufacturing or
quality problems. Such adverse publicity harms the brand image of our Company and products. We
may be subject to claims resulting from manufacturing defects or negligence in storage and handling of
our products.

Any loss of our reputation or brand image, for whatsoever reason may lead to a loss of existing
business contracts and adversely affect our ability to enter into additional business contracts in the
future.

17. The land and premises on which our Manufacturing Facility and Registered Office are located are
held by us on a leasehold and rental basis, and has been taken on lease from our Promoter which
subjects us to certain risks.

All of the land and premises on which the Manufacturing Facility is located are held by us on a
leasehold basis for a period of 10 years. The land on which the Manufacturing Facility is located is in
the name of our Promoter Mr. P. Sundaraparipooranan. The Company is payin a rent of `. 1,00,000
per month. Further, the rent agreement for the property on which our registered office is situated has
been also entered into with Mr. P. Sundaraparipooranan. Company is paying a rent of `. 14,000 per
month to the promoter for said property.

We cannot assure you that we will own, or have the right to occupy, these premises in the future,
or that we will be able to continue with the uninterrupted use of these premises, which may impair our
operations and adversely affect our financial condition. If any of the property arrangements are
terminated, we may be unable to procure premises similar to the ones on which we currently operate
and may suffer a disruption in our operations or be required to pay increased rental rates, which could
have a material adverse effect on our business, financial condition, results of operations and cash flows.
In the event that we are required to change the locations of our laboratories or other business premises,
we may be unable to recover the costs of moving. If we are forced to move, we may also be required to
obtain fresh regulatory licenses and approvals. Until we receive such approvals and licenses, we may
suffer disruptions in our operations and our business which may adversely affect our financial
condition and results of operations.

In the event of default on behalf of the lessor/licensor, we may be unable to enforce our leases/licenses
if they are not duly registered provided that in case of licenses, registration is required depending on the
state law. For lease/license agreements that are deemed as insufficiently stamped, we may be required
to pay additional stamp duty or make similar payments, which could have an adverse effect on our
business, results of operations, cash flows and financial condition.

18. Our lease agreement with our promoter, Mr. P. Sundaraparipooranan, for lease of land in relation
to our facility for a period of ten years has not been registered. This exposes us to certain risks which
will materially adversely affect our business.

Title to the land, we have leased from our Promoter Mr P. Sundaraparipooranan may be affected by
being unregistered. Currently the said document is not registered. In the event it is insufficiently
stamped then in addition to title uncertainties, there may be other irregularities, defects,
noncompliance, or unsettled claims in relation to the properties that we lease or hold on a leave and
license basis from time to time, including issues that we may not be aware of. For example, our
properties may be subject to restrictions under our lease or license agreements or under municipal
zoning or other property related laws and regulations. Our properties could also be subject to legal
proceedings regarding the restrictions on use that involve local municipal councils or regulatory
authorities.

Any of the above factors may affect uninterrupted possession and use of the properties we occupy,
cause us to incur significant additional compliance costs or rental expenses, or may curtail our future
expansion, which may adversely affect our business, financial condition, results of operations and
prospects.

19. Our business depends substantially on the continued efforts of our Promoters Dr. P. Murali, and
Mr. P. Sundaraparipooranan, our business may be severely disrupted if we lose their services.

Our success is dependent largely on the efforts of Mr. P. Sundaraparipooranan and Dr. P. Murali our
Promoters and Managing Director. We do not have insurance related to the continued employment of

20
 our key employees, and therefore do not have any insurance that would help compensate any losses
incurred as a result of the loss of Dr. P. Murali or Mr. P. Sundaraparipooranan. If we were to lose the
services of Dr. P. Murali or Mr. P. Sundaraparipooranan for any reason, or if their other business
interests compete for their time and services, we may not be able to replace their services effectively,
which could have an adverse effect on our business, results of operations and financial condition.

20. Any delay in production at or shutdown of our manufacturing facility, could adversely affect our
business, results of operations and financial condition.

The success of our manufacturing activities depends on, among other things, the productivity of our
workforce, compliance with regulatory requirements and the continued functioning of our
manufacturing processes and machinery. Disruptions in our manufacturing activities could delay
production or require us to shut down the affected manufacturing facility.

We may also be subject to manufacturing disruptions due to delays in receiving regulatory approvals,
which may require our manufacturing facilities to cease or limit production until the required approvals
are received, or disputes concerning these approvals are resolved. Moreover, as regulatory approvals
for manufacturing drugs are site specific, production cannot be transferred to another location which
could adversely affect our business, results of operations and financial condition.

Any interruption at our manufacturing facilities, including natural or man-made disasters, work force
disruptions, regulatory approval delays, fire or the failure of machinery, could reduce our ability to
meet the demand under our contracts for the affected period, which could affect our business,
prospects, results of operations and financial condition.

21. We participate in a competitive tender process for supply to various government agencies and
institutions. We may face an inability to successfully obtain tenders in future, which would impact
our revenues and profitability and the tenders we have successfully obtained may be withdrawn in
the future.

We participate in a competitive tender process for supply to various government agencies, private
entities and institutions. If we are unable to successfully win tenders, our future revenues and
profitability may suffer. Additionally, for any reason, if we are disqualified from the tender process by
a government agency, we may automatically be disqualified by other central and state government
agencies.

22. Stricter marketing norms prescribed by a new code of conduct in India for companies doing business
in the pharmaceuticals industry could affect our ability to effectively market our products which may
affect our profitability.

In December 2014, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers of the
Government of India announced details of the UCPMP which became effective across India from
January 1, 2015. This code of conduct for marketing practices for the Indian pharmaceutical industry is
expected to be voluntarily adopted by pharmaceutical companies for a period of six months (extended
by a further period of two months) after which it would be reviewed by the Government.

The UCPMP amongst other things provides detailed guidelines about promotional materials, conduct
of medical representatives, physician samples, gifts and relationships with healthcare professionals. For
example, under the UCPMP, pharmaceutical companies may not supply or offer any gifts, pecuniary
advantages or benefits in kind to persons qualified to prescribe or supply drugs. Further, the Managing
Director or the chief executive officer of the company is responsible for ensuring adherence to the
UCPMP and a self-declaration is required to be submitted by the managing director or the chief
executive officer within two months of the closure of every financial year to the industry association.
Although these guidelines are voluntary in nature, they may be codified in the future and we may have
to spend a considerable amount of time and resources to conform to the requirements of the UCPMP.

23. We have not yet registered our corporate logo and other intellectual property rights. We may be
unable to adequately protect our intellectual property. Furthermore, we may be subject to claims
alleging breach of third party intellectual property rights.

We have not applied for the registration of our corporate logo and other trademarks,
including words and logos in connection with our business except the ‘UROVAC’. Consequently, we
do not enjoy the statutory protection accorded to a registered trademark. Though our vaccine and drugs

21
 are generic in nature and do not require to be patented. Further, if we do apply, our applications may or
may not be allowed by the Registrar of Trademarks for our corporate name and logo, and our
competitors could challenge the validity or scope of the applications or these trademarks. If we fail to
successfully obtain or enforce these trademarks, we may need to change our corporate logo. Any such
change could adversely affect our branding and may have an adverse effect on our business, reputation
and, consequently, on our results of operation, cash flows and financial condition.

There can be no assurance that third parties will not infringe on our intellectual property, causing
damage to our business prospects, reputation and goodwill. We may need to litigate to protect our
intellectual property or to defend against third party infringement. Additionally, we may not be able to
detect any unauthorized use or take appropriate and timely steps to enforce or protect our intellectual
property. Serum Institute India Limited has already filed a suit in relation to use of words BCG ONCO
BP. For details of the said case please refer to “Outstanding Litigations and Material Developments”
on page 167. Any failure to obtain registrations for our intellectual property rights or any inability to
use or protect our intellectual property could affect our relationships with our customers and our ability
to market our business, which could materially and adversely affect our business, cash flows, results of
operations and financial condition.

24. Our Company has a limited operating history that may not provide an adequate basis on which to
judge its future prospects and results of operations.

Our Company was incorporated in 2005 and commenced commercial production in the year 2009. We
got WHO Pre-Qualification during the year 2015 only and subsequently acquired the UNICEF Long
Tem Arrangement which has enabled export of the BCG vaccine to UNICEF. As our operating history
is limited, it may not provide a meaningful basis for you to evaluate our business, financial
performance and prospects. Accordingly, you should not rely on our results of operations for any prior
periods as an indication of our future performance. You should consider our business and prospects in
light of the risks, uncertainties, expenses and challenges that we will face as an early-stage company
operating in a growing market. Going forward, we may not be successful in addressing the risks and
uncertainties we will confront, which may materially and adversely affect our company’s results of
operations, financial condition and business prospects.

25. If we cannot respond adequately to the increased competition we expect to face, we will lose market
share and our profits will decline, which will adversely affect our business, results of operations and
financial condition.

We compete with local companies in India, multi-national corporations and companies in the countries
in which we operate.

Whilst we are among a few vaccine companies in India, we intend to expand internationally. Some of
our competitors may have greater financial, manufacturing, research and development, marketing and
other resources, more experience in obtaining regulatory approvals, greater geographic reach, broader
product ranges and stronger sales forces. Our competitors may succeed in developing products that are
more effective, more popular or cheaper than any we may develop, which may render our products
obsolete or uncompetitive and adversely affect our business and financial results.

26. Changes in technology may render our current technologies obsolete or require us to make
substantial capital investments

Our industry is continually changing due to technological advances and scientific discoveries. These
changes result in the frequent introduction of new products and significant price competition. If our
pharmaceutical technologies become obsolete our business and results of operations could be adversely
affected. Although we strive to maintain and upgrade our technologies, facilities and machinery
consistent with current national and international standards, the technologies, facilities and machinery
we currently use may become obsolete. The cost of implementing new technologies and upgrading our
manufacturing facilities could be significant, which could adversely affect our business, results of
operations and financial condition.

27. Changes in policy and cuts in government spending on research development and national health
care policy will adversely affect our business.

A major challenge in vaccine production in India is sub-optimal investment by public sector for
vaccine research. The vaccine manufacturing units set in India are still producing some of the

22
 traditional vaccines and there appears to be a need for more funding and research on newer antigens.
Indian manufacturers are participating in the development and clinical trials of a number of other
candidate vaccines which would ensure that these vaccines are accessible to Indian population, as and
when these become available. The national vaccine policy of India has suggested that linkages need to
be explored between academia, industry and international institutions such as National Institute of
Health Gates Foundation, the GAVI Alliance, PATH), World Health Organization and the IICGEB
etc.

Public health consciousness and economic perspectives have automatically enhanced the importance of
vaccines world over. While vaccines have proven to be the single most cost effective means of
controlling the spread of infectious diseases, there is a need for effective, affordable vaccines for a wide
variety of potentially preventable infections. This is especially true for diseases such as HIV/AIDS,
tuberculosis, malaria, and dengue fever that disproportionately affect the resource poor countries.
Existing vaccines that have dramatically reduced the burden of infectious diseases in wealthy countries
are often not accessible in the developing world because of the costs associated with manufacturing,
delivering and administering these vaccines. India has made significant strides in vaccines and has been
one of the major players in affordable vaccine development and a resource for the global market.
However, market study suggests that it hasn’t hit its peak still due to some regulatory and supply chain
issues, including cold storage. Government support to vaccine firms on these crucial aspects could
facilitate their further growth.

The low budget for research and development of new vaccines is a hindrance to promote R&D; infact,
the immunisation budget as a whole has declined from a little over 9 percent of the total healthcare
budget in 2007-08 to around 3 percent in FY16. If this trend of reduced investment and spending
continues it will materially and adversely affect our business.

28. The products that we may commercialize may not perform as expected which could adversely affect
our business, financial condition and results of operations.

Our success depends significantly on our ability to commercialize new vaccines and products in India
and across various markets around the world. Commercialization requires us to successfully develop,
test, manufacture and obtain the required regulatory approvals for our products, while complying with
applicable regulatory and safety standards. In order to develop a commercially viable product, we must
demonstrate, through extensive developmental studies that the products are safe and effective for use
on humans. Our products currently under development, if and when fully developed and tested, may
not perform as we expect, necessary regulatory approvals may not be obtained in a timely manner, if at
all, and we may not be able to successfully and profitably produce and market such products.

29. If our research and development efforts do not succeed, this may hinder the introduction of new
vaccine products which could adversely affect our business and results of operations.

In order to remain competitive, we must develop, test and manufacture new vaccine products, which
must meet regulatory standards and receive requisite regulatory approvals. To accomplish this, we
commit substantial effort, funds and other resources towards research and development. Delays in any
part of the process, our inability to obtain necessary regulatory approvals for our products or failure of
a product to be successful at any stage and therefore not reach the market could adversely affect our
goodwill and affect our operating results. We may or may not be able to take our research and
development innovations through the different testing stages without repeating our research and
development efforts or incurring additional amounts towards such research. Additionally, our
competitors may commercialize similar products before us.

30. Our success depends on our ability to retain and attract key qualified personnel and, if we are not
able to retain them or recruit additional qualified personnel, we may be unable to successfully
develop our business.

Our business and operations are led by a qualified, experienced and capable management team,
comprising scientists, engineers and management school graduates, the loss of whose services might
significantly delay or prevent the achievement of our business or scientific objectives. Competition
among pharmaceutical companies for qualified employees is intense, and the ability to retain and
attract qualified individuals is critical to our success.

Further, the members of our management team and other key personnel are employed pursuant to
customary employment agreements, which may not provide adequate incentive for them to remain with

23
 us or adequately protect us in the event of their departure or otherwise. If we lose the services of any of
the management team or key personnel, we may be unable to locate suitable or qualified replacements,
and may incur additional expenses to recruit and train new personnel, which could adversely affect our
business operations and affect our ability to continue to manage and expand our business. Furthermore,
as we continue to expand our operations and develop new products, we will need to continue to attract
and retain experienced management and key research and development personnel.

31. Our Performance may be affected if we are not successful in assessing demand for our products and
managing our inventory

We evaluate our production requirements based on anticipated demand based on forecasted customer
order activity for our products. Our inventory balances of materials is influenced by our production
requirements, shelf life of the raw materials and expected sourcing.

It is important for us to anticipate demand for our products and any failure to anticipate, identify,
interpret and react on the basis of anticipated/ desired demand or our failure to generate consumer
acceptance or recognition of our new products, could lead to, among others, reduced demand for our
products, which can adversely affect our results of operations.

Efficient inventory management is also a key component of the success of our business, results of
operations and profitability. To be successful, we must maintain sufficient inventory levels to meet
demand for our products, without allowing those levels to increase to such an extent that the costs
associated with storing and holding the inventory adversely affects our results of operations. If our raw
materials purchase decisions do not accurately predict sourcing levels or our expectations about
demand for our products are inaccurate, we may either not be able to manufacture products to service
the demands, resulting in us having to cede market share to competitors or would have to take
unanticipated markdowns or impairment charges to dispose of the excess or obsolete inventory, which
can adversely affect our results of operations For more information please refer to the chapter
“Management’s Discussion and Analysis of Financial Condition and Result of Operations” on page
149.

32. If any third parties on whom we may rely for clinical trials do not perform their obligations as
contractually required or as we expect, and do not comply with Good Laboratory Practice (“GLP”)
we may not be able to obtain regulatory approval for commercialize our products.

We depend on independent clinical investigators, contract research organizations and other third-party
service providers to conduct clinical trials and pre-clinical investigations of our new products and
expect to continue to do so. We rely on such parties for the successful execution of our clinical trials,
but we do not control many aspects of their activities. Third parties may also not complete activities on
schedule or may not conduct our studies in accordance with applicable trial, plans and protocols.
Nonetheless, we would be responsible for confirming that each of our clinical trials is conducted in
accordance with its general investigational plan and protocol. If third parties fail to carry out their
obligations, product development, approval and commercialization could be delayed or prevented or an
enforcement action could be brought against us.

Our reliance on these third parties does not relieve us of our responsibility to comply with the
regulations and standards of in India and abroad related to good clinical practices. In particular, these
third party manufacturers and service providers must comply with GLP and their failure to do so could
result in warning or deficiency letters from regulatory authorities, which could interfere with or disrupt
their ability to complete our studies on time, thereby affecting our product approval process or even
forcing a withdrawal of our product which may adversely affect our business, financial condition and
results of operations.

33. Timely and successful implementation of our contracts, including our business arrangements,
depends on our performance and co-operation from our vendors. Delay or failure in the
implementation of our contracts, may adversely affect our business, financial condition and results
of operations. Further, increased costs will reduce our margins and profitability.

Our contracts with our partners require us to supply our products, or require our partners to supply us
their products, in compliance with specific delivery schedules. Our, or their, failure to adhere to
contractually agreed timelines may have the following consequences:

 Delayed payment to our products;

24
  Claims may be bought against us for losses suffered as a result of our non-performance;
 Our clients may terminate our contracts;
 Disruption in manufacturing schedule;
 Increase in cost; and
 Damage to our reputation.

Our failure to deliver or receive our products on a timely basis or at all could adversely affect our
business, financial condition and results of operations. Our licensing and supply agreements with our
vendors for supply of packaging materials are crucial. Any interruption in the supply by third party
suppliers of raw materials, or any disruptions in production at our manufacturing facilities, could
adversely affect our ability to supply certain quantities of our products and result in a breach of our
contractual obligations.

Delay or failure on the part of a vendor to deliver, for any reason, could also result in one or a number
of the above listed consequences.

Presently the cost of our packaging material as a percentage to our product cost is 14.67%. In the
event our vendors increase their price such increase will amount to an added cost for us and will affect
the price of our product, which is already under a regulatory ceiling, this will in turn reduce our profit
margins.

Further , the cost of transporting our products as a percentage to our product cost is 3.76%. In the event
there is an increase in such cost then such increase will amount to an added cost for us and will affect
the price of our product (BCG Vaccine), which is already under a regulatory ceiling, which will in turn
reduce our profit margins.

34. Our results of operations are subject to risk arising from exchange rate fluctuations.

UNICEF is our major client and all our tenders are quoted in US$ and payments are also received in
USD. Revenues attributable to sales from outside India is ` 941.96 Lacs, forming 46.20% of our total
revenue for the fiscal year ended March 31, 2016. For the period ended June 30, 2016 sale attributable
to exports was ` 667.58 Lacs forming 65.79 of our total revenues.

We are thus exposed to exchange rate fluctuations due to the revenue that we receive that are
denominated in currencies other than the Indian Rupee. Further, we are engaged with Indian clients and
companies and the transactions are in Indian Rupees, we have and may enter into agreements,
including financing agreements and agreements to acquire components and capital equipment, which
are denominated in foreign currencies. Accordingly, any fluctuation in the value of the Rupee against
these currencies has and will affect the cost of servicing and repaying any obligations we may incur
that expose us to exchange rate risk.

35. Our insurance coverage is limited and may not adequately protect us against all material hazards.

Our insurance coverage is limited. We have insurance policies covering our vehicles, fire and special
perils insurance for our Manufacturing Facility, equipment contained therein. While the policies that
we maintain would reasonably be adequate to cover all normal risks associated with the operation of
our business, there can be no assurance that any claim under the insurance policies maintained by us
will be honoured fully, in part or on time, or that we have obtained sufficient insurance (either in
amount or in terms of risks covered) to cover all material losses. To the extent that we suffer loss or
damage for events for which we are not insured or for which our insurance is inadequate, the loss
would have to be borne by us, and, as a result, our business, financial condition and results of
operations could be adversely affected.

As of the date of this Draft Red Herring Prospectus, we do not have key-man insurance policies for any
of our Promoters and key managerial personnel and therefore, do not have any insurance that would
help compensate any losses as a result of loss of their services. Further we do not have any product
liability insurance either and may be adversely exposed to claims.

36. We have not declared any dividends since incorporation. Further, we cannot assure payment of
dividends in the future.

Our Company has not declared any dividend since incorporation. The decision to pay dividends and the
amount of such dividends, if declared, depends on a number of factors, including our future earnings,

25
 financial condition, cash flows, working capital requirements, capital expenditures and any other
factors that our Board and Shareholders deem to be relevant. While our Board had adopted a dividend
policy, if we decide to retain our earnings to finance the development and expansion of our business,
we may not declare dividends on the Equity Shares. Therefore, there can be no assurance that we will
be able to pay dividends at any point the future.

37. We may require additional financing for our business operations, and the failure to obtain the same
on terms commercially acceptable to us may adversely affect our ability to grow and our future
profitability. Further, fluctuations in interest rates could adversely affect our results of operations.

We may require additional capital for our business operations. The actual amount and timing of our
future capital requirements may differ from estimates as a result of, among other things, unforeseen
delays or cost overruns in developing our products, changes in business plans due to prevailing
economic conditions, unanticipated expenses and regulatory changes. To the extent our planned
expenditure requirements exceed our available resources, we will be required to seek additional debt or
equity financing. Additional debt financing could increase our interest costs and require us to comply
with additional restrictive covenants in our financing agreements. Additional equity financing could
dilute our earnings per Equity Share and your interest in the Company, and could adversely impact our
Equity Share price.

Our ability to obtain additional financing on favourable terms, if at all, will depend on a number of
factors, including our future financial condition, results of operations and cash flows, the amount and
terms of our existing indebtedness, security, general market conditions and market conditions for
financing activities and the economic, political and other conditions in the markets where we operate.
We cannot assure you that we will be able to raise additional financing on acceptable terms in a timely
manner or at all. Our failure to renew arrangements for existing funding or to obtain additional
financing on acceptable terms and in a timely manner could adversely impact our capital expenditure,
our business, results of operations and financial condition.

Further, an increase in the interest rates on our existing or future debt will increase the cost of servicing
such debt. We have entered into certain interest rate hedging transactions in connection with such debt
and we may continue to enter into interest hedging contracts or other financial arrangements in the
future to minimize our exposure to interest rate fluctuations. We cannot assure you, however, that we
will be able to do so on commercially reasonable terms or that any such agreements we enter into will
protect us fully against our interest rate risk. Any increase in interest expense may have an adverse
effect on our business prospects, financial condition and results of operations.

38. Our lenders may impose certain restrictive conditions on us under our financing arrangements,
which may limit our ability to expand our business and our flexibility in planning for, or reacting to,
changes in our business and industry.

We have entered into agreement for working capital loan with Union Bank of India. In future we may
require additional financial requirements and may enter into financial agreements for same. This
agreement contain requirements to maintain certain security margins, financial ratios and inter alia
contain restrictive covenants.

There can be no assurance that we will be able to comply with these financial or other covenants, or
that we will be able to obtain the consents necessary to proceed with the actions which we believe are
necessary to operate and grow our business, which may in turn have a material adverse effect on our
business and operations. We cannot provide any assurance that our lenders will not enforce their rights
relating to our breach of financial covenants, or grant us waivers with respect to any such breaches. In
the event that any lender seeks the accelerated repayment of any such loan or seeks to enforce any other
rights against us, it may have a material adverse effect on the business, cash flows and financial
condition of the entity against which repayment is sought.

39. We rely extensively on our standard operating procedures and information technology systems in
areas such as financial reporting, compliance and products processing/quality assurance and non-
compliance with such procedures or systems or their failure could adversely affect our operations.

We rely on standard operating procedures and information technology systems in certain key areas of
our business, such as accounting or book keeping, financial reporting and compliance with laws. We
rely extensively on the capacity and reliability of such standard operating procedures, information
technology systems, processing and quality assurance systems supporting our operations. Any failures

26
 in these systems or in following/implementing standard operating procedures could have a material
adverse effect on our business, financial reporting, financial condition and results of operations.

40. Our Promoters will be able to exercise significant influence and control over us after the Offer and
may have interests that are different from those of our other shareholders.

After completing the Offer, our Promoters and Promoter Group, will hold a majority of the issued and
outstanding Equity Shares of our Company i.e. 51.79% (assuming the Offer gets fully subscribed). By
virtue of their shareholding, our Promoters will have the ability to exercise significant control and
influence over our Company and our affairs and business, including the election of directors, the timing
and payment of dividends, the adoption of and amendments to our Memorandum and Articles of
Association, the approval of a merger or sale of substantially all of our assets and the approval of most
other actions requiring the approval of our shareholders.

The interests of our Promoters may be different from or conflict with the interests of our other
shareholders and their influence may result in the delay or prevention of a change of management or
control of our Company, even if such a transaction may be beneficial to our other shareholders.

41. The average cost of acquisition of Equity Shares by our Promoters could be lower than the floor
price.

Our Promoters average cost of acquisition of Equity Shares in our Company may be lower than the
Floor Price of the Price Band as may be decided by the Company and the Selling Shareholders, in
consultation with the BRLM. For further details regarding average cost of acquisition of Equity Shares
by our Promoters in our Company and build-up of Equity Shares by our Promoters in our Company,
please refer to the chapters“ Prominent Notes” and “Capital Structure” beginning on pages 34 and 48,
respectively.

42. We will not receive any proceeds from this Offer.

As this Offer is an offer for sale of Equity Shares by the Selling Shareholders, the proceeds from this
Offer will be remitted to the Selling Shareholders and our Company will not benefit from such
proceeds. For further details, please refer to “Objects of the Offer” on page 57

43. The statistical and market information contained in this Draft Red Herring Prospectus relating to
India, the Indian Economy and the Vaccine Manufacturing Sector has been derived or extracted
from the IRR Report commissioned by us and from various government and other publicly available
publications.

The statistical and market information contained in this Draft Red Herring Prospectus relating to India,
the Indian economy and the diagnostic testing sector have been derived or extracted from the IRR
Report commissioned by us, and from government publications and reports from other publicly-
available publications that we believe are reliable. These statistics and market information include the
data and statistics included in the section “Industry Overview” on page 64. Investors should note that
IRR was engaged to prepare the IRR Report for use in this Draft Red Herring Prospectus.

IRR has advised that the statistical and other market information contained in the IRR Report and
reproduced in this Draft Red Herring Prospectus is drawn from sources that it considers reliable. As
this Draft Red Herring Prospectus contains information from an external industry report we do not
guarantee the accuracy, adequacy or completeness of the information and disclaim responsibility for
any errors or omissions in the information or for the results obtained from the use of the information.

Investors should also note that no independent verification has been carried out on any facts or statistics
that are directly or indirectly derived from official government publications, other publications, as well
as the IRR Report. We believe that the sources of the information are appropriate sources for such
information and have taken reasonable care in extracting and reproducing such information. We and
our affiliates or advisors or any other party involved in the Offer, other than IRR with respect to the
information contained in the IRR Report, make no representation as to the accuracy or completeness of
such information. Such statistics and other market information may not be consistent or comparable to
statistics compiled elsewhere and should not be unduly relied upon.

EXTERNAL RISK FACTORS

27
44. Our business is substantially affected by prevailing economic, political and other prevailing
conditions in India.

Our Company is incorporated in India, and our assets and employees are located in India. As a result,
we are highly dependent on prevailing economic conditions in India and our results of operations are
significantly affected by factors influencing the Indian economy. Factors that may adversely affect the
Indian economy, and hence our results of operations, may include:

 any increase in Indian interest rates or inflation;

 any exchange rate fluctuations;
 any scarcity of credit or other financing in India, resulting in an adverse impact on economic
conditions
 in India and scarcity of financing of our developments and expansions;
 prevailing income conditions among Indian consumers and Indian corporations;
 volatility in, and actual or perceived trends in trading activity on, India’s principal stock
exchanges;
 changes in India’s tax, trade, fiscal or monetary policies;
 political instability, terrorism or military conflict in India or in countries in the region or
globally, including in India’s various neighbouring countries
 occurrence of natural or man-made disasters;
 prevailing regional or global economic conditions, including in India’s principal export
markets; and
 other significant regulatory or economic developments in or affecting India or its
pharmaceutical sector.

High rates of inflation in India could increase our costs without proportionately increasing our
revenues, and as such decrease our operating margins. Any slowdown or perceived slowdown in the
Indian economy, or in specific sectors of the Indian economy, could adversely impact our business,
results of operations and financial condition and the price of the Equity Shares.

45. Communal disturbances, riots, terrorist attacks and other acts of violence or war involving India
and/or other countries could adversely affect India’s economy and the financial markets, result in
loss of client confidence, and adversely affect our business, financial condition, cash flows and
results of operations.

India has experienced communal disturbances, terrorist attacks and riots during recent years. Any
major hostilities or other acts of violence, including civil unrest or similar events that are beyond our
control, could have a material adverse effect on India’s economy and our business and may adversely
affect the Indian stock markets where our Equity Shares will trade as well as global equity markets
generally. Such acts could negatively impact business sentiment and consumer confidence, which could
adversely affect our business and profitability.

India and other countries may enter into armed conflict or war with other countries or extend pre-
existing hostilities. For example, neighbour countries in West and South Asia have experienced
instances of civil unrest and hostilities. Military activity or terrorist attacks could adversely affect the
Indian economy by, for example, disrupting communications and making travel more difficult. Such
events could also create a perception that investments in Indian companies involve a higher degree of
risk. This could adversely affect client confidence in India, which could have a negative impact on the
economies of India and other countries, on the markets for our products and services and on our
business. Additionally, such events could have a material adverse effect on the market for securities of
Indian companies, including the Equity Shares.

46. Health epidemics and natural calamities in Asia or elsewhere could adversely affect the Indian
economy or our business and the price of our Equity Shares.

Since 2003, outbreaks of Severe Acute Respiratory Syndrome in Asia, avian influenza across Asia and
Europe, Ebola virus in Western Africa, and Influenza A (H1N1) across the world have adversely
affected a number of countries and companies. Any future outbreak of infectious diseases or other
serious public health epidemics may have a negative impact on the economies, financial markets and
level of business activity in affected areas, which may adversely affect our Company’s business. India
has also experienced natural calamities such as earthquakes, floods, drought and a tsunami in the recent
past. In recent years, Chennai also faced floods. The length and severity of these natural disasters
determine the extent of their impact on the Indian economy. Prolonged spells of abnormal rainfall and

28
 other natural calamities could have an adverse impact on the Indian economy. Any future outbreak of
infectious disease among humans and/or animals or any other serious public health concerns or the
occurrence of any natural calamities could materially and adversely affect our business, prospects,
financial condition, cash flows and results of operations, and the price of our Equity Shares.

47. Changing laws, rules and regulations and legal uncertainties in India, including adverse application
of tax laws and regulations, may adversely affect our business and financial performance.

Our business and financial performance could be adversely affected by changes in law or
interpretations of existing, or the promulgation of new, laws, rules and regulations in India applicable
to us and our business. For further details please refer to the chapter “Government and Other
Approvals” on page 172 for details of the laws currently applicable to us. There can be no assurance
that the central or the state governments in India may not implement new regulations and policies
which will require us to obtain approvals and licenses from the central or the state governments in India
and other regulatory bodies or impose onerous requirements and conditions on our operations. Any
such changes and the related uncertainties with respect to the implementation of the new regulations
may have a material adverse effect on all our business, financial condition and results of operations. In
addition, we may have to incur capital expenditures to comply with the requirements of any new
regulations, which may also materially harm our results of operations. For instance, the Government
has proposed a comprehensive national goods and services tax , regime that will combine taxes and
levies by the Central and state Governments into a unified rate structure. Given the limited availability
of information in the public domain concerning the GST, we are unable to provide any assurance as to
the tax regime following implementation of the GST. The implementation of this new structure may be
affected by any disagreement between certain state Governments, which could create uncertainty. Any
such future amendments may affect our overall tax efficiency, and may result in significant additional
taxes becoming payable.

The Government has proposed major reforms in Indian tax laws, namely the goods and services tax,
and provisions relating to the GAAR. GAAR is proposed to be effective from April 1, 2017. The tax
consequences of the GAAR provisions being applied to an arrangement could result in denial of tax
benefit amongst other consequences. In the absence of any precedents on the subject, the application of
these provisions is uncertain. If the GAAR provisions are made applicable to our Company, it may
have an adverse tax impact on us. The goods and services tax would replace the indirect taxes on goods
and services such as central excise duty, service tax, customs duty, central sales tax, state VAT,
surcharge and excise currently being collected by the central and state governments. The GAAR
provisions intend to catch arrangements declared as “impermissible avoidance arrangements”, which is
any arrangement, the main purpose or one of the main purposes of which is to obtain a tax benefit and
which satisfy at least one of the following tests (i) creates rights, or obligations, which are not
ordinarily created between persons dealing at arm’s length; (ii) results, directly or indirectly, in misuse,
or abuse, of the provisions of the Income Tax Act, 1961; (iii) lacks commercial substance or is deemed
to lack commercial substance, in whole or in part; or (iv) is entered into, or carried out, by means, or in
a manner, which are not ordinarily employed for bona fide purposes. If GAAR provisions are invoked,
then the Indian tax authorities have wide powers, including denial of tax benefit or benefit under a tax
treaty. As the taxation system is intended to undergo significant overhaul, its consequent effects on us
cannot be determined at present and there can be no assurance that such effects would not adversely
affect our business and future financial performance.

We have not determined the impact of such proposed legislations on our business. Uncertainty in the
applicability, interpretation or implementation of any amendment to, or change in, governing law,
regulation or policy, including by reason of an absence, or a limited body, of administrative or judicial
precedent may be time consuming as well as costly for us to resolve and may impact the viability of
our current business or restrict our ability to grow our business in the future.

48. We may be affected by competition law in India and any adverse application or interpretation of the
Competition Act, 2002 (“Competition Act”) could adversely affect our business.

The Competition Act was enacted for the purpose of preventing practices that have or are likely to have
an adverse effect on competition in India and has mandated the Competition Commission of India
(“CCI”) to separate such practices. Under the Competition Act, any arrangement, understanding or
action, whether formal or informal, which causes or is likely to cause an appreciable adverse effect on
competition is void and attracts substantial penalties.

29
 Further, any agreement among competitors which directly or indirectly involves determination of
purchase or sale prices, limits or controls production, distribution, shares the market by way of
geographical area or number of subscribers in the relevant market is presumed to have an appreciable
adverse effect in the relevant market in India and shall be void. The Competition Act also prohibits
abuse of a dominant position by any enterprise. On March 4, 2011, the Government notified and
brought into force the combination regulation (merger control) provisions under the Competition Act
with effect from June 1, 2011. These provisions require acquisitions of shares, voting rights, assets or
control or mergers or amalgamations that cross the prescribed asset and turnover based thresholds to be
mandatorily notified to and pre-approved by the CCI. Additionally, on May 11, 2011, the CCI issued
the Competition Commission of India (Procedure for Transaction of Business Relating to
Combinations) Regulations, 2011 (as amended) which sets out the mechanism for implementation of
the merger control regime in India.

The Competition Act aims to, among others, prohibit all agreements and transactions which may have
an appreciable adverse effect in India. Consequently, all agreements entered into by us could be
within the purview of the Competition Act. Further, the CCI has extra-territorial powers and can
investigate any agreements, abusive conduct or combination occurring outside India if such agreement,
conduct or combination has an appreciable adverse effect in India. However, the impact of the
provisions of the Competition Act on the agreements entered into by us cannot be predicted with
certainty at this stage.

49. Foreign Investors are subject to foreign investment restrictions under Indian law that limits our
ability to attract foreign investors, which may adversely impact the market price of our Equity
Shares.

In terms of the Consolidated FDI Policy, foreign direct investment in Indian companies carrying on
brownfield investments (investments in existing companies) in the pharmaceuticals sector is permitted
up to100% subsequent to the approval of the Government and the satisfaction of certain conditions.
Foreign investment in our Company under the foreign portfolio investment and portfolio investment
scheme, as the case may be, cannot exceed 24%.

Also, under the foreign exchange regulations currently in force in India, transfers of shares between
non residents and residents are permitted (subject to certain exceptions) if they comply with, among
other things, the pricing guidelines and reporting requirements specified by the RBI. If the transfer of
shares does not comply with such pricing guidelines or reporting requirements, or falls under any of the
exceptions referred to above, then prior approval of the RBI will be required.

Additionally, shareholders who seek to convert the Rupee proceeds from sale of shares in India into
foreign currency and repatriate any such foreign currency from India will require a no objection or a
tax clearance certificate from the Indian income tax authority. We cannot assure you that any required
approval from the RBI or any other Government agency can be obtained on any particular terms or at
all.

50. Significant differences could exist between Indian GAAP, other accounting principles, such as US
GAAP and IFRS, which may affect investors assessment of our Company’s IND IFRS financial
condition.

We have not attempted to explain in a qualitative manner the impact of the IFRS or U.S. GAAP on the
financial information included in this Draft Red Herring Prospectus, nor do we provide a reconciliation
of our financial information to those of U.S. GAAP or IFRS. U.S. GAAP and IFRS differ in significant
respects from Indian GAAP. Indian GAAP differs from accounting principles with which prospective
investors may be familiar in other countries. Accordingly, the degree to which the financial information
included in this Draft Red Herring Prospectus will provide meaningful information is entirely
dependent on the reader’s level of familiarity with Indian accounting practices, Indian GAAP, the
Companies Act and the SEBI ICDR Regulations.

Accordingly, the degree to which the financial information included in this Draft Red Herring
Prospectus will provide meaningful information is dependent on your familiarity with Indian GAAP
and the Companies Act, 2013. Any reliance by persons not familiar with Indian GAAP on the financial
disclosures presented in this Draft Red Herring Prospectus should accordingly be limited.

51. Our failure to successfully adopt new accounting standard when required under Indian law could
have a material adverse effect on our stock price.

30
 Our Company may be required to prepare our annual and interim financial statements under new Indian
accounting standards that the Ministry of Corporate Affairs has announced will be implemented in
phases. Because there is significant lack of clarity on the adoption of and convergence with the new
Indian accounting standards and there is not yet a significant body of established practice on which to
draw in forming judgments regarding its implementation and application, we have not determined with
any degree of certainty the impact that such adoption will have on our financial reporting. There can be
no assurance that our financial condition, results of operations, cash flows or changes in shareholders'
equity will not appear materially worse under the new Indian accounting standards than under current
Indian GAAP. As we transition to reporting under the new Indian accounting standards, we may
encounter difficulties in the ongoing process of implementing and enhancing our management
information systems. Moreover, there is likely to be increasing competition for the small number of
IFRS experienced accounting personnel as the new Indian accounting standards have been derived
from IFRS. There can be no assurance that our adoption of new Indian accounting standards will not
adversely affect our reported results of operations or financial condition. Any failure to successfully
adopt new Indian accounting standards when required under Indian law could have a material adverse
effect on our stock price.

52. After this Offer, the Equity Shares may experience price and volume fluctuations or an active
trading market for the Equity Shares may not develop.

The price of the Equity Shares may fluctuate after this Offer as a result of various factors, including
volatility in the Indian and global securities markets, the results of our operations, the performance of
our competitors, significant developments in India’s economic fiscal, liberalization and deregulation
policies,adverse media reports and changes in developments in, perceptions in the market about
investments in or estimates by financial analysts of us and the Indian pharmaceutical industry.

There has been no public market for the Equity Shares prior to this Offer and an active trading market
for the Equity Shares may not develop or be sustained after this Offer. Further, the price at which the
Equity Shares are initially traded may not correspond to the prices at which the Equity Shares will trade
in the market subsequent to this Offer.

53. Future issuance of Equity Shares may dilute your shareholding and sales of the Equity Shares by
our Promoter or other major shareholders may adversely affect the trading price of the Equity
Shares.

We may be required to finance our growth through future equity offerings. Any future equity issuances
by us, including a primary offering, may lead to the dilution of investors’ shareholdings in our
Company. Any future equity issuances by us or sales of the Equity Shares by our Promoter or other
major shareholders may adversely affect the trading price of the Equity Shares, which may lead to
other adverse consequences for us including difficulty in raising capital through offering of the Equity
Shares or incurring additional debt. In addition, any perception by investors that such issuances or sales
might occur may also affect the market price of the Equity Shares.

54. You may not be able to sell immediately on an Indian stock exchange any of the Equity Shares you
purchase in the Offer.

Our Equity Shares will be listed on the Stock Exchanges. Pursuant to Indian regulations, certain actions
must be completed before the Equity Shares can be listed and trading may commence. Investor’ book
entry, or demat accounts, with depository participants in India are expected to be credited within two
working days of the date on which Allotment is approved by the Board.

We cannot assure you that the Equity Shares will be credited to investors demat accounts, or that
trading in the Equity Shares will commence, within the time periods specified above.

55. You may be subject to Indian taxes arising out of capital gains on sale of the Equity Shares.

Under current Indian tax laws, unless specifically exempted, capital gains arising from the sale of
Equity Shares in an Indian company are generally taxable in India. Any gain realized on the sale of
listed equity shares on a stock exchange held for more than 12 months will not be subject to capital
gains tax in India if Securities Transaction Tax (“STT”) has been paid on the transaction. STT will be
levied on and collected by a domestic stock exchange on which the Equity Shares are sold. Any gain
realized on the sale of equity shares held for more than 12 months, which are sold other than on a

31
 recognized stock exchange and on which no STT has been paid to an Indian resident, will be subject to
long term capital gains tax in India. Further, any gain realized on the sale of listed equity shares held
for a period of 12 months or less will be subject to short term capital gains tax in India. Capital gains
arising from the sale of the Equity Shares will be exempt from taxation in India in cases where the
exemption is provided under a treaty between India and the country of which the seller is resident.
Generally, Indian tax treaties do not limit India’s ability to impose tax on capital gains. As a result,
residents of other countries may be liable for tax in India as well as in their own jurisdiction on gain
upon the sale of the Equity Shares.

56. A decline in India’s foreign reserves may affect liquidity and interest rates in Indian economy,
which could adversely affect us.

A decline or future material decline in India’s foreign exchange reserves could impact the valuation of
the Rupee and could result in reduced liquidity and higher interest rates which could adversely affect
our financial condition and future financial performance.

57. Rights of shareholders under Indian laws may be more limited than under the laws of other
jurisdictions

Indian legal principles related to corporate procedures, directors’ fiduciary duties and liabilities, and
shareholders’ rights may differ from those that would apply to a company in another jurisdiction.
shareholders’ rights under Indian law, including those related to class actions, may not be as extensive
as shareholders’ rights under the laws of other countries or jurisdictions. Investors may have more
difficulty in asserting their rights as a shareholder in an Indian company than as a shareholder of a
corporation in another jurisdiction.

58. Investing in securities that carry emerging market risks can be affected generally by volatility in the
emerging markets.

The markets for securities bearing emerging market risks, such as risks relating to India, are influenced
by economic and securities market conditions in other emerging market countries to varying degrees.
Although economic conditions differ in each country, investors’ reactions to developments in one
country may affect securities of issuers in other countries, including India. Accordingly, the price and
liquidity of our Equity Shares may be subject to significant fluctuations, which may not necessarily be
directly or indirectly related to our financial performance.

59. Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under
Indian law and thereby may suffer future dilution of their ownership position.

Under the Companies Act, 2013 a company having share capital and incorporated in India must offer
its holders of equity shares pre-emptive rights to subscribe and pay for a proportionate number of
equity shares to maintain their existing ownership percentages before the issuance of any new equity
shares, unless the preemptive rights have been waived by adoption of a special resolution by our
company. However, if the laws of the jurisdiction in which the investors are located in do not permit
them to exercise their pre-emptive rights without our Company filing an offering document or
registration statement with the applicable authority in such jurisdiction, the investors will be unable to
exercise their pre-emptive rights unless our Company makes such a filing. If we elect not to file a
registration statement, the new securities may be issued to a custodian, who may sell the securities for
the investor’s benefit. The value the custodian receives on the sale of such securities and the related
transaction costs cannot be predicted. In addition, to the extent that the investors are unable to exercise
pre-emptive rights granted in respect of the Equity Shares held by them, their proportional interest in
our Company would be reduced.

60. Indian law limits our ability to raise capital outside of India and may limit the ability of others to
acquire us, which could prevent us from operating our business or entering into a transaction that is
in the best interests of our shareholders.

As an Indian company, we are subject to exchange controls that regulate borrowing in foreign
currencies. Such regulatory restrictions limit our financing sources for our business and could therefore
constrain our ability to obtain financing on competitive terms and refinance existing indebtedness. In
addition, we cannot assure you that any required regulatory approvals for borrowing in foreign
currencies will be granted to us without onerous conditions, or at all. Limitations on foreign debt may
have an adverse effect on our business growth, financial condition and results of operations.

32
61. Investors may have difficulty enforcing foreign judgments against us or our management.

We are a limited liability company incorporated under the laws of India. Substantially all of our
directors and executive officers are residents of India and a substantial portion of our assets and such
persons are located in India. As a result, it may not be possible for investors to effect service of process
upon us or such persons outside of India, or to enforce judgments obtained against such parties outside
of India. Recognition and enforcement of foreign judgments is provided for under Section 13 of CPC
on a statutory basis. Section 13 of the CPC provides that foreign judgments shall be conclusive
regarding any matter directly adjudicated upon, except: (i) where the judgment has not been
pronounced by a court of competent jurisdiction; (ii) where the judgment has not been given on the
merits of the case; (iii) where it appears on the face of the proceedings that the judgment is founded on
an incorrect view of international law or a refusal to recognise the law of India in cases to which such
law is applicable; (iv) where the proceedings in which the judgment was obtained were opposed to
natural justice; (v) where the judgment has been obtained by fraud; and (vi) where the judgment
sustains a claim founded on a breach of any law then in force in India. Under the CPC, a court in India
shall, upon the production of any document purporting to be a certified copy of a foreign judgment,
presume that the judgment was pronounced by a court of competent jurisdiction, unless the contrary
appears on record. Such presumption may be displaced by proving that the court did not have
jurisdiction.

India is not a party to any international treaty in relation to the recognition or enforcement of foreign
judgments. Section 44A of the CPC provides that where a foreign judgment has been rendered by a
superior court, within the meaning of that Section, in any country or territory outside of India which
the Indian central government has by notification declared to be in a reciprocating territory, it may be
enforced in India by proceedings in execution as if the judgment had been rendered by the relevant
court in India. However, Section 44A of the CPC is applicable only to monetary decrees, which are
dissimilar to amounts payable in respect of taxes, other charges of a like nature, a fine or other
penalties.

United States and India do not currently have a treaty providing for reciprocal recognition and
enforcement of judgments in civil and commercial matters, other than arbitration awards. Therefore, a
final judgment for the payment of money rendered by any federal or state court in the United States on
civil liability, whether or not predicated solely upon the federal securities laws of the United States,
would not be enforceable in India. However, the party in whose favour such final judgment is rendered
may bring a new suit in a competent court in India based on a final judgment that has been obtained in
the United States. The suit must be brought in India within three years from the date of the judgment in
the same manner as any other suit filed to enforce a civil liability in India.

It is unlikely that a court in India would award damages on the same basis as a foreign court if an
action was brought in India. Furthermore, it is unlikely that an Indian court would enforce a foreign
judgment if that court were of the view that the amount of damages awarded was excessive or
inconsistent with public policy or Indian practice. It is uncertain as to whether an Indian court would
enforce foreign judgments that would contravene or violate Indian law. However, a party seeking to
enforce a foreign judgment in India is required to obtain approval from the RBI under the Indian
Foreign Exchange Management Act, 1999, to execute such a judgment or to repatriate any amount
recovered.

62. We cannot assure you that our Equity Shares will be listed on the Stock Exchanges in a timely
manner or at all, which may restrict your ability to dispose of the Equity Shares.

In accordance with Indian law and practice, permission for listing of the Equity Shares will not be
granted until after the Equity Shares in this Issue have been allotted. Approval will require all other
relevant documents authorizing the sale of the Equity Shares to be submitted. There could be failure or
delays in listing the Equity Shares on the Indian Stock Exchanges.

The Equity Shares are proposed to be listed on the Indian Stock Exchanges. Further, pursuant to Indian
regulations, certain actions must be completed before the Equity Shares can be listed and trading can
commence. Investors’ “book entry”, or “demat”, accounts with Depository Participants are expected to
be credited with in certain days of the date on which the Basis of Allotment is approved by the
Designated Stock Exchange. Thereafter, upon receipt of final approval from the Designated Stock
Exchange, trading in the Equity Shares is expected to commence within 6 Working Days from Bid/
Offer Closing Date.

33
 We cannot assure you that the Equity Shares will be credited to the investors’ demat account, or that
the trading in the Equity Shares will commence in a timely manner or at all. Any failure or delay in
obtaining the approvals would restrict your ability to dispose of the Equity Shares.

PROMINENT NOTES

1. Offer of 1,45,79,560 Equity Shares for cash at in price band of [•] to [•] by way of an Offer of Sale by
the Selling Sharereholders, aggregating upto [•]. The Offer shall constitute upto 38% of the fully
diluted post-Offer paid up Equity Share Capital of the Company.

2. The Net Worth of the Company was ` 4,769.82 Lacs on restated basis as on June 30, 2016 and `
4,476.73 Lacs on a restated basis as on and March 31, 2016. Further, the Net Worth was ` 2527.02
Lacs as on March 31,2015 and ` 2548.36 Lacs as on March 31, 2014.

3. The Net Asset Value Per Equity Share on a restated basis was ` 12.43 on June 30, 2016 and ` 29.17,
` 18.62 and ` 18.78 on March 31, 2016, March 31, 2015 and March 31, 2014.

4. The average cost of acquisition per Equity Share by our Promoter Mr. P. Sundaraparipooranan is: `
25.64 before bonus and ` 12.44 after bonus. Dr. P. Murali has received all the shares through gift
therefore cost of Acquistionfor Dr. P. Murali is Nil. For details please refer to “Capital Structure” on
page 48.

For further details, please refer to the chapter “Capital Structure – Build Up of Promoters
Shareholding, Promoters Contribution and Lock-in” on page 50. The average cost of acquisition per
Equity Share by our Promoters has been calculated by taking the average of amounts paid by each our
Promoters to acquire Equity Shares.

5. During the period commencing from six months immediately preceding the date of filing of the Draft
Red Herring Prospectus, till date, no financing arrangements existed pursuant to which our Promoters,
Directors or their relatives have financed the purchase of Equity Shares by any other person.

6. The following are the changes to our name:

Our Company was incorporated as a Private Limited Company “Green Signal Bio Pharma Private
Limited” on November 21, 2005 at Chennai under the Companies Act, 1956. Pursuant to our Company
passing a resolution under section 13 (2), of the Companies Act 2013 on March 24, 2016, and upon
the issuance of a fresh certificate of incorporation consequent to the name change, the name of our
Company was changed to GreenSignal Bio Pharma Private Limited with effect from April 21, 2016.
Further, the shareholders of our Company passed a resolution dated March 24, 2016 and the Company
was changed to a Public Limited Company with effect from May 12, 2016

There have been no changes to the objects of our Company except as disclosed in this Draft Red
Herring Prospectus.

7. Any clarification or information relating to the Offer shall be made available by the BRLM and our
Company to the investors at large and no selective or additional information would be available for a
section of investors in any manner whatsoever. Investors may contact the BRLM who have submitted
the due diligence certificate to SEBI for any complaints pertaining to the Offer.

34
 SECTION III: INTRODUCTION
SUMMARY OF INDUSTRY

Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. The last decade saw
significant advances in developing, introducing and expanding the reach of vaccines globally. During the 20th
century, the average human life span has increased by approximately 30 years, a significant portion of which has
been attributed directly to vaccination. More people than ever before were vaccinated, resulting in significant
achievements, including the near eradication of polio and significant reductions in deaths caused by vaccine-
preventable diseases (diphtheria, measles, neonatal tetanus, pertussis).Around 2 million deaths among children under
5 years of age are prevented annually despite an increase in birth cohorts every year.

The Indian vaccine industry began as a work of state-owned manufacturers supplying basic childhood vaccines to
the national immunization program. In recent decades, the number of privately owned firms active in the sector has
grown rapidly. Their success in brining low cost vaccine solutions to public vaccine markets is an important driver
behind the emergence of the sector. The industry is now able to produce new and more complex vaccines such as the
meningitis, Haemophilusinfluenzae type b, and pneumococcal conjugate vaccines, rotavirus vaccine and influenza
A (H1N1) vaccines, aided by attractive investment environment, governmental support, international partnerships
and the growing technical work force. The vaccine industry has also been supplying a large share of basic vaccines
to a number of developing countries, and is now exporting more advanced vaccines as well. From a public health
perspective, it is a significant contribution that our industry has made, by bringing down prices and keeping them
low. Even though price will continue to play an important role, the industry is now in a translational phase, moving
from a ‘price- driven’ to an ‘innovation-driven’ model.

Though vaccines have transformed public health throughout the world, for children in particular, the burden of
vaccine-preventable diseases in India is still substantial and hence the usage of this powerful tool is still not optimal
in our country. The Indian vaccines market has a lot of ground to cover in terms of the potential to substantially
increase lives saved by improving access to the types of vaccines available and the depth of coverage of those
vaccines across the country. So for individual players in the vaccines space, the Indian healthcare presents new vistas
of growth, provided challenges in terms of policy barriers, lack of awareness and affordability issues are successfully
tackled.

The Biotechnology sector is among one of the sectors which have highlighted the profile of the country in the last
decade. At the beginning of the decade itself, this industry began to take shape with the sprouting of dozens of start-
up innovation companies as well as the diversification of established Pharma players by setting up biotech divisions,
to focus on this segment. Biotechnology is a highly interdisciplinary field that combines biological sciences with
computational, chemical as well as engineering technologies to manipulate living organisms or their components to
aid simplified and economical processes to produce products that advances healthcare, medicine, agriculture, food,
pharmaceuticals and environment control.

Biotechnology can be classified into two broad categories: R&D and discovery of new services and new products in
Biological Sciences and Industrial Processes. Being multidisciplinary in nature, the category biological sciences
encompasses subjects ranging from computational biology to microbiology, cell biology, genetics, molecular
biology, pharmaceuticals etc. for understanding the basic pathology of illness and treatment of diseases including
new drug development, development of agriculture, food production, protection of the environment, waste disposal,
and many more. The industrial processes aspect deals with the processes of production of drugs, vaccines, biofuels,
pharmaceuticals, engineered industrial enzymes, biodegradable polymers, on an industrial scale using biochemical
processes and techniques.

With numerous comparative advantages in terms of research and development (R&D) facilities, knowledge, skills,
and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.
Some of the best innovations and developments that have come out of Biotechnology and allied fields include:
genomic sequencing technology, better understanding of various pathologies, novel and improved diagnostic
systems, production of new biopharmaceuticals , procedure to develop vaccine that are more effective, natural
alternatives to pesticides, better yielding and resistant crops, production of biofuels, production of industrial enzymes
that are engineered for better activity, biodegradable polymers, and developments in stem cells technology.

Growing at a CAGR of 20 percent, the Indian Biotechnology Industry has evolved rapidly over the last three
decades. India’s biotech sector is currently valued at over USD7bn, having grown at a CAGR of ~20% over the last
decade. India is already ranked among the top 12 biotech destinations worldwide and third largest in the Asia Pacific
region. Biotechnology in India has already made a significant impact in agricultural, industrial, pharmaceutical and
medical sectors. The year-on-year growth of the biotech market is expected to accelerate driven by high demand for
vaccines, bio pesticides, bio fertilizers, biodiesel, bio therapeutics and medical devices in India as well as at the
global level.

35
 SUMMARY OF BUSINESS

The global vaccines market is expected to reach USD57bn by 2019 from USD33bn in 2014, growing at a
CAGR of 11.8% from 2014 to 2019. Among various end users, the paediatrics segment is expected to account
for the largest share of the market with highest CAGR growth during 2014 to 2019. On the back of strong focus
of the Government on increasing the immunization activities across the country, increasing awareness,
availability of affordable vaccines, the Indian vaccine industry is expected to continue to grow a t a CAGR of
12-15% over the next five years.

India is one of the largest manufacturers and exporters of vaccines world-wide, with 12 major vaccine
manufacturing facilities. These vaccines are used for the national and international markets (150 countries),
which makes India a major vaccine supplier across the globe. UN agencies and partnerships such as UNICEF,
UNFPA , UNITAID, the Global Fund and the GAVI Alliance facilitate the supply of life-saving quality assured
medicines and vaccines to millions of patients in resource-limited countries across the world. These agencies
only buy products that have been through the WHO Prequalification Scheme, which ensures that medicines,
vaccines and diagnostics meet international standards of quality, safety and efficacy. India has about seven
vaccine manufacturers producing 67 prequalified vaccines (dosage forms). Currently 16 vaccines are
prequalified by WHO and exported through United Nations agencies. More than 70% of all measles vaccines
used globally are produced in India. Nearly a third of prequalified vaccines, and over two thirds of medicines
purchased through these international organizations are produced in India.

We are one of the four companies worldwide who have been WHO-prequalified to supply the BCG vaccine to
UNICEF. And we have secured a long term arrangement dated November 23, 2015 with UNICEF to supply the
BCG vaccine to UNICEF subject to the purchase orders placed with our company. We also supply the BCG
vaccine to the Ministry of Health, India pursuant to the tendering process, in which we have placed successful
bids since the year 2010 (except for years 2013-14 and 2014-15). We also supply the BCG vaccine to
Indonesia, and Nepal which are countries outside the UNICEF ambit. Our BCG-ONCO for Immunotherapy
drug is distributed throughout India vide commercial arrangements in India and we intend to market this
immunotherapy drug in overseas jurisdictions as well. Presently, we have made several limited supplies to
various countries such Lebanon, Saudi Arabia, Turkey and Switzerland.

We are an Indian vaccine manufacturing company with global operations. As on date we produce two products:

1. BCG Vaccine for immunization against Tuberculosis

2. BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of Urinary Bladder Carcinoma
and our brand name for the same is ‘Urovac’.

As both vaccines produced by us are generic drugs we do not require any patents for the same, however we have
procured a registered trademark for our BCG ONCO for Immunotherapy drug, name, ‘Urovac’.

Our business is organized into domestic (i.e. Indian) and international operations, according to the geographies
in which we operate. For fiscal year 2016, our domestic and international operations accounted for 53.80% and
46.20%, respectively, of our net revenues from operations. Our consolidated net revenues from operations grew
at a CAGR of 210.70% in the period from fiscal year 2015 to fiscal year 2016.

We have a manufacturing facility located at Pappankuppam Village, Gummidipoondi, Tiruvallur District, Tamil
Nadu equipped with advanced equipment dedicated for the manufacturing of live attenuated BCG Vaccine and
the BCG-ONCO for immunotherapy.

36
 SUMMARY FINANCIAL INFORMATION

The following tables set forth summary financial information derived from:

The Restated Financial Statements of our Company, prepared in accordance with Indian GAAP and the
Companies Act, 1956 and 2013 as applicable and restated in accordance with the SEBI ICDR Regulations as at
for the period ended June 30, 2016 and for the fiscal year ended 31, 2016, 2015, 2014, 2013 and 2012.

The Restated Financial Statements referred to above are presented under the section “Financial Information”
on page 124. The summary financial information presented below should be read in conjunction with the
Restated Financial Statements, the notes thereto and the sections entitled “Financial Statements” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 124
and 149, respectively.

RESTATED STATEMENT OF ASSETS AND LIABILITIES

Particulars As on 2016 2015 2014 2013 2012

June 30,
2016
` in Lacs
A EQUITY AND LIABILITIES
1. Shareholders’ funds
0
(a) Share capital 3,836.73 1,534.69 1,357.35 1,357.35 1,357.35 1,357.35
(b) Reserves and surplus 2,129.33 4,138.28 2,365.91 2,221.01 2,350.72 2,400.73
5,966.06 5,672.97 3,723.26 3,578.36 3,708.07 3,758.08
Share application money pending 762.19 698.23
allotment
2. Non-current liabilities
0
(a) Long-term borrowings - 2.67 399.68
(b) Deferred tax liabilities (net) 317.46 313.95 292.59 272.55 248.75 215.91
Total of Non Current Liabilities 317.46 313.95 292.59 272.55 251.42 615.59
3. Current liabilities
0
(a) Short-term borrowings 387.61 558.07 392.32 398.45 657.96 537.60
(b) Trade payables 107.22 89.46 33.76 25.57 1.38 32.27
(c) Other current liabilities 321.45 299.72 1,425.05 1,419.57 6.46 76.31
Total of Current Liabilities 816.28 947.25 1,851.13 1,843.59 665.80 646.18
TOTAL 7,099.80 6,934.17 5,866.98 5,694.50 5,387.48 5,718.08
B ASSETS
1. Non-current assets
0
(a) Fixed assets
(i) Tangible assets 3,873.09 3,892.44 3,979.67 3,648.69 3,761.48 3,868.27
(ii) Capital work-in-progress 1,146.79 1,146.79 1,159.67 1,124.16 1,000.63 849.81
Total Non Current Assets 5,019.88 5,039.23 5,139.34 4,772.85 4,762.11 4,718.08
2. Current assets
0
(b) Inventories 693.29 738.50 529.70 491.75 477.82 617.87
(c) Trade receivables 867.88 472.32 71.02 342.79 76.28 278.63
(d) Cash and cash equivalents 286.34 404.15 65.26 (0.61) (3.10) 11.78
(e) Short-term loans and advances 232.41 279.97 61.66 87.72 74.37 91.72
(f) Other current assets - - - -
Total of Current Assets 2,079.92 1,894.94 727.64 921.65 625.37 1,000.00

TOTAL 7,099.80 6,934.17 5,866.98 5,694.50 5,387.48 5,718.08

37
 RESTATED STATEMENT OF PROFIT AND LOSS

Particulars For the period 2016 2015 2014 2013 2012

ended on June 30,
2016
` in Lacs
A CONTINUING OPERATIONS
1 Revenue from operations (gross) 1014.70 2,038.72 656.16 350.99 1,167.78 1,126.58
Less: Excise duty - - - - - -
Revenue from operations (net) 1014.70 2,038.72 656.16 350.99 1,167.78 1,126.58
2 Other income 5.85 10.53 4.13 1.81 2.02 -
3 Total revenue (1+2) 1,020.55 2,049.25 660.29 352.80 1,169.80 1,126.58
4 Expenses
(a) Cost of materials consumed 135.73 573.90 160.05 77.27 265.66 348.38
(b) Changes in inventories of 162.43 (164.39) 25.25 (8.15) 138.91 77.57
finished goods, work-in-progress
and stock-in-trade
(c) Operations Cost 74.49 200.91 64.31 50.33 130.60 142.35
(d) Employee benefits expense 88.81 172.00 106.42 61.82 219.10 127.67
(e) Finance costs 12.36 66.41 71.15 116.07 158.13 210.89
(f) Depreciation and amortisation 30.39 119.17 115.10 112.79 112.55 112.33
expense
(g) Other expenses 143.79 387.49 119.30 48.58 162.02 112.37
Total expenses 648.00 1,355.49 661.58 458.71 1,186.97 1,131.56
5 Restated Profit / Loss before 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
exceptional and extraordinary items
and tax (3 - 4)
6 Exceptional items - - - - -
7 Restated Profit / Loss before 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
extraordinary items and tax (5 + 6)
8 Extraordinary items - - - - -
9 Restated Profit / Loss before tax (7 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
+ 8)
10 Tax expense:
(a) Current tax expense for current 75.95 141.45 - - - -
year
(b) (Less): MAT credit (where - - - - - -
applicable)
(c) Current tax expense relating to - - - - - -
prior years
(d) Net current tax expense 75.95 141.45 - - - -
(e) Deferred tax 3.51 21.36 20.04 23.80 32.84 43.13
Total Tax Expense 79.46 162.81 20.04 23.80 32.84 43.13
11 Restated Profit / (Loss) from 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
continuing operations (9 +10)
12 Restated Profit / (Loss) for the year 293.09 530.95 (21.33) (129.71) (50.01) (48.11)

38
 RESTATED STATEMENT OF CASH FLOW

As on June 2016 2015 2014 2013 2012

PARTICULARS 30, 2016
` in Lacs
A. Cash flow from Operating Activities
Net profit as per Profit and loss account 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
ADJUSTMENTS FOR
Depreciation in books 30.39 119.17 115.10 112.79 112.55 112.33
Preliminary expenditure written off
Deferred Tax 3.51 21.36 20.04 23.80 32.84 43.13
Share Issue Expenses written off
Provision for Income tax & FBT 75.95 141.45 - - - -
Operating cash flows before adjusting for working 402.94
capital changes 812.93 113.81 6.88 95.38 107.35
Adjustment for Working Capital changes - - - -
Decrease/(Increase) in Sundry debtors (395.56) (401.30) 271.77 (266.51) 202.35 (233.73)
Decrease/(Increase) In other Current assets (92.77) (427.11) (11.88) (27.28) 157.40 76.92
Increase / (Decrease) in Current liabilities and
provisions (206.92) (1,045) 7.53 1,177.78 (100.73) 26.77
Operating cash flow after Adjusting for working
Capital changes (106.77) (1,060.81) 381.23 890.87 354.40 (22.69)
Net Cash Flow from operating activities – A (107.77) (1,060.81) 381.23 890.87 354.40 (22.69)
B. Cash Flow from Investing Activities
Purchase of Fixed Assets (11.04) (31.94) (279.85) - (5.76) (11.87)
Capital Work in Progress - 12.88 (35.51) (123.53) (150.82) (146.23)
Net cash From Investing activities – B (11.04) (19.06) (315.36) (123.53) (156.58) (158.10)
C. Cash flow from Financing Activities
Proceeds from Bank Loans - - (2.66) (276.65) (266.72)
Proceeds from issue of shares - 1,418.76 (762.19) 63.95 443.30
Net Cash Flow From Financing Activities – C - 1,418.76 - (764.85) (212.70) 176.58
Net Increase in cash and Cash equivalents (A + B
+ C) (117.81) 338.89 65.87 2.49 (14.88) (4.21)
Add: Cash and cash equivalents at the beginning of
the year 404.15 65.26 (0.61) (3.10) 11.78 15.99
Cash and cash equivalents at the end of the year 286.34 404.15 65.26 (0.61) (3.10) 11.78
(a) Cash on hand 3.81 1.52 1.75 0.11 0.17 0.13
(c) Balances with banks
(i) In current accounts 13.92 179.81 0.78 (0.72) (3.27) 11.65
(i) In deposit accounts 256.83 221.67 62.73 - - -
Interest accrued thereon 11.78 1.15 - - - -
Total 286.34 404.15 65.26 (0.61) (3.10) 11.78

39
 THE OFFER

Offer for Sale of Equity Shares Upto 1,45,79,560 Equity Shares aggregating to `
14,57,95,600 lacs1
Of which
Offer for sale by P Sundaraparipooranan Upto 81,69,430 Equity Shares2
Offer for sale by P. Murali Up to 33,91,980 Equity Shares3
Offer for sale by Avon Cycles Limited Up to 23,75,000 Equity Shares4
Offer for sale by R. Srinivasan Up to 19,000 Equity Shares5
Offer for sale by Mallika Murali Upto 6,24,150 Equity Shares6
The offer consist of
A) QIB Portion 1,09,34,670
Of which Anchor Portion 65,60,802
Balance available for allocation to QIBs other than 43,73,868
Anchor Investors (assuming Anchor Investor Portion
is fully subscribed)
Of which
Available for allocation to Mutual Funds only (5% of 2,18,693
the QIB Portion, excluding the Anchor Investor
Portion)
Balance of QIB Portion for all QIBs including Mutual 41,55,175
Funds
B) Non-Institutional Portion 21,86,934
C) Retail Portion 14,57,956
Pre-Offer and Post-Offer Equity Shares
Equity Shares outstanding prior to the Offer and after 38,36,72,750
the Offer
1. Offer has been authorised by Board of Directors vide resolution dated May 23, 2016.
2. Offer for sale of up to 81,69,430 Equity Shares by P Sundaraparipooranan has been authorised through consent letter dated May 23,
2016.
3. Offer for sale of up to 33,91,980 Equity Shares by P. Murali has been authorised through consent letter dated May 23, 2016.
4. Offer for sale of up to 23,75,000 Equity Shares by Avon Cycle Limited has been authorised through Resolution of Board of Avon Cycle
Limited dated May 23, 2016.
5. Offer for sale of up to 19,000 Equity Shares by R. Srinivasan has been authorised through consent letter dated May 23, 2016.
6. Offer for sale of up to 6,24,150 Equity Shares by Mallika Murali has been authorised through consent letter dated May 23, 2016.

Allocation to Bidders in all categories, except the Retail Portion and the Anchor Investor Portion, if any, shall be
made on a proportionate basis subject to valid Bids received at or above the Offer Price.

For details of the Offer procedure, including the grounds for rejection of Bids, please refer to “Offer
Procedure” on page 193. For details of the terms of the Offer, please refer to “Terms of the Offer” on page
185.

40
 GENERAL INFORMATION

Our Company was incorporated as a Private Limited Company “Green Signal Bio Pharma Private Limited”
on November 21, 2005. Pursuant to our Company passing a resolution under Section 13 of the Companies Act,
2013 and Rule 29 of the Companies (Incorporation) Rules, 2014 on March 24, 2016 and upon the issuance of
a fresh certificate of incorporation dated April 21, 2016 consequent to the name change, the name of our
Company was changed to GreenSignal Bio Pharma Private Limited. Further, the shareholders of our Company
passed a resolution dated March 24, 2016 under Section 18 of the Companies Act, 2013 Company was
changed to a Public Limited Company with effect from May 12, 2016. For further details relating to
incorporation, corporate structure, please refer chapter “History and Certain other Corporate Matters” on page
106. The CIN of our Company is U24232TN2005PLC058068.

Registered Office

Old No.5, New No.13/A3,

Sai Nikethan, Circular Road,
United India Colony,
Kodambakkam, Chennai 600 024.
Tamil Nadu, India.
Telephone No: +91 44 2472 2244
Fax No: +91 44 2472 2233
Website: www.gsbpl.com
Registration Number: 58068
Corporate Identity Number: U24232TN2005PLC58068

Address of the RoC

Registrar of Companies, Chennai, Tamil Nadu
Block No.6, “B” Wing,
2nd Floor, 26 Shastri Bhawan,
Chennai- 600 034.
Tamil Nadu, India.

Board of Directors

Our Board of Directors comprises of:

Name Designation DIN Address

Mr. N. Gopalaswami Chairman, Non Executive, 02779229 Flat No.5, Leo Madhuram, 39 Giri Road, T
Independent Director Nagar, Chennai 600 017.
Dr. P. Murali Managing Director 02277738 No.215, ICC 5th Street, W Block, B Sector, Anna
Nagar West Extn, Chennai 600 101.
Mr. E. S. Executive Director 02377328 Flat No.3, Orchid Krish Aruna, No.7, 31 st Cross
Chandrasekaran St, Besant Nagar, Chennai 600 090.
Dr. P. Perumalsamy Non-Executive Independent 07497868 No.86, 2nd Main Road, Mogappair West Garden,
Director Nolambur, Chennai 600 037.
Mrs. Lakshmi V Iyer Non-Executive Independent 07498857 No.29, Block I, Sindur Green Park, Jayachandran
Director Nagar, Jalandanpet, Chennai 600 100.

For further details of our Board of Directors, please refer to the Chapter “Our Management – Board of
Directors” on page 109.

Chief Financial Officer

Mr. E. Mullaivalavan
Old No.5, New No.13/A3,
Sai Nikethan, Circular Road,
United India Colony,
Kodambakkam, Chennai 600 024.
Tamil Nadu, India.
Telephone No: +91 44 2472 2244
Fax No: + 91 44 24722233
E Mail: [email protected]

41
Company Secretary and Compliance Officer

Ms. S. Rathna Prabha

Old No.5, New No.13/A3,
Sai Nikethan, Circular Road,
United India Colony,
Kodambakkam, Chennai 600 024.
Tamil Nadu, India.
Telephone No: +91 44 2772 2244, Extn. 25
Fax No: +91 44 2472 2233
E Mail: [email protected]

Bidders can contact the Compliance Officer, the Registrar to the Offer or the BRLM, in case of any pre-
Offer or post-Offer related problems, such as non-receipt of Allotment Advice, credit of allotted shares in
the respective beneficiary account or refund orders, etc.

Bidders may contact the Book Running Lead Managers for complaints, information or clarifications pertaining
to the Offer.

All grievances other than of Anchor Investors may be addressed to the Registrar to the Offer with a copy to the
relevant Designated Intermediary with whom the ASBA Form was submitted. The Bidder should give full
details such as name of the sole or first Bidder, ASBA Form number, Bidder DP ID, Client ID, PAN, date of the
ASBA Form, address of the Bidder, number of the Equity Shares applied for and the name and address of the
Designated Intermediary where the ASBA Form was submitted by the Bidder.

Further, the investor shall also enclose the Acknowledgment Slip from the Designated Intermediaries in addition
to the documents/information mentioned hereinabove.

All grievances of the Anchor Investors may be addressed to the Registrar and Share Transfer Agent to the offer,
giving full details such as the name of the sole or first Bidder, Anchor Investor Application Form number, Bidders DP
ID. Client ID, PAN, date of the Anchor Investor Application Form, address of the Bidder, number of the Equity
Shares applied for, Bid Amount paid on submission of the Anchor Investor Application Form and the name and
address of the Book Running Lead Manager where the Anchor Investor Application Form was submitted by the
Anchor Investor. Further, with respect to the Bid cum Application Forms submitted with the Registered Brokers, the
Bidder shall also enclose the acknowledgement from the Registered Broker in addition to the document or
information mentioned hereinabove.

Book Running Lead Manager to the Offer

INDIAN OVERSEAS BANK

Merchant Banking Division,
763, Anna Salai,
Chennai- 600 002
Tel.: + 91 44 2851 9548/ 2888 9367;
Email: [email protected]
Investor Grievance Email:[email protected]
Website: www.iob.in
Contact Person: (i) Mrs. B. Gomathy/Mrs. S. Chandra, Merchant Banking Division, Chennai
(ii) Mr.Muralidharan, Capital Market Services Branch, Mumbai
Tel: + 91 22 226 22017/2262 2018
Compliance Officer: Mrs. B. Gomathy
SEBI Registration No: INM000001386

Registrar to the Offer

BIGSHARE SERVICES PRIVATE LIMITED

E2 Ansa Industrial Estate, Sakivihar Road, Sakinaka
Andheri East, Mumbai – 400 072
Tel: + 91 22 4043 0200;
Facsimile: + 91 22 2847 5207
Email: [email protected];
Investor Grievance Email: [email protected]
Website: www.bigshareonline.com

42
Contact Person: Mr. Ashok Shetty
SEBI Registration No.: INR000001385

Auditor to the Company

M/s. RAJ AND RAVI, Chartered Accountants

New 7 A, Plot No.16, Ganesh Nagar 2nd Street,
Adambakkam, Chennai 600 088.
Firm Registration Number: 10935S

Bankers to the Company

Union Bank of India Kotak Mahindra Bank

New No.42, Old No.51 Sri Sai Building, # 337
Thirumalai Road Arcot Road, Kodambakkam
T. Nagar, Chennai 600017. Chennai – 600 024
Tel: + 91 44 2346 0811 Tel : + 91 44 43587800/05

Indian bank
4/12, Trustpuram III cross
Kodambakkam
Chennai – 600 024
Tel: +91 44 24843531

Legal Counsel to the Offer

MVKini, Law Firm

Kini House, 261-263,
Near Citi Bank
D.N. Road. Fort,
Mumbai-400 001

Escrow Banker to the Offer

[]

Refund Bank

[]

Syndicate Members

[]

Credit Rating

As this Offer is an offer for sale of the Equity Shares, there is no credit rating for this Offer.

Monitoring Agency

The Offer being an offer for sale, our Company will not receive any proceeds from the Offer and is not required
to appoint a monitoring agency for the Offer.

IPO Grading

No credit rating agency registered with SEBI has been appointed for grading the Offer.

Appraising Entity

None of the objects for which the Offer Proceeds will be utilised have been appraised by any agency.

43
Trustees

The Offer being an offer for sale of the Equity Shares, the appointment of trustees is not required.
.
Experts

Except for the report of our Auditors on the restated standalone financial statements and the Statement Of Tax
Benefits included in this Draft Red Herring Prospectus on pages 124 and 60, respectively, our Company has
not obtained any expert opinion. However, the term “expert” shall not be construed to mean an “expert” as
defined under the U.S. Securities Act.

Our Company has received consent from M/s. RAJ AND RAVI, Chartered Accountants, to include in the Draft
Red Herring Prospectus, and report dated July 2, 2016 the statement of tax benefits available. For details, please
refer to “Statement of Tax Benefits” on page 60.

Statement of Responsibilities for the Offer

The following table sets forth the responsibilities of the BRLM in relation to this Offer.

S. No. Activity
1. Capital Structuring with relative components and formalities such as type of instruments, etc.
2. Due diligence of Company's operations / management / business plans / legal etc. Drafting and design
of Draft Red Herring Prospectus, Red Herring Prospectus including memorandum containing salient
features of the Prospectus. The BRLM shall ensure compliance with stipulated requirements and
completion of prescribed formalities with the Stock Exchanges, RoC and SEBI including finalization
of Prospectus and RoC filing, follow up and coordination till final approval from all regulatory
authorities
3. Drafting and approval of all statutory advertisement
4. Drafting and approval of all publicity material other than statutory advertisement as mentioned in 3
above including media monitoring, corporate advertisement, brochure etc.
5. Appointment of other intermediaries viz., Registrar's, Printers, Advertising Agency and Bankers to the
Offer
6. International institutional marketing strategy
 Preparation of road show presentation
 Finalize the list and division of investors for one to one meetings, in consultation with the
Company, and
 Finalize the list and division of investors for one to one meetings, in consultation with the
Company, and Finalizing the International road show schedule and investor meeting schedules
7. Domestic institutions / banks / mutual funds marketing strategy
 Finalize the list and division of investors for one to one meetings, institutional allocation in
consultation with the Company.
 Finalizing the list and division of investors for one to one meetings, and
 Finalizing investor meeting schedules
8. Non-Institutional and Retail marketing of the Offer, which will cover, inter alia,
 Formulating marketing strategies, preparation of publicity
 budget
 Finalize Media and PR strategy
 Finalizing centres for holding conferences for press and brokers
 Finalising collection centres;
 Follow-up on distribution of publicity and Offer material including form, prospectus and
deciding on the quantum of the Offer material
9. Co-ordination with Stock Exchanges for Book Building software, bidding terminals and mock trading.
10. Coordination with Stock-Exchanges for payment of 1% security deposit through cash and bank guarantee
11. Finalization of pricing, in consultation with the Company
12. Post-issue activities, which shall involve essential follow-up steps including follow-up with bankers to
the issue and Self Certified Syndicate Banks to get quick estimates of collection and advising the issuer
about the closure of the issue, based on correct figures, finalisation of the basis of allotment or weeding
out of multiple applications, listing of instruments, dispatch of certificates or demat credit and refunds

44
 and coordination with various agencies connected with the post-issue activity such as registrars to the
issue, bankers to the issue, Self Certified Syndicate Banks etc. Including responsibility for
underwriting arrangements, as applicable.

Self Certified Syndicate Banks

The list of banks that have been notified by SEBI to act as the SCSBs for the ASBA process is provided on the
website of SEBI at http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries. For details of
the Designated Branches which shall collect Bid cum Application Forms, please refer to the above-mentioned
link.

Registered Brokers

The list of the Registered Brokers, including details such as postal address, telephone number and e-mail
address, is provided on the websites of the BSE and the NSE at www.bseindia.com and www.nseindia.com,
respectively, as updated from time to time.

Registrar to Offer and Share Transfer Agents

The list of the RTAs eligible to accept Bid cum Applications forms at the Designated RTA Locations, including
details such as address, telephone number and e-mail address, are provided on the websites of BSE and the NSE
at www.bseindia.com and www.nseindia.com, respectively, as updated from time to time.

Collecting Depository Participants

The list of the CDPs eligible to accept Bid cum Application Forms at the Designated CDP Locations, including
details such as name and contact details, are provided on the websites of BSE and the NSE at
www.bseindia.com and www.nseindia.com, respectively, as updated from time to time.

The list of branches of the SCSBs named by the respective SCSBs to receive deposits of the Bid cum
Application Forms from the Designated Intermediaries will be available on the website of the SEBI
(www.sebi.gov.in) and updated from time to time.

Book Building Process

The book building, in the context of the Offer, refers to the process of collection of Bids on the basis of the Red
Herring Prospectus within the Price Band, which will be decided by our Company and the Selling Shareholders,
in consultation with the BRLM, and advertised at least five Working Days prior to the Bid/Offer Opening Date.
The Offer Price shall be determined by our Company and the Selling Shareholders in consultation with the
BRLM after the Bid/Offer Closing Date.

Subject to valid Bids being received at or above the Offer Price pursuant to the Net Offer is being made for at
least 25% of the post-Offer paid-up Equity Share capital of our Company. The Offer is being made through the
Book Building Process, wherein not less than 75% of the Net Offer will be available for allocation to QIBs on a
proportionate basis, provided that our Company and the Selling Shareholders may, in consultation with the
BRLM, allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Offer Price to the
Anchor Investor, on a discretionary basis subject to valid bids being received at Anchor Investor Offer Price.
Further, not more than 15% of the Net Offer will be available for allocation on a proportionate basis to Non-
Institutional Investors, subject to valid Bids being received at or above the Offer Price and not more than 10% of
the Net Offer will be available for allocation to Retail Individual Investors in accordance with SEBI ICDR
Regulations, subject to valid Bids being received at or above the Offer Price. Allotment of Equity Shares to each
of the Retail Individual Investors shall not be less than the minimum Bid Lot, subject to availability of Equity
Shares in the Retail Portion and the remaining available Equity Shares, if any, shall be allotted on a
proportionate basis. Any unsubscribed portion in any reserved category shall be added to the Net Offer. In case
of under-subscription, if any, in Non-Institutional and Retail Individual categories, the under subscription would
be allowed to be met with spill over inter-se from any other categories, at the discretion of our Company and
Selling Shareholders in consultation with the BRLM and subject to applicable provisions of SEBI ICDR
Regulations. However, under-subscription in the Net QIB Portion would not be allowed to be met with spill-
over from any other category.

All Bidders (excluding Anchor Investors) can participate in the Offer only through the ASBA process.
Anchor Investors are not permitted to participate through the ASBA process.

45
In accordance with the SEBI ICDR Regulations, QIBs bidding in the QIB Portion and Non-institutional
Bidders bidding in the Non-Institutional Portion are not allowed to withdraw or lower the size of their
Bids (in terms of the quantity of the Equity Shares or the Bid Amount) at any stage. Retail Individual
Bidders can revise or withdraw their Bids prior to the Bid/Offer Closing Date. Further, Anchor Investors
cannot withdraw their Bids after the Anchor Investor Bid/Offer Period. Except Allocation to Retail
Individual Investors and the Anchor Investors, Allocation in the Offer will be on a proportionate basis.

For further details, see section entitled “Offer Procedure” on page 193
.
Our Company will comply with the SEBI ICDR Regulations and any other directions issued by SEBI for this
Offer. In this regard, our Company and the Selling Shareholders have appointed the BRLM to manage the Offer
and procure purchases for the Offer.

The process of Book Building under the SEBI ICDR Regulations and the ASBA process is subject to change
from time to time and the investors are advised to make their own judgment about investment through this
process prior to making a Bid or application in the Offer.

Illustration of Book Building Process and Price Discovery Process

Investors should note that this example is solely for illustrative purposes and is not specific to the Offer; it also
excludes bidding by Anchor Investors.

Bidders can bid at any price within the price band. For instance, assume a price band of ₹ 20 to ₹ 24 per share,
offer size of 3,000 equity shares and receipt of five bids from bidders, details of which are shown in the table
below. A graphical representation of the consolidated demand and price would be made available at bidding.

Bid Quantity Bid Price Cumulative Quantity Subscription (%)

500 24 500 16.7
1,000 23 1,500 50.0
1,500 22 3,000 100.0
2,000 21 5,000 166.7
2,500 20 7,500 250.0

The price discovery is a function of demand at various prices. The highest price at which the issuer is able to
issue the desired number of equity shares is the price at which the book cuts off, i.e., ` 22 in the above
example. The issuer and the Selling Shareholders, in consultation with the Book Running Lead Manager will
finalise the issue price at or below such cut-off price, i.e., at or below ` 22. All bids at or above this issue price
and cut-off bids are valid bids and are considered for allocation in the respective categories.

Notwithstanding the foregoing, the Offer is also subject to obtaining (i) the final approval of the Registrar of
Companies after the Prospectus is filed with the Registrar of Companies; and (ii) final listing and trading
approvals of the Stock Exchanges, which our Company shall apply for after Allotment.

Underwriting Agreement

After the determination of the Offer Price and allocation of the Equity Shares, but prior to filing of the
Prospectus with the Registrar of Companies, our Company and the Selling Shareholders intend to enter into an
Underwriting Agreement with the Underwriters for the Equity Shares proposed to be offered through the Offer.

It is proposed that pursuant to the terms of the Underwriting Agreement, the BRLM shall be responsible for
bringing in the amount devolved in the event that the Syndicate Members do not fulfil their underwriting
obligations. The Underwriting Agreement is dated [●]. Pursuant to the terms of the Underwriting Agreement,
the obligations of the Underwriters are several and are subject to certain conditions specified therein.

The Underwriters have indicated their intention to underwrite the following number of the Equity Shares:

This portion has been intentionally left blank and will be filled in before filing of the Prospectus with Registrar
of Companies.

Name, address, telephone Indicative Number of the Equity Amount Underwritten

number, fax number and e-mail Shares to be Underwritten (₹ In lacs)
of the Underwriters

46
 [•] [•] [•]

The abovementioned underwriting commitments are indicative and will be finalised after pricing of the Offer
and actual allocation and subject to the provisions of Regulation 13(2) of the SEBI ICDR Regulations.

In the opinion of the Board of Directors (based on certificates provided by Underwriters), resources of the
above-mentioned Underwriters are sufficient to enable them to discharge their respective underwriting
obligations in full. The above-mentioned Underwriters are registered with SEBI under Section 12(1) of the
SEBI Act or registered as stock brokers with the Stock Exchanges. The Board of Directors/ Committee of
Directors, has accepted and entered into the Underwriting Agreement on behalf of our Company.

Allocation among the Underwriters may not necessarily be in proportion to their underwriting commitment set
forth in the table above.

Notwithstanding the above table, the BRLM and the Syndicate Members shall be severally responsible for
ensuring payment with respect to the Equity Shares allocated to Bidders procured by them. In the event of any
default in payment, the respective Underwriter, in addition to other obligations defined in the Underwriting
Agreement, will also be required to procure purchases for or purchase the Equity Shares to the extent of the
defaulted amount in accordance with the Underwriting Agreement.

47
 CAPITAL STRUCTURE

The Equity Share Capital of our Company as on the date of this Draft Red Herring Prospectus is set forth below:

Sl. No. Particulars Aggregate Value at Face Aggregate Value at Offer

Value of ` 10 each Price
A. Authorised Share Capital
4,00,00,000 Equity Shares 40,00,00,000

B. Issued, Subscribed and Paid Up Capital

before the Offer
3,83,67,275 Equity Shares 38,36,72,750

C. Present Offer
1,45,79,560 Equity Shares 14,57,95,600 [•]

D Issued, Subscribed and Paid Up Capital

after the Offer
3,83,67,275 Equity Shares 38,36,72,750

E Share Premium Account

Before the Offer 5,95,07,500
After the Offer 5,95,07,500

The Equity Shares offered by the Selling Shareholders in the offer are eligible for being offered for sale in terms
of Regulation 26(6) of the SEBI ICDR Regulations. The Offer for Sale has been authorised by the Selling
Shareholders as follows:

Sl. No. Name of the Selling Shareholder Number of Equity Date of the consent
Shares offered letter and offer letter
1 P. Sundaraparipooranan 81,69,430 May 23, 2016
2 P. Murali 33,91,980 May 23, 2016
3 Avon Cycles Limited 23,75,000 May 23, 2016
4 R. Srinivasan 19,000 May 23, 2016
5 Mallika Murali 6,24,150 May 23, 2016
TOTAL 1,45,79,560

The offer has been authorised by the Board of Directors pursuant to the resolution dated May 23, 2016

Changes in the Authorised Share Capital of our Company

The changes in the Equity Share Capital of our company are provided in the following table:

Date No of Equity Cumulative Authorised Face Value Details of changes

Shares No. Of Equity Share Capital (in ` )
increased Shares (in ` )
November 21, 2005 50,000 50,000 5,00,000 10 Initial Authorised Share
Capital out of which 10,000
shares were allotted
March 29, 2007 1,99,50,000 2,00,00,000 20,00,00,000 10 Increase in the Authorised
Share Capital
May 02, 2016 2,00,00,000 4,00,00,000 40,00,00,000 10 Increase in the Authorised
Share Capital

Notes to Capital Structure

1. Equity Share Capital History of our Company

48
 a. The history of the equity share capital and share premium account of our Company is
provided for in the following table:

Date of No. of Face Issue Reason for Consideration Cumulative Cumulative Cumulative
allotment Equity Value Price Allotment No. of Paid up Securities
Shares Equity equity Premium
Allotted shares capital
Novembe 10,000 10 10 Initial Cash 1,00,000 1,00,000 -
r 21, 2005 Subscription
to MoA
March 6,17,000 10 50 Preferential Cash 62,70,000 62,70,000 2,46,80,000
28,2008 Allotment(1)
64,73,000 10 10 Preferential Cash 7,10,00,000 7,10,00,000
Allotment(2)
January 29,23,460 10 10 Preferential Cash 10,02,34,600 10,02,34,600
30, 2010 Allotment(3)
4,00,000 10 50 Conversion Cash 10,42,34,600 10,42,34,600 4,08,80,000
of loan(4)
5,000 10 50 Preferential Cash 10,42,84,600 10,42,84,600
Allotment(5)
April 01, 15,00,000 10 50 Conversion Cash 11,92,84,600 11,92,84,600 9,97,69,650*
2010 of loan(6)
1,45,000 10 50 Preferential Cash 12,07,34,600 12,07,34,600 10,55,69,650
Allotment(7)
March 01, 15,00,000 10 50 Preferential Cash 13,57,34,600 13,57,34,600 16,55,69,650
2011 Allotment(8)
March 26, 17,73,450 10 80 Preferential Cash 15,34,69,100 15,34,69,100 28,97,11,150
2016 Allotment(9)
May 2, 2,30,20,365 10 NA Bonus(10) Bonus 38,36,72,750 38,36,72,750 5,95,07,500#
2016
* After deduction for Preliminary Expenses of ` 11,10,350/- incurred before incorporation of the Company.
# After issue of Bonus Shares by capitalization of Reserves.

(1) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Meeting held on March 28, 2008.
(2) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Meeting on March 28, 2008.
(3) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Resolution held on January 30, 2010.
(4) The company has allotted equity shares on conversion of a loan, as authorised by the Board through a
resolution dated January 30, 2010.
(5) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Resolution held on January 30, 2010.
(6) The company has allotted equity shares on conversion of a loan, as authorised by the Board through a
resolution dated April 1, 2010.
(7) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Meeting held on April 1, 2010.
(8) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
Resolution held on March 1, 2011.
(9) Preferential Allotment has been authorised by our shareholders through a resolution passed in the Board
resolution held on March 26, 2016.
(10) Bonus issue in the ratio of 3:2 to the then existing Shareholders, authorised by our shareholders through a
resolution passed at the AGM held on May 2, 2016.

b. As on date of this Draft Red Herring Prospectus, our Company has not issued any Preference
Shares.
2. Our Company has not allotted any shares in terms of any scheme approved under sections 391-
394 of the Companies Act, 1956.
3. Our Company has not revalued its assets, except as disclosed below:

The Company has revalued the land held by it to an extent of 34.01 acres in Kunnavalam Village,
Thiruvallur District during the financial year 2014-15. The land was revalued to ` 459.20 Lacs as per

49
 the prevailing guideline value. The revaluation was done for administrative purposes and the same was
reflected in the financial statements for the year ended March 31, 2015.

4. Our Company has not issued any Equity Shares at a price which may be lower than the Offer
Price in the preceding one year from the date of the Draft Red Herring Prospectus

5. Details of shares allotted for consideration other than cash

The company has allotted the following shares for a consideration other than cash:

Date of allotment No. of Equity Shares Face Value Issue Price Reason for Allotment
Allotted
May 2, 2016 2,30,20,365 10 NA Bonus(3)
(1) Bonus issue in the ratio of 3:2 to the then existing Shareholders, authorised by our shareholders through a
resolution passed at the AGM held on May 2, 2016

6. Build-up of Promoters Shareholding, Promoters Contribution and Lock-in

As on date of this Draft Red Herring Prospectus, our Promoters hold 30363500 Equity shares,
constituting 79.14% of the issued, subscribed and paid-up Equity Share Capital of our Company. The
details regarding our Promoter’s Shareholding in our Company is set below:

A. Build-Up of Equity Shares held by our Promoters in our company

1. Mr. P. Sundaraparipooranan

Sl. Date of Nature of Number of Face Issue Price Details of

No. allotment/ Transaction equity Value per Equity Pledged Equity
transfer shares Share Shares
1 November 21, Cash 9,900 10 10.00 None
2005
2 August 03, 2006 Gift(1) (10) 10 No None
consideration
3 March 28, 2008 Preferential 59,63,100 10 10.00 None
Allotment in
Cash
4 January 30, 2010 Preferential 27,56,460 10 10.00 None
Allotment in
Cash
5 April 01, 2010 Preferential 15,00,000 10 40.00 None
Allotment in
Cash
6 April 01, 2010 Preferential 1,45,000 10 40.00 None
Allotment in
Cash
7 September 29, Gift(2) (59,73,000) 10 No None
2010 consideration
8 March 26, 2016 Gift(3) 24,00,000 10 No None
consideration
9 March 26, 2016 Purchase(4) 20,000 10 10.00 None
10 March 26, 2016 Preferential 17,73,450 10 80.00 None
Allotment
11 May 2, 2016 Bonus issue in 1,28,92,350 10 0.00 None
the ratio of 3:2
(1) Equity shares gifted to Mr. Ilayaraja.
(2) Equity Shares are gifted by Mr. P. Sundaraparipooranan to his brother Dr. P. Murali.
(3) 24,00,000 Equity Shares gifted to Mr. P. Sundaraparipooranan by his brother Dr. P. Murali.
(4) 20000 Equity Shares are purchased from Ms.B. Dhakshayani by Mr. P. Sundaraparipooranan.
(5) The company has made a Preferential Allotment of 1,773,450 Equity Shares at the premium to Mr.P.
Sundaraparipooranan.

50
2. Dr. P. Murali

Sl. Date of allotment/ Nature of Number of Face Value Issue Price Details of
No. transfer Transaction equity (`) per Equity Pledged
shares Share ((`) Equity Shares
1 September 29, 2010 Gift(1) 59,73,000 10 0.00 None
2 March 26, 2016 Gift(2) (24,00,000) 10 0.00 None
3 March 26, 2016 Cash (2,500) 10 80.00 None
4 May 23, 2016 Bonus issue in the 53,55,750 10 0.00 None
ratio of 3:2
(1) Equity Shares are received by Dr. P. Murali as gift from Mr. P. Sundaraparipooranan.
(2) 2400000 Equity shares gifted to Mr. P. Sundaraparipooranan by Dr. P. Murali

All the equity shares were fully paid-up at the time of allotment

B. Details of the Shareholding of our Promoters and Promoter Group

The table below presents the Shareholding Pattern of our Promoters and Promoter
Group as on date of this Draft Red Herring Prospectus

Sl. Name of the Pre-Offer Post-Offer No. Of Equity

No. Shareholder No. Of Equity % of No. Of % of Shares
Pledged
Share holding Equity Share holding
1 P. Sundaraparipooranan 2,14,87,250 56.00 1,33,17,820 34.71 -
2 P. Murali 89,26,250 23.27 55,34,270 14.42 -
3 Mallika Murali 16,42,500 4.28 10,18,350 2.65 -
Total 32,0,56,000 83.55 1,98,70,440 51.79 -

C. Details of Equity Shares offered as Offer for Sale by the Selling Shareholders

The following Shareholders are offering for sale an aggregate of 1,45,79,560 Equity Shares in
this Offer pursuant to the consent letters issued to our Board of Directors:

Sl. Name of the Shareholder Category No. Of Equity No. Of Date of the
No. Shares held as on Equity Consent Letter
date of this Draft Shares
Red Herring Offered
Prospectus
1 P. Sundaraparipooranan Promoter 2,14,87,250 81,69,430 May 23, 2016
2 P. Murali Promoter 89,26,250 33,91,980 May 23, 2016
3 Mallika Murali Promoter Group 16,42,500 6,24,150 May 23, 2016
4 Avon Cycles Limited Public 62,50,000 23,75,000 May 23, 2016
5 R Srinivasan Public 50,000 19,000 May 23, 2016
Total 38,356,000 14,579,560

The Equity shares being offered in this Offer by the Selling Shareholders are eligible for
being offered for sale in accordance with Regulation 26(6) of SEBI ICDR Regulations.
The bonus share which are being offered for sale in the Offer (i) have been issued out of
share premium existing in the books of accounts as at March 31, 2016 and (ii) have not
been issued by utilization of revaluation reserves or unrealized profits of the Company.
D. Details of Promoter’s contribution locked-in for three years

Pursuant to the SEBI ICDR Regulations, an aggregate of 20% of the fully diluted post-Offer
Equity Share capital of our Company held by our Promoters shall be locked in as minimum
Promoters’ contribution for a period of three years from the date of Allotment and our
Promoters’ shareholding in excess of 20% shall be locked in for a period of one year. The
Equity Shares that are being locked-in are not ineligible for computation of Promoters’
contribution under Regulation 33 of the SEBI ICDR Regulations. In this connection, our
Company confirms the following:

51
 i) The Equity Shares offered for minimum 20% Promoters’ contribution have not been
acquired in the last three years for consideration other than cash and revaluation of
assets or capitalization of intangible assets or bonus shares out of revaluation
reserves, or unrealised profits of our Company or from a bonus issue against Equity
Shares which are otherwise ineligible for computation of Promoters’ contribution;

ii) The Company has not been formed by the conversion of a partnership firm into a
company;

iii) The Equity Shares offered towards Promoters’ contribution does not include any
Equity Shares acquired during the preceding one year at a price lower than the price
at which the Equity Shares are being offered to the public in the Offer except as
stated below:

iv) All the Equity Shares held by the Promoters are in dematerialized form and the
Equity Shares being offered towards minimum Promoter’s contribution are not
subject to any pledge.
v) Other Equity shares offered shall also be applicable to the one year lock in period.

The details of the Equity Shares which are eligible for lock-in towards minimum Promoter’s
contribution for a period of three years from the Date of Allotment are set out in the following
table:

Sl. Name of Promoter No. Of Equity Face % of

No. Shares Value Pre Offer Post Offer
Capital Capital**
1 P. Sundaraparipooranan 72,67,820 10 18.94 14.31
2 P. Murali 55,34,270 10 14.43 5.69
Total 1,28,02,090 10 33.37 20.00
**subject to the finalization of the Basis of Allotment

Our Promoters have confirmed to our Company and the BRLM that all Equity Shares that
have been allotted or acquired by our Promoters and eligible to be offered towards minimum
Promoters’ contribution have been financed from own funds of the Promoters and that no
loans were availed for such purpose.
For details of the build-up of our Promoters shareholding, please refer to “Build-Up of Equity
Shares held by our Promoters” on page 50 of this Draft Red Herring Prospectus.
Our Promoters have confirmed to our Company and the BRLM that all Equity Shares that
have been allotted or acquired by our Promoters and eligible to be offered towards minimum
Promoters’ contribution have been financed from own funds of the Promoters and that no
loans were availed for such purpose.

The minimum Promoters’ contribution has been brought to the extent of not less than the
specified minimum lot and from persons defined as ‘Promoter’ under the SEBI ICDR
Regulations. All Equity Shares offered as minimum Promoters’ contribution were fully paid-
up at the time of their Issue.

E. Other Requirements in respect of Lock-in

In addition to 20% of the fully diluted post-Offer shareholding of our Company held by our
Promoters and locked in for three years as specified above and except the Equity Shares
offered by the Selling Shareholders in the Offer, the entire pre-Offer equity share capital of
our Company, will be locked-in for a period of one year from the date of Allotment.

The Equity Shares held by our Promoters which are locked-in from the date of Allotment as
mentioned above may be pledged only with scheduled commercial banks or public financial
institutions as collateral security for loans granted by such banks or public financial
institutions, provided that such pledge of the Equity Shares is one of the terms of the sanction
of such loans.

The Equity Shares held by our Promoters which are locked-in may be transferred to and
amongst the Promoter Group entities or to any new promoter or persons in control of our
Company, subject to continuation of the lock-in in the hands of the transferees for the
remaining period and compliance with the SEBI Takeover Regulations, as applicable.

52
 The Equity Shares held by persons other than our Promoters and locked-in for a period of one
year from the date of Allotment in the Offer may be transferred to any other person holding
the Equity Shares which are locked-in, subject to the continuation of the lock-in in the hands
of transferees for the remaining period and compliance with the SEBI Takeover Regulations.

Balance of the Equity Shares offered as part of the Offer and remaining unsold shall be
locked-in for one year.

F. Lock-in of Equity Shares allotted to Anchor Investors

Equity Shares allotted to the Anchor Investors in the Anchor Investor Portion shall be locked-
in for a period of 30 days from the date of Allotment.

7. Shareholding Pattern of our Company

The table below represents the Shareholding Pattern of our Company as on date of this Draft Red
Herring Prospectus:

Category Category of No. of No. of fully No. of No. of Total nos Shareholding
(I) Shareholder Shareholders paid up partly shares shares held as a % of
(II) (III) equity paid up underlying (VII) = total no. of
shares equity Depository (IV)+(V)+(VI) shares
held shares Receipt (VI) (calculated as
(IV) held per SCRR,
(V) 1957) (VIII)
As a % of
A+B+C )
1 2 3 4 5 6 7 8
A Promoter & 3 3,20,56,000 0 0 3,20,56,000 83.55%
Promoter
Group
B Public 5 63,11,275 0 0 63,11,275 16.45%
C Non Promoter 0 0 0 0 0 0
Non Public
C1 Shares 0 0 0 0 0 0
underlying
DRs
C2 Shares held by 0 0 0 0 0 0
Employee
Trusts
Total 8 3,83,67,275 3,83,67,275 100.00

Number of Voting Rights held in each class No. of Shareholdin Number of Number of Number of
of securities shares g as a % Locked in Shares equity shares
(IX) Under- assuming full Shares Pledged or held in
lying conversion of (XII) otherwise dematerialize
Outstand convertible encumbered d form
- ing securities (XIII) (XIV)
No. of Voting Rights Total as converti- (as a % of No. As a No. As a
Class X Cl Total a % of ble diluted share (a) % of (a) % of
ass (A+B+C securities capital ) total total
eg. ) (include- (XI) = share share
Y ing (VII)+(X) As s held s held
Warrants a % of (b) (b)
) (A+B+C2)
(X)
9 10 11 12 13 14 15 16 17 18 19
3,20,56,000 0 3,20,56,000 83.55% 0 83.55% 0 0 0 0 3,20,56,000
6311275 0 63,11,275 16.45% 0 16.45% 0 0 0 0 63,11,275
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0

53
 0 0 0 0 0 0 0 0 0 0 0
38367275 0 3,83,67,275 100.00 100.00 3,83,67,275

The list of public shareholders holding more than 1% of the Pre-Offer paid-up capital of our Company is given
below:

S. No. Name of the Shareholder No. of Equity Shares Percentage (%)

1 Avon Cycles Limited 62,50,000 16.29
Total 62,50,000 16.29

8. Equity Shares held by Top Ten Shareholders

a) On date of this Draft Red Herring Prospectus

Sl. No. Name of the Shareholder No. of Equity Shares Percentage (%)
1 P. Sundaraparipooranan 2,14,87,250 56.00
2 P. Murali 89,26,250 23.27
3 Avon Cycles Limited 62,50,000 16.29
4 Mallika Murali 16,42,500 4.28
5 R. Srinivasan 50,000 0.13
6 Madhu Kataria 6,250 0.02
7 E. S. Chandrasekaran 5,000 0.01
8 Ilayaraja 25 0.00
Total 3,83,67,275 100.00

b) Ten days prior to the date of this Draft Red Herring Prospectus

Sl. No. Name of the Shareholder No. of Equity Shares Percentage (%)
1 P. Sundaraparipooranan 2,14,87,250 56.00
2 P. Murali 89,26,250 23.27
3 Avon Cycles Limited 62,50,000 16.29
4 Mallika Murali 16,42,500 4.28
5 R. Srinivasan 50,000 0.13
6 Madhu Kataria 6,250 0.02
7 E. S. Chandrasekaran 5,000 0.01
8 Ilayaraja 25 0.00
Total 3,83,67,275 100.00

c) Two years prior to the date of this Draft Red Herring Prospectus

S. No. Name of the Shareholder No. of Equity Shares Percentage (%)

1 P. Sundaraparipooranan 44,01,450 32.43
2 P. Murali 59,73,000 44.00
3 Avon Cycles Limited 25,00,000 18.42
4 Mallika Murali 6,57,000 4.84
5 B Dhakshayini 20,000 0.15
6 R. Srinivasan 20,000 0.15
7 Arjun Chandrasekaran 2,000 0.01
8 Ilayaraja 10 0.00
Total 1,35,73,460 100.00

54
9. Our Company, Promoters, Promoter Group, our Directors and the BRLM have not entered into any
buyback and/ or standby arrangements and or any other similar arrangements for the purchase of
Equity Shares being offered through this Offer.

10. Neither the members of our Promoter Group, nor our Promoters, nor our Directors and their relatives
have sold or purchased or financed the purchase of Equity Shares by any other person, other than in the
normal course of business of the financing entity during the period of six months immediately
preceding the date of filing of the Draft Red Herring Prospectus with SEBI. However our Promoters,
Directors and their relatives have been involved in the following transfers in the six months
immediately preceding the date of filing of the Draft Red Herring Prospectus with SEBI:

Sl. Name of the Date of No. of Equity Transfer Transferee Reasons

No. Transferor Transfer Shares Price per for
transferred Equity Transfer
Share
1 P. Murali March 26, 24,00,000 0.00 P. Sundaraparipooranan Gift
2016
2 P. Murali March 26, 2,500 80.00 Madhu Kataria Sale
2016
3 E. S. March 26, 5,000 10.00 Arjun Chandrasekaran Transfer
Chandrasekaran 2016

11. There has been no subscription to or sale or purchase/transfer of the Equity Shares, within three years
preceding the date of filing of this Draft Red Herring Prospectus, by our Promoters or Directors or
Promoter Group, which in aggregate equals to or is greater than 1% of the pre-Offer Equity Share
capital of our Company except between Mr. P. Sundaraparipooranan and Dr. P. Murali. For details
please refer to “Capital Structure” on page 48.

12. As on the date of this Draft Red Herring Prospectus there are no outstanding warrants, financial
instruments or any rights, which would entitle the Promoters, Promoter Group or the shareholders or
any other person any option to acquire/ receive any Equity Shares after the Offer.

13. As on the date of this Draft Red Herring Prospectus, our Company has not allotted any Equity Shares
pursuant to any scheme approved under Sections 391 to 394 of the Companies Act, 1956.

14. Our Company has not raised any bridge loans against the proceeds of the Offer as the same is not
applicable since the Offer is a pure offer for sale.

15. The Equity Shares are fully paid-up and there are no partly paid-up Equity Shares as on date of this
Draft Red Herring Prospectus. The Equity Shares allotted pursuant to this Offer shall be fully paid-up.

16. Our Company shall not make any further issue of Equity Shares and/ or any securities convertible into
Equity Shares, whether by way of issue of bonus shares, preferential allotment, rights issue or in any
other manner, during the period commencing from filing of the Draft Red Herring Prospectus with
SEBI until the Equity Shares have been listed on the Stock Exchanges.

17. Our Company currently does not intend or propose to alter its capital structure for a period of six
months from the Bid/ Offer Opening Date, by way of split or consolidation of the denomination of
Equity Shares or, further issue of Equity Shares (including issue of securities convertible into or
exchangeable, directly or indirectly for Equity Shares) whether on a preferential basis or by way of
issue of bonus issue or on a rights basis or by way of further public issue of Equity Shares or qualified
institutional placements or otherwise.

18. There shall be only one denomination of the Equity Shares, unless otherwise permitted by law.

19. Except, for the sale of Equity Shares in the Offer, our Promoters will not participate in the Offer.

20. Our Company does not have any employee stock option plan.

21. Total numbers of shareholders of our Company as on the date of this Draft Red Herring Prospectus is
8.

55
22. As on the date of this Draft Red Herring Prospectus, none of the Equity Shares of our Company are
subject to pledge.

23. No person connected with the Offer, including, but not limited to, the BRLM, the members of the
Syndicate, our Company, our Promoters, Promoter Group, the Selling Shareholders, the Directors, and
the KMPs, shall offer any incentive, whether direct or indirect, in any manner, whether in cash or kind
or services or otherwise to any Bidder for making a Bid.

24. Our Company has not issued any Equity Shares out of its revaluation reserves.

25. Our Company has not made any public issue of its Equity Shares or rights issue of any kind since its
incorporation.

26. As on the date of this Draft Red Herring Prospectus, neither the BRLM nor their associates (in
accordance with the definition of “associate company” as provided under section 2(6) of the
Companies Act, 2013) hold any Equity Shares.

27. Save and except as stated below none of our Directors have any shareholding in our Company as on the
date of this Draft Red Herring Prospectus:

Sl. No. Name of the Director Designation No. of Equity Percentage (%)
Shares
1 P. Murali Managing Director 89,26,250 23.27
2 E. S. Chandrasekaran Executive Director 5,000 0.01

28. The Net Offer is being made for at least 25% of the post-Offer paid-up Equity Share capital of our
Company. The Offer is being made through the Book Building Process, wherein not less than 75% of
the Net Offer will be available for allocation to QIBs on a proportionate basis, provided that our
Company and the Selling Shareholders may, in consultation with the BRLM, allocate up to 60% of the
QIB Portion to Anchor Investors at the Anchor Investor Offer Price to the Anchor Investor, on a
discretionary basis subject to valid bids being received at Anchor Investor Offer Price. Further, not
more than 15% of the Net Offer will be available for allocation on a proportionate basis to Non-
Institutional Investors, subject to valid Bids being received at or above the Offer Price and not more
than 10% of the Net Offer will be available for allocation to Retail Individual Investors in accordance
with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price.
Allotment of Equity Shares to each of the Retail Individual Investors shall not be less than the
minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining
available Equity Shares, if any, shall be allotted on a proportionate basis. Any unsubscribed portion in
any reserved category shall be added to the Net Offer. In case of under-subscription, if any, in Non-
Institutional and Retail Individual categories, the under subscription would be allowed to be met with
spill over inter-se from any other categories, at the discretion of our Company and Selling Shareholders
in consultation with the BRLM and subject to applicable provisions of SEBI ICDR Regulations.
However, under-subscription in the Net QIB Portion would not be allowed to be met with spill-over
from any other category.

29. A Bidder cannot make a Bid for more than the number of Equity Shares offered through the Offer,
subject to the maximum limit of investment prescribed under relevant laws applicable to each category
of Bidder. For further details, please refer to “Offer Procedure – Who Can Bid?” on page 194.

30. An oversubscription to the extent of 10% of the Offer can be retained for the purposes of rounding off
to the nearer multiple of minimum allotment lot.

31. Our Company shall ensure that transactions in the Equity Shares by the Promoters between the date of
Registering the Red Herring Prospectus with the RoC and the Bid/ Offer Closing Date, if any, shall be
reported to the Stock Exchanges within 24 hours of such transaction.

56
 OBJECTS OF THE OFFER

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the BSE and the NSE and to
carry out the sale of up to 14,579,560 Equity Shares by the Selling Shareholders. Further, our Company
expects that the listing of the Equity Shares will enhance our visibility and brand image among our existing and
potential customers and provide liquidity to the existing shareholders. The listing of the Equity Shares will also
provide a public market for the Equity Shares in India. Our Company will not receive any proceeds of the Offer
and all the proceeds will go to the Selling Shareholders.

Offer Expenses

The total offer expenses of the Offer are estimated to be approximately ` [•] Lacs. The expenses of this Offer
include, among others, listing fees, underwriting and management fees, printing and distribution expenses,
advertisement expenses and legal fees, as applicable. The offer expenses except listing fees will be paid by
Selling Shareholders, in case Company has to pay certain expenses same shall be reimbursed by the Selling
Shareholders. The estimated Offer expenses are as follows:

Activity Estimated As a % of the total As a % of the

Expenses* estimated total Offer
expenses** Size***
Book Running Lead Manager (including [•] [•] [•]
underwriting commission, brokerage and selling
commission)
Commission And Processing Fee For SCSBs And [•] [•] [•]
Bankers to the Offer
Brokerage and Selling commission for Registered [•] [•] [•]
Brokers, RTA’s and CDPs etc.
Fees to Registrar and Share Transfer Agent to the [•] [•] [•]
Offer
Other advisors to the Offer [•] [•] [•]
Bankers to the Offer
Other Expenditure – Listing Fees, Printing & [•] [•] [•]
Stationery expenses, Advertising, Marketing etc.
TOTAL ESTIMATED OFFER EXPENSES [•] [•] [•]

*To be completed after finalization of the Offer Price

** TheSCSBs would be entitled to a processing fees of ₹ [●] per Bid cum Application Form, for processing
the Bid cum Application Forms procured by the members of the Syndicate or the Registered Brokers and
submitted to the SCSBs.
***Registered Brokers, the RTAs and the CDPs will be entitled to a commission of ₹[●] per every valid Bid
cum Application Form submitted to them

Monitoring of Utilization of Funds

Since the offer is an offer for sale and our Company will not receive any proceeds from the Offer, our Company
is not required to appoint a monitoring agency for the Offer.

57
 BASIS FOR THE OFFER PRICE

The Offer Price will be determined by our Company and the Selling Shareholders in consultation with the
BRLM, on the basis of assessment of market demand for the Equity Shares offered through the Book Building
Process and on the basis of qualitative and quantitative factors as described below. The face value of the Equity
Shares is ` 10 and the Offer Price is [•] times the face value at the lower end of the Price Band and [•] times the
face value on the higher end of the Price Band.

Bidders should also refer to “Risk Factors” ,“Our Business”, and “Financial Statements” on pages 14, 82 and
124 respectively, to have an informed view before making an investment decision.

QUALITATIVE FACTORS

Some of the qualitative factors which form the basis for the Offer Price are:

1. Niche Products
2. Strong Order Book
3. Impeccable Track Record in Research and Compliances
4. Strong Research and Development Capabilities
5. Fast Growing international operations
6. Experienced Founders and Professional Management Team

For further details, please refer to “Our Business – Competitive Strengths” on page 88.

QUANTITATIVE FACTORS

Information presented in this chapter is derived from the Restated Financial Information of our Company.

1. Basic and Diluted EPS

Fiscal Year Ended Basic EPS (`)* Diluted EPS (`)* Weight
March 31,2016 3.90 3.90 3
March 31,2015 (0.16) (0.16) 2
March 31,2014 (0.96) (0.96) 1
#
Weighted Average 1.74 1.74 6
Period ended June 30, 1.17 1.17
2016**
* Based on restated financial statements of our Company
#
derived by multiplication of weight with their respective EPS dividend by sum of weights.
**Not annualised

2. P/E Ratio in relation to the floor price of ` [•] per Equity Share and a cap price of [•] per
Equity Share

Particulars Ratio
P/E Ratio based on basic EPS for Fiscal Year 2016 at the Floor Price [•]
P/E Ratio based on diluted EPS for Fiscal Year 2016 at the Floor Price [•]

Particulars Ratio
P/E Ratio based on basic EPS for Fiscal Year 2016 at the Cap Price [•]
P/E Ratio based on diluted EPS for Fiscal Year 2016 at the Cap Price [•]

3. RoNW

Fiscal Year Ended RONW (%) Weight

March 31,2016 11.86 3
March 31,2015 (0.84) 2
March 31,2014 (5.09) 1
Weighted Average# 4.80 6

58
 Period ended June 30, 6.14
2016
#
derived by multiplication of weight with their respective RoNW dividend by sum of weights.

4. Net Asset Value per Equity Share (adjusted for Bonus issue)

Particulars Restated
March 31,2016 29.17
March 31,2015 18.62
March 31,2014 18.78
Period ended June 30, 2016 12.43
Offer Price [•]
After the Offer# [•]

Note: Net asset value per Equity Share represents Net Worth as per the Restated Financial Information
as divided by the number of equity shares outstanding as at the end of fiscal year. The net asset
value per equity share have been adjusted for the bonus issue.
#
There will be no change in NAV post the Offer as the Offer is by way of Offer for Sale by the Selling
Shareholders.

5. Comparison with Industry Peers

As such there is no company in India whose business portfolio is comparable with that of our business
to be compared as a peer group companies, although Serum Institute India Limited is a company which
is acting in the same field as we are. However it is an a unlisted company.

The Offer Price of [•] has been determined by our Company and Selling Shareholders, in consultation
with the BRLM on the basis of the demand from investors for the Equity Shares through the Book
Building Process and is justified in view of the above qualitative and quantitative parameters. Investors
should read the above mentioned information along with “Risk Factors” and “Financial Statements”
on pages 14 and 124, respectively, to have a more informed view. The trading price of the Equity
Shares of our Company could decline due to the factors mentioned in “Risk Factors” or any other
factors that may arise in the future and you may lose all or part of your investments.

59
 STATEMENT OF TAX BENEFITS

STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS AVAILABLE TO GREENSIGNAL BIO

PHARMA LIMITED AND ITS SHAREHOLDERS UNDER THE APPLICABLE LAWS IN INDIA

To, Date: July 2, 2016

The Board of Directors

GreenSignal Bio Pharma Limited
A-3, 13, Sai Niketan, Circular Road,
United India Colony, Kodambakkam,
Chennai- 600 024.

Dear Sirs,

Subject: Statement of possible special tax benefits (‘the Statement’) available to GreenSignal Bio Pharma
Limited (“the Company”) and its shareholders prepared in accordance with the requirement in
SCHEDULE VIII – CLAUSE (VII) (L) of Securities and Exchange Board of India (Issue of
Capital Disclosure Requirements) Regulations 2009, as amended (‘the Regulations’)
We hereby report that the enclosed Annexure prepared by the Company, states the possible special tax benefits
available to the Company and to the shareholders of the Company under the Income-tax Act, 1961 (‘the Act’) as
amended by the Finance Act, 2015 presently in force in India as on the signing date. Several of these benefits
are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant
provisions of the Act. Hence, the ability of the Company or its shareholders to derive the special tax benefits is
dependent upon fulfilling such conditions, which is based on business imperatives the Company may face in the
future and accordingly, the Company may or may not choose to fulfill.

Further, the preparation of the Statement and its contents is the responsibility of the Management. The benefits
discussed in the enclosed Annexure are not exhaustive and the preparation of the contents stated is the
responsibility of the Company's management. We were informed that this statement is only intended to provide
general information to the investors and is neither designed nor intended to be a substitute for professional tax
advice. In view of the individual nature of the tax consequences and the changing tax laws, each investor is
advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their
participation in the offer for sale.

We do not express any opinion or provide any assurance as to whether:

The Company or its shareholders will continue to obtain these benefits in future; or

The conditions prescribed for availing the benefits have been/ would be met with.

The contents of the enclosed statement are based on information, explanations and representations obtained from the
Company and on the basis of our understanding of the business activities and operations of the Company.

Our views expressed herein are based on the facts and assumptions indicated to us. No assurance is given that
the revenue authorities / courts will concur with the views expressed herein. Our views are based on the existing
provisions of law and its interpretation, which are subject to change from time to time. We do not assume
responsibility to update the views consequent to such changes. We shall not be liable to the Company for any
claims, liabilities or expenses relating to this assignment except to the extent of fees relating to this assignment,
as finally judicially determined to have resulted primarily from bad faith or intentional misconduct. We will not
be liable to any other person in respect of this statement.
This enclosed annexure is intended for your information and inclusion in the Draft Red Herring Prospectus in
connection with the proposed offer for sale of equity shares and is not to be used, referred to or distributed for
any other purpose without our prior written consent.

Yours faithfully,
For M/s. RAJ AND RAVI
ICAI firm registration number: 10935S
Chartered Accountants

RAJ VISVANATHAN
Partner
Membership No.: 23211
Place: Chennai
Date: July 2, 2016

60
 ANNEXURE TO THE STATEMENT OF POSSIBLE TAX BENEFITS AVAILABLE TO
GREENSIGNAL BIO PHARMA LIMITED AND ITS SHAREHOLDERS

Outlined below are the possible benefits available to the Company and its shareholders under the current direct
tax laws in India. These benefits are dependent on the Company or its shareholders fulfilling the conditions
prescribed under the relevant tax laws. Hence, the ability of the Company or its shareholders to derive the
possible tax benefits is dependent upon fulfilling such conditions, which based on business imperatives it faces
in the future, it may or may not choose to fulfill.

UNDER THE INCOME TAX ATC, 1961 (THE ACT)

A. Benefits to the Company under the Act

The Company will be entitled to deduction under the sections mentioned hereunder from its total
income chargeable to Income Tax.

i. Deduction under section 35(2AB):

As per section 35(2AB), where a company engaged in the business of bio-technology or in any
business of manufacture or production of any article or thing, incurs any expenditure on scientific
research (not being expenditure in the nature of cost of any land or building) on in-house research and
development facility as approved by the prescribed authority, then, there shall be allowed a deduction
of a sum equal to two times of the expenditure so incurred. Such weighted deduction under section
35(2AB) is available till assessment year 2017-18.

The Company is eligible to claim a weighted deduction of 200% on the expenditure incurred on clinical
trial research, Research expenses, tangible and intangible assets (other than land and building) and
other revenue expenditure specified for deduction under section 35(2AB) on in-house research and
development facility as approved by the prescribed authority.

ii. Deduction under section 35(1)(iv):

As per section 35(1)(iv), expenditure of capital nature on scientific research related to the business
carried on by the assesse, would be allowed as deduction in the year in which such capital expenditure
is incurred.

The company is eligible to claim 100% deduction of expenditure incurred on the prescribed assets,
which qualify as per section 35(1)(iv).

iii. Business income

The Company is entitled to claim depreciation on specified tangible and intangible assets owned by it
and used for the purpose of its business as per the provisions of Section 32 of the Act. In case of any
new plant and machinery (other than specified exclusions) acquired by the Company, the company is
entitled to a further sum equal to twenty per cent of the actual cost of such machinery or plant subject
to conditions specified in Section32 of the Act. Unabsorbed business losses, if any, for an assessment
year can be carried forward and set off against business profits for eight subsequent years. Unabsorbed
depreciation if any, for an assessment year can be carried forward and set off against any sources of
income (except salary) in the same assessment year or any subsequent assessment years as per the
provisions of Section 32(2) read with section 72 of the Act.

As per the provisions of Section 35D of the Act, any specified preliminary expenditure incurred after
31 March 1998 by an Indian company before the commencement of its business or after
commencement of its business, in connection with the extension of an undertaking or setting up a new
unit, shall be allowed a deduction of an amount equivalent to one-fifth of such expenditure for each of
the five successive financial years beginning with the financial year in which the extension of the
undertaking is completed or the new unit commences production or operation. However, any
expenditure in excess of 5% of the cost of the project or the capital employed in the business of the
Company, shall be ignored for the purpose of computing the deduction allowable under section 35D of
the Act.

As per the provisions of Section 35DD of the Act, any expenditure incurred by an Indian Company, on
or after 1 April 1999, wholly and exclusively for the purpose of amalgamation or demerger of an

61
 undertaking, shall be allowed a deduction of, an amount equal to one-fifth of such expenditure for each
of five successive financial years beginning with the financial year in which the amalgamation or
demerger takes place.

As per the provisions of Section 35DDA of the Act, if a Company incurs any expenditure in any
financial year by way of payment of any sum to an employee in connection with his voluntary
retirement, in accordance with any scheme or schemes of voluntary retirement, the Company would be
eligible to claim a deduction of one-fifth of the amount so paid in computing the profits and gains of
the business for that financial year, and the balance shall be deducted in equal instalments for each of
the four immediately succeeding financial years.

As per the provisions of Section 35CCD of the Act, if a Company incurs any expenditure (not being in
the nature of cost of any land or building) on any skill development project notified by the Central
Board of Direct Taxes in this behalf in accordance with the guidelines as may be prescribed, then, the
Company shall be allowed a deduction of sum equal to one and one-half times of such expenditure.

As per the newly inserted explanation to Section 37 of the Act, any expenditure incurred by the
Company on the activities relating to Corporate Social Responsibility (‘CSR’) referred to in section
135 of the Companies Act, 2013 shall not be deemed to be an expenditure incurred by the Company for
the purpose of the business or profession. However, CSR expenditure which is of the nature described
in provisions of Sections 30 to 36 of the Act shall be allowed as deduction under the respective
sections, subject to the fulfilment of conditions, if any, specified therein.

As per the provisions of Section 72A of the Act, pursuant to business reorganizations, such as
amalgamation, demerger, etc., the successor company shall be allowed to carry forward any
accumulated tax losses/ unabsorbed depreciation of the predecessor company subject to fulfilment of
prescribed conditions.

iv. MAT credit

As per provisions of Section 115JAA of the Act, the Company is eligible to claim credit for Minimum
Alternate Tax (MAT) paid for any assessment year commencing on or after April 1, 2006. The amount
of credit available shall be the difference between MAT paid under section 115JB of the Act and taxes
payable on total income computed under other provisions of the Act. MAT credit shall be allowed to be
set-off in the subsequent assessment years to the extent of difference between the tax payable as per the
normal provisions of the Act and the taxes payable under Section 115JB of the Act for that assessment
year.

MAT credit is eligible for carry forward and set-off for up to 10 years succeeding the assessment year
in which the MAT credit arises.

v. Special Tax Benefits available to the company

We have been given to understand that the Company has not availed any specific tax benefits.

B. Benefits to the Resident members / shareholders of the Company under the Act

i. Special Tax Benefits

We have been given to understand that there are no specific benefits available to the shareholders

ii. Dividends

As per the provisions of Section 10(34) of the Act, dividend (both interim and final), if any, received
by the members/ shareholders from the Company is exempt from tax. However, as per Section 94(7) of
the Act, losses arising from purchase and sale of securities or units, where such securities or units are
bought or acquired within a period of three months prior to the record date and such securities or units
are sold or transferred within three or nine months respectively from the record date, will be disallowed
to the extent of the amount of dividend claimed as exempt.

62
C. Benefits available to Venture Capital Companies/ Funds under the Act:

In terms of section 10(23FB) of the Act, all venture capital companies/ fund registered with Securities
and Exchange Board of India, subject to the conditions specified, are eligible for exemption from
income tax on any income from investment in a venture capital undertaking. Further, the Finance Act,
2015 has inserted a proviso providing that nothing contained in this clause shall apply in respect of any
income of a venture capital fund or venture capital company, being an “ investment fund” of the
previous year relevant to the assessment year beginning on or after April 1, 2016.

“Investment fund” has been defined under in clause (a) of Explanation 1 to Section 115UB of the Act
to mean any fund established or incorporated in India in the form of a trust or a company or a limited
liability partnership or a body corporate which has been granted a certificate of registration as a
Category I or Category II Alternative Investment Fund and is regulated under the Securities and
Exchange Board of India (Alternative Investment Fund) Regulations, 2012, made under the Securities
and Exchange Board of India Act, 1992.

D. Benefits available to Investment Funds under the Act:

The Finance Act, 2015 has inserted Chapter XII-FB in the Act which provides for special taxation
regime for Category I and Category II Alternative Investment Funds referred to as “ investment fund”
as per clause (a) of Explanation 1 to Section 115UB of the Act. Further, the said Act has also inserted
Section 10(23FBA) in terms of which income of any investment fund other than income chargeable
under the head “Profits and gains of business or profession” shall be exempt from income tax.

E. Benefits available to Mutual Funds under the Act:

In terms of Section 10(23D) of the Act, all Mutual funds set up by public sector banks or public sector
financial institutions or Mutual Funds registered under the Securities and Exchange Board of India Act/
Regulations there under or Mutual Funds authorized by the Reserve Bank of India, subject to the
conditions specified, are eligible for exemption from income taxes on all their income, including
income from investment in the shares of the company. The Finance Act, 2015 has inserted clause
(xviii) to Section 47 of the Act according to which an y transfer by a unit holder of a capital asset,
being a unit or units, held by him in the consolidating scheme of a mutual fund, made in consideration
of the allotment to him of a capital asset, being unit or units, in the consolidated scheme of the mutual
fund shall not be considered as transfer for the purpose of Section 2(47) of the Act.

Notes:

i) All the above benefits are as per the current tax laws and any change or amendment in the laws/
regulation, which when implemented would impact the same.

ii) The possible tax benefits are subject to conditions and eligibility criteria which need to be examined for
tax implication

Yours faithfully,

For M/s. RAJ AND RAVI

Chartered Accountants
ICAI firm registration number: 10935S

RAJ VISVANATHAN
Partner
Membership No.: 23211
Place: Chennai
Date: July 2, 2016

63
 SECTION IV: ABOUT THE COMPANY

INDUSTRY OVERVIEW

Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. The last decade
saw significant advances in developing, introducing and expanding the reach of vaccines globally. During the
20th century, the average human life span has increased by approximately 30 years, a significant portion of
which has been attributed directly to vaccination. More people than ever before were vaccinated, resulting in
significant achievements, including the near eradication of polio and significant reductions in deaths caused by
vaccine-preventable diseases (diphtheria, measles, neonatal tetanus, pertussis).Around 2 million deaths among
children under 5 years of age are prevented annually despite an increase in birth cohorts every year.

The Indian vaccine industry began as a work of state-owned manufacturers supplying basic childhood vaccines
to the national immunization program. In recent decades, the number of privately owned firms active in the
sector has grown rapidly. Their success in brining low cost vaccine solutions to public vaccine markets is an
important driver behind the emergence of the sector. The industry is now able to produce new and more
complex vaccines such as the meningitis, Haemophilusinfluenzae type b, and pneumococcal conjugate vaccines,
rotavirus vaccine and influenza A (H1N1) vaccines, aided by attractive investment environment, governmental
support, international partnerships and the growing technical work force. The vaccine industry has also been
supplying a large share of basic vaccines to a number of developing countries, and is now exporting more
advanced vaccines as well. From a public health perspective, it is a significant contribution that our industry has
made, by bringing down prices and keeping them low. Even though price will continue to play an important
role, the industry is now in a translational phase, moving from a ‘price- driven’ to an ‘innovation-driven’ model.

Though vaccines have transformed public health throughout the world, for children in particular, the burden of
vaccine-preventable diseases in India is still substantial and hence the usage of this powerful tool is still not
optimal in our country. The Indian vaccines market has a lot of ground to cover in terms of the potential to
substantially increase lives saved by improving access to the types of vaccines available and the depth of
coverage of those vaccines across the country. So for individual players in the vaccines space, the Indian
healthcare presents new vistas of growth, provided challenges in terms of policy barriers, lack of awareness and
affordability issues are successfully tackled.

The Biotechnology sector is among one of the sectors which have highlighted the profile of the country in the
last decade. At the beginning of the decade itself, this industry began to take shape with the sprouting of dozens
of start-up innovation companies as well as the diversification of established Pharma players by setting up
biotech divisions, to focus on this segment. Biotechnology is a highly interdisciplinary field that combines
biological sciences with computational, chemical as well as engineering technologies to manipulate living
organisms or their components to aid simplified and economical processes to produce products that advances
healthcare, medicine, agriculture, food, pharmaceuticals and environment control.

Biotechnology can be classified into two broad categories: R&D and discovery of new services and new
products in Biological Sciences and Industrial Processes. Being multidisciplinary in nature, the category
biological sciences encompasses subjects ranging from computational biology to microbiology, cell biology,
genetics, molecular biology, pharmaceuticals etc. for understanding the basic pathology of illness and treatment
of diseases including new drug development, development of agriculture, food production, protection of the
environment, waste disposal, and many more. The industrial processes aspect deals with the processes of
production of drugs, vaccines, biofuels, pharmaceuticals, engineered industrial enzymes, biodegradable
polymers, on an industrial scale using biochemical processes and techniques.

With numerous comparative advantages in terms of research and development (R&D) facilities, knowledge, skills,
and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.
Some of the best innovations and developments that have come out of Biotechnology and allied fields include:
genomic sequencing technology, better understanding of various pathologies, novel and improved diagnostic systems,
production of new biopharmaceuticals , procedure to develop vaccine that are more effective, natural alternatives to
pesticides, better yielding and resistant crops, production of biofuels, production of industrial enzymes that are
engineered for better activity, biodegradable polymers, and developments in stem cells technology.

Growing at a CAGR of 20 percent, the Indian Biotechnology Industry has evolved rapidly over the last three decades.
India’s biotech sector is currently valued at over USD7bn, having grown at a CAGR of ~20% over the last decade.
India is already ranked among the top 12 biotech destinations worldwide and third largest in the Asia Pacific region.
Biotechnology in India has already made a significant impact in agricultural, industrial, pharmaceutical and medical
sectors. The year-on-year growth of the biotech market is expected to accelerate driven by high demand for vaccines,
bio pesticides, bio fertilizers, biodiesel, bio therapeutics and medical devices in India as well as at the global level.

64
 Biotechnology market in India

The Indian Biotechnology sector comprises of the following segments:

1. Biopharma
2. Bio services
3. Bio agriculture
4. Bio industrial
5. Bioinformatics

Composition of the Biotechnology industry in terms of the key segments along with the products/ services is
indicated in the chart below:

Key segments in the Indian biotechnology industry

Source: BioSpectrum, Association of Biotechnology Led Enterprises, IRR Advisory

Key products/services in the Indian biotechnology industry

Source: BioSpectrum, Association of Biotechnology Led Enterprises, IRR Advisory

65
The biopharmaceutical segment holds the largest market share in the biotech industry in India and continues to grab
the highest share (~62%) of the entire sector, followed by bio services (18%) and bio agriculture (15%). Bio services
includes services ranging from analytical services like molecular diagnostics, supply of vectors, etc. to manufacturing
components including cell biological tools to other biotech companies and services provided by Contract Research
and Innovation Service Provider (CRISP) companies; while the bio agriculture segment includes production of
genetically modified high yielding or pest resistant crops, bio fertilizers, plant extracted library of molecules to bio
pesticides.

Biotechnology industry breakup

Comprising primarily of biologics (biosimilar), vaccines, diagnostics, and stem cells; the biopharmaceutical
industry has made great strides in the healthcare related challenges that India presently faces. The large majority
of biopharmaceutical products are pharmaceuticals that are derived from life forms. Small molecule drugs are
not typically regarded as biopharmaceutical in nature by the industry. The biopharma market comprise mainly
of vaccines, diagnostics, therapeutic drugs, insulin, animal biologics and statins. Therapeutics, vaccines and
diagnostics formed the backbone of the growth story, each contributing significantly to the revenue. Vaccines
are the largest contributor to the biopharma segment (estimated at ~60%), followed by diagnostics (estimated at
~20%). India is a world leader in vaccines, producing nearly 60 percent of the world’s supply.

TYPES OF VACCINES

Vaccines are composed of either the entire disease-causing microorganism or some of its components. The key
types include:

 From living microorganisms that have been weakened, usually from cultivation under sub-optimal
conditions (also called attenuation), or from genetic modification, which has the effect of reducing their
ability to cause disease;
 From whole microorganisms that have been inactivated by chemical, thermal, or other means;
 From components of the disease-causing microorganism, such as specific proteins and polysaccharides, or
nucleic acids;
 From inactivated toxins of toxin-producing bacteria;
 From the linkage (conjugation) of polysaccharides to proteins (this increases the effectiveness of
polysaccharide vaccines in young children).

Examples of each type of vaccine are indicated in the table below:

Types of vaccines
Type of vaccine Examples
Live-attenuated Measles, Mumps, Rubella, Varicella zoster
Inactivated Hepatitis A, Influenza, Pneumococcal polysaccharide
Recombinant sub-unit Hepatitis B
Toxoid Tetanus, Diphtheria
Pneumococcal, meningococcal, Haemophilus
Conjugate polysaccharide-protein
influenzae type b (Hib)
Source: Pharmaceutical Research and Manufacturers of America

66
They may be constructed in several ways as indicated in the chart below:

In addition to combining several serotypes of a disease-causing microorganism in a single vaccine (e.g. 13-
valent

VACCINE DEVELOPMENT

The development process for vaccines is unique. Vaccine development is highly capital intensive and risky.
Given the importance of safety with biologics, the vaccine industry is highly regulated. Vaccine development
proceeds in an iterative fashion. Less than one in 10 vaccine candidates achieve licensure. The high failure rate
is due to the unpredictability of the biological micro organisms needed to produce vaccines, and to the
uncertainty of how the human immune system will process and react to the vaccine antigen. Some vaccine
candidates may produce appropriate levels of immune response, but induce important adverse reactions. Other
vaccine candidates may be safe, but ineffective at preventing diseases. With the current tendency to combine
several antigens into a single vaccine, the challenges associated with developing safe and effective vaccines are
even greater. Research to discover new vaccine antigens and novel approaches to immunization usually takes
several years, and costs tens of millions of dollars. Once a discovery is made, several developments must be
undertaken to reach the licensing stage. Those developments include:

Vaccine development process

Source: Pharmaceutical Research and Manufacturers of America, IRR Advisory

After being thoroughly tested in an animal model, vaccine candidates that are found to be safe and induce
immunity can advance to testing in humans. To license a vaccine, three phases of clinical testing must be
completed in healthy subjects, as indicated in the chart below:

Vaccines: Clinical trials

Source: Pharmaceutical Research and Manufacturers of America, IRR Advisory

MANUFACTURING PROCESS

The manufacture of vaccines is achieved from the propagation of living microorganisms. Some of these may be
dangerous human pathogens. Therefore, the manufacture of vaccines is conducted in a highly regulated and

67
controlled environment. Manufacturing is conducted in an aseptic environment and closely monitored by quality
control measures. Vaccines also require a strict cold chain to maintain their stability. Under most circumstances
vaccines are shipped and stored under refrigeration. The actual production processes vary somewhat for
different types of vaccines. Some components of the manufacturing process are specific to either viral or
bacterial vaccine production. In general, the production of vaccines entails four basic steps:

Manufacturing process

Source: Pharmaceutical Research and Manufacturers of America, IRR Advisory

 Propagation entails the multiplication (or amplification) of the living microorganism used in the vaccine;
 Isolation entails the separation of the living microorganism from the cells or growth media used in the
propagation step;
 Purification removes all materials that may be adhering to the isolated microorganisms, or selectively
separates the portion of the living microorganism to be used in the vaccine; and,
 Formulation involves the mixing of the purified product in solutions to obtain a desired concentration. It may
also include the addition of preservatives to some vaccines, to ensure the sterility of the product over a longer
period of time, or to prevent cross contamination during dose extraction from vials.

VACCINE MANUFACTURING

India has a long history of vaccine manufacture, dating to the early 19th century. Of several institutes established in
the pre independence era, only Haffkine Institute in Mumbai remains on the list of manufacturers that produce WHO
prequalified vaccines. Of the major publically funded establishments, the BCG Vaccine Laboratory, HLL Life Care
Limited and Indian Immunologicals Limited still manufacture vaccines for human use. The entry of private enterprise
into vaccine manufacturing started with Biological E Limited of Hyderabad in 1953, followed by the Serum Institute
of India Limited in 1966—both family-owned enterprises. Panacea Biotech emerged during the critical need for
filling and packaging of imported bulk oral polio vaccines in quick response to a national need. The last two decades
have witnessed the entry of scientist and engineer entrepreneurs into the vaccine industry, with establishment of
biotechnology companies. Shantha Biotech, Bharat Biotech International Limited, are examples of this change. In
addition, several Indian pharmaceutical companies with established business in biopharmaceuticals, such as Zydus
Cadila, Cadila Pharmaceuticals Limited, Pfizer India, Wockhardt, are now finding it attractive to expand into the
vaccine business. Details of the vaccine manufacturers in India are provided in the table below:

Vaccine manufacturers in India

No. Institute/Company Vaccines produced/Marketed (Product Portfolio)
1. Bharat Biotech R-HB typhoid, anti-rabies
2. Bharat Serums and Vaccines DPT, typhoid
3. Biological Evans DTP, TT, R-HB
4. Biovaccines TT
5. Cadila Laboratories Typhoid
6. Childcare Biotech Triple antigen
7. Chowgule & Co. Triple antigen
8. GreenSignal Bio Pharma BCG
9. GSK India Varicella, DTP-HB, Hb, Hib, DPT, hepatitis A, TT
10. Ishita India Polio, DTP, DTAP, measles, MMR, hepatitis A, hepatitis B,
BCG, chicken pox, anti-rabies
11. LG Life Science India R-HB
12. Panacea Biotech OPV, R-HB, DTP-HB, DTP-Hib, DTP-HB, Hib
13. Pfizer India R-HB
14. Sanofi Pasteur India Typhoid, hib, anti-rabies, varicella, OPV, pneumococcal Hb,
hepatitis A, meningococcal
15. Serum Institute of India TT, DTP, tetanus, measles, rubella, MR & MMR, DTP, R-HB,

68
 No. Institute/Company Vaccines produced/Marketed (Product Portfolio)
BCG, HDC rabies, DTP-HB, Hib.
16. Shantha Biotech R-HB, DTP-HB, JE
17. Solvay Pharma India Influenz
18. UniChem Laboratories R-HB
19. VHB Life Sciences R-HB, typhoid, anti-rabies, varicella
20. Wyeth India Hib, DTP
21. ZydusCadila R-HB, typhoid, anti-rabies, chicken pox
22. ZydusCadila Healthcare Varicella, typhoid
Source: Netherlands Office of Science & Technology, IRR Advisory

The global vaccine market is largely divided between numerous Indian manufacturers and global
pharmaceutical companies headquartered in the West, such as GSK, Sanofi Pasteur, Novartis, Merck and Pfizer.
Vaccines from Indian manufacturers are generally substantially cheaper than those sold by the global
companies. Until the creation of Gavi, an alliance of public and private sector organisations, in the year 2000,
vaccines developed by global pharmaceutical firms were generally only distributed in high-income countries.
Older vaccines, such as those for measles and polio, were bought for less than a dollar per child, primarily from
Indian manufacturers.

Gavi has since raised more than USD9bn from donors and philanthropists and spends most of its funds on
introducing vaccines into the poorest countries in the world.A major leap forward was seen in 2010 when a new
meningitis vaccine solely developed for African strains came to market. The vaccine was developed by the
Serum Institute of India, which promised not to charge more than USD0.50 per dose after the Bill and Melinda
Gates Foundation agreed to fund the development work. The vaccine has since been bought by Gavi and
reached more than 217mn people. Continuous vaccine procurement by Gavi over the past 15 years has increased
the confidence of manufacturers to invest in development.

India has annual birth cohort of 27 million children and has become a home of approx. 6.8 million or roughly a
third of the world's total unimmunized children. Indian vaccines producers have shown their ability to produce
both innovative and cost effective vaccines to meet the global demand. By increasing availability of vaccine for
free, more than 100,000 deaths can be prevented annually.

Immunization is a way of protecting the human body against infectious diseases through vaccination.
Immunisation prepares our bodies to fight against diseases in case we come into contact with them in the future
– vaccines stimulate the body’s own immune system to protect the person against subsequent infection or
disease. Babies are born with some natural immunity which they get from their mother and through
breastfeeding. This gradually wears off as the baby's own immune system starts to develop. Having your child
immunized gives extra protection against illnesses which can kill. Immunization is one of the most cost-
effective health investments, with proven strategies that make it accessible to even the most hard-to-reach and
vulnerable populations.

Immunization in India – implemented via Universal Immunization Program (UIP), is a part of the Immunization
division of the Reproductive & Child Health (RCH) program under National Rural Health Mission (NRHM) and
is placed in the MoH. This division provides all the technical assistance required to undertake the activities
under UIP. The division reviews the state Program implementation plans and facilitates in its approval process
as per norms and guidelines. The key roles of this division include activities related to routine immunization
(RI), campaigns such as polio, measles, and Japanese encephalitis, monitoring adverse events following
immunization (AEFI), vaccine and cold chain logistics, strategic communication related to immunization
program and trainings related to immunization program. The program consists of vaccination for nine diseases –
tuberculosis, diphtheria, pertussis (whooping cough), tetanus, poliomyelitis, measles, hepatitis B, diarrhoea,
Japanese encephalitis and pneumonia. The following immunization schedule has been recommended under the
UIP and is one of the most widely followed by the child health care providers:

69
 Vaccination schedule in India

Vaccine Immunization Schedule Route

For Pregnant Women
TT - 1 Early pregnancy Intra muscular
TT - 2 4 weeks after 1st dose of TT Intra muscular
TT booster If received 2 TT doses in a pregnancy within the last 3 years Intra muscular
For Infants
BCG At birth or as early as possible till 1 year of age Intra-dermal
Hepatitis B At birth or as early as possible within 24 hours Intra-muscular
OPV - 0 At birth or as early as possible within first 15 days Oral
OPV - 1,2,3, 6 weeks, 10 weeks & 14 weeks Oral
DPT- 1,2,3, 6 weeks, 10 weeks & 14 weeks Intra-muscular
Hepatitis B - 1, 2, & 3 6 weeks, 10 weeks & 14 weeks Intra-muscular
9 completed months - to 12 months. Given up to 5 years if
Measles
not received at 9 - 12 months age Sub-cutaneous
Vitamin A At 9 months with measles Oral
For Children
DPT booster 16 - 24 months Intra- muscular
OPV Booster 16 -24 months Oral
Japanese Encephalitis 16 - 24 months with DPT/OPV booster Sub-cutaneous
Measles 16 - 24 months age Sub-cutaneous
16 months with DPT/OPV booster. Then, one dose every 6
Vitamin A
months upto the age of 5 years Oral
DT booster 5 - 6 years Intra-muscular
TT 10 years & 16 years Intra-muscular
Source: Ministry of Health and Family Welfare, IRR Advisory

Routine vaccination targets to vaccinate 27 million new born each year with all primary doses and ~100 million
children of 1-5 year age with booster doses of UIP vaccines. In addition, 30 million pregnant mothers are
targeted for TT vaccination each year. To vaccinate this cohort of 157 million beneficiaries, ~9 million
immunization sessions are conducted, majority of these are at village level. Nearly 90% of vaccination in India
is provided through the public sector. A network of ~27,000 cold chain points have been created across the
country where vaccines are stored to ensure potent and safe vaccines are delivered to children.

Over 40 vaccines have been developed for the prevention of human diseases. Several vaccines protect against
multiple serotypes of virus or bacteria (e.g. polio types 1, 2, and 3). Several vaccines are delivered in
combination to protect against multiple diseases. Most countries routinely use only a portion of vaccines
available to them. The selection of vaccines for use in a national schedule is based on the local epidemiology
and the risks associated with each specific vaccine-preventable disease. Now WHO recommendations are part of
an overarching strategy and vision for immunization that promotes routine immunization of all age groups and
includes several additional target diseases. Snapshot of the WHO recommended immunization schedule is
indicated in the table below:
WHO recommended immunization schedule

Regional Recommendations
Antigen Children Adolescents Adult
Japanese Encephalitis Virus  Booster
Yellow Fever 
Some High- Risk recommendations
Typhoid Primary Series and booster
Cholera Primary Series and booster
Meningococcal A 
Hepatitis A Primary Series
70
Rabies Primary Series
Recommendations for some immunization programs
 Regional Recommendations
Antigen Children Adolescents Adult
Japanese Encephalitis Virus  Booster
Yellow Fever 
Some High- Risk recommendations
Typhoid Primary Series and booster
Cholera Primary Series and booster
Meningococcal A 
Hepatitis A Primary Series
Rabies Primary Series
Regional
Recommendations forRecommendations
some immunization programs
Antigen
Mumps 
Children Adolescents Adult
Japanese Encephalitis Virus  Booster girls and women of
Or adolescent
Rubella 
Yellow Fever  child-bearing age
Influenza Some High- Risk recommendations
 Revaccinate annually
Typhoid Primary Series and booster
Cholera Primary Series and booster
Meningococcal A 
Hepatitis A Primary Series
Rabies Primary Series
Recommendations for some immunization programs
Mumps 
Or adolescent girls and women of
Rubella 
child-bearing age
Influenza  Revaccinate annually
Source: WHO, IRR Advisory

Historical immunization coverage of India as well as comparison with countries across the globe is indicated in
the chart below:

Global immunization coverage: 2015

*2014
Source: WHO, IRR Advisory

71
 Immunization coverage in India

Source: WHO, IRR Advisory

BCG: BCG vaccine is given for protection against tuberculosis, mainly severe forms of childhood tuberculosis.
24 million children below one year age were administered BCG vaccine during 2015. The achievement in 2015
was 87% in 2015 as against 91% in 2014. 13 states/ Union territories achieved more than 100% immunization in
2014 and 2015. Puducherry achieved the highest percent immunization in 2014 and 2015.

Bacillus Calmette-Guérin (BCG) is an attenuated strain of Mycobacterium bovis that is used as a live vaccine
against human and bovine tuberculosis. BCG vaccination has several beneficial effects. First, BCG vaccination
reduces rates of Mycobacterium tuberculosis infection, helping to shrink the pool of latent infection from which
future cases of active disease may arise. Second, BCG provides strong protection against disseminated forms of
the disease in infants and young children; tuberculosis is a major contributor to under-5mortality in tuberculosis-
endemic settings. Third, BCG vaccination reduces all-cause mortality through beneficial non-specific
(heterologous) effects on the immune system; the importance of these effects has been formally recognised by
WHO. BCG vaccination is compulsory in 64 countries including India and is officially recommended in an
additional 118 countries.

Apart from tuberculosis, BCG is also the main intravesical immunotherapy for treating early-stage bladder
cancer. Intravesical therapy for bladder cancer means putting liquid drugs directly into the bladder through a
tube called a catheter. The aim of this treatment is to treat the cancer and stop it from coming back or spreading
into the deeper layers of the bladder. The body’s immune system cells are attracted to the bladder and activated
by BCG, which in turn affects the bladder cancer cells. BCG was the first FDA approved immunotherapy and
helps reduce the risk of bladder cancer recurrence by stimulating an immune response that targets the bacteria as
well as any bladder cancer cells. People who have a moderate risk of the cancer recurrence usually have further
treatment with chemotherapy into the bladder (intravesical chemotherapy), while people who have a high risk of
the cancer recurrence or spreading into the deeper layers of the bladder usually have treatment with BCG into
the bladder (intravesical BCG). Immunotherapy with BCG has reduced the risk of bladder cancer recurrence and
increased the percentage of patients who experience a complete response after surgery. Approximately 70% of
bladder cancer patients go into remission after BCG therapy. The annual demand for BCG for intravesical
immunotherapy is estimated at 3 lakh doses in India and 1 million doses globally, as per GreenSignal Bio
Pharma’s estimates.

The Demand for BCG vaccination via the universal immunization program was historically catered to by the
public (BCG Vaccine Laboratory in Guindy, Chennai) and private sector (Serum Institute of India) combined.
However, a 2008 shutdown of the government owned vaccine manufacturing facility due to poor manufacturing
facilities has led to complete reliance on largely two private sector companies – Serum Institute of India and
GreenSignal Bio Pharma – which started manufacturing live attenuated vaccine in January 2009.Though the
institute reopened in February 2010, so far, the BCG Vaccine Laboratory has not contributed much to the
immunisation programme. The price of BCG vaccination has more than doubled since FY07, increasing from
INR 13 per vial in FY07 to INR30 in FY13, as indicated in the chart below.

72
 BCG vaccine price trend

The total BCG vaccination procurement requirement by the Government of India for the country’s
immunization programme, along with India’s BCG vaccination need assessment, along with the achievement
during the last 5 years is indicated in the chart below.

BCG vaccination in India

*Minimum supply
Source: Government of India, Ministry of Health and Family Welfare, GSBPL, IRR Advisory

Vaccination efforts global are catered to by the concerted efforts of UNICEF, WHO, respective governments,
non-governmental organizations as well as various global and regional immunization initiatives. The total
vaccine demand can be estimated to be the summation of the vaccination requirements of the UNICEF (~54%)
and the requirement of individual countries (46%).The Global Alliance for Vaccines and Immunization (GAVI)
is an international coalition of partners. It includes national governments, international organizations such as the
United Nations Children's Fund (UNICEF), the World Health Organization (WHO) and the World Bank;
philanthropic institutions, such as the Bill and Melinda Gates Children's Vaccine Program and the Rockefeller
Foundation; the private sector, represented by the International Federation of Pharmaceutical Manufacturers
Associations (IFPMA); and research and public health institutions. GAVI purchases vaccines through UNICEF
for countries with gross national income (GNI) per capita of below USD1,570.

UNICEF procurement

BCG vaccine demand through UNICEF over

the past decade has been relatively stable at
approximately 120 million doses per year.
BCG vaccine demand through UNICEF increased from 123 million doses in 2014 to reach 152.2 million doses
in 2015 on account of increased country requirements including from some large middle-income countries

73
(MICs) that typically self-procure, and country buffer stock replenishments. However, requirement of only
135.7 million doses was met, resulting in a shortfall of 16.5 million doses.
UNICEF procurement – projected
share

UNICEF has concluded its 2016-2018 BCG vaccine tender in September 2015 and awarded four manufacturers
three-year long-term arrangements (LTAs) to supply 400 million doses. The increase in total 2016 supply
availability from existing manufacturers, together with supply from a new WHO prequalified vaccine
(GreenSignal Bio Pharma), indicates total supply is sufficient to meet both suppressed 2015 demand carried
over to 2016, as well as total forecast demand through 2016-2018.To smoothen demand, country buffer stocks
depleted over the past three years will be replenished over a two to three year period subject to supply
availability. GreenSignal Bio Pharma’s planned contribution to the UNICEF over 2016-2018 is indicated in the
chart alongside. The historical procurement price as well as price agreed for supply during 2016-2018 is
indicated in the table below:

UNICEF historical procurement cost

BCG Vial Cost (USD)

Supplier Name
FY11 FY12 FY13 FY14 FY15
Intervax 1.4 1.4 1.4 1.5 1.5
Japan BCG Laboratory 2.1 2.1 2.7 2.7 2.7
Serum Institute of India 1.1 1.1 1.3 1.3 1.4
Statems Serum Institute 2.9 3.0 3.0 3.1 3.1
Source: UNICEF, IRR Advisory

The global demand for BCG vaccination is estimated at ~280 million doses annually, with the highest
requirement coming from India. The total shortfall for BCG vaccination is estimated at nearly ~30 million doses
annually. The BCG requirement in different countries across the globe, as well shortfall in BCG demand and
supply is indicated in the chart below:

UNICEF planned procurement cost

BCG Vial Cost (USD)

Supplier Name
FY16 FY17 FY18
Green Signal Bio Pharma 1.4 1.5 1.8
Intervax 1.6 1.7 1.8
Japan BCG Laboratory 3.2 3.3 3.4
Serum Institute of India 2.1 2.1 2.1
Source: UNICEF, IRR Advisory

The following table enumerates the BCG vaccination requirement in Asia and South America, as well the global
landscape, based on the birth cohort in the respective countries.

74
 BCG vaccination: Global scenario

A: Country currently recommends BCG vaccination for everyone at a certain age (Example: BCG at birth or for school-
age children, etc.).
B: Country used to recommend BCG vaccination for everyone, but currently does not
C: BCG vaccination was never recommended for everyone in this country (Never gave BCG or given only to high risk
groups such as health care workers).
R: Requirement, Sp: Supply, Sh: Shortage
Source: Public Health Agency of Canada, IRR Advisory Estimates

The following table enumerates the BCG vaccination requirement in Asia and South America, as well the global
landscape, based on the birth cohort in the respective countries

BCG vaccination: Asia

Existing Supply* Shortage** (Million Total Requirement
Birth Count(MN) Immunization Coverage
Country (Million Dose) Dose) (Million Dose)
2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015
Afghanistan 1.1 1.1 1.1 89% 97% 97% 1.9 2.1 2.1 0.2 0.1 0.1 2.2 2.2 2.2
Armenia 0.0 0.0 0.0 99% 99% 99% 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1
Azerbaijan 0.2 0.2 0.2 98% 98% 98% 0.3 0.3 0.4 0.0 0.0 0.0 0.3 0.3 0.4
Bahrain 0.0 0.0 0.0 99% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bangladesh 3.2 3.1 3.1 99% 99% 99% 6.3 6.2 6.2 0.1 0.1 0.1 6.3 6.3 6.3
Bhutan 0.0 0.0 0.0 97% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Brunei Darussalam 0.0 0.0 0.0 99% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cambodia 0.4 0.4 0.4 93% 99% 99% 0.7 0.7 0.7 0.1 0.0 0.0 0.7 0.7 0.7
China 16.4 16.9 16.6 99% 99% 99% 32.5 33.5 32.8 0.3 0.3 0.3 32.8 33.8 33.2
Georgia 0.1 0.1 0.0 95% 96% 96% 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1
India 26.0 25.9 25.8 91% 89% 87% - - 68.4*** - - 10.2*** - - 78.6***
Indonesia 5.1 5.1 5.0 92% 90% 89% 9.4 9.2 9.0 0.8 1.0 1.1 10.2 10.2 10.1
Iran, Islamic Rep. 1.4 1.4 1.4 99% 99% 99% 2.7 2.7 2.7 0.0 0.0 0.0 2.8 2.7 2.7
Iraq 1.2 1.2 1.2 93% 91% 80% 2.2 2.2 2.0 0.2 0.2 0.5 2.4 2.4 2.5
Japan 1.0 1.0 1.0 93% 93% 84% 1.9 1.9 1.7 0.1 0.1 0.3 2.1 2.0 2.1
Jordan 0.2 0.2 - 98% 95% - 0.3 0.3 - 0.0 0.0 - 0.4 0.4 -
Kazakhstan 0.4 0.4 - 95% 95% - 0.7 0.8 - 0.0 0.0 - 0.8 0.8 -
Kuwait 0.1 0.1 0.1 99% 99% 99% 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.2 0.2
Kyrgyz Republic 0.2 0.2 0.2 98% 97% 97% 75 0.3 0.3 0.3 0.0 0.0 0.0 0.3 0.3 0.3
Lao PDR 0.2 0.2 0.2 82% 82% 83% 0.3 0.3 0.3 0.1 0.1 0.1 0.4 0.4 0.4
Malaysia 0.5 0.5 0.5 99% 99% 99% 1.0 1.0 1.0 0.0 0.0 0.0 1.0 1.0 1.0
Maldives 0.0 0.0 0.0 99% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 Armenia 0.0 0.0 0.0 99% 99% 99% 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1
Azerbaijan 0.2 0.2 0.2 98% 98% 98% 0.3 0.3 0.4 0.0 0.0 0.0 0.3 0.3 0.4
Bahrain 0.0 0.0 0.0 99% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bangladesh 3.2 3.1 3.1 99% 99% 99% 6.3 6.2 6.2 0.1 0.1 0.1 6.3 6.3 6.3
Bhutan 0.0 0.0 0.0 97% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Brunei Darussalam 0.0 0.0 0.0 99% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cambodia 0.4 0.4 0.4 93% 99% 99% 0.7 0.7 0.7 0.1 0.0 0.0 0.7 0.7 0.7
China 16.4 16.9 16.6 99% 99% 99% 32.5 33.5
Existing 32.8
Supply* 0.3 0.3 (Million
Shortage** 0.3 32.8 33.8
Total Requirement 33.2
Birth Count(MN) Immunization Coverage
Georgia
Country 0.1 0.1 0.0 95% 96% 96% 0.1(Million
0.1 Dose)0.1 0.0 0.0
Dose) 0.0 0.1(Million
0.1 Dose)0.1
India 2013
26.0 2014
25.9 2015
25.8 2013
91% 2014
89% 2015
87% 2013
- 2014
- 2015
68.4*** 2013
- 2014
- 2015
10.2*** 2013
- 2014
- 2015
78.6***
Afghanistan
Indonesia 1.1
5.1 1.1
5.1 1.1
5.0 89%
92% 97%
90% 97%
89% 1.9
9.4 2.1
9.2 2.1
9.0 0.2
0.8 0.1
1.0 0.1
1.1 2.2
10.2 2.2
10.2 2.2
10.1
Armenia
Iran, Islamic Rep. 0.0
1.4 0.0
1.4 0.0
1.4 99% 99% 99% 0.1
2.7 0.1
2.7 0.1
2.7 0.0 0.0 0.0 0.1
2.8 0.1
2.7 0.1
2.7
Azerbaijan
Iraq 0.2
1.2 0.2
1.2 0.2
1.2 98%
93% 98%
91% 98%
80% 0.3
2.2 0.3
2.2 0.4
2.0 0.0
0.2 0.0
0.2 0.0
0.5 0.3
2.4 0.3
2.4 0.4
2.5
Bahrain
Japan 0.0
1.0 0.0
1.0 0.0
1.0 99%
93% 99%
93% 99%
84% 0.0
1.9 0.0
1.9 0.0
1.7 0.0
0.1 0.0
0.1 0.0
0.3 0.0
2.1 0.0
2.0 0.0
2.1
Bangladesh
Jordan 3.2
0.2 3.1
0.2 3.1
- 99%
98% 99%
95% 99%
- 6.3
0.3 6.2
0.3 6.2
- 0.1
0.0 0.1
0.0 0.1
- 6.3
0.4 6.3
0.4 6.3
-
Bhutan
Kazakhstan 0.0
0.4 0.0
0.4 0.0
- 97%
95% 99%
95% 99%
- 0.0
0.7 0.0
0.8 0.0
- 0.0 0.0 0.0
- 0.0
0.8 0.0
0.8 0.0
-
Brunei Darussalam
Kuwait 0.0
0.1 0.0
0.1 0.0
0.1 99% 99% 99% 0.0
0.1 0.0
0.1 0.0
0.2 0.0 0.0 0.0 0.0
0.1 0.0
0.2 0.0
0.2
Cambodia
Kyrgyz Republic 0.4
0.2 0.4
0.2 0.4
0.2 93%
98% 99%
97% 99%
97% 0.7
0.3 0.7
0.3 0.7
0.3 0.1
0.0 0.0 0.0 0.7
0.3 0.7
0.3 0.7
0.3
China
Lao PDR 16.4
0.2 16.9
0.2 16.6
0.2 99%
82% 99%
82% 99%
83% 32.5
0.3 33.5
0.3 32.8
0.3 0.3
0.1 0.3
0.1 0.3
0.1 32.8
0.4 33.8
0.4 33.2
0.4
Georgia
Malaysia 0.1
0.5 0.1
0.5 0.0
0.5 95%
99% 96%
99% 96%
99% 0.1
1.0 0.1
1.0 0.1
1.0 0.0 0.0 0.0 0.1
1.0 0.1
1.0 0.1
1.0
India
Maldives 26.0
0.0 25.9
0.0 25.8
0.0 91%
99% 89%
99% 87%
99% -
0.0 -
0.0 68.4***
0.0 -
0.0 -
0.0 10.2***
0.0 -
0.0 -
0.0 78.6***
0.0
Indonesia
Mongolia 5.1
0.1 5.1
0.1 5.0
0.1 92%
99% 90%
99% 89%
99% 9.4
0.1 9.2
0.1 9.0
0.1 0.8
0.0 1.0
0.0 1.1
0.0 10.2
0.1 10.2
0.1 10.1
0.1
Iran, Islamic Rep.
Myanmar 1.4
1.0 1.4
1.0 1.4
0.9 99%
86% 99%
92% 99%
94% 2.7
1.6 2.7
1.8 2.7
1.8 0.0
0.3 0.0
0.2 0.0
0.1 2.8
1.9 2.7
1.9 2.7
1.9
Iraq
Nepal 1.2
0.6 1.2
0.6 1.2
0.6 93%
97% 91%
99% 80%
94% 2.2
1.1 2.2
1.1 2.0
1.1 0.2
0.0 0.2
0.0 0.5
0.1 2.4
1.2 2.4
1.2 2.5
1.2
Japan Dem. Rep.
Korea, 1.0
0.4 1.0
0.4 1.0
0.4 93%
98% 93%
98% 84%
97% 1.9
0.7 1.9
0.7 1.7
0.7 0.1
0.0 0.1
0.0 0.3
0.0 2.1
0.7 2.0
0.7 2.1
0.7
Jordan
Oman 0.2
0.1 0.2
0.1 0.1- 98%
99% 95%
99% 99%- 0.3
0.2 0.3
0.2 0.2- 0.0 0.0 -
0.0 0.4
0.2 0.4
0.2 -
0.2
Kazakhstan
Pakistan 0.4
5.4 0.4
5.4 5.4- 95%
80% 95%
82% 83%- 0.7
8.6 0.8
8.9 9.0- 0.0
2.1 0.0
1.9 -
1.8 0.8
10.7 0.8
10.8 -
10.9
Kuwait
Philippines 0.1
2.3 0.1
2.3 0.1
- 99%
91% 99%
87% 99%
- 0.1
4.2 0.1
4.1 0.2
- 0.0
0.4 0.0
0.6 0.0
- 0.1
4.6 0.2
4.7 0.2
-
Kyrgyz Republic
Qatar 0.2
0.0 0.2
0.0 0.2
0.0 98%
99% 97%
90% 97% 0.3
0.0 0.3
0.0 0.3
0.1 0.0 0.0 0.0 0.3
0.1 0.3
0.1 0.3
0.1
Lao PDRFederation
Russian 0.2
1.9 0.2
1.9 0.2
1.8 82%
96% 82%
96% 83%
96% 0.3
3.6 0.3
3.7 0.3
3.5 0.1
0.2 0.1
0.2 0.1 0.4
3.8 0.4
3.8 0.4
3.7
Malaysia
Saudi Arabia 0.5
0.6 0.5
0.6 0.5
0.6 99%
99% 99%
99% 99%
98% 1.0
1.2 1.0
1.2 1.0
1.2 0.0
0.0 0.0
0.0 0.0
0.0 1.0
1.2 1.0
1.2 1.0
1.2
Maldives
Singapore 0.0
0.1 0.0
0.1 0.0
0.0 99%
99% 99%
99% 99%
99% 0.0
0.1 0.0
0.1 0.0
0.1 0.0
0.0 0.0
0.0 0.0
0.0 0.0
0.1 0.0
0.1 0.0
0.1
Mongolia
Korea, Rep. 0.1
0.4 0.1
0.4 0.1
0.5 99%
99% 99%
99% 99%
98% 0.1
0.9 0.1
0.9 0.1
0.9 0.0
0.0 0.0
0.0 0.0
0.0 0.1
0.9 0.1
0.9 0.1
0.9
Myanmar
Sri Lanka 1.0
0.3 1.0
0.3 0.9
0.3 86%
99% 92%
99% 94%
99% 1.6
0.7 1.8
0.7 1.8
0.6 0.3
0.0 0.2
0.0 0.1
0.0 1.9
0.7 1.9
0.7 1.9
0.7
Nepal Arab Republic
Syrian 0.6
0.5 0.6
0.5 0.6
0.5 97%
86% 99%
83% 94%
66% 1.1
0.9 1.1
0.8 1.1
0.7 0.0
0.1 0.0
0.2 0.1
0.3 1.2
1.0 1.2
1.0 1.2
1.0
Korea, Dem. Rep.
Tajikistan 0.4
0.2 0.4
0.3 0.4
0.3 98%
98% 98%
98% 97%
98% 0.7
0.5 0.7
0.5 0.7
0.5 0.0
0.0 0.0
0.0 0.0
0.0 0.7
0.5 0.7
0.5 0.7
0.5
Oman
Thailand 0.1
0.7 0.1
0.7 0.1
0.7 99%
99% 99%
99% 99%
99% 0.2
1.5 0.2
1.4 0.2
1.4 0.0
0.0 0.0
0.0 0.0
0.0 0.2
1.5 0.2
1.5 0.2
1.4
Pakistan
Timor-Leste 5.4
0.0 5.4
0.0 5.4
0.0 80%
82% 82%
79% 83%
90% 8.6
0.1 8.9
0.1 9.0
0.1 2.1
0.0 1.9
0.0 1.8
0.0 10.7
0.1 10.8
0.1 10.9
0.1
Philippines
Turkey 2.3
1.3 2.3
1.3 -- 91%
96% 87%
95% -- 4.2
2.5 4.1
2.4 -- 0.4
0.1 0.6
0.1 -- 4.6
2.6 4.7
2.6 --
Qatar
Turkmenistan 0.0
0.1 0.0
0.1 0.0
0.1 99%
99% 90%
99% 97%
99% 0.0
0.2 0.0
0.2 0.1
0.2 0.0
0.0 0.0
0.0 0.0
0.0 0.1
0.2 0.1
0.2 0.1
0.2
RussianArab
United Federation
Emirates 1.9
0.1 1.9
0.1 1.8
0.1 96%
94% 96%
90% 96%
96% 3.6
0.2 3.7
0.2 3.5
0.2 0.2
0.0 0.2
0.0 0.1
0.0 3.8
0.2 3.8
0.2 3.7
0.2
Saudi Arabia
Uzbekistan 0.6
0.7 0.6
0.7 0.6
0.7 99%
99% 99%
99% 98%
99% 1.2
1.3 1.2
1.4 1.2
1.4 0.0
0.0 0.0
0.0 0.0
0.0 1.2
1.4 1.2
1.4 1.2
1.4
Singapore
Vietnam 0.1
1.6 0.1
1.6 0.0
1.5 99%
95% 99%
96% 99%
97% 0.1
3.0 0.1
3.0 0.1
3.0 0.0
0.2 0.0
0.1 0.0
0.1 0.1
3.1 0.1
3.1 0.1
3.1
Korea, Rep.
Yemen, Rep. 0.4
0.8 0.4
0.8 0.5
0.9 99%
69% 99%
73% 98%
47% 0.9
1.2 0.9
1.2 0.9
0.8 0.0
0.5 0.0
0.5 0.0
0.9 0.9
1.7 0.9
1.7 0.9
1.7
Sri Lanka
Total 0.3
76.7 0.3
77.2 0.3
72.5 99%
94% 99%
94% 99%
90% 0.7
95.4 0.7
96.7 0.6
155.6 0.0
6.0 0.0
5.9 0.0
16.4 0.7
101.5 0.7
102.6 0.7
172.0
Syrian Arab Republic 0.5 0.5 0.5 86% 83% 66% 0.9 0.8 0.7 0.1 0.2 0.3 1.0 1.0 1.0
*Tajikistan
Assuming wastage of 0.250% 0.3- as per0.3WHO98% 98%
estimates 98% 0.5 0.5 0.5 0.0 0.0 0.0 0.5 0.5 0.5
Thailand 0.7 0.7 0.7 99% 99% 99% 1.5 1.4 1.4 0.0 0.0 0.0 1.5 1.5 1.4
** Assuming immunization shortfall is due to shortage in vaccine supply
Timor-Leste 0.0 0.0 0.0 82% 79% 90% 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1
***Government
Turkey
of India1.3estimate
1.3
– FY16- 96% 95% - 2.5 2.4 - 0.1 0.1 - 2.6 2.6 -
Source: WHO, IRR Advisory
Turkmenistan 0.1 Estimates
0.1 0.1 99% 99% 99% 0.2 0.2 0.2 0.0 0.0 0.0 0.2 0.2 0.2
United Arab Emirates 0.1 0.1 0.1 94% 90% 96% 0.2 0.2 0.2 0.0 0.0 0.0 0.2 0.2 0.2
Uzbekistan 0.7 0.7 0.7 BCG
99% vaccination:
99% 99% South
1.3 America
1.4 1.4 0.0 0.0 0.0 1.4 1.4 1.4
Vietnam 1.6 1.6 1.5 95% 96% 97% 3.0 3.0 3.0 0.2 0.1 0.1 3.1 3.1 3.1
Yemen, Rep. 0.8 0.8
Birth Count(MN)
0.9 Immunization
69% 73%Coverage
47% 1.2
Existing1.2
Supply*0.8 0.5 0.5(Million
Shortage** 0.9 1.7 Requirement
Total 1.7 1.7
Country
Total 76.7 77.2 72.5 94% 94% 90% 95.4(Million Dose)155.6
96.7 6.0 Dose)
5.9 16.4 (Million
101.5 102.6Dose)172.0
2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015
Argentina 0.75 0.75 0.76 99% 99% 99% 1.5 1.5 1.5 0.0 0.0 0.0 1.5 1.5 1.5
Bolivia 0.25 0.25 0.25 85% 96% NA 0.4 0.5 - 0.1 0.0 - 0.5 0.5 -
Brazil 3.04 3.03 3.01 99% 99% 99% 6.0 6.0 6.0 0.1 0.1 0.1 6.1 6.1 6.0
Chile 0.24 0.23 0.23 98% 98% 93% 0.5 0.5 0.4 0.0 0.0 0.0 0.5 0.5 0.5
Colombia 0.76 0.76 0.75 85% 89% 90% 1.3 1.3 1.3 0.2 0.2 0.1 1.5 1.5 1.5
Ecuador 0.33 0.33 0.33 90% 89% 88% 0.6 0.6 0.6 0.1 0.1 0.1 0.7 0.7 0.7
Guyana 0.01 0.01 0.01 98% 99% 99% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Paraguay 0.14 0.14 0.14 73% 77% 84% 0.2 0.2 0.2 0.1 0.1 0.0 0.3 0.3 0.3
Peru 0.62 0.62 0.61 95% 94% 91% 1.2 1.2 1.1 0.1 0.1 0.1 1.2 1.2 1.2
Suriname 0.01 0.01 0.01 NA NA NA - - - - - - - - -
Uruguay 0.05 0.05 0.05 98% 99% NA 0.1 0.1 - 0.0 0.0 - 0.1 0.1 -
Venezuela, RB 0.60 0.60 0.60 95% 95% 82% 1.1 1.1 1.0 0.1 0.1 0.2 1.2 1.2 1.2
Total 6.8 6.8 6.8 95% 96% 95% 12.9 13.0 12.2 0.7 0.5 0.7 13.6 13.6 12.9
* Assuming wastage of 50% - as per WHO estimates
** Assuming immunization shortfall is due to shortage in vaccine supply
Source: WHO, IRR Advisory Estimates

76
 BCG vaccination: Key countries

Existing Supply* Shortage** (Million Total Requirement

Birth Count(MN) Immunization Coverage
Country (Million Dose) Dose) (Million Dose)
2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015 2013 2014 2015
Bangladesh 3.1 3.2 3.1 99% 99% 99% 6.2 6.3 6.2 0.1 0.1 0.1 6.3 6.4 6.3
Brazil 3.1 3.1 3.0 99% 99% 99% 6.1 6.1 6.0 0.1 0.1 0.1 6.1 6.2 6.0
China 16.3 16.4 16.6 99% 99% 99% 32.3 32.4 32.8 0.3 0.3 0.3 32.6 32.7 33.2
Egypt 2.5 2.5 2.5 98% 96% 96% 4.8 4.8 4.8 0.1 0.2 0.2 4.9 5.0 5.0
Ethiopia 2.3 2.3 3.2 77% 78% 97% 3.5 3.6 6.1 1.0 1.0 0.2 4.5 4.7 6.3
India 25.6 25.9 25.8 91% 89% 87% - - 68.4*** - - 10.2*** - - 78.6***
Indonesia 5.0 5.1 5.1 92% 90% 89% 9.3 9.2 9.0 0.8 1.0 1.1 10.1 10.2 10.1
Japan 1.0 1.0 1.0 93% 93% 84% 1.9 1.9 1.7 0.1 0.1 0.3 2.0 2.0 2.1
Mexico 2.4 2.4 2.4 91% 96% 99% 4.3 4.6 4.7 0.4 0.2 0.0 4.7 4.8 4.7
Nigeria 6.9 7.1 7.1 69% 73% 74% 9.5 10.4 10.5 4.3 3.8 3.7 13.8 14.2 14.2
Pakistan 5.4 5.4 5.4 80% 82% 83% 8.7 8.8 9.0 2.2 1.9 1.8 10.9 10.7 10.9
Philippines 2.3 2.4 2.4 91% 87% 87% 4.3 4.1 4.1 0.4 0.6 0.6 4.7 4.8 4.7
Russian Federation 1.9 1.9 1.8 96% 96% 96% 3.6 3.6 3.5 0.1 0.1 0.1 3.7 3.7 3.7
Vietnam 1.5 1.5 1.6 95% 96% 97% 2.9 3.0 3.0 0.2 0.1 0.1 3.1 3.1 3.1
Global 129.0 129.9 125.2 91% 91% 90% 186.9 189.5 248.2 19.2 18.4 28.5 206.1 207.9 276.6
* Assuming wastage of 50% - as per WHO estimates
** Assuming immunization shortfall is due to shortage in vaccine supply
***Government of India estimate – FY16
Source: WHO, IRR Advisory Estimates

BCG VACCINATION: DEMAND COMPOSITION

Vaccines for tuberculosis can be given as pre-exposure, post-exposure, or therapeutic vaccines. Pre exposure
vaccines are targeted at infants and children younger than 5 years. Options include recombinant(r) live
mycobacteria and subunit vaccines designed to boost responses to BCG or its potential replacement. Post-
exposure vaccines target adolescents and adults with latent M tuberculosis infection; latencyantigen subunit
vaccines have been tailored for this application. Therapeutic vaccines aim to short entreatment or supplement
the treatment of drug resistant tuberculosis. Although various preparations of Mycobacterium vaccae showed no
therapeutic benefit, killed Mycobacterium indicuspranii has been licensed for restricted use in tuberculosis
therapy in India.

Two BCG replacement vaccines are in advanced stages of development: rBCG VPM1002 andMTBVAC.10 In
experimental mouse models, rBCGVPM1002, which expresses listeriolysin (hly) from Listeria monocytogenes
with deletion of the urease C (ureC) gene, induced superior protection against M tuberculosis compared with
BCG. This superior protection has been attributed to the translocation of vaccine antigens to the cytosol and
increased apoptosis of infected macrophages, resulting in enhanced T-cell stimulation. Results from an
unpublished phase 2a trial suggests that VPM1002is safe and well tolerated in infancy. MTBVAC is a double-
deletion mutant of M tuberculosis from which a broad range of virulence genes and critical enzymes have been
deleted. MTBVAC has shown similar safety and immunogenicity to BCG in a provisional phase 1 study.
Despite these exciting advances, field trials to assess potential BCG replacements are complicated by the
excellent protection provided by BCG, the absence of reliable immune correlates of protection, and the lack of
robust clinical endpoints in highly regulated vaccine trial sites. Widespread availability of a live attenuated
vaccine that could replace BCG is likely to be many years away, but an unintended consequence of the
expectation that new vaccines will soon replace BCG is a reluctance to invest in continued BCG production.

Vaccine market, which was once considered as a commodity market, is now among the fastest developing
markets for the global pharma industry. The global vaccine industry has witnessed impressive growth in recent
times and has surpassed many of the traditional businesses in the global pharmaceutical market. It has now
captured almost 3% of the overall global pharmaceutical industry. The growth in the global vaccine industry is
fuelled by continuous product innovation, increasing awareness, availability of funding support and positive
response from diverse demographics. In addition, increasing investments by government and non-government
organizations to enhance vaccine research and supply worldwide is expected to further grow in the vaccine
industry. The global vaccines market is expected to reach USD57bn by 2019 from USD33bn in 2014, growing

77
at a CAGR of 11.8% from 2014 to 2019. Among various end users, the paediatrics segment is expected to
account for the largest share of the market with highest CAGR growth during 2014 to 2019. Growth in this
segment can be attributed to the rising prevalence of diseases and the increasing number of initiatives taken by
government organizations for vaccination programs. On the back of strong focus of the Government on
increasing the immunization activities across the country, increasing awareness, availability of affordable
vaccines, the Indian vaccine industry is expected to continue to grow a t a CAGR of 12-15% over the next five
years.

India is one of the largest manufacturers and exporters of vaccines world-wide, with 12 major vaccine
manufacturing facilities. These vaccines are used for the national and international markets (150 countries),
which makes India a major vaccine supplier across the globe. UN agencies and partnerships such as UNICEF,
UNFPA, UNITAID, the Global Fund and the GAVI Alliance facilitate the supply of life-saving quality assured
medicines and vaccines to millions of patients in resource-limited countries across the world. These agencies
only buy products that have been through the WHO Prequalification Scheme, which ensures that medicines,
vaccines and diagnostics meet international standards of quality, safety and efficacy. India has about seven
vaccine manufacturers producing 67 prequalified vaccines (dosage forms). Currently 16 vaccines are
prequalified by WHO and exported through United Nations agencies. More than 70% of all measles vaccines
used globally are produced in India. Nearly a third of prequalified vaccines, and over two thirds of medicines
purchased through these international organizations are produced in India.

UNICEF supplies vaccines reaching 40 per cent of the world's children as part of its commitment to improving
child survival. The procurement of vaccines and related supplies is UNICEF's largest procurement activity. In
2014, UNICEF procured 2.71 billion doses of vaccines for 100 countries, from polio and measles to tetanus,
BCG and yellow fever vaccines, at a value of USD1.5bn. These vaccines are used in routine immunization as
well as in immunization campaigns. In 2014, UNICEF also purchased 180 million doses of measles vaccines,
134 million doses of BCG and 133 million doses of tetanus vaccines. India is the largest vaccine supplier to the
UNICEF, supplying nearly ~37% of the vaccines procured by UNICEF annually.

UNICEF suppliers – Significant Indian share

Source: UNICEF, IRR Advisory

The table below lists the top Indian companies supplying vaccines across the globe:

Top Indian vaccine exporters

Company Vaccine Exported

Chikungunya Vaccine
Liquid Rabies Vaccine
Malaria Vaccine
Bharat Biotech
Oral Rotavirus Vaccine
Rotavirus Vaccine "Rotavac"
Typhoid Conjugate Vaccine
Antisera
Bharat Serum and Vaccines Ltd Monoclonal Human Anti-rhesus Immunoglobulin
Monoclonal tetanus immunoglobulin
Green Signal Bio Pharma BCG
Antisera
Haffkine Biopharmaceuticals
Oral Polio Vaccines
78
FMD vaccine
Indian Immunologicals
Vaccine for the blue tongue disease
Easyfour (Diptheria Tetanus Pertussis + Hib)
 Rotavirus Vaccine "Rotavac"
Typhoid Conjugate Vaccine
Antisera
Bharat Serum and Vaccines Ltd Monoclonal Human Anti-rhesus Immunoglobulin
Monoclonal tetanus immunoglobulin
Green
CompanySignal Bio Pharma BCG
Vaccine Exported
Antisera
Chikungunya Vaccine
Haffkine Biopharmaceuticals
Oral
LiquidPolio Vaccines
Rabies Vaccine
FMD vaccine
Malaria Vaccine
Indian
Bharat Immunologicals
Biotech
Vaccine for theVaccine
Oral Rotavirus blue tongue disease
Easyfour (Diptheria Tetanus Pertussis + Hib)
Rotavirus Vaccine "Rotavac"
Ecovac
Typhoid(DTP + HepB)Vaccine
Conjugate
Panacea Biotech
Hepatitis
Antisera B vaccine
Bharat Serum and Vaccines Ltd Oral Polio vaccine
Monoclonal Human Anti-rhesus Immunoglobulin
BCG
Monoclonal tetanus immunoglobulin
Green Signal Bio Pharma Diphtheria
BCG
Measles
Antisera
Haffkine Biopharmaceuticals
Mumps
Oral Polio Vaccines
Serum Institute of India
Pertussis
FMD vaccine
Indian Immunologicals
R-hepatitis
Vaccine for Bthe blue tongue disease
Rubella
Easyfour (Diptheria Tetanus Pertussis + Hib)
Tetanus
Ecovac (DTP + HepB)
Panacea Biotech
Hepatitis B vaccine
Source: Consulate General of India, IRR Advisory
Oral Polio vaccine
Indian manufacturers producing World Health Organization prequalified vaccines include:
BCG
Indian manufacturers producing World Health Organization prequalified Vaccines
Diphtheria
Manufacturer Measles WHO prequalified products
Polio Vaccine - Oral (OPV) Bivalent Types 1 and 3, Polio
Bharat Biotech International LimitedMumps
Serum Institute of India Vaccine - Oral (OPV) Trivalent
Pertussis
Tetanus
R-hepatitis B Toxoid, Diphtheria-Tetanus (reduced antigen
Rubella content), Diphtheria-Tetanus-Pertussis (whole cell), Diphtheria-
Biological E. Limited
Tetanus-Pertussis (whole cell)-Hepatitis B-Haemophilus
Tetanus
influenzae type b, Japanese Encephalitis Vaccine (Inactivated)

Chiron Behring Vaccines Private Limited Rabies

Green Signal Bio Pharma Limited BCG
Polio Vaccine - Oral (OPV) Bivalent Types 1 and 3, Polio
Haffkine Bio Pharmaceutical Corporation
Vaccine - Oral (OPV) Monovalent Type 1, Polio Vaccine - Oral
Limited
(OPV) Trivalent
Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B-
Panacea Biotec Limited
Haemophilus influenzae type b
BCG, Diphtheria-Tetanus, Diphtheria-Tetanus (reduced antigen
content), Diphtheria-Tetanus-Pertussis (whole cell), Diphtheria-
Tetanus-Pertussis (whole cell)-Haemophilus influenzae type b,
Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B,
Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B-
Haemophilus influenzae type b, Haemophilus influenzae type
Serum Institute of India Private Limited
b, Hepatitis B, Influenza, pandemic H1N1, Influenza, seasonal,
Measles, Measles and Rubella, Measles, Mumps and Rubella,
Meningococcal A Conjugate, Meningococcal A Conjugate
(paediatric), Polio Vaccine - Oral (OPV) Bivalent Types 1 and 3,
Polio Vaccine - Oral (OPV) Trivalent, Rabies, Rubella, Tetanus
Toxoid
Tetanus Toxoid, cholera: inactivated oral, Diphtheria-Tetanus-
Shantha Biotechnics Limited Pertussis (whole cell)-Hepatitis B-Haemophilus influenzae
type b, Hepatitis B

79
Source: WHO, IRR Advisory

The list of manufacturers prequalified during 2015 and 2016, along with the vaccine type, is indicated in the
chart below:
Prequalified manufacturers in 2015 and 2016

Date Type No of Doses Manufacturer

2015
Polio Vaccine - Oral (OPV) Bivalent Types 1
20/03/2015 20 Bharat Biotech International Limited
and 3
20/03/2015 Polio Vaccine - Oral (OPV) Trivalent 20 Bharat Biotech International Limited
20/03/2015 Polio Vaccine - Oral (OPV) Trivalent 10 Bharat Biotech International Limited
09/06/2015 Influenza, seasonal 1 Hualan Biological Bacterin Co., Ltd
30/09/2015 Influenza, seasonal 1 Serum Institute of India Pvt. Ltd.
04/11/2015 Influenza, seasonal 1 Sanofi Pasteur-USA
04/11/2015 Influenza, seasonal 10 Sanofi Pasteur-USA
Polio Vaccine - Oral (OPV) Bivalent Types 1
05/11/2015 10 PT Bio Farma (Persero)
and 3
06/11/2015 BCG 20 GreenSignal Bio Pharma Limited
23/12/2015 cholera: inactivated oral 1 Eubiologics Co., Ltd.
2016
14/01/2016 Polio Vaccine - Oral (OPV) 20 Sanofi Pasteur SA
25/01/2016 Polio Vaccine - Oral (OPV) Monovalent Type 3 20 Sanofi Pasteur SA

Diphtheria-Tetanus-Pertussis (whole cell)

10/02/2016 Hepatitis B 1 LG Life Sciences
Haemophilus influenzae type b
Diphtheria-Tetanus-Pertussis (whole cell)
10/02/2016 Hepatitis B 10 LG Life Sciences
Haemophilus influenzae type b
Diphtheria-Tetanus-Pertussis (whole cell)
29/02/2016 Hepatitis B 5 Janssen Vaccines Corp.
Haemophilus influenzae type b
Diphtheria-Tetanus-Pertussis (whole cell)
29/02/2016 Hepatitis B 10 Janssen Vaccines Corp.
Haemophilus influenzae type b
Source: WHO, IRR Advisory

To ensure a supply of good quality and innovative products at an affordable price to the Indian population, the
Ministry of Science and Technology, through its Department of Biotechnology and Council for Scientific and
Industrial Research, has initiated new funding mechanisms. The Small Business Innovation Research Initiative
supports innovative ideas generated by start-ups, and the New Millennium Indian Technology Leadership
Initiative supports novel projects from both industry and academia very early in development. These initiatives
have been used by domestic vaccine manufacturers to cushion risks in the initial development of vaccines,
especially complex one such as rotavirus, pneumococcal conjugate and human papillomavirus vaccines. The
Government of India provided funds to four manufacturers to develop and manufacture influenza A
(H1N1)vaccines following the pandemic in 2009 (Serum Institute of India Limited (SII), Cadila
Pharmaceuticals Limited, Bharat Biotech International Limited (BBIL), and Panacea Biotec Limited). The
Technology Development Board of the Department of Science and Technology provides funding to industry for
setting up manufacturing and other facilities; an example of such support is that provided to Biological E
Limited for development of their HBV and Hib pentavalent vaccines. Recently, the Biotechnology Ignition
Grant was launched to support innovation in affordable health care products in the initial phase of development.
These grants are available to students, faculty and small and medium enterprises that have incubator space or
their own infrastructure to carry out the proposed work. Several science ministries and the Department of Health
Research are generously funding academic and other research institutions to working the area of vaccinology for
product development and supporting science . The Biotechnology Industry Partnership Program, on the other
hand, funds product development with industry partners and has supported some major projects in the area of
vaccines (e.g., H1N1, human papillomavirus, hepatitis C virus and pneumococcalconjugate vaccines)

80
Regulatory Overview

Ministry of Health & Family Welfare has formulated the National Vaccine Policy for the country. The policy
addresses broad issues of strengthening the institutional framework, processes, need for strengthening Universal
Immunization Programme in India and to streamline the decision making process on new and underutilized
vaccine Introduction. The Central Drugs and Standards Control Organization (CDSCO) is the National
Regulatory Authority (NRA) in India. CDSCO is headed by the Drugs Controller General (India). It approves
vaccines that are introduced in the country, grants permission to conduct clinical trials, registers and controls the
quality of imported vaccines, as well as lays down standards for updating the India Pharmacopoeian. It also
approves licenses as the Central License Approving Authority (CLAA) for the manufacture of vaccines,
coordinates the activities of the states and advises them on matters relating to uniform administration of the Act
and Rules. The Central Drugs Laboratory (CDL), Kasauli performs lot release for all imported vaccines as well
as locally produced vaccines.

Vaccine development is a lengthy process in India and requires approvals from numerous agencies/committees
in the Government. Biosafety regulations in India comprise biosafety rules and guidelines. India’s biosafety
rules apply to manufacture, import and storage of microorganism sand gene technology products and include
products made of micro organisms that are genetically engineered. The rules cover research and large scale
applications of Genetically Modified Organisms(GMOs) and products. They also deal with hazardous organisms
that are not genetically modified. There are a number of approvals and clearances that one needs to take, once a
vaccine has been conceptualized.

Disclaimer of the IRR Advisory Services Private Limited: IRR Advisory in the provision of service has
received information and documents from the company and/or or its agents and third parties as well as relied on
information available in public domain. IRR Advisory relied on Company and/or its agents and advisors and
these third parties foe accuracy of the information. IRR advisory has taken utmost care to ensure accuracy and
objectivity while preparing this report. IRR Advisory is not responsible for any errors or omission in
analysis/inference/views or from results obtained from the use of information contained in this report and
specially advises that IRR Advisory has no financial liability whatsoever to the user of this report. IRR advisory
has not independently verified such information. IRR advisory does not represent , warrant or guarantee: (i)
financial advice, auditing, accounting , appraisal or actuarial services.; (ii) the accuracy, correctness, integrity,
completeness or timeliness of any part of the services described herein, due the fact that all of the results of the
IRR Advisory’s analysis are based or information provided to IRR Advisory by the Company and/ or its agents
and advisors and third parties, or information available in public domain; and (iii) that the information , analysis
and agreed upon procedure contained , and constituting a part of service, as described in proposal signed
between company and IRR Advisory, will fulfil any of your particulars purpose or need. IRR advisory is not
responsible for any underwriting, credit or investment decision, or damages or other losses resulting from use of
the services. The Service is provided “as is” and all faults and entire risk as to satisfactory quality, performance,
accuracy and effort is with the Company. In providing the service, IRR advisory is not making any
recommendation to buy, sell make or hold any investment, loan security.

81
 OUR BUSINESS

This chapter should be read in conjunction with, and is qualified in its entirety by, the more detailed information
about us, our Restated Standalone Financial Information, including the notes thereto, in the chapters “Risk
Factors”, “Industry Overview”, “Financial Statements”, and “Management’s Discussion and Analysis of
Financial Condition and Results of Operation” on pages 14, 64, 124 and 149, respectively.

Overview

The global vaccines market is expected to reach USD57bn by 2019 from USD33bn in 2014, growing at a
CAGR of 11.8% from 2014 to 2019. Among various end users, the paediatrics segment is expected to account
for the largest share of the market with highest CAGR growth during 2014 to 2019. On the back of strong focus
of the Government on increasing the immunization activities across the country, increasing awareness,
availability of affordable vaccines, the Indian vaccine industry is expected to continue to grow at a CAGR of 12-
15% over the next five years.

India is one of the largest manufacturers and exporters of vaccines world-wide, with 12 major vaccine
manufacturing facilities. These vaccines are used for the national and international markets (150 countries),
which makes India a major vaccine supplier across the globe. UN agencies and partnerships such as UNICEF,
UNFPA, UNITAID, the Global Fund and the GAVI Alliance facilitate the supply of life-saving quality assured
medicines and vaccines to millions of patients in resource-limited countries across the world. These agencies
only buy products that have been through the WHO Prequalification Scheme, which ensures that medicines,
vaccines and diagnostics meet international standards of quality, safety and efficacy. India has about seven
vaccine manufacturers producing 67 prequalified vaccines (dosage forms). Currently 16 vaccines are
prequalified by WHO and exported through United Nations agencies. More than 70% of all measles vaccines
used globally are produced in India. Nearly a third of prequalified vaccines, and over two thirds of medicines
purchased through these international organizations are produced in India.

UNICEF supplies vaccines reaching 40 per cent of the world's children as part of its commitment to improving
child survival. The procurement of vaccines and related supplies is UNICEF's largest procurement activity. In
2014, UNICEF procured 2.71 billion doses of vaccines for 100 countries, from polio and measles to tetanus,
BCG and yellow fever vaccines, at a value of USD1.5bn. These vaccines are used in routine immunization as
well as in immunization campaigns. In 2014, UNICEF also purchased 180 million doses of measles vaccines,
134 million doses of BCG and 133 million doses of tetanus vaccines. India is the largest vaccine supplier to the
UNICEF, supplying nearly ~37% of the vaccines procured by UNICEF annually.

UNICEF suppliers – Significant Indian share

Source: UNICEF, IRR Advisory

The table below lists the top Indian companies supplying vaccines across the globe:

82
Top Indian vaccine exporters

Company Vaccine Exported

Chikungunya Vaccine
Liquid Rabies Vaccine
Malaria Vaccine
Bharat Biotech
Oral Rotavirus Vaccine
Rotavirus Vaccine "Rotavac"
Typhoid Conjugate Vaccine
Antisera
Bharat Serum and Vaccines Ltd Monoclonal Human Anti-rhesus Immunoglobulin
Monoclonal tetanus immunoglobulin
Green Signal Bio Pharma BCG
Antisera
Haffkine Biopharmaceuticals
Oral Polio Vaccines
FMD vaccine
Indian Immunologicals
Vaccine for the blue tongue disease
Easyfour (Diptheria Tetanus Pertussis + Hib)
Ecovac (DTP + HepB)
Panacea Biotech
Hepatitis B vaccine
Oral Polio vaccine
BCG
Diphtheria
Measles
Mumps
Serum Institute of India
Pertussis
R-hepatitis B
Rubella
Tetanus
Source: Consulate General of India, IRR Advisory

We are one of the two Indian pharmaceutical companies engaged in the development, manufacture and sale of the
BCG vaccine. Our products include one vaccine, namely the BCG vaccine as well as the BCG-ONCO- Urovac, an
immunotherapy drug which is not a vaccine but it is used in the treatment of urinary bladder cancer.

We are one of the four companies worldwide who have been WHO-prequalified to supply the BCG vaccine to
UNICEF. And we have secured a long term arrangement dated November 23, 2015 with UNICEF to supply the
BCG vaccine to UNICEF subject to the purchase orders placed with our company. We also supply the BCG
vaccine to the Ministry of Health, India pursuant to the tendering process, in which we have placed successful
bids since the year 2010 (except for years 2013-14 and 2014-15). We also supply the BCG vaccine to
Indonesia, and Nepal which are countries outside the UNICEF ambit. Our BCG-ONCO for Immunotherapy
drug is distributed throughout India vide commercial arrangements in India and we intend to market this
immunotherapy drug in overseas jurisdictions as well. Presently, we have made several limited supplies to
various countries such Lebanon, Saudi Arabia, Turkey and Switzerland.
We are an Indian vaccine manufacturing company with global operations. As on date we produce two products:

1. BCG Vaccine for immunization against Tuberculosis

2. BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of Urinary Bladder
Carcinoma and our brand name for the same is ‘Urovac’.

As both vaccines produced by us are generic drugs we do not require any patents for the same, however we have
procured a registered trademark for our BCG ONCO for Immunotherapy drug, name, ‘Urovac’.

83
Under our arrangement with Cadila Healthcare Limited, we were producing the BCG ONCO for
Immunotherapy under the brand name ‘Oncovac’. Our agreement is expiring on June 29, 2016 and we do not
intend to renew the same. For further details kindly refer to Risk factor on page 14.

Our Company was incorporated as a Private Limited Company “Green Signal Bio Pharma Private Limited” on
November 21, 2005 at Chennai under the Companies Act, 1956. Pursuant to our Company passing a resolution
under section 13 (2), of the Companies Act 2013 on March 24, 2016, and upon the issuance of a fresh
certificate of incorporation consequent to the name change, the name of our Company was changed to
GreenSignal Bio Pharma Private Limited with effect from April 21, 2016. Further, the shareholders of our
Company passed a resolution dated March 24, 2016 and the Company was changed to a Public Limited
Company with effect from May 12, 2016. The CIN of our Company is U24232TN2005PLC058068. The
Registered Office of our Company is located at Old No.5, New No.13/A3, Sai Niketan, Circular Road, United
India Colony, Kodambakkam, Chennai 600 024.

Our business is organized into domestic (i.e. Indian) and international operations, according to the geographies
in which we operate. For fiscal year 2016, our domestic and international operations accounted for 53.79% and
46.20%, respectively, of our net revenues from operations. Our consolidated net revenues from operations grew
at a CAGR of 210.70% in the period from fiscal year 2015 to fiscal year 2016.

We have a manufacturing facility located at Pappankuppam Village, Gummidipoondi, Tiruvallur District, Tamil Nadu equipped
with advanced equipment dedicated for the manufacturing of live attenuated BCG Vaccine and the BCG-ONCO for
immunotherapy.

Objective and Aim

The main objective of our Company is to provide the much needed vaccine against tuberculosis to new born
children, thereby reducing the mortality and morbidity in children which occurs due to tuberculosis and also to
provide the essential drug for immunotherapy against urinary bladder cancer to people, thereby reducing the
mortality due to cancer.

The motto of our Company is “Wellness for All”.

After incorporation in 2005 our Company made efforts to Seed & Technical Know-how and setting up of
manufacturing unit for Measles Vaccine in India in collaboration with M/s.Wuhan Institute of Biological
Products (WIBP) China, a Government of China undertaking. GSBPL procured a property of 1.4 Acres at
Gummidipoondi, near the outskirts of Chennai for setting up of modern facilities for the manufacture of human
vaccines. It also entered into agreement with M/s. Pasteur Institute of India for transfer for manufacture of
Measles and Rubella Vaccines by the PII on the basis of profit sharing with our Company.

We started manufacturing the live attenuated vaccine in January 2009, after receiving approval from Drug
Controller General of India.

Our Strategy

The key pillar of growth for our Company is to export vaccines globally in various jurisdictions. We can do this
by directly liaising with countries and their health ministries as well as providing our products to global
suppliers such as UNICEF. Within India our BCG vaccine is already being provided to MoH vide it’s tendering

84
process and we have been securing this since financial year 2010 except for the years 2013-14 and 2014-15.
However, there is a considerable scope for marketing our other product BCG-ONCO for Immunotherapy or
Urovac. We can do this in partnership with other such entities or directly ourselves. We intend to associate with
prominent international marketing agencies for more effective and fruitful business development worldwide for
promoting BCG-ONCO-Urovac.

Apart from increasing our presence geographically, our Company plans to add new vaccines to its portfolio and in
this regard we have acquired land admeasuring about 34.01 acres for a fresh facility at Tiruvallur, Chennai, Tamil
Nadu. For further details on land please refer to “Our Facility” and “Land and Other Properties” on page 89 and
90.

With an optional upstream and downstream processes, the company plans to do the Fill / Finish and sell with
greater volumes of a variety of newer Vaccines for anti serum, cancer, Dengue, H1N1, Type-I Diabetes and
other dreaded diseases with better margins to the more demanding markets in India as well as globally. Our
Company, aims to produce new and unique novel vaccine products to take advantage of higher margins in sales
in the global market with PQ certification . At the same time, we are also planning to upgrade to Fill / Finish
process for the existing products which are already in the market giving decent profit margins. We also intend to
optimally market usage of the BCG Vaccine, our existing product for treatment of Type-I Diabetes as and when
same is approved by MoH.

Our Company is focused on expanding its presence geographically. An important milestone in that process was
achieved during November 6, 2015, as our Company became a WHO Pre-Qualified supplier.

Advantages of WHO – Pre-Qualification:

 The product can reach every part of the globe with ease.
 Our Company becomes eligible to participate in tenders of UNICEF, PAHO and other Global
Agencies which are among the largest buyer of BCG Vaccines.
 A considerable increase in price of the product is assured.
 Regular export opportunities to other countries including non-UNICEF Countries.

UNICEF Orders

There are a limited number of manufacturers supplying BCG Vaccines who are WHO Pre-Qualified (maximum of
four, including our Company), even though the demand from UNICEF has been constant over the past decade. Over
the past three years there has been an insufficient supply and a deficit of approximately 15 million doses each year.

UNICEF procurement – projected share

Source: UNICEF Study on Demand and Supply on Vaccines

UNICEF has concluded its 2016-2018 BCG vaccine tender in September 2015 and awarded four manufacturers
three-year long-term arrangements (LTAs) to supply 400 million doses. The increase in total 2016 supply
availability from existing manufacturers, together with supply from a new WHO prequalified vaccine
(GreenSignal Bio Pharma), indicates total supply is sufficient to meet both suppressed 2015 demand carried
over to 2016, as well as total forecast demand through 2016-2018.To smoothen demand, country buffer stocks
depleted over the past three years will be replenished over a two to three year period subject to supply
availability. GreenSignal Bio Pharma’s planned contribution to the UNICEF over 2016-2018 is indicated in the
chart alongside.

85
The historical procurement price as well as price agreed for supply during 2016-2018 is indicated in the table
below:

UNICEF historical procurement cost

BCG Vial Cost (USD)

Supplier Name
FY11 FY12 FY13 FY14 FY15
Intervax 1.4 1.4 1.4 1.5 1.5
Japan BCG Laboratory 2.1 2.1 2.7 2.7 2.7
Serum Institute of India 1.1 1.1 1.3 1.3 1.4
Statems Serum Institute 2.9 3.0 3.0 3.1 3.1

UNICEF has contracted with all the four WHO Pre Qualified BCG Vaccine Manufacturers. To meet the
growing demand UNICEF has awarded an additional 37.82 million doses to increase its initial 2015 allocation
from 107 to 144.82 million doses. As per UNICEF projections the shortfall for the year 2015 is 16.5 Million
Doses. To mitigate the deficit, UNICEF is taking a number of actions namely:

 Extensive Consultations with 120+ countries receiving BCG through UNICEF

o Agree on critical dates for deliveries of vaccine

o Advocate for reduction of wastage rates
o Using buffer stocks in countries

 Extensive Follow up with suppliers

 Close follow up with pipeline manufacturers seeking WHO Pre-Qualification.

The UNICEF orders present an increasing order pipeline for the Company, as our Company is one of the few
WHO Pre Qualified BCG Vaccine manufacturers.

History of our BCG Vaccine and BCG ONCO for Immunotherapy Seed Strain and our Manufacturing
process

The Bacillus Calmette Guerin (BCG) Strain 1331 of Danish origin was prepared for immunization against
tuberculosis. The strain has been exclusively used in the immunization programs for the past 55 years. The
mother culture was procured from Statens Serum Institute Denmark by BCG Laboratory, Guindy, Chennai and
the Secondary Seed was prepared in 1995. Our Company was granted permission by MoH to procure the seed
from BCG Laboratory, Guindy, Chennai. The seed was transferred to our Company in March 2007.

Our Business

Having established ourselves in the Indian vaccines market, we have expanded internationally through organic
growth. which is our key focus area for further expansion. Our products are exported to 17 countries, either
directly through UNICEF or indirectly, through supply, distribution and other arrangements.

86
Our Products

BCG Vaccine

BCG Vaccine is live, freeze dried product, made from an attenuated strain of Mycobacterium bovis, Danish
1331 strain. It is used for immunization against Tuberculosis. It contains monosodium glutamate as a stabilizer.
BCG cultures are propagated on Sauton growth medium, then harvested, mixed with monosodium glutamate
and finally lyophilized (freeze-dried). We have the following kinds of BCG vaccines namely, BCG Vaccine IP,
BCG Vaccine BP, BCG Vaccine EP and BCG Vaccine USP.

For prevention of Tuberculosis, BCG Vaccination is accepted as one of the most important measures. It is
compulsory in 64 countries including India and is officially recommended in an additional 118 countries and
territories. BCG is most effective known adjuvant in animals and humans. It is also cheap, stable and safe. The
BCG Vaccine is required to be routinely given to all infants since they are at a higher risk of early exposure to
tuberculosis. This vaccine should be given soon after the child is born. BCG administered early in life provides
high level of protection particularly against severe forms of childhood tuberculosis and tubercular meningitis.

Registration Details of BCG Vaccine:

The BCG Vaccine is registered in India since 2008, in Indonesia since 2010 and in Nepal since 2016. For India
the certificate to manufacture under the Drugs and Cosmetics Rules has been issued by the Director of Drugs
Controller, Chennai. For Nepal the Ministry of Health and Population, Department of Drug Administration has
provided a letter of recommendation for import of drugs, for UNICEF countries registration is not required for
the concerned UNICEF country(ies) and for Non-UNICEF countries since we supply limited supplies which are
prescription based, we are not required to obtain such registrations.

BCG-ONCO for Immunotherapy - Urovac:

BCG for Immunotherapy or Urovacisa live, freeze dried product, made from an attenuated strain of
Mycobacterium bovis, Danish 1331 strain. BCG-ONCO for immunotherapy has been widely acceptedas the
optimal treatment for carcinoma in situ and high-grade superficial transitional Urinary Bladder Carcinoma. Our
Company produces this drugs under the registered name of ‘Urovac’. However, earlier our company was
producing the same product under the brand name ‘Oncovac’ for Cadila Healthcare Ltd.

We have entered into a sales and distribution agreement with Cadila Healthcare Ltd. for five years and the same is
expiring in June 2016. Under this contract, Cadila Healthcare Ltd. shall market our product BCG-ONCO for
Immunotherapy under it’s own brand name namely ‘Oncovac’ in the domestic Indian market on an exclusive basis.
We have not taken any active steps for renewal of this contract and upon expiry of this exclusive sale and distribution
agreement the challenge will be to market our product under our own registered brand name ‘Urovac’ in India.

Registration Details of BCG-ONCO-Urovac:

The BCG -ONCO-Urovac is registered in India since 23-01-2012 with Trademark Registry.

Revenue from our Products

The following table sets forth certain information regarding our revenue from the sale of products for our
geographic segments and is provided below:

For the For the year ended March 31, (In ` Lacs)
Geographic period ended 2016 2015 2014 2013 2012
Segment June 30,
2016
Domestic
revenue 347.12 1,096.76 101.88 350.99 1,167.78 1,126.58
Overseas
Revenue 667.58 941.96 554.28 - - -

The years 2014 and 2015 saw a deep decline in domestic sales of both BCG vaccine and BCG-ONCO for
Immunotherapy. The decline in the revenues for the BCG Vaccine was due to us not being the lowest bidder in
MoH tenders. The decline in the revenues from BCG ONCO for Immunotherapy was due to price increase
under the arrangement with Cadila Healthcare Limited and corresponding lower quantity ordered by Cadila

87
Healthcare Limited. Subsequently in fiscal 2016, our domestic revenue increased to more stable numbers and
this was mainly due to us getting the tenders from MoH. Also, our overseas revenue increased from 554.28
lacs to 941.96 lacs mainly due to signing the LTA with UNICEF and other Non UNICEF countries.
The following table sets forth certain information regarding our revenue from the domestic sales for the past five
years ending March 31, 2016 and period ended June 30, 2016 as follows:
(In ` Lacs)
Domestic Sale of products For the For the year ended March 31
period June
Manufactured goods 2016 2015 2014 2013 2012
30, 2016
Product BCG VACCINE 304.05 907.41 39.06 329.13 1,044.72 990.41
Product BCG ONCO for 43.07 189.35 62.82 21.86 123.06 136.17
Immunotherapy
Total - Domestic Sales 347.12 1,096.76 101.88 350.99 1,167.78 1,126.58

The years 2014 and 2015 saw a deep decline in domestic sales of both BCG vaccine and BCG-ONCO for
Immunotherapy ,wherein our BCG Vaccine Sale declines to 39.06 lacs and our Product BCG ONCO declined to
62.82 lacs in the fiscal year 2015. The decline in the revenues for the BCG Vaccine was due to us not being the
lowest bidder. The decline in the revenues from BCG ONCO was due to price increase under the arrangement with
Cadila Healthcare Limited and corresponding lower quantity ordered. Subsequently in fiscal 2016, our domestic
revenue increased to more stable numbers and this was mainly due to us getting the tenders from MoH.

The following table sets forth certain information regarding export sales for our two products:
(In ` Lacs)
Export Sale of For the
products period For the year ended March 31
Manufactured
June 30, 2016 2015 2014 2013 2012
goods
2016
Product BCG 667.58
VACCINE 941.96 552.31 - - -
Product BCG ONCO -
- 1.97 - - -
667.58
Total - Export Sale 941.96 554.28 - - -

Our export revenues for the BCG vaccine is primarily due to our arrangement with UNICEF with marginal
revenues from other non UNICEF Countries.

Our Company has been earning positive profits on the operational front. But owing to the fixed costs of finance
and depreciation and the tax charges, the company turns into losses. However, on account of the widening of the
export market over the last two years, the profitability of the company has improved over the earlier years. The
company registered a profit figure in the last financial year 2015-16. For details of the same please refer to
“Financial Statement” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” on page 124 and 149 respectively.

Clinical Trials

We had outsourced clinical trials of our BCG Vaccine to Contract Research Organisations (“CRO”). These
were registered in the clinical trial registry, India. Also, every batch of our vaccine and BCG ONCO undergoes
interalia ‘mandatory animal testing’ at our own facility and we hold an approval for animal testing facility.
Simultaneously each batch is independently tested by Central Drugs Laboratory, Kasauli, Himachal Pradesh.

Competitive Strengths

Our primary competitive strength is that we are a low cost producer of the vaccine. Even though domestically
our price is regulated by National Pharmaceutical Pricing Authority (“NPPA”), even in the international sphere
we have maintained the lowest cost as is apparent from the table below which provides the cost presentation of
suppliers to UNICEF.

BCG Vaccine Supply Metrics to UNICEF

Presentation Supplier Name Years

2016 2017 2018

88
 Presentation Supplier Name Years
2016 2017 2018
BCG Vaccine in a 20 GSBPL $1.36 $1.50 $1.80
dose presentation (in $) Intervax $1.60 $1.72 $1.84
(Per Vial Cost)
Japan BCG Laboratory $3.24 $3.32 $3.40
Serum Institute of India Limited $2.10 $2.10 $2.10
Source: UNICEF.org/supply/files/BCG.pdf; Last updated December 3, 2015.

From the above table we can infer that our Company vaccine is priced the lowest in comparison to other
suppliers. India is one of the major supplier of vaccines for UNICEF programs with the value exceeding 10
million. Further, we are one among the two WHO Pre Qualified suppliers from India. Also, our supply price is
much lower than our main competitor, the Serum Institute of India Limited.

 Niche Product Profile: Immunotherapy market is a niche market and we are one among the few
players active in this segment. Our product UROVAC is one among the brands available in this
segment globally.

 As cure for Other diseases: Recent research has suggested that BCG can be used for treatment of
Diabetes.

 Lower costs in manufacturing and research and development: Indian vaccine manufacturers to
develop vaccines on par with global standards at costs lower than the existing international costs.

 Lower costs of clinical trials: Theer is high potential for contrat services by Indian vaccine
manufacturers in areas like basic research, molecular cloning and gene expression, development of cell
lines for vaccines, fermentation and purification processes, clinical trials and manufacturing.

 Increased support from the Government: The Indian Government’s National Immunization Program
and implementation of national preventing policies effectively backed by global organizations like the
WHO, UNICEF and GAVI and increasing Private-Public Partnerships has provided a major thrust to
the vaccine industry.

 Innovations bringing in new possibilities: New uses of vaccines, new routes of administering them,
new combinations, new antigens and new therapeutic segments of discovering vaccines at lower costs
have all helped fuel greater growth in this space.

 Growing and ageing population: India has the world’s second largest population which has a strong
prevalence of all major adult and pediatric diseases. This, in conjunction with the country’s increasing
per-capita income and growing health consciousness of its populace is providing for a strong domestic
market.

Our Company being one of the few companies focused on vaccine manufacturing is rightly poised to take
advantage of the growing opportunities in this sector.

Experienced Senior Leadership and Management Team

We have seen strong growth under the vision, leadership and guidance of our founders, Mr. P.
Sundaraparipooranan, Dr. P. Murali, who have both been associated with the pharmaceutical business for over
two decades. Our founders have played a key role in developing our business and we benefit from their industry
expertise, vision and leadership. We also have a qualified senior management team including Shri E. S.
Chandrasekaran, Executive Director and Mrs. Sudha Varadrajan, Chief Technical Officer and Advisor with
considerable experience in the vaccine industry, exclusive knowledge in regulatory guidelines and pharma
audits including packaging of sterile drug products. We believe that the vaccine domain knowledge and
experience of our founders and our management team provides us with a significant competitive advantage for
the growth of our business.

Our Facility

Our manufacturing facility is located at No.49, Pappankuppam Village, Gummidipoondi, Tiruvalluvar, Dist -
601 201. The facility is located on 1.4 acres of land space, with a build-up area of 35250.96 sq.ft. Our centre is
built as per the WHO standards. Apart from the Vaccine Manufacturing Facility, the campus also houses our
Research & Development centre. Our R&D Centre is approved by Department of Scientific and Industrial

89
Research, Government of India. The land appurtenant to this facility has been leased from Mr.
Sundaraparipoornan, promoter of our company for a term of ten years commencing from February 23, 2016.
Prior to this the said land was leased from Mr. Sundaraparipoornan as well as Ms. Dakshayani, whose 30%
share in the land was subsequently acquired by Mr. P. Sundaraparipoornan so as to become 100% owner of the
same.

We produced a total of 6 Million doses in 2009, the start of our commercial production. During the last 5 years
we have produced a total of 15,912,183 doses of our vaccines. Our detailed production statistics are given
below:

Capacity For Peripd 2016 2015 2014 2013 2012

ended on
June 30,
2016
Approved Capacity 10,800,000 Vials
Installed Capacity 10,800,000 Vials
Actual Production 15,26,508 52,52,325 19,15,083 14,09,414 29,44,906 43,90,455
Capacity Utilization 14.13% 48.63% 17.73% 13.05% 27.27% 40.65%

Our Company is World Health Organisation, Geneva certified, Good Manufacturing Practices Company.

Land and Other Properties

The Company has purchased 34.01 acres of land at a cost of ` 2,92,97,500/- at No.62, Kunnavalam village
Thiruvalangada, Tiruvallur District from R. Palani, G. Ramamoorthy Naidu and Ors. for further development
and manufacture of other vaccines in addition to our existing facility which the company has acquired on lease.
The 32.14 ½ acres of said land has been mortgaged in favour of Union Bank of India against the total facilities
amounting to ` 15, 36,00,000. None of the person from which Company has bought the land is related to
Promoter/Director.

Also, the land and premises on which the Manufacturing Facility is located are held by us on a leasehold basis
for a period of 10 years. The land on which the Manufacturing Facility is located is in the name of our Promoter
Mr. P. Sundaraparipooranan. The Company is paying a rent of ` 1,00,000 per month .

Further the Registered Office of our Company is located at Kodambakkam, Chennai and the same is held by
our Company on a rental basis from Mr P. Sundaraparipooranan through executed on April 1, 2016 for a period
of eleven months vide lease deed executed on April 1, 2016. Our Company is paying a rent of ` 14,000 per
month

Revaluation of Property:

The Company has revalued the land held by it to an extent of 34.01 acres in Kunnavalam Village, Thiruvallur
District during the financial year 2014-15. Thland was purchased for an amount of ` 2,92,97,500. The land was
revalued upwards to ` 459.20 Lacs as per the prevailing guidelines values. The revaluation was done for
administrative purposes and the same was reflected in the financial statements for the year ended March 31,
2015.

Our Clients

Our major domestic client is Ministry of Health & Family Welfare, Government of India and overseas client is
UNICEF. Further, we also export to our products to clients present in Indonesia, Nepal. For countries like
Nepal, Indonesia we have separate import permits with the concerned countries.

Present Order Book

As on date of this Draft Red Herring Prospectus, our Order Book for our BCG Vaccine is as follows:

Institution Year Number of Vials Rates per Vial

Government of India 2016-2017 25 Lacs ` 36.75
2017-2018 25 Lacs ` 39.50
UNICEF 2016 8 Lacs US $ 1.36

90
 2017 10 Lacs US $ 1.5
2018 10 Lacs US $ 1.8
Nepal 2016 2 Lacs US $ 1.5
2017 2 Lacs US $ 1.5
2018 2 Lacs US $ 1.5

Competition

We function in a sector which manufactures life-saving vaccines, and has a long incubation and gestation period
in comparison with other pharmacological products. Our Company also has to adhere to strict and stringent
WHO – GMP standards to be able to supply to WHO, UNICEF and other such organisations. Due to such
stringent restrictions, apart from our Company, there is one other exclusive manufacturers of the BCG Vaccine
in India i.e. Serum Institute of India. Globally, WHO certified BCG vaccine manufacturers are Statens Serum
Institute, Denmark, Serum Institute of India, India, Japan BCG Lab, Tokyo and InterVax Limited, Canada.

However out other immunotherapy drug BCG-ONCO-Urovac has one producer domestically and very few
producers on a worldwide level.

Employees

Our ability to maintain growth depends to a large extent on our ability to attract, train, motivate and retain
employees. To facilitate our growth, we have 68 full time employees.

We devote significant resources to training our employees and our human resources and compensation practices
proactively address the factors that impact retention. Our comprehensive rewards, recognition programs and
opportunities help to ensure that our employees are motivated and performance oriented.

Intellectual Property

Our Company has registered its BCG-ONCO for Immunotherapy as “UROVAC” in the Trademarks Registry,
Government of India. Our vaccines/ products do not require patents as they are generic in nature.

Insurance

We also maintain insurance policies covering our plant & machinery, vehicles, fire and special perils insurance
for our manufacturing facility. Where insurance has not been maintained, we may be exposed to indefinite
liability in the future.

Environmental Matters

We are subject to significant Indian national and state environmental laws and regulations, including
Regulations relating to the prevention and control of water pollution and air pollution, environmental protection,
hazardous waste management and noise pollution.

We have entered into an agreement with Tamil Nadu Waste Management Limited, a Government of Tamil
Nadu undertaking, for disposal of Animal Waste.

Corporate Social Responsibility

We demonstrate our commitment towards our communities by committing our resources and energies to social
development and we have aligned our CSR programs with Indian legal requirements. The Net Profit of the
company has increased beyond the limit prescribed for applicability of CSR provisions in the financial year
2015-16 and spending under CSR policy does not arise for the financial year 2015-16. In the following year we
have plans to provide basic amenities to villages near our factory.

91
 REGULATIONS AND POLICIES

Except as otherwise specified in this Draft Red Herring Prospectus, the Companies Act, 1956 / the Companies
Act, 2013, We are subject to a number of central and state legislations which regulate substantive and
procedural aspects of our business. Additionally, our operations require sanctions from the concerned
authorities, under the relevant Central and State legislations and local bye–laws. The following description is
an overview of the relevant sector specific laws, policies and regulations, as prescribed by the Government or
State Governments which are applicable for our Company. The information detailed in this chapter has been
obtained from publications available in the public domain. The statements below are based on the current
provisions of Indian law, and the judicial and administrative interpretations thereof, which are subject to
change or modification by subsequent legislative, regulatory, administrative or judicial decisions. The
regulations set out below are not exhaustive, and are only intended to provide general information to the
investors and is neither designed nor intended to be a substitute for professional legal advice.

APPROVALS

For the purpose of the business undertaken by the Company, the Company is required to comply with various
laws, statutes, rules, regulations, executive orders, etc. that may be applicable to the company from time to time.
The details of such approvals have more particularly been described for your reference in the chapter titled
“Government and Other Approvals” beginning on page number 172 of this Draft Red Herring Prospectus.

A. LAWS APPLICABLE TO THE PHARMACEUTICAL INDUSTRY

1. The Drugs and Cosmetics Act, 1940 (“DCA”)

The Drugs and Cosmetics Act, 1940regulates the import, manufacture, distribution and sale of
drugs in India as well as aspects relating to labelling, packing and testing as well as matters
pertaining to drug formulations, biologicals and APIs (“Active Pharmaceutical Ingredient”).
It provides the procedure for testing and licensing new drugs (which includes Vaccines).
These procedures involve obtaining a series of approvals for different stages at which the
drugs are tested, before the Drug Controller General of India (hereinafter referred to as the
“DCGI”) an authority established under the DCA Act grants the final license to allow the
drug to be manufactured and marketed. Obtaining an approval from DGCI involves an
application to be made to the DCGI. Upon examining the medical data, the chemical data and
the toxicity of the drug, the DCGI issues a no objection certificate. The no objection certificate
allows the manufacturer of the drug to move on to the next stage of testing at the central drug
laboratories. The drug is subject to a series of tests at the central drug laboratories, for its
chemical integrity and analytical purity. If the drug meets the standards required by the
authority, the authority issues a certificate in that respect. The DCGI issues a manufacturing
and marketing license in respect of APIs. These licenses are submitted by the company
seeking to produce the drug, to the drug control administration of the state which clears the
drug for manufacturing and marketing. The drug control administration also provides the
approval for technical staff as per the DCA Act and Drugs and Cosmetics Rules, 1945 framed
under the legislation abiding by the WHO and GMP inspection norms. The approvals for
licensing are to be obtained from the drug control administration. The Central Drugs Standard
Control Organisation is responsible for testing and approving APIs and formulations in
consultation with the DCGI. The approval process for conducting clinical trials,
manufacturing and marketing of a drug depends on whether the drug is new chemical entity or
a Recombinant Deoxyribonucleic Acid (“RDNA”) product. Our company is engaged into
vaccines which would be covered under new medicines. For new chemical entities, the DCGI
is the approving authority.

 The DCA regulates the import, manufacture, distribution and sale of drugs and
cosmetics. In view of the provisions of the DCA, no person can import, manufacture,
distribute, stock and sell any drugs and cosmetics, except under the license granted
for respective operations by the authority notified under the DCA. The DCA
prescribes the standards for purity, identity and strength of drugs and cosmetics while
also prohibiting the import of certain categories of drugs and cosmetics. The DCA
mandates that every person holding a license must keep and maintain such records,
registers and other documents as may be prescribed which may be subject to
inspection by the relevant authority.

92
2. The Drugs and Cosmetics Rules, 1945 (“DC Rules”)

The Drugs and Cosmetics Rules, 1945 enacted to give effect to the provisions of the DCA to
regulate the manufacture, distribution and sale of drugs and cosmetics in India. The DC Rules
prescribe the procedure for submission of report to the Central Drugs Laboratory, of samples
of drugs for analysis or test, the forms of Central Drugs Laboratory’s reports thereon and the
fees payable in respect of such reports. The DC Rules also prescribe the drugs or classes of
drugs or cosmetics or classes of cosmetics for the import of which a licence is required, and
prescribe the form and conditions of such licences, the authority empowered to issue the same
and the fees payable therefore. The DC Rules provide for the cancellation or suspension of
such licence in any case where any provisions or rule applicable to the import of drugs and
cosmetic is contravened or any of the conditions subject to which the licence is issued is not
complied with. The DC Rules further prescribe the manner of labelling and packaging of
drugs.

The DC Rules lay down the process mechanics and guidelines for clinical trial, including
procedure for approval for clinical trials. Clinical trials require obtaining of free, informed and
written consent from each study subject. The DC Rules also provide for compensation in case
of injury or death caused during clinical trials. The Central Drugs Standard Control
Organization has issued the guidance for industry for submission of clinical trial application
for evaluating safety and efficacy, for the purpose of submission of clinical trial application as
required under the DC Rules. The Indian Council of Medical Research has issued the Ethical
Guidelines for Biomedical Research on Human Participants, 2006 which envisages that
medical and related research using human beings as research participants must, necessarily,
inter alia, ensure that the research is conducted in a manner conducive to, and consistent with,
their dignity, well-being and under conditions of professional fair treatment and transparency.
Further such research is subjected to evaluation at all stages of the same.

3. The Essential Commodities Act, 1955 (“ECA”)

The ECA gives powers to the Central Government, to control production, supply and
distribution of, trade and commerce in certain essential commodities for maintaining or
increasing supplies and for securing their equitable distribution and availability at fair prices
or for securing any essential commodity for the defence of India or the efficient conduct of
military operations. Using the powers under it, various ministries/ departments of the Central
Government have issued control orders for regulating production, distribution, quality aspects,
movement and prices pertaining to the commodities which are essential and administered by
them. The State Governments have also issued various control orders to regulate various
aspects of trading in essential commodities such as food grains, edible oils, sugar and drugs.
Penalties in terms of fine and imprisonment are prescribed under the ECA for contravention of
its provisions.

4. National Pharmaceuticals Pricing Policy, 2012 (“2012 Policy”)

This 2012 Policy replaced the drug policy of 1994 and laid down the principles for pricing of
essential drugs as specified in the National List of Essential Medicines - 2011 (“NLEM”)
declared by the Ministry of Health and Family Welfare, Government of India and modified
from time to time, so as to ensure the availability of such medicines at reasonable price, while
providing sufficient opportunity for innovation and competition to support the growth of the
Industry. The prices are regulated based on the essential nature of the drugs rather than the
economic criteria/ market share principle adopted in the drug policy of 1994. Further, the 2012
Policy regulates the price of formulations only, through market based pricing which is
different from the earlier principle of cost based pricing. Accordingly, the formulations are
priced by fixing a ceiling price and the manufacturers of such drugs will be free to fix any
price equal to or below the ceiling price.

5. The Drugs (Price Control) Order, 2013 (“DPCO 2013”)

The DPCO was issued by the Central Government under section 3 of the ECA and in
supersession of the Drugs (Prices Control) Order, 1995, thereby giving effect to the 2012
Policy. The DPCO 2013, inter alia, provides that the Central Government may issue

93
 directions to the manufacturers of active pharmaceutical ingredients or bulk drugs and
formulations to increase production or sell such active pharmaceutical ingredient or bulk drug
to such manufacturer of formulations and direct the formulators to sell the formulations to
institutions, hospitals or any agency, procedures for fixing the ceiling price of scheduled
formulations of specified strengths or dosages, retail price of new drug for existing
manufacturers of scheduled formulations, method of implementation of prices fixed by
Government and penalties for contravention of its provisions. The Government has the power
under the DPCO 2013 to recover amounts charged in excess of the notified price from the
manufacturer, importer or distributor and the said amounts are to be deposited in the Drugs
Prices Equalization Account. The DPCO 2013 prescribes certain instances in which case the
provision of the DPCO 2013 will not be applicable. These provisions are applicable to all
scheduled formulations irrespective of whether they are imported or patented, unless they are
exempted. However, the prices of other drugs can be regulated, if warranted in public interest.

6. Clinical Establishments (Registration and Regulation) Act, 2010 (“CERR Act”)

The CERR Act has been enacted by the Central Government to provide for registration and
regulation of all clinical establishments in the country with a view to prescribing the minimum
standards of facilities and services provided by them. The CERR Act also seeks to prescribe
minimum standards of facilities and services which may be provided by such clinical
establishments.

7. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (“DMRA”) seeks
to control advertisements of drugs in certain cases and prohibits advertisement of remedies
that claim to possess magic qualities. In terms of the DMRA, advertisements include any
notice, circular, label, wrapper or other document or announcement. It also specifies the
ailments for which no advertisement is allowed and prohibits advertisements that
misrepresent, make false claims or mislead. Further, the Drugs and Magic Remedies
(Objectionable Advertisements) Rules, 1955 have been framed for effective implementation
of the provisions of the DMRA.

8. The Pharmacy Act, 1948

The Pharmacy Act, 1948 was enacted to regulate the profession of pharmacy. The Pharmacy
Act, 1948 provides for the Constitution and Composition of Central Pharmacy Council and
State Pharmacy Council as well the Registration of Pharmacists. The Central Council is
empowered to make education regulations prescribing the minimum standard of education
required for qualification as a pharmacist.

9. The National List of Essential Medicines, 2011

The National List of Essential Medicines, 2011(“NLEM”), has been introduced to replace the
National List of Essential Medicines, 2003. This new list provides for 348 drugs as essential
instead of the earlier 354. In comparison to NLEM 2003, number of medicines deleted is 47
and 43 medicines have been added. Under which Section: 19 Immunologicals) sub
category 19.3: Vaccines, sub-sub category 19.3.1: For Universal Immunisation covers BCG
Vaccines.

10. Guidelines for Care and Use of Animals in Scientific Research:

The Indian National Science Academy has framed the guidelines for care and use of animals
in biomedical research. There is provision for each laboratory using animals in research to
have an Animal Ethics Committee to regulate and supervise the experiments on animals and
ensure that these guidelines are followed. Objective of guidelines is development of training
facilities for scientists, technicians and other supportive staff for care of animals and their use
in experiments, acceptable experimentation techniques and procedures for anesthesia and
euthanasia, replacing animal experimentation through in vitro systems and constitution of
institutional ethics committee.

94
 11. Clinical Establishments (Registration and Regulation) Act, 2010 (“CERR Act”)

The CERR Act has been enacted by the Central Government to provide for registration and
regulation of all clinical establishments in the country with a view to prescribing the minimum
standards of facilities and services provided by them. The CERR Act also seeks to prescribe
minimum standards of facilities and services which maybe provided by such clinical
establishments.

12. Foreign Trade (Development and Regulation) Act, 1992

The act deals with Development and Regulation of foreign trade by facilitating imports and
exports from and to India. The Import-Export Code number and licence to import or export
includes a customs clearance permit and any other permission issued or granted under this act.
The Export and Import policy, provision for development and regulation of foreign trade shall
be made by the Central Government by publishing an order. The Central Government may
also appoint Director General of Foreign Trade (DGFT) for the purpose of Export-Import
Policy formulation. If any person makes any contravention to any law or commits economic
offence or imports/exports in a manner prejudicial to the trade relations of India or to the
interest of other person engaged in imports or exports then there shall be no Import Export
Code number granted by Director-General to such person and if in case granted shall stand
cancelled or suspended.

B. ENVIRONMENTAL LAWS

Pharmaceutical manufacturers must also ensure compliance with environmental legislation. Some of
the important environmental legislations that are applicable to us are the Water (Prevention and Control
of Pollution) Act, 1974, the Air (Prevention and Control of Pollution) Act, 1981, the Water (Prevention
and Control of Pollution) Cess Act, 1977 and the Environment Protection Act, 1986. Prior to the
undertaking of a project for construction, development or modification of a plant, system or structure,
our Company will be required to file an Environment Impact Assessment (“EIA”) with the State
Pollution Control Board and the Ministry of Environment and Forests (“MOEF”). The relevant
authority will assess the impact of the project on the environment before granting clearance. The
clearance may be granted subject to certain conditions/alterations required to be made in the project.

1. Environment (Protection) Act, 1986 (“EP Act”)

The EP Act was enacted as a general legislation to safeguard the environment from all sources
of pollution by enabling coordination of the activities of the various regulatory agencies
concerned, to enable creation of an authority with powers for environmental protection,
regulation of discharge of environmental pollutants etc. The purpose of the EP Act is to act as
an “umbrella” legislation designed to provide a frame work for Central government co-
ordination of the activities of various central and state authorities established under previous
laws, such as Water Act and Air Act. It includes water, air and land and the interrelationships
which exist among water, air and land, and human beings and other living creatures, plants,
micro-organisms and property. Where the discharge of any environmental pollutant in excess
of the prescribed standards occurs or is apprehended to occur due to any accident or other
unforeseen act, the person responsible for such discharge and the person in charge of the place
at which such discharge occurs or is apprehended to occur is bound to prevent or mitigate the
environmental pollution caused as a result of such discharge and should intimate the fact of
such occurrence or apprehension of such occurrence; and (b) be bound, if called upon, to
render all assistance, to such authorities or agencies as may be prescribed.

2. Air (Prevention and Control of Pollution) Act, 1981 (“Air Act”)

The Air Act has been enacted to provide for the prevention, control and abatement of air
pollution. With a view to curb air pollution, the Air Act has declared several areas as air
pollution control area and also prohibits the use of certain types of fuels and appliances. Prior
written consent is required of the board constituted under the Air Act, if a person intends to
commence an industrial plant in a pollution control area. It lays down the limits with regard to
emissions and pollutants that are a direct result of any operation or activity. Periodic checks on
the factories are mandated in the form of yearly approvals and consents from the
corresponding pollution control boards in the state. Consent to Operate and Consent to
Establish has to be obtained by the company to whom the act is applicable.

95
3. Water (Prevention and Control of Pollution) Act, 1974 (“Water Act”)

The Water Act was enacted in 1974 in order to provide for the prevention and control of water
pollution by factories and manufacturing industries and for maintaining or restoring the
wholesomeness of water. The Water Act prohibits the discharge of toxic and poisonous matter
in the river and streams without treating the pollutants as per the standard laid down by the
Pollution control boards constituted under the Water Act. A person intending to commence
any new industry, operation or process likely to discharge pollutants must obtain prior consent
of the board constituted under the Water Act. Consent to Operate and Consent to Establish has
to be obtained by the company to whom the act is applicable.

4. Water (Prevention and Control of Pollution) Cess Act, 1977 (“Water Act”)

The Water Cess Act has been enacted to provide for the levy and collection of a cess on water
consumed by persons carrying on certain industries and by local authorities with a view to
augment the resources of Central and State Pollution Control Board for the prevention and
control of water pollution , constituted under the Water Act. Schedule II of the act gives
details regarding purpose for which water is consumed in different industries. The act lays
down levy and collection of cess for the purpose of Water Act, 1974.

5. The Bio Medical Waste (Management and Handling) Rules, 2016(“BMW Rules”)

Under the new regime, the coverage has increased and also provides for pre-treatment of lab
waste, blood samples, etc. It mandates bar code system for proper control. It has simplified
categorisation and authorisation. The ambit of the rules has been expanded to include
vaccination camps, blood donation camps, surgical camps or any other healthcare activity.
The BMW Rules apply to all persons who generate, transport, treat, dispose or handle bio-
medical waste in any form. The BMW Rules mandate every occupier of an institution
generating bio-medical waste to take steps to ensure that such waste is handled without any
adverse effect to human health and environment and to set up biomedical waste treatment
facilities as prescribed under the BMW Rules. The BMW Rules further require such persons
to apply to the prescribed authority for grant of authorization and submit an annual report to
the prescribed authority and also to maintain records related to the generation, collection,
storage, transportation, treatment, disposal, and/ or any form of handling of bio-medical waste
in accordance with the BMW Rules and the guidelines issued thereunder.

6. The Manufacturing, Storage & Import of Hazardous Chemicals Rules, 1989 (“MSIHC
Rules”)

The MSIHC Rules, as amended in the year 2000, stipulate that an occupier in control of an
industrial activity has to provide evidence for having identified the major accident hazards and
taking adequate steps to prevent such major accidents and to limit their consequences to
persons and the environment. Further, the occupier has an obligation to show that he has
provided necessary information, training and equipment including antidotes to the persons
working on the site to ensure their safety. Also, the occupier is under an obligation to notify
the concerned authority on the occurrence of a major accident on the site or pipeline within 48
hours.

7. The Hazardous Wastes (Management, Handling and Transboundary Movement) Rules,

2008

The Hazardous Waste Rules define the term ‘hazardous waste’ and any person who has
control over the affairs of a factory or premises or any person in possession of the hazardous
waste is classified as an ‘occupier’. In terms of the Hazardous Waste Rules, occupiers have
been, inter alia, made responsible for safe and environmentally sound handling of hazardous
wastes generated in their establishments and are required to obtain license/authorisation from
the respective state pollution control board for generation, processing, treatment, package,
storage, transportation, use, collection, destruction, conversion, offering for sale, transfer or
the like of the hazardous waste.

96
 8. Noise Pollution (Regulation and Control) Rules, 2000

The Noise Pollution (Regulation and Control) Rules, 2000 seek to regulate and control the
noise producing and generating sources including from industrial activity. In terms of the
Environment Protection Rules, 1986, as amended from time to time, the maximum
permissible sound pressure level for new diesel generator sets with rated capacity up to 1000
Kilovolt Ampere, manufactured on or after January 1, 2005 shall be 75 dB(A) at one meter
from the enclosure surface. Integral acoustic enclosure should be provided at the
manufacturing stage itself. Every manufacturer / importer of diesel generator sets is further
required to have valid certificates of Type Approval and Conformity of Production for each
year, for all the product models being manufactured / imported from January 1, 2005. The
Central Pollution Control Board is the nodal agency.

9. Public Liability Insurance Act, 1991

The Public Liability Act as amended, imposes liability on the owner or controller of hazardous
substances for any damage arising out of an accident involving such hazardous substances. A
list of ‘hazardous substances’ covered by the legislation has been enumerated by the
Government by way of a notification. The owner or handler is also required to take out an
insurance policy insuring against liability under the legislation. The rules made under the
Public Liability Act mandates that the employer has to contribute towards the Environment
Relief Fund, a sum equal to the premium paid on the insurance policies. The amount is
payable to the issuer.

10. The Explosives Act, 1884 (“The Explosives Act”)

The Explosives Act, as amended, regulates the manufacture, possession, use, sale, transport,
import and export of explosives and empowers the Central Government to make rules for the
regulation and prohibition of these activities in relation to any specified class of explosives.
Persons lawfully involved in these activities are required to obtain a license from the
appropriate authority in terms of the provisions of the Explosives Act.

C. EMPLOYMENT AND LABOUR LAWS

1. Factories Act, 1948

The Factories Act, 1948 (“Factories Act”) aims at regulating labour employed in factories. A
“factory” is defined as “any premises whereon ten or more workers are working or were
working on any day of the preceding twelve months, and in any part of which a manufacturing
process is being carried on with the aid of power, or is ordinarily so carried on, or whereon
twenty or more workers are working, or were 81 working on any day of the preceding twelve
months, and in any part of which a manufacturing process is carried on without the aid of
power, or is ordinarily so carried on.”. The main aim of the said Act is to ensure adequate
safety measures and to promote the health and welfare of the workers employed in factories
initiating various measures from time to time to ensure that adequate standards of safety,
health and welfare are achieved at all the places.

Under the Factories Act, the State Government may make rules mandating approval for
proposed factories and requiring licensing and registration of factories. The Factories Act
makes detailed provision for ensuring sanitary conditions in the factory and safety of the
workers and also lays down permissible working hours, leave etc. In addition, it makes
provision for the adoption of worker welfare measures. The prime responsibility for
compliance with the Factories Act and the rules thereunder rests on the “occupier”, being the
person who has ultimate control over the affairs of the factory. The Factories Act states that
save as otherwise provided in the Factories Act and subject to provisions of the Factories Act
which impose certain liability on the owner of the factory, in the event there is any
contravention of any of the provisions of the Factories Act or the rules made thereunder or of
any order in writing given thereunder, the occupier and the manager of the factory shall each
be guilty of the offence and punishable with imprisonment or with fine. The occupier is
required to submit a written notice to the chief inspector of factories containing all the details
of the factory, the owner, manager and himself, nature of activities and such other prescribed
information prior to occupying or using any premises as a factory. The occupier is required to

97
 ensure, as far as it is reasonably practicable, the health, safety and welfare of all workers while
they are at work in the factory.

2. Industrial (Development and Regulation) Act, 1951

The development and regulation of certain industries are governed under this act. For the
purpose of advising on matters relating to development and regulation, the central government
may establish a council known as central advisory council. This council shall have not more
than 31 members including the chairman who shall be appointed by the Central Government.
Every industrial undertaking shall be registered within such period as the central government
may notify in this regard. The Central Government has direct power to assume management or
control of an industrial undertaking owned or for companies in liquidation.

The suits pertaining to this act shall be tried by no court inferior to that of the presidency
magistrate or magistrate of first class. The Central Government has sole power to grant
exemption in certain cases. The First schedule to the act mentions the list of industries to
which the act applies and it includes industry in the business of plastic and synthetic resins as
well as plastic moulded goods.

3. Industrial Disputes Act, 1947 and Industrial Dispute (Central) Rules, 1957

Industrial Dispute Act, 1947 provides for the investigation and settlement of industrial
disputes. It also contains various provisions to prohibit strikes and lock-outs, declaration of
strikes and lockouts as illegal and provisions relating to lay-off and retrenchment and closure,
Conciliation and adjudication of industrial disputes by; Conciliation Officers, a Board of
Conciliation, Courts of Inquiry, Labour Courts, Industrial Tribunals and a National Industrial
Tribunal.

4. Employees’ Provident Funds and Miscellaneous Provisions Act, 1952 (“the EPF Act”)

The EPF Act is applicable to the establishment employing more than 20 employees and as
notified by the government from time to time. All the establishments under the EPF Act are
required to be registered with the appropriate Provident Fund Commissioner. Also, in
accordance with the provisions of the EPF Act, the employers are required to contribute to the
employees’ provident fund the prescribed percentage of the basic wages, dearness allowances
and remaining allowance (if any) payable to the employees. The employee shall also be
required to make the equal contribution to the fund.

5. Employees Provident Fund Scheme, 1952

The Central Government under section 5 of the EPF Act (as mentioned above) frames
Employees Provident Scheme, 1952. The Chairman of the Central Board shall call a meeting
of the Board for the purpose of election to the Executive Committee of the members
representing the employer or the employees as the case may be. In case of meetings a notice of
not less than 15 days from the date of posting with all the required details of the meeting shall
be dispatched by registered post or by special messenger to each trustee or the member of
committee that are present in India. The provisions relating to Chairman presiding over the
meeting or Quorum or nomination of the business are laid down under the scheme. A previous
sanction of the Central Government for undertaking any work by the Central provident fund
commissioner and the financial advisor. The act gives an express provision for classes of
employees and membership of the fund.

6. Employees Deposit Linked Insurance Scheme, 1976

The scheme shall be administered by the Central Board constituted under section 5A of the
EPF Act. The Central Board may by resolution delegate all or any of its power to the
Chairman or Commissioner or both, to sanction the expenditure on any single item. The
provisions relating to recovery of damages for default in payment of contribution with the
percentage of damages are laid down under 8A of the act. The employer falling under the
scheme shall send to the Commissioner within fifteen days of the close of each month a return
in the prescribed form. The register and other records shall be produced by every employer to
Commissioner or other officer so authorized shall be produced for inspection from time to
time. The amount received as the employer’s contribution and also Central Government’s

98
 contribution to the insurance fund shall be credited to an account called as “Deposit-Linked
Insurance Fund Account.”

7. The Employees Family Pension Scheme, 1971

Family pension in relation to this act means the regular monthly amount payable to a person
belonging to the family of the member of the Family Pension Fund in the event of his death
during the period of reckonable service. The scheme shall apply to all the employees who
become a member of the EPF or PF of the factories provided that the age of the employee
should not be more than 59 years in order to be eligible for membership under this act. Every
employee who is member of EPF or PF has an option of for joining scheme. The employer
shall prepare a Family Pension Fund contribution card in respect of the entire employee who
is member of the fund.

8. Employees’ State Insurance Act, 1948 (the “ESI Act”)

All the establishments to which the ESI Act applies are required to be registered under the ESI
Act with the Employees State Insurance Corporation. This Act requires all the employees of
the establishments to which this Act applies to be insured in the manner provided there under.
Employer and employees both are required to make contribution to the fund. The return of the
contribution made is required to be filed with the Employee State Insurance department.

9. Payment of Wages Act, 1936

Payment of Wages Act, 1936 contains provisions as to the minimum wages that are to be
fixed by the appropriate Governments for the employees, fixation and revision for the
minimum wages of the employees, entitlement of bonus to the employees, fixing the payment
of wages to workers and ensuring that such payments are disbursed by the employers within
the stipulated time frame and without any unauthorized deductions.

10. Payment of Bonus Act, 1965

The Payment of Bonus Act, 1965 imposes statutory liability upon the employers of every
establishment covered under this Act to pay bonus to their employees. It further provides for
payment of minimum and maximum bonus and linking the payment of bonus with the
production and productivity.

11. Payment of Gratuity Act, 1972

The act deals with payment of gratuity to employees engaged in factories, mines and allied
companies. The act applies to every factory, mines, oilfield, plantation, port and railway
company or every shop or establishment in which ten or more people are employed on any
day in preceding twelve months. A shop or establishment to which this act has become
applicable shall be continued to be governed by this act irrespective of the number of persons
falling below ten at any day. The gratuity shall be payable to an employee on termination of
his employment after he has rendered continuous service of not less than five years on
superannuation or his retirement or resignation or death or disablement due to accident or
disease. The five year period shall be relaxed in case of termination of service due to death or
disablement.

12. Minimum Wages Act, 1948

The Minimum Wages Act, 1948 (“MWA”) came into force with an objective to provide for
the fixation of a minimum wage payable by the employer to the employee. Under the MWA,
every employer is mandated to pay the minimum wages to all employees engaged to do any
work skilled, unskilled, manual or clerical (including out-workers) in any employment listed
in the schedule to the MWA, in respect of which minimum rates of wages have been fixed or
revised under the MWA. Construction of Buildings, Roads, and Runways are scheduled
employments. It prescribes penalties for non-compliance by employers for payment of the
wages thus fixed.

13. Industrial Employment (Standing Orders) Act, 1946

99
 In order to strengthen the bargaining powers of the workers this act is established, it requires
the employers to formally define the working conditions to the employee. The employer is
required to submit five copies of standing orders required by him for adoption of his industrial
establishment. The standing order shall unless in case of an appeal, come into operation on the
expiry of thirty days from the date on which authenticated copies were sent. An employer
failing to submit the draft standing order as required by the act shall be liable to pay fine as
per section 13 of the act.

14. Maternity Benefit Act, 1951

The Maternity Benefit Act, 1951 provides for leave and right to payment of maternity benefits
to women employees in case of confinement or miscarriage etc. The act is applicable to every
establishment which is a factory, mine or plantation including any such establishment
belonging to government and to every establishment of equestrian, acrobatic and other
performances, to every shop or establishment within the meaning of any law for the time
being in force in relation to shops and establishments in a state, in which ten or more persons
are employed, or were employed, on any day of the preceding twelve months; provided that
the state government may, with the approval of the Central Government, after giving at least
two months’ notice shall apply any of the provisions of this act to establishments or class of
establishments, industrial, commercial, agricultural or otherwise.

15. Equal Remuneration Act, 1979

The Equal Remuneration Act 1979 provides for payment of equal remuneration to men and
women workers and for prevention discrimination, on the ground of sex, against Female
employees in the matters of employment and for matters connected therewith. The act was
enacted with the aim of state to provide Equal Pay and Equal Work as envisaged under Article
39 of the Constitution.

16. Child Labour Prohibition and Regulation Act, 1986

The Child Labour Prohibition and Regulation Act 1986 prohibits employment of children
below 14 years of age in certain occupations and processes and provides for regulation of
employment of children in all other occupations and processes. Employment of Child Labour
is prohibited in Building and Construction Industry.

17. Trade Union Act, 1926

Provisions of the Trade Union Act, 1926 provides that any dispute between employers and
workmen or between workmen and workmen, or between employers and employers which is
connected with the employment, or non-employment, or the terms of employment or the
conditions of labour, of any person shall be treated as trade dispute. For every trade dispute a
trade union has to be formed. For the purpose of Trade Union Act, 1926, Trade Union means
combination, whether temporary or permanent, formed primarily for the purpose of regulating
the relations between workmen and employers or between workmen and workmen, or
between employers and employers, or for imposing restrictive condition on the conduct of any
trade or business etc.

18. The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal)
Act, 2013

In order to curb the rise in sexual harassment of female at workplace, this act was enacted for
prevention and redressal of complaints and for matters connected therewith or incidental
thereto. The terms sexual harassment and workplace are both defined in the act. Every
employer should also constitute an “Internal Complaints Committee” and every officer and
member of the company shall hold office for a period of not exceeding three years from the
date of nomination. Any aggrieved woman can make a complaint in writing to the Internal
Committee in relation to sexual harassment of female at workplace. Every employer has a
duty to provide a safe working environment at workplace which shall include safety from the
persons coming into contact at the workplace, organising awareness programs and workshops,
display of rules relating to the sexual harassment at any conspicuous part of the workplace,
provide necessary facilities to the internal or local committee for dealing with the complaint,
such other procedural requirements to assess the complaints.

100
 19. Contract Labour (Regulation and Abolition) Act, 1970

Contract Labour (Regulation and Abolition) Act, 1970 regulates the employment of contract
labour in certain establishments, provides for its abolition in certain circumstances. It applies:

 to every establishment which does not carry on intermittent / casual work in which 20 or
more workmen are employed on any day of the preceeding 12 months as contract
labour.
 to every contractor who employ or employed on any data of the preceeding 12 months,
20 or more workmen.

Every Establishment must, within the specified period, apply to the registering officer for
registration of the Establishment and obtain a certificate of registration containing such
particulars as may be prescribed. Further, a contractor can only undertake or execute any work
through contract labour under and in accordance with a licence issued in that behalf by the
licensing officer. The license may contain conditions including, in particular, conditions as to
hours or work, fixation of wages and other essential amenities in respect of contract labour.
The license will be valid for the period specified therein. Every contractor is duty-bound to
provide and maintain supply of drinking water, canteens, rest-rooms latrines and urinals,
washing facilities, first- aid box in the prescribed manner for contract labour employed in
connection with the work of an Establishment to which the Act applies. If such amenities are
not provided by the contractor within the prescribed time, such amenities shall be provided by
the principal employer of the Establishment. Contractor shall be responsible for payment of
wages to each worker employed by him as contract labour within the prescribed period and in
case he fails to do so, the principal employer of the Establishment will be so responsible.

D. TAXATION LAWS

1. Income Tax Act, 1961

The Company will be entitled to deduction under the sections mentioned hereunder from its
total income chargeable to Income Tax.

i) Deduction under section 35(2AB):

As per section 35(2AB), where a company engaged in the business of bio-technology or

in any business of manufacture or production of any article or thing, incurs any
expenditure on scientific research (not being expenditure in the nature of cost of any
land or building) on in-house research and development facility as approved by the
prescribed authority, then, there shall be allowed a deduction of a sum equal to two
times of the expenditure so incurred. Such weighted deduction under section 35(2AB) is
available till assessment year 2017-18.

The Company is eligible to claim a weighted deduction of 200% on the expenditure

incurred on clinical trial research, Research expenses, tangible and intangible assets
(other than land and building) and other revenue expenditure specified for deduction
under section 35(2AB) on in-house research and development facility as approved by
the prescribed authority.

ii) Deduction under section 35(1)(iv):

As per section 35(1)(iv), expenditure of capital nature on scientific research related to

the business carried on by the assesse, would be allowed as deduction in the year in
which such capital expenditure is incurred.

The company is eligible to claim 100% deduction of expenditure incurred on the

prescribed assets, which qualify as per section 35(1)(iv).

2. Excise Regulations

101
 The Central Excise Act, 1944 seeks to impose an excise duty on excisable goods which are
produced or manufactured in India. The rate at which such a duty is imposed is contained in
the Central Excise Tariff Act, 1985. However, the Indian Government has the power to
exempt certain specified goods from excise duty by notification.

3. Value Added Tax

The levy of Sales Tax within the state is governed by the VAT Act and Rules of the respective
states. VAT has resolved the problem of Cascading effect (double taxation) that were being
levied under the hitherto system of sales tax. Under the current regime of VAT the trader of
goods has to pay the tax (VAT) only on the Value added on the goods sold. Hence VAT is a
multi-point levy on each of the entities in the supply chain with the facility of set-off of input
tax- that is the tax paid at the stage of purchase of goods by a trader and on purchase of raw
materials by a manufacturer. Only the value addition in the hands of each of the entities is
subject to tax. Periodical returns are required to be filed with the VAT Department of the
respective States by the Company.

4. Central Sales Tax Act, 1956

Central Sales Tax Act, as amended, formulates principles for determining (a) when a sale or
purchase takes place in the course of inter-state trade or commerce; (b) when a sale or
purchase takes place outside a State and (c) when a sale or purchase takes place in the course
of imports into or export from India. The Central Sales Tax Act provides for levy, collection
and distribution of taxes on sales of goods in the course of inter-state trade or commerce and
also declares certain goods to be of special importance in inter-state trade or commerce and
specifies the restrictions and conditions to which state laws imposing taxes on sale or purchase
of such goods of special importance (called as declared goods) shall be subject. Central sales
tax is levied on interstate sale of goods. Sale is considered to be inter-state when (a) sale
occasions movement of goods from one state to another or (b) is effected by transfer of
documents during their movement from one state to another. Central sales tax is payable in the
state from which movement of goods commences (that is, from which goods are sold). The tax
collected is retained by the state in which it is collected. The Central Sales Tax Act is
administered by sales tax authorities of each State. The liability to pay tax is on the dealer,
who may or may not collect it from the buyer. In accordance with the Central Sales Tax Act,
every dealer registered under the Act shall be required to furnish a return in Form I (Monthly/
Quarterly/ Annually) as required by the State sale Tax laws of the assesse authority together
with treasury challan or bank receipt in token of the payment of taxes due.

5. The Customs Act, 1962

All the laws relating to customs are consolidated under the Indian Customs Act, 1962. The
officers of customs shall be appointed by the Central Government as it thinks fit. An
officer of customs may exercise the powers and discharge the duties conferred on him. The
provisions relating to appointment of customs ports, airports, warehousing stations are laid
down under the act. There shall be absolute or partial prohibition on import or export of goods
by the Central Government for maintenance of security in India. The interest on levy of or
exemption of Customs duty is thus laid down under the act. The clearance of imported goods
and export shall not apply to baggage and goods imported or to be exported by post.

F. FOREIGN INVESTMENT LAWS

The Consolidated FDI Policy allows for FDI up to 100%, under the automatic route for Greenfield
investments in the pharmaceuticals sector and FDI up to 100%, for brownfield investments
(investments in existing companies) under the government approval route.

G. INTERNATIONAL STANDARDS/ REGULATIONS/GUIDELINES:

1. WHO Technical Report Series no. 979, 2013

Recommendations refer to freeze-dried BCG vaccines for national regulatory authorities

(NRAs) and for manufacturers of biological products. If an NRA so desires, these
Recommendations may be adopted as definitive national requirements, or modifications may
be justified and made by the NRA. It is recommended that modifications to these

102
 Recommendations be made only on condition that such modifications ensure that the vaccine
is at least as safe and efficacious as that prepared in accordance with the recommendations set
out. This document provides: recommendations for the production and control of BCG
vaccines (Part A);guidelines for nonclinical evaluation (Part B); guidelines for the content of
the clinical development programme applicable to BCG vaccines (Part C); and
recommendations for NRAs (Part D). Report deals with general manufacturing conditions and
precaution which are to be taken along with recommendations about filling containers, control
test, labelling, distribution, transport, storage and expiry date. It also provides for general
guideline to NRA regarding certification.

2. Revised Requirements for Biological Substances:

Revised Requirements for Biological substances are issued by WHO which covers
Manufacturing Establishments and Control Laboratories involved in the production of
Inactivated (Poliomyelitis Vaccines and Poliomyelitis Vaccines (Oral). The same was revised
in 1965. Purpose of the requirements are to ensure exchange of these substances between the
countries. Our company is following General Requirements for Manufacturing Establishments
and control Laboratories (Requirements for Biological Substances No.1) wherein it lays down
the general requirement for the personnel, building and equipment, production control, filling
and containers, tests, records, labelling, storage and expiry date.

3. Good Manufacturing Practice (GMP)

Good manufacturing practices: main principles for pharmaceutical products. In: WHO Expert
Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report. Geneva,
World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 3.

Good manufacturing practice (GMP) is that part of quality assurance by WHO which ensures
that products are consistently produced and controlled to the quality standards appropriate to
their intended use and as required by the marketing authorization. The first WHO draft text on
good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the
request of the Twentieth World Health Assembly GMP is aimed primarily at diminishing the
risks inherent in any pharmaceutical production, which may broadly be categorized in two
groups: cross contamination/mix-ups and false labelling. Above all, manufacturers must not
place patients at risk due to inadequate safety, quality or efficacy; for this reason, risk
assessment has come to play an important role in WHO quality assurance guidelines. In 1992,
the revised draft requirements for GMP were presented in three parts, of which Part one is (1).
“Quality management in the medicines industry: philosophy and essential elements” and Part
2 is “Good practices in production and quality control, of which Annexure 2 specifically deals
with the main Principles of pharmaceutical products titled as “WHO Good Manufacturing
Practices For Pharmaceutical Products: Main Principles” containing provisions relating to
sanitation, qualification and validation, complaint, product recalls, contract production,
analysis and other activities, self-inspection, quality audits and suppliers, training, material
and quality control standards which are to be adopted by pharmaceuticals. Quality Assurance
of Pharmaceuticals: A compendium of guidelines and related materials is also released by
WHO having 2 volumes covering aspects related to product assessment and registration,
distribution, laboratories services, manufacturing, hazards and inspection and training
requirements.

4. Recommendations to Ensure the Quality, Safety and Efficacy of BCG Vaccines issued by
WHO:

These recommendations are published by WHO which are scientific or advisory in nature.
These are guidance to National Regulatory Authorities regarding manufacturing of biological
products. These include recommendations for individual vaccines, and also more general
guidelines on technical or regulatory topics such as cell substrates, nonclinical evaluation, or
clinical evaluation. This activity is critical to ensure the quality of essential vaccines in a
global market. These includes recommendation with relation to Manufacturing, Non clinical
evaluation of BCG vaccines, clinical evaluation of BCG vaccines and guidelines for NRAs.

5. Uniform Code of Pharmaceuticals Marketing Practices, 2015

103
 It is expected to encourage good marketing practices by pharmaceutical companies. This Code
prohibits companies from paying cash or monetary incentives to any healthcare professionals
under any pretext and restricts pharmaceutical companies to provide free samples of drugs to
any person, not qualified to prescribe such product. It has been described in the Code that the
information about the medicinal products must be accurate, balanced, fair, and objective and
also must not mislead either directly or by implication. It is necessary to declare the clear
information about the medicinal products because it may somehow cause danger to the
consumers.

6. Good manufacturing practices for biological products. In: WHO Expert Committee on
Biological Standardization. Forty-second report. Geneva, World Health Organization,
1992 (WHO Technical Report Series, No. 822), Annex 1.

These Guidelines are complimentary to the “Good Manufacturing Practices for

Pharmaceutical Products”. These guidelines provide manufacturing procedure relating to
growth of strains of microorganisms, extraction of substances from biological tissues and
hybridomatachniques. This guideline cover aspects related to premises, production, labelling,
lot processing records and quality assurance.

7. Guidelines for stability evaluation of vaccines. In: WHO Expert Committee on Biological
Standardization. Fifty-seventh report. Geneva, World Health Organization, 2011 (WHO
Technical Report Series, No. 962), Annex 3.

The aim of this document is to provide the scientific basis and guiding principles for
evaluation of vaccine stability for the purpose of clinical trial approval, licensing, and post-
licensure monitoring. These recommendations feature stability as an important element and
provide guidance for stability testing for individual vaccines. Regulatory expectations for
stability studies is to be conducted at different stages of development (i.e. clinical trial
approval, licensing, lot release and post-licensure monitoring). Focus of these guidelines is on
how to evaluate vaccine stability, not to provide guidance on how to stabilize a vaccine.

8. Guideline for establishing or improving primary and intermediate vaccine stores.

Geneva, World Health Organization, 2002

Guidelines provides for different categories of packaging. For BCG Vaccine Class B
packaging is to be adopted. Class B packaging is designed to ensure that the temperature of
the vaccine does not rise above +30°C for a minimum exposure of 48 hours at an ambient
temperature of 43°C. It must also prevent the temperature of the vaccine from dropping below
+2°C for a minimum of 48 hours at an ambient temperature of -5°C. Class B packaging is
used for transporting BCG. Furthermore, as BCG vaccines are damaged by exposure to
daylight and florescent light therefore guidelines provide for keeping them in dark brown
glass or protecting it through vials and artificially lighting the area where it is kept. Hence the
guidelines are framed with a view of promoting a good storage and distribution system.

9. Temperature sensitivity of vaccines. Geneva, World Health Organization, 2006

(WHO/IVB/06.10).

The document incorporates detailed information on vaccine management related issues and
especially concerns on exposure of freeze sensitive vaccines to freezing temperatures. Vaccine
vial monitor information has also been expanded to explain how different categories apply to
different types of vaccines. The document also discusses the future of the cold chain in
reducing the dependency by exploiting the stability of each vaccine to the greatest possible
extend. Detailed information is also included on the use of shake test along with provision of a
learning guide as an annex. Point 9 of Part II deals with BCG vaccine which includes impact
of temperature, stability, packaging, effect of light and stability of reconstituted BCG vaccine.
Most freeze-dried BCG vaccines are stable at temperatures of 2-8°C for at least two years. At
room temperature stability varies; after storage for several months a loss of viability of
approximately 30% can be expected. The daily loss of viability in vaccines kept for a few
weeks at a temperature of 37°C ranges between 1% and 2%.

G. OTHER LAWS/ SCHEMES/ PROGRAMS:

104
 1. “UIP” or Universal Immunisation Program:

Universal Immunisation Programme is a vaccination program launched by Government of

India in 1985. With objectives of increase immunisation coverage, improve the quality of
services, establish a reliable code chain system of health facility level, introduce a district wise
system of monitoring of performance and achieve self-sufficiency in vaccine production.
Diseases protected by vaccination under UIP include 1. Diphtheria, Pertussis, Tetanus, Polio,
Tuberculosis, Measles, Hepatitis B, Japanese Encephalitis( brain fever), Meningitis and
Pneumonia caused by HaemophilusInfluenzae type b. Under UIP, following vaccines are
provided: 1. BCG (Bacillus Calmette Guerin) 2. DPT (Diphtheria, Pertussis and Tetanus
Toxoid) 3. OPV (Oral Polio Vaccine) 4. Measles 5. Hepatitis B 6. TT (Tetanus Toxoid) 7. JE
vaccination (in selected high disease burden districts) 8. Hib containing Pentavalent vaccine
(DPT+HepB+Hib). As a key element of the national child survival strategy, UIP has
contributed significantly to reducing mortality and morbidity due to vaccine-preventable
diseases and the infant mortality rate over the last decade. While surveillance information for
specific VPDs is limited, the steady fall of IMR from 123 to 50 deaths per 1000 live-births
does in part reflect the impact of the UIP. This program is under the Immunisation Division
which is a part of the RCH program under National Rural Health Mission (NRHM) and is
placed in the Ministry Of Health and Family Welfare, Nirman Bhawan New Delhi. This
division provides all the technical assistance required to undertake the activities under UIP.
The division reviews the state Program implementation plans and facilitates in its approval
process as per norms and guidelines The key roles of this division include activities related to
Routine Immunization, Campaigns (SIAs) such as Polio, Measles, and Japanese Encephalitis,
Monitoring Adverse Events Following Immunization (AEFI), Vaccine and Cold Chain
Logistics, Strategic communication related to immunization program and trainings related to
Immunization Program. The goal of the current comprehensive multiyear plan for 2013-2017
is to reduce mortality and morbidity due to vaccine preventable diseases through high quality
immunization programs. Its key objectives are to:

 Improve program service delivery for equitable and efficient immunization services in
all districts;
 Increase demand and reduce barriers for people to access immunization services
through improved advocacy at all levels and social mobilization;
 Strengthen and maintain robust surveillance system for Vaccine Preventable Diseases
(VPDs) and Adverse Events Following Immunization (AEFI);
 Introduce and expand the use of new and underutilized vaccines and technology in UIP;
 Strengthen health system for the immunization program; and
 Contribute to global polio eradication and the elimination of measles, maternal and
neonatal tetanus.

H. GENERAL LAWS APPLICABLE:

In addition to the above, our Company is also required to comply with the provisions of the Companies
Act, 2013, Indian Contract Act, 1872, Sale of Goods Act, 1926, intellectual property laws and other
applicable statutes imposed by the Centre or the State for its day-to-day operations. Our Company is
also amenable to various central and state labour laws and tax laws.

105
 HISTORY AND CERTAIN CORPORATE MATTERS

Our Company was incorporated as a Private Limited Company “Green Signal Bio Pharma Private Limited” on
November 21, 2005 at Chennai under the Companies Act, 1956. Pursuant to our Company passing a resolution
under section 13 (2), of the Companies Act 2013 on March 24, 2016, and upon the issuance of a fresh
certificate of incorporation consequent to the name change, the name of our Company was changed to
GreenSignal Bio Pharma Private Limited with effect from April 21, 2016. Further, the shareholders of our
Company passed a resolution dated March 24, 2016 and the Company was changed to a Public Limited
Company with effect from May 12, 2016.

The CIN of the Company is U24232TN2005PLC58068.

We are into Vaccine Manufacturing and as on date we produce two products:

1. BCG Vaccine for immunization against Tuberculosis

2. BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of Urinary Bladder Carcinoma
and our brand name for the same is ‘Urovac’.

Our manufacturing facility is located at No.49, Pappankuppam Village, Gummidipoondi, Tiruvalluvar Dist -
601 201. The facility is located on a sprawling 3 acres of land space, with a build-up area of 10,000 sq.ft.
Our centre is built as per the WHO standards and HVAC regulations. Apart from the Vaccine
Manufacturing Facility, the campus also houses our DSIR approved Research & Development centre. Our
Company is Good Manufacturing Practices (GMP) as laid down by World Health Organisation (WHO)
certified.

For more information on our Company’s activities, services, market, growth, technology, managerial
competence, competitive strengths, please refer to the chapters and “Industry Overview” , “Our
Business” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations”, on pages 64, 82 and 149 respectively.

Changes in the Registered Office of the Company:

Our Registered Office is located at: Old No.5, New No.13/A3, “Sai Nikethan”. Circular Road, United India
Colony, Kodambakkam, Chennai 600 024. There have been no changes in the Registered Office of the
Company since inception.

Major Events in the Company

The major events in the history of our company are:

Sl. No. MILESTONE / EVENT MONTH / YEAR

1. Incorporation of our Company November, 2005
2. Vaccine Seed Transfer December, 2006
3. Animal House Qualified for Clinical Trials February, 2008
4. COPP & BCG Vaccine Approval by Drug Authority March, 2009
5. Commencement of Commercial Manufacturing January, 2009
6. GMP Audit completed and certification received May. 2010
7. First Shipment of Vaccine to Government of India July, 2010
8. GMP Approval April, 2011
9. Audit by WHO and award of PQ certification November 2015
10. First Order received from UNICEF for BCG Vaccine December, 2015
11. Conversion from Private Limited to Public Limited Company May, 2016
12. Letter of recommendation for import of BCG Vaccine from government of Nepal April 2016

Changes in the Memorandum of Association of our Company:

The following changes have been made to the Memorandum of Association of our Company since its
incorporation:

106
 Date of Shareholders approval Nature of Change
March 24, 2016 1.The following two objects clauses were included under the Main Object
in the MoA:
a.To carry on in India, abroad or elsewhere all or any of the business of
manufacture, trade etc. related areas pertaining to bio-technology
b.To carry on in India, abroad or elsewhere all or any of the business of
consulting, development etc. pertaining to bio-technology.

2. Company name changed from Green Signal Bio Pharma Private Limited
to GreenSignal Bio Pharma Private Limited

3. Company deleted Clause III C of the MoA pertaining to Incidental and

other Object Clauses

4. Clause IV & V – Liability Clause and Capital Clause has been

reworded to incorporate the requirements of Companies Act, 2013.

5. Conversion from private limited company to public limited company.

May 2, 2016 1.The Capital Clause of the MoA – Authorised Share Capital increased
from Rs.200 Lakhs to Rs.400 Lakhs.

Main Objects of our Company

1. To carry on in India, abroad or elsewhere all or any of the business of manufacture, trade import,
export, pharmaceutical products to be used for the well being of human beings and animals, Cosmetics
and the business of running, set up, managing, establishing hospitals, clinics, pharmacies and other like
entities.

2. To carry on in India, abroad or elsewhere the business of trading, entering into dealership, hiring, renting of
medical equipments, appliances and other similar gadgets of diagnostic agents, diagnostic tools, diagnostic
equipments, vaccines, para medical activities and to do all other allied activities incidental thereto.

3. To carry on in India, abroad or elsewhere the business of establishing, running hiring of medical
diagnostic laboratories clinical, pathological or research laboratories for the well being of human
beings and animals.

4. To carry on in India, abroad or elsewhere all or any of the business of manufacture, trade, import,
export, research, development of all types of products that include vaccines, Bio-Technology, Bio-
informatics, seeds for vaccines, raw material for vaccines and other products involving the field of Bio-
Technology, Bio-informatics, information technology and other technology related areas pertaining to
bio technology.

5. To carry on in India, abroad or elsewhere all or any of the business of consulting, development,
advisory services in the field of pharmaceutical, medical, para-medical, bio-technology, bio-
informatics, and all other technology and information technology areas pertaining to bio technology.

Our Shareholders

As on date of the Draft Red Herring Prospectus, the total number of holders of Equity Shares is 8. For further
details of our shareholding pattern, please refer to the chapter “Capital Structure- Shareholding Pattern of our
Company” on page 53.

Our Holding Companies

As on date of this Draft Red Herring Prospectus, our Company does not have any Holding Companies.

107
Our Subsidiaries

As on date of this Draft Red Herring Prospectus, our Company does not have any Subsidiaries.

Time/Cost Overrun, Defaults and Lock out/Strikes

There has been no time/cost overrun, defaults and lock our/strikes in our Company as on date of filing of this
Draft Red Herring Prospectus.

Injunction or Restraining Order

Except as mentioned in the chapter “Outstanding Litigation and Material Developments” on page 167 Our
Company is not operating under any and there are no injunctions or restraining orders.
Technology, Market Competence and other details regarding our Company
For details of our Company’s business, products and services, its growth, standing with reference to the prominent
competitors, management, technologies and services, please refer to the chapters “Industry Overview”and
“Our Business” and on pages 64 and 82, respectively.

Capital Raising through Equity and Debt

Except as mentioned in the chapter “Capital Structure” on page 48, our Company has not raised any capital by
way of equity or convertible debentures. For details of debts facilities availed by our Company, please refer to
“Financial Indebtedness” on page 166.

Defaults or Rescheduling of borrowings with Financial Institutions/Banks

There have been no defaults or rescheduling of borrowings with the financial institutions/banks for which a notice
has been issued or any action has been taken by any financial institutions/banks.

Revaluation of Assets

Our Company has not revaluated its assets for a period five years prior to the filing of this Draft Red Herring
Prospectus except as stated below:

The Company has revalued the land held by it to an extent of 34.01 acres in Kunnavalam Village, Thiruvallur
District during the financial year 2014-15. The land was revalued to ` 459.20 lacs as per the prevailing
guideline value. The revaluation was done for administrative purposes and the same was reflected in the
financial statements for the year ended March 31, 2015.
Scheme of Arrangement and Amalgamations

We have not entered into any Scheme of Arrangement and Amalgamations as on date of filing of this Draft Red
Herring Prospectus.

Summary of Key Agreements

Agreement with Cadila Healthcare Limited

We have entered into a sales and distribution agreement with Cadila Healthcare Ltd. For five years and the same
is expiring in June 2016. Under this contract, Cadila Healthcare Ltd. Shall market our product BCG-ONCO for
Immunotherapy under it’s own brand name namely ‘Oncovac’ in the domestic Indian market on an exclusive
basis. We have not taken any active steps for renewal of this contract and upon expiry of this exclusive sale and
distribution agreement the challenge will be to market our product under our own registered brand name
‘Urovac’ in India.

Financial and strategic partners

Our Company does not have any financial and strategic partners as of the date of this Draft Red Herring
Prospectus.
Our Associates

The Company does not have any Associate Companies.

108
 OUR MANAGEMENT

Board of Directors

The Articles of Association of the Company provides that our Company shall not have less than 3 (Three)
Directors and not more than 14 (Fourteen) Directors. We currently have 5 (Five) Directors on our Board of
Directors.

The following table sets forth the details of our Board of Directors as of date of filing of this Draft Red Herring
Prospectus:

Sl. Name, Designation, Occupation, DIN, Nationality, Age Other Directorships/

No. Address, Date of Appointment and Term Partnerships/Trusteeships
1 Mr. N. Gopalaswami 72 1.Span Divergent Limited
Designation: Chairman
2.Code Consulting Private
Occupation: Business Limited

DIN: 02779229

Address: Flat No.5, Leo Madhuram, 39, Giri Road, T

Nagar, Chennai 600 017.

Nationality: Indian

Date of Appointment: February 20, 2011

Date of reappointment May 2, 2016

Term: 5 years
2 Dr. P. Murali 43 1.Chennai Mall Properties
Designation: Managing Director Private Limited

Occupation: Business

DIN: 02277738

Address: No.21S, ICC 5th Street, W Block, B Sector,

Anna Nagar West Extn., Chennai 600 101.

Nationality: Indian

Date of Appointment: October 6, 2008

Date of Reappointment: April 2, 2016
Term: 5 years
3 Mr. E. S. Chandrasekaran 64 Nil
Designation: Executive Director

Occupation: Business

DIN: 02377328

Address: Flat No.3, Orchid Krish Aruna, No.7, 31 st

Cross Street, Besant Nagar, Chennai 600 090.

Nationality: Indian

Date of Appointment: October 6, 2008

Date of Reappointment: April 2, 2016

Term: 5 years
4 Dr. P. Perumalsamy 62 Nil
Designation: Non Executive Independent Director

109
Sl. Name, Designation, Occupation, DIN, Nationality, Age Other Directorships/
No. Address, Date of Appointment and Term Partnerships/Trusteeships
Occupation: Business
DIN: 07497868

Address: No.86, 2nd Main Road, Mogappair West

Garden, Nolambur, Chennai 600 037.

Nationality: Indian

Date of Appointment: March 26, 2016

Term: 5 years
5 Mrs. Lakshmi V Iyer 47 Nil
Designation: Non Executive Independent Director

Occupation: Business

DIN: 07498857

Address: No.29, Block I, Sindur Green Park,

Jayachandran Nagar, Jaladanpet, Chennai 600 100.

Nationality: Indian

Date of Appointment: March 26, 2016

Term: 5 years

Relationship between Directors/Promoters

None of our Directors/Promoter are related to each other except the following:

Name of the Director Related To Nature of Relationship

P. Murali P. Sundaraparipooranan Brother
(Promoter)

CONFIRMATIONS

None of our Directors is or was a director of any listed company whose shares have been or were suspended from
being traded on BSE or NSE, during the last five years preceding the date of this Draft Red Herring Prospectus,
during the term of his/ her directorship in such company.

None of our Directors is or was, a director of any listed company which has been or was delisted from any stock
exchange during the tenure of directorship in such company.

BRIEF PROFILE OF OUR DIRECTORS

Mr. N. Gopalaswami, aged 72 years is a former Chief Election Commissioner of India. He was awarded
Padma Bhushan, one of India’s highest civilian honours in 2015. He is a graduate in Chemistry from St.
Joseph’s College, Tiruchirappalli and is a gold medallist in his Post Graduation in Chemistry from Delhi
University. He is a Diploma holder in Urban Development Planning from University of London. He is a 1996
batch Indian Administrative Services Officer belonging to the Gujarat Cadre and worked in various capacities in
Gujarat. He took charge as the Chief Election Commissioner (CEC) of India on June 30, 2006 and retired in
April 2009. Prior to his appointment as CEC, he was serving as Union Home Secretary to the Government of
India. Presently, he is also the Chairman of Kalakshetra, Chennai and also the President of Vivekananda
Educational Society, running a group of schools in and around Chennai.

Dr. P. Murali, aged 43 years, is an Arts Graduate and a Masters in Labour Management. He holds a Doctorate
in Management from Madras University. He is Ph.D. from Madras University and is the Managing Director
and the Principal Officer of GreenSignal Bio Pharma Limited (GSBPL). He has over 20 years of rich &
extensive global experience in Education Industry and Pharma Production, Installation & Commissioning, and
Quality Management. He joined the company in 2008 and since then has held positions of increasing

110
responsibility as Managing Director. He leads the core team at GSBPL Along with his responsibilities as
Managing Director & CEO, Dr. Murali work on other causes that he holds dear. He has been involved with the
Madurai Kamaraj University (MKU) as a syndicate member. He is also a social activist and has conducted Child
Labour Elimination programme / awareness campaign across Tamil Nadu. As a Founder Member of Green Plus
foundation conducted huge ’CHILD LABOUR ELIMINATION’ awareness programme at Virudhunagar and
been honoured by District Collector of Viridhunagar (1996). Ministry of Railways honoured him as Social
Activist and issued Honorary Free Rail Travel Pass throughout India. He was also a Member Telephone
Advisory Committee honoured by Ministry of Telecommunications, Government of India between 1996 and
1999.

Mr. E. S. Chandrasekaran, aged 64 years, graduated as Bachelor of Engineering and holds a Master’s Degree
in Engineering from Madras University. He has also completed his Post Graduate Diploma in Management
Studies from Bombay University. He has over 8 years of experience in Planning, Installation, Commissioning
of Vaccine Plant and was instrumental in getting WHO – Pre Qualification Certification. He has worked for 32
years in various capacities in Government of India and retired from the rank of Principal Secretary,
Government of India"

Dr. P. Perumalsamy, aged 62 years, pursued Masters in Chemistry in American College and completed
Masters in Education from Madurai Kamaraj University. He was awarded Doctorate by Alagappa University,
Karaikudi for his research on “Appraisal of Performance Indicators on Effective Schooling”. He served as
District Educational Officer through Tamil Nadu Public Service Commission and held post of Joint Director and
later as Director of School Education for more than a decade.

Mrs. Lakshmi V Iyer, aged 47 years, is a qualified Chartered Financial Analyst (CFA) is a science graduate
from Stella Maris College, University of Madras and holds a Post Graduate Diploma in Management from
Indian Institute of Management, Calcutta. She has worked as Deputy Manager with State Bank of India Funds
Management Limited. Later she was with CRISIL as Senior Rating Analyst and later in Societe Generale and
Bank of America in Key Managerial Positions. She served as Director, Credit Research for HVB Asset
Management, Singapore during the years 2004-2006. Currently, she is an Independent Financial consultant.

TERMS OF APPOINTMENT OF NON-INDEPENDENT DIRECTORS

1. Dr. P. Murali

Dr. P. Murali, was designated as Managing Director of our Company pursuant to a Board resolution
dated April 2, 2016 and Shareholders Resolution dated May 2, 2016 for a period of 5 years with effect
from April 2, 2016. He is entitled to a remuneration of ` 1.50 Lacs per month with effect from April
2, 2016. He is not entitled to sitting fees for attending the meeting of our Board of Directors or
Committees.

2. Mr. E. S. Chandrasekaran

Mr. E. S. Chandrasekaran, was designated as Executive Director of our Company pursuant to a Board
resolution dated April 2, 2016 and Shareholders Resolution dated May 2, 2016 for a period of 5 years
with effect from April 2, 2016. He is entitled to a remuneration of ` 1.50 Lacs per month with effect
from April 2, 2016. He is not entitled to sitting fees for attending the meeting of our Board of
Directors or Committees.

DETAILS OF SERVICE CONTRACTS

Our Company has not entered into any service contracts with any of the Directors of our Company.

AGREEMENT WITH DIRECTORS AND SENIOR MANAGEMENT

Our Company has not entered into any arrangement or understanding with major shareholders, customers,
suppliers or others, pursuant to which of the directors was selected as a director or member of senior
management.

BORROWING POWERS OF DIRECTORS

In accordance with the Articles of Association, our Board of Directors has been empowered to borrow funds in
accordance with applicable law. The shareholders of our Company in their resolution passed at the AGM held on
May 2, 2016 permitted our Board to borrow funds not exceeding ` 400 lacs.

111
REMUNERATION OF OUR DIRECTORS

The Non-Executive and Independent Directors are paid remuneration by way of sitting fees, and other expenses
(travelling, boarding and lodging incurred for attending our Board of Directors / committee meetings/ shareholders
meetings) and commission if any. The remuneration of the Executive Directors is fixed by the Nomination and
Remuneration committee which is subsequently approved by our Board of Directors and shareholders at a general
meeting.
a. Non Executive/Independent Directors

Our Company pays a sitting fees of ` 10,000 per meeting to the Non Executive/Independent Directors
for attending meetings of our Board of Directors and ` 5000 for attending meetings of our Committees

The following table sets forth sitting fees paid by the Company to our Non Executive/Independent
Directors for the fiscal year 2016-17

Name of the Director Total (`)

Mr. N. Gopalaswami 35,000.00
Dr. P. Perumalsamy 35,000.00
Mrs. Lakshmi V Iyer 20,000.00

b. Executive Director

The following table sets for the remuneration payable to our Executive Director for FY 2016-17.

Name of the Director Total (`)

Dr. P. Murali 18,00,000.00
Mr. E. S. Chandrasekaran 18,00,000.00

Shareholding of our Directors in our Company

The Articles of Association do not require the Directors to hold any qualification Equity Shares in our
Company.

The following table sets forth the Shareholding of our Directors as on date of this Draft Red Herring Prospectus.

Name of the Director No. of Equity Shares % Pre-Offer Shareholding

Dr. P. Murali 89,26,250 23.27
Mr. E. S. Chandrasekaran 5,000 0.01

Shares Purchased or sold by our Directors and/or their relatives in our Company in the last six months
prior to the date of filing of the Draft Red Herring Prospectus.

Except as stated below our Directors and/ or their relatives have not purchased or sold any Equity Shares of our
Company in the last six months prior to the date of filing of the Draft Red Herring Prospectus.

Sl. No. Name of the Date of Transfer No. of Equity Transfer Transferee Reasons for
Transferor Shares Price per Transfer
transferred Equity Share
(`)
1 P. Murali March 26, 2016 24,00,000 0.00 P. Sundaraparipooranan Gift
2 P. Murali March 26, 2016 2,500 80.00 Madhu Kataria Sale
3 E. S. Chandrasekaran March 26, 2016 5,000 10.00 Arjun Chandrasekaran Transfer

Bonus or Profit Sharing Plans

Our Company does not have any Bonus or Profit sharing plans.
Interest of Directors

All of our Directors may be deemed to be interested to the extent of fees, if any, payable to them for attending
meetings of our Board of Directors or a committee or shareholders’ meetings thereof as well as to the extent of

112
reimbursement of expenses payable to them under our Articles of Association, and to the extent of remuneration
or commission paid to them. Some of our Directors may be deemed to be interested to the extent of transactions
carried out with related parties as stated in “Financial Statements - Restated Statement of Related Party
Transactions” on page 148. Our Directors may also be regarded as interested in the Equity Shares, if any, held
by them in our Company.
Our Directors have no interest in any property acquired by us within two years of the date of this Draft Red
Herring Prospectus.

LOANS TO DIRECTORS

No loans have been availed by our Directors from our Company.

Also, none of Directors are related to our sundry debtors.

Changes in the Board of Directors in the last three years

The following changes have occurred in our Board of Directors in the last three years:

Name Date of appointment/change/cessation Reason for change

Ms. B Dakshayini February 29, 2016 Resignation as Director
Dr. P. Perumalsamy March 26, 2016 Appointment
Mrs. Lakshmi V Iyer March 26, 2016 Appointment

Corporate Governance

The provisions of the Listing Regulations with respect to corporate governance will be applicable to our
Company immediately upon the listing of the Equity Shares on the Stock Exchanges. We are in compliance
with the requirements of the applicable regulations including the Listing Regulations and the Companies Act,
2013, in respect of corporate governance including the constitution of our Board of Directors and committees.

Our Board of Directors consists of a total of 5 Directors (including one woman director) of which three are
independent directors (as defined under Regulation 17 of the Listing Regulations), which constitutes more than
50% of our Board of Directors.

The Board functions either as a full board or through various committees constituted to oversee specific
operational areas. Our Company’s executive management provides the Board with detailed reports on its
performance periodically.

The details of the Audit committee, Nomination and Remuneration committee, Stakeholders’ Relationship
committee, Corporate Social Responsibility Committee and Risk Management committee are given below:

Committees of the Board

A. Audit Committee

The Audit Committee was constituted on March 26, 2016 and the constitution of the audit committee is as
follows:

Name of the director Designation in the committee

Mr. N. Gopalaswami Chairman
Mrs. Lakshmi V Iyer Member
Dr. P. Perumalsamy Member

Ms. S Rathna Prabha, Company Secretary and Compliance Officer is the secretary of the Committee.

Terms of reference of the Audit Committee

1. Oversight of the company’s financial reporting process, examination of the financial statement and
the auditors’ report thereon and the disclosure of its financial information to ensure that the financial
statement is correct, sufficient and credible;

113
2. Providing recommendation for appointment, re-appointment and replacement, remuneration and terms
of appointment of auditors of the company and the fixation of audit fee;
3. Review and monitor the statutory auditor’s independence and performance and effectiveness of
audit process;
4. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
5. Reviewing, with the management, the annual financial statements before submission to the board
for approval, with particular reference to:
6. Matters required to be included in the ‘Director’s Responsibility Statement’ to be included in the Board’s
report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013, as amended;
7. Changes, if any, in accounting policies and practices and reasons for the same;
8. Major accounting entries involving estimates based on the exercise of judgment by management;
9. Significant adjustments made in the financial statements arising out of audit findings;
10. Compliance with listing and other legal requirements relating to financial statements;
11. Disclosure of any related party transactions; and
12. Qualifications in the draft audit report.
13. Reviewing, with the management, the quarterly and half-yearly financial statements before submission
to the Board for approval;
14. Reviewing, with the management, the statement of uses / application of funds raised through an
issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes
other than those stated in the offer document/prospectus/notice and the report submitted by the
monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making
appropriate recommendations to the Board to take up steps in this matter;
15. Reviewing, with the management, performance of statutory and internal auditors, and adequacy of
the internal control systems;
16. Reviewing the adequacy of internal audit function, if any, including the structure of the internal
audit department, staffing and seniority of the official heading the department, reporting structure
coverage and frequency of internal audit;
17. Discussion with internal auditors any significant findings and follow up there on;
18. Reviewing the findings of any internal investigations by the internal auditors into matters where there
is suspected fraud or irregularity or a failure of internal control systems of a material nature and
reporting the matter to the Board;
19. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as
well as post-audit discussion to ascertain any area of concern;
20. Look into the reasons for substantial defaults in the payment to the depositors, debenture
holders, shareholders (in case of non-payment of declared dividends) and creditors;
21. Review the functioning of the whistle blower mechanism;
22. Approval of appointment of the chief financial officer (i.e., the whole time finance Director or any
other person heading the finance function or discharging that function) after assessing the
qualifications, experience and background etc. of the candidate;
23. To investigate any activity within its terms of reference;
24. To seek information from any employee;
25. To obtain outside legal or other professional advice;
26. To secure attendance of outsiders with relevant expertise, if it considers necessary;
27. Approval or any subsequent modification of transactions of the company with related parties and
omnibus approval for related party transactions proposed to be entered into by the Company subject to
such conditions as may be prescribed;
28. Scrutiny of inter-corporate loans and investments;
29. Valuation of undertakings or assets of the company, wherever it is necessary;
30. Evaluation of internal financial controls and risk management systems; and
31. Carry out any other function as mentioned in the terms of reference of the Audit Committee.

Powers of the Audit Committee

1. To investigate any activity within its terms of reference;

2. To seek information from any employee;
3. To obtain outside legal or other professional advice; and
4. To secure attendance of outsiders with relevant expertise, if it considers necessary.

The Audit Committee also reviews the following information:

1. Management’s discussion and analysis of financial condition and results of operations;

2. Statement of significant related party transactions (as defined by the Audit Committee), submitted by
the management;

114
3. Management letters / letters of internal control weaknesses issued by the statutory auditors;
4. Internal audit reports relating to internal control weaknesses; and
5. The appointment, removal and terms of remuneration of the Chief Internal Auditor;

The Audit Committee met thrice during the FY 2016-17.

B. Nomination and Remuneration Committee

Our Board of Directors has constituted the Nomination and Remuneration Committee in its meeting
held on March 26, 2016. The present constitution of the Committee is as follows:

Name of the director Designation in the committee

Dr. P. Perumalsamy Chairman
Mr. N. Gopalaswami, Member
Mrs. Lakshmi V Iyer Member

Terms of reference of the Nomination & Remuneration Committee

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a
director and recommend to the Board a policy, relating to the remuneration of the directors, key
managerial personnel and other employees;
2. Formulation of criteria for evaluation of independent directors and the Board;
3. Devising a policy on Board diversity;
4. Identifying persons who are qualified to become directors and who may be appointed in senior
management in accordance with the criteria laid down, and recommend to the Board their appointment
and removal. Our Company shall disclose the remuneration policy and the evaluation criteria in its
Annual Report;
5. Analysing, monitoring and reviewing various human resource and compensation matters;
6. Determining the company’s policy on specific remuneration packages for executive directors
including pension rights and any compensation payment, and determining remuneration packages of
such directors;
7. Determining compensation levels payable to the senior management personnel and other staff (as
deemed necessary), which shall be market-related, usually consisting of a fixed and variable
component;
8. Reviewing and approving compensation strategy from time to time in the context of the then current
Indian market in accordance with applicable laws;
9. Performing such functions as are required to be performed by the compensation committee under
the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
10. Framing suitable policies and systems to ensure that there is no violation, by an employee of any
applicable laws in India or overseas, including the Insider Trading Regulations and the Securities and
Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices relating to the Securities
Market) Regulations, 2003.
11. Performing such other activities as may be delegated by the Board of Directors and/or are
statutorily prescribed under any law to be attended to by the Nomination and Remuneration Committee.

The Nomination and Remuneration committee met one time during FY 2016-17.

C. Stakeholders Relationship Committee

The Board of Directors of the Company has constituted a Stakeholders’ Relationship Committee in its
meeting held on March 26, 2016. The present constitution of the Stakeholders’ Relationship Committee
is as follows:

Name of the director Designation in the committee

Mrs. Lakshmi V Iyer Chairman
Dr. P. Perumalsamy Member
Mr. E. S. Chandrasekaran Member

The Stakeholders’ Relationship Committee was constituted for redressing of shareholders and
investors complaints including but not limited to transfer of shares, non-receipt of annual report and

115
 non-receipt of dividend. The scope and function of the Stakeholders’ Relationship committee is in
accordance with section 178 of the Companies Act, 2013.

The terms of reference of the Stakeholders’ Relationship Committee of our Company include the following:

1. Considering and resolving the grievances of security holders of the Company, including complaints
related to transfer of shares, non-receipt of balance sheet, non-receipt of declared dividends, balance
sheets of the Company or any other documents or information to be sent by the Company to its
shareholders etc.
2. Investigating complaints relating to allotment of shares, approval of transfer or transmission of
shares, debentures or any other securities;
3. Giving effect to all transfer/ transmission of shares and debentures, dematerialization of shares
and rematerialisation of shares, split and issue of duplicate/consolidated share certificates, allotment
and listing of shares, buy back of shares, compliance with all the requirements related to shares,
debentures and other securities from time to time;
4. Oversee the performance of the registrars and transfer agents of the Company and to recommend
measures for overall improvement in the quality of investor services and also to monitor the
implementation and compliance of the code of conduct for prohibition of insider trading pursuant
to the Insider Trading Regulations, and other related matters as may be assigned by the board of
directors; and
5. Carrying out any other function as prescribed under the equity listing agreement.
D. Corporate Social Responsibility Committee

The Corporate Social Responsibility Committee was constituted on March 26, 2016. The scope and
functions of the Corporate Social Responsibility Committee is in accordance with Section 135 of the
Companies Act, 2013. The present constitution of the Committee is detailed below:

Name of the director Designation in the committee

N. Gopalaswami Chairman
P. Murali Member
E. S. Chandrasekaran Member

The terms of reference of the Corporate Social Responsibility Committee of our Company include the following:

1. Formulate and recommend to the board of directors, a “Corporate Social Responsibility Policy” which
shall indicate the activities to be undertaken by the Company as specified in Schedule VII of the
Companies Act;
2. Review and recommend the amount of expenditure to be incurred on the activities referred to in clause (a);
3. Monitor the Corporate Social Responsibility Policy of the Company and its implementation from
time to time; and
4. Any other matter as the Corporate Social Responsibility Committee may deem appropriate after
approval of the Board of Directors or as may be directed by the Board of Directors from time to time.

E. Internal Compliance Committee for Woman Welfare

The Internal Compliance Committee for Woman Welfare was constituted by our Board of Directors in
the meeting held on March 26, 2016. The present constitution of the Committee is detailed below:

Name of the Member Designation in the committee

Sunitha Chairman
Aishwarya Member
Divya Member

F. Policy on Prevention of Insider Trading

We are in compliance with the provisions of the Insider Trading Regulations.

Ms. S Rathna Prabha, Company Secretary and Compliance Officer, is responsible for setting forth
policies, procedures, monitoring and adhering to the rules for the prevention of dissemination of price
sensitive information and the implementation of the code of conduct under the overall supervision of
the Board.

116
 MANAGEMENT ORGANISATION STRUCTURE

KEY MANAGERIAL PERSONNEL

Other than Managing Director and Executive Director as mentioned above following forms are the Key
Managerial Persons.

Ms. S Rathna Prabha, aged 40 years is the Company Secretary and Compliance Officer of our Company. She
holds a Bachelor’s degree in Law from Dr. Ambedkar Government Law College, Puducherry. She is also a
qualified Company Secretary. She has been associated with our Company since 2016. Prior to joining our
Company, she was associated with Rakindo Kovai Township Pvt Ltd, Essel Finance VKC Forex Ltd, I Nautix
Technologies Pvt. Ltd and Igarashi Motors India Ltd. Her Compensation is ₹ 1,800,000 for fiscal year 2016-17.

Mr. E. Mullaivalavan, aged 37 years is the Chief Financial Officer of our Company. He holds a Bachelor’s
degree in Bank Management from and a higher Diploma in Software Engineering. He has been with the
Company since inception. His Compensation is Rs.756,000 for fiscal year 2016-17.

Senior Managerial Personnel

Mrs. Sudha Varadharajan, aged 69 is our Chief Technical Officer & Advisor. She holds a Bachelor's degree
in Zoology from Madras University. She has been associated with BCG Vaccine Laboratory, MoH, Govt. of
India for the past 33 years. She has over 15 years of experience in Quality Control and over 18 years in other
departments. She has presented papers on BCG Vaccines at various international conferences and has been part
of various research studies. She has a WHO Fellowship for 3 months on Production, Testing and Quality
Control and trained in Statenus Serum Institute, Denmark. She is with our Company since 2008."

Dr. J Rajesh Kumar, aged 37 years is the Head Quality Assurance & Quality Control of our Company. He is a
Doctor of Philosophy in Life Sciences. He is associated with our company since 2013. He was previously
associated with Vimta Labs, Hyderabad as Scientist “C” – Analytical Microbiology. He has over 8 years of
experience in quality control and quality assurance in Microbiological Processes across the industry in different
capacities.

Mr. Premkumar, Vice President, Operations, aged 37 years, hold degree of M.Sc (Biochemistry), B.Sc
(Microbiology), and working as Vice President (Opeartions). He has an experince of about 15 years in the field
of micro biology. He has conducted various audits. Before joining our Company he has worked in various other
companies including Burgeon Pharmaceuticals Pvt Ltd, Sanvi Organics Pvt Ltd, Shantha Biotechnic Ltd,
Orchid Chemicals and Pharmaceuticals Ltd. and Mederich Sterilab Ltd. He has acted in various capacities.

117
Mr. K. Kumaragurubaran, aged 44 years is the Head – Quality Control of our Company. He is a Veterinarian
with a Bachelor’s degree in Veterinary Sciences from the Tamil Nadu Veterinary and Animal Sciences
University. He has underwent training on the introduction of GLP Principles at International Institute of Bio
Technology and Toxicology (IIBAT), Padappai. He has attended several workshops and training programs on
uses of animals in Research, Testing and Diagnostic & Toxicologic Pathology. He is associated with our
Company since 2008. He was previously into private practice and was associated IIBAT as Animal House In-
charge.

Mr. P. Kandavel, aged 39 years is the General Manager, Production of our Company. He is a Masters in
Microbiology from Sri Parama Kalyani College, Manonmaniam Sundaranar University. He is pursuing his
Doctors (Part-time) in Microbiology from Bharathiar University, Coimbatore. He is associated with us since
March 2016. He was previously associated with Dr.Reddy’s Laboratories as Resource Leader. He has over 16
years of experience in Fill Finish and packing of sterile drug products.

Dr K. R. Mani, aged 64 years is our President – Technical & Advisor to the Board. He is in charge of our
Research & Development. He holds a Master Degree in Veterinary Public Health in Microbiology, Master of
Science & Technology from BITS, Pilani and Doctor of Philosophy in Microbiology from Bharathiar
University, Coimbatore. He is also a Master in Business Management from Indira Gandhi National Open
University, New Delhi with specialisation in Human Resources. He is the former Deputy Director, Pasteur
Institute of India, Coonoor and Former Director, Central Research Institute, Kasauli Himachal Pradesh. He has
over 29 years of experience in research, teaching and administration. He has attended various Seminars,
Symposiums and Trainings and is a member of various professional institutes. He has presented various
Research publications and papers in various symposiums.

Nature of any family relationship between the Key Managerial Personnel: None of the Key Managerial
Personnel are related to each other and to the Promoters/ Directors of our Company.

Shareholding of Key Managerial Personnel: Except Managing Director and Executive Director as mentioned
above none of the Key Managerial Personnel hold shares in our Company.

Stock Option Plans/ Stock Purchase Schemes: Our Company does not have any Stock Option Plans / Stock
Purchase schemes

Nature of Employment.

All the Key Managerial Person are permanent employees of our Company.

Changes in the Key Managerial Personnel:

The following are the changes in the Key Managerial Personnel during the preceding 5 financial years

Sr. No. Name of the employee Designation Date of change Reason

1. P. Murali Managing Director April 2, 2016 Reappointment as
Managing Director
2. E. S. Chandrasekaran Executive Director April 2, 2016 Reappointment as
Executive Director
3. E. Mullaivalavan Chief Financial Officer April 1, 2016 Promoted as Chief
Financial Officer
4. S Rathna Prabha Company Secretary & April 1, 2016 Appointment
Compliance Officer

Bonus or Profit Sharing Plan for Managerial Personnel: Our Company does not have any bonus or profit
sharing plans for our Managerial Personnel

Interest of Key Managerial Personnel: The key managerial personnel do not have any interest in the
Company other than to the extent of the remuneration to which they are entitled, as per their terms of
appointment, reimbursement of expenses incurred by them during the ordinary course of business.

Arrangements and understanding with major Shareholders, Customers, Suppliers or others: None of our
key management personnel have been selected pursuant to any arrangement or understanding with any of our
major shareholders, customers, suppliers or others.

118
Payment of benefits to Officers: Except as disclosed in this Draft Red Herring Prospectus, other than statutory
payments and remuneration, in the last two years, we have not paid or have intended to pay any other amount or
benefit to any of our officers.

Loans taken by key managerial personnel

None of the key managerial personnel has taken loan from our Company.

Employees: As of March 31, 2016, we had a total of 68 employees on the rolls of the Company.

119
 OUR PROMOTERS AND PROMOTER GROUP

The details of our Promoters are given below:

1. Mr. P. Sundaraparipooranan

Aged 46 years is the Promoter of the Company. He is not involved in the

day to day management of the Company. He is a Resident Indian National.
He is a resident of India.

His Passport Number is Z2823806 and Driving license no. is TN09

19940000268

2. Dr. P. Murali

Aged 43 years, is an Arts Graduate and a Masters in Labour Management.

He holds a Doctorate in Management from Madras University. He has
about 15 years of experience in Information Technology and
Pharmaceutical Productions, Installation, Commissioning, Quality
Management, Financial Planning and Human Resources Management. He
is the Managing Director of the Company.

His Passport Number is Z3257930 and Aadhar no. is 627778201623

Our Company’s Promoters jointly hold 3,04,13,500 Equity Shares, which in aggregate constitutes
79.27% of the issued and paid-up share capital of our Company.

Interest of Promoters

Except as disclosed in this Draft Red Herring Prospectus, our Promoters are interested in our Company to the
extent of their respective shareholding, the dividends received by them on such shareholding, and the
remuneration/ commission received by some of our Promoters who are Directors on the Board of our Company
or are employed by our Company as the case may be. For details of the our Promoters’ shareholding in our
Company, please refer to “Capital Structure - Build-up of Promoters’ Shareholding, Promoters’ contribution
and Lock-in” on page 50. Our Promoter, Dr. P. Murali, is also interested to the extent of being a Director on our
Board, as well as any remuneration and reimbursement of expenses payable to him.

Except as disclosed above, our Promoters confirm that they have no interest in any property acquired by our
Company during the two years immediately preceding the date of this Draft Red Herring Prospectus or in
any transaction in acquisition of land, construction of building or supply of machinery.

Our Promoters are not related to any sundry debtors of our Company as on June 30, 2016.

Our Company has provided any loans or advances to our Promoters.

Payment or Benefits to Promoters

Except as disclosed above and stated in “Financial Statements – Restated Statement of Related Party
Transactions” and “Our Management – Interest of our Directors” on pages 148 and 112, respectively, there
has been no payment or benefit provided to our Promoters by our Company during the two years preceding the
date of this Draft Red Herring Prospectus.

Confirmations

Our Promoters and their relatives (as defined under section 2(77) of the Companies Act 2013) have not been
declared as wilful defaulters by the RBI or any other governmental authority. Further, there are no violations
of securities laws committed by our Promoters in the past and no proceedings for violation of securities laws
are pending against them.

Our Promoters or Promoter Group are not prohibited from accessing or operating in capital markets under
any order or direction passed by SEBI or any other regulatory or governmental authority. Further, our

120
Promoters have never been, a promoter, director or person in control of any other company which is
prohibited from accessing or operating in capital markets under any order or direction passed by SEBI or any
other regulatory or governmental authority.

Except as disclosed in this Draft Red Herring Prospectus, our Promoters are not interested in any entity which
holds any intellectual property rights that are used by our Company.

Our Company confirms that the permanent account number, bank account number and passport number of our
Promoters have been submitted to the Stock Exchanges at the time of filing of this Draft Red Herring
Prospectus to the Stock Exchanges.

PROMOTER GROUP

Individual forming part of the Promoter Group

1. Ms. Mallika Murali w/o Dr. P. Murali

Corporate and other entities forming part of Promoter Group

Nil

Companies with which our Promoters have disassociated in the last three years

Our Promoters have not disassociated themselves from any Company during the preceding three years.

Change in the Management and Control of our Company

There has not been any change in the management or control of our Company since incorporation.

Our Company does not have any Group/Associate Company.

121
 RELATED PARTY TRANSACTIONS

Related Party Transactions, as per the requirements under Accounting Standard 18 “Related Party
Disclosures” issued by the Institute of Chartered Accountants of India and as reported in the Restated Financial
Statements, please see the section entitled “Financial Statements” on pages 124, respectively.

122
 DIVIDEND POLICY

The declaration and payment of dividends will be recommended by our Board of Directors and approved by our
shareholders, in their discretion, subject to the provisions of the Articles of Association and the Companies Act.
The dividends, if any, will depend on a number of factors, including but not limited to our earnings, general
financial conditions, capital requirements, result of operations, contractual obligations, overall financial position
and other factors considered relevant by our Board of Directors.

In addition, our ability to pay dividends may also be impacted by a number of factors, including restrictive
covenants under the loan or financing arrangements our Company may enter into to finance our fund requirements
for our business activities. For further details, please refer to the chapter “Financial Indebtedness” on page 166.

Dividends declared in the last five fiscal years

Our Company has not declared any dividends in any of the five fiscal years preceding the filing of this Draft
Red Herring Prospectus.

123
 SECTION V – FINANCIAL INFORMATION
FINANCIAL STATEMENTS
AUDITOR REPORT AND FINANCIAL INFORMATION

INDEPENDENT AUDITOR’S REPORT ON RESTATED FINANCIAL INFORMATION AS

REQUIRED UNDER SECTION 26 OF THE COMPANIES ACT, 2013 READ WITH RULE 4 OF
COMPANIES (PROSPECTUS AND ALLOTMENT OF SECURITIES) RULES, 2014.

The Board of Directors

GreenSignal Bio Pharma Limited
A-3, Sai Niketan, Circular Road
United India Colony,
Kodambakkam, Chennai 600024.

Dear Sirs,

We have examined the attached restated standalone financial information of GreenSignal Bio Pharma Limited
(the Company) as approved by the Board of Directors of the Company on July 2, 2016, prepared by the
management of the Company in terms of the requirements of Section 26 of the Companies Act, 2013 read with
The Companies (Prospectus and Allotment of Securities) Rules, 2014 the Securities and Exchange Board of
India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended from time to time (the
‘SEBI Regulations’), the Guidance Note on ‘Reports in Company’s Prospectus (Revised)’ issued by the Institute
of Chartered Accountants of India (‘ICAI’) to the extent applicable (‘Guidance Note’), and in terms of our
engagement agreed with you in accordance with our engagement letter dated May 23, 2016 in connection with
the proposed issue of Equity Shares of the Company by way of an offer for sale by the existing shareholders
.
These restated standalone financial information have been extracted by the Management from the Company’s
standalone audited financial statements for the period ended June 30, 2016, and for the years ended March 31,
2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012.

We have audited the standalone financial statements of the Company for the period ended June 30, 2016, and
for the years ended March 31, 2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012.

We further report that

a) The Restated Standalone Summary Statement of Assets and Liabilities as at June 30, 2016, March 31,
2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012 examined by us, as set
out in Annexure I to this report read with the significant accounting policies in Annexure IV are after
making such adjustments and regroupings as in our opinion were appropriate and are more fully
described in the Notes to the Restated Standalone Financial Information enclosed as Annexure V to this
report.

b) The Restated Standalone Summary Statement of Profit and Loss of the Company for the period ended
June 30, 2016 and for the years ended March 31, 2016, March 31, 2015, March 31, 2014, March 31,
2013 and March 31, 2012 as set out in Annexure II to this report read with the significant accounting
policies in Annexure IV are after making such adjustments and regroupings as in our opinion were
appropriate and are more fully described in the Notes to the Restated Standalone Financial Information
enclosed as Annexure V to this report.

c) The Restated Standalone Summary Statement of Cash Flows of the Company for the period ended June
30, 2016 and for the years ended March 31, 2016, March 31, 2015, March 31, 2014, March 31, 2013
and March 31, 2012as set out in Annexure III to this report read with the significant accounting
policies in Annexure IV are after making such adjustments and regroupings as in our opinion were
appropriate and are more fully described in the Notes to the Restated Standalone Financial Information
enclosed as Annexure V to this report

Based on the above, we are of the opinion that the Restated Standalone Financial Information

i. have been made after incorporating adjustments for prior period and other material amounts in the
respective financial years to which they relate to; and

124
ii. do not contain any extra-ordinary items that need to be disclosed separately other than those presented
in the Restated Standalone Financial Information and do not contain any qualifications requiring
adjustments.

We have also examined the following restated standalone financial information as set out in the Annexures
prepared by the management of the Company and approved by the Board of Directors on July 2, 2016, relating
to the Company for the period ended June 30, 2016 and for the years ended March 31, 2016, March 31, 2015,
March 31, 2014, March 31, 2013 and March 31, 2012:

i. Restated Standalone Statement of Share Capital, included in Annexure VI;

ii. Restated Standalone Statement of Reserves and Surplus, included in Annexure VII;
iii. Restated Standalone Statement of Long-term Borrowings, included in Annexure VIII
iv. Restated Standalone Statement of Short-term Borrowings, included in Annexure IX
v. Restated Standalone Statement of Trade Payables, included in Annexure X
vi. Restated Standalone Statement of Other Current Liabilities, included in Annexure XI
vii. Restated Standalone Statement of Inventories, included in Annexure XII
viii. Restated Standalone Statement of Trade Receivables, included in Annexure XIII
ix. Restated Standalone Statement of Cash and Cash equivalents, included in Annexure XIV
x. Restated Standalone Statement of Short-term Loans and Advances, included in Annexure XV;
xi. Restated Standalone Statement of Revenue from operations, included in Annexure XVI.
xii. Restated Standalone Statement of Other Income, included in Annexure XVII.
xiii. Restated Standalone Statement of Cost of Materials Consumed, included in Annexure XVIII.
xiv. Restated Standalone Statement of Changes in Inventories, included in Annexure XIX
xv. Restated Standalone Statement of Operations Cost, included in Annexure XX
xvi. Restated Standalone Statement of Employee Expenses, included in Annexure XXI
xvii. Restated Standalone Statement of Finance Cost, included in Annexure XXII
xviii. Restated Standalone Statement of Other Expenses, included in Annexure XXIII
xix. Restated Standalone Statement of Accounting Rations, included in Annexure XXIV.
xx) Capitalization statement, as appearing in Annexure XXV
xxi) Restated Standalone Tax Shelter, included in Annexure XXVI;
xxii) Restated Standalone Statement of Related Party Transactions, included in Annexure XXVII

1. We have no responsibility to update our report for events and circumstances occurring after the date of
the report.

2. In our opinion, the above restated standalone financial information contained in Annexure I to XXVI of
this report read along with the Significant Accounting Policies and Notes to Restated Standalone
Financial Information (Refer Annexure IV) are prepared after regrouping as considered appropriate and
have been prepared in accordance with Section 26 of the Companies Act, 2013 read with The
Companies (Prospectus and Allotment of Securities) Rules, 2014, to the extent applicable, SEBI
Regulations, the Guidance note issued in this regard by the ICAI, as amended from time to time, and in
terms of our engagement as agreed with you.

3. Our report is intended solely for use of the management and for inclusion in the offer document in
connection with the proposed issue of Equity Shares of the Company by way of an offer for sale by the
existing shareholders
.
Our report should not be used, referred to or distributed for any other purpose except with our consent in writing

For M/s. RAJ AND RAVI

ICAI firm registration number: 10935S
Chartered Accountants

RAJ VISVANATHAN
Partner
Membership No.: 23211
Place: Chennai
Date: July 2, 2016

125
Annexure I – Restated Standalone Summary of Statement of Assets and Liabilities.

Particulars As on 2016 2015 2014 2013 2012

June 30,
2016
` in Lacs
A EQUITY AND LIABILITIES
1. Shareholders’ funds
0
(a) Share capital 3,836.73 1,534.69 1,357.35 1,357.35 1,357.35 1,357.35
(b) Reserves and surplus 2,129.33 4,138.28 2,365.91 2,221.01 2,350.72 2,400.73
5,966.06 5,672.97 3,723.26 3,578.36 3,708.07 3,758.08
Share application money pending 762.19 698.23
allotment
2. Non-current liabilities
0
(a) Long-term borrowings - 2.67 399.68
(b) Deferred tax liabilities (net) 317.46 313.95 292.59 272.55 248.75 215.91
Total of Non Current Liabilities 317.46 313.95 292.59 272.55 251.42 615.59
3. Current liabilities
0
(a) Short-term borrowings 387.61 558.07 392.32 398.45 657.96 537.60
(b) Trade payables 107.22 89.46 33.76 25.57 1.38 32.27
(c) Other current liabilities 321.45 299.72 1,425.05 1,419.57 6.46 76.31
Total of Current Liabilities 816.28 947.25 1,851.13 1,843.59 665.80 646.18
TOTAL 7,099.80 6,934.17 5,866.98 5,694.50 5,387.48 5,718.08
B ASSETS
1. Non-current assets
0
(a) Fixed assets
(i) Tangible assets 3,873.09 3,892.44 3,979.67 3,648.69 3,761.48 3,868.27
(ii) Capital work-in-progress 1,146.79 1,146.79 1,159.67 1,124.16 1,000.63 849.81
Total Non Current Assets 5,019.88 5,039.23 5,139.34 4,772.85 4,762.11 4,718.08
2. Current assets
0
(b) Inventories 693.29 738.50 529.70 491.75 477.82 617.87
(c) Trade receivables 867.88 472.32 71.02 342.79 76.28 278.63
(d) Cash and cash equivalents 286.34 404.15 65.26 (0.61) (3.10) 11.78
(e) Short-term loans and advances 232.41 279.97 61.66 87.72 74.37 91.72
(f) Other current assets - - - -
Total of Current Assets 2,079.92 1,894.94 727.64 921.65 625.37 1,000.00

TOTAL 7,099.80 6,934.17 5,866.98 5,694.50 5,387.48 5,718.08

Notes: The above statement should be necessarily read with the basis of preparation and significant
accounting policies annexed to this statement.

126
Annexure II - Restated Standalone Summary Statement of Profit and Loss

Particulars For the period 2016 2015 2014 2013 2012

ended on June 30,
2016
` in Lacs
A CONTINUING OPERATIONS
1 Revenue from operations (gross) 1014.70 2,038.72 656.16 350.99 1,167.78 1,126.58
Less: Excise duty 1014.70 - - - - -
Revenue from operations (net) 2,038.72 656.16 350.99 1,167.78 1,126.58
2 Other income 5.85 10.53 4.13 1.81 2.02 -
3 Total revenue (1+2) 1,020.55 2,049.25 660.29 352.80 1,169.80 1,126.58
4 Expenses
(a) Cost of materials consumed 135.73 573.90 160.05 77.27 265.66 348.38
(b) Changes in inventories of 162.43 (164.39) 25.25 (8.15) 138.91 77.57
finished goods, work-in-progress
and stock-in-trade
(c) Operations Cost 74.49 200.91 64.31 50.33 130.60 142.35
(d) Employee benefits expense 88.81 172.00 106.42 61.82 219.10 127.67
(e) Finance costs 12.36 66.41 71.15 116.07 158.13 210.89
(f) Depreciation and amortisation 30.39 119.17 115.10 112.79 112.55 112.33
expense
(g) Other expenses 143.79 387.49 119.30 48.58 162.02 112.37
Total expenses 648.00 1,355.49 661.58 458.71 1,186.97 1,131.56
5 Restated Profit / Loss before 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
exceptional and extraordinary items
and tax (3 - 4)
6 Exceptional items - - - - -
7 Restated Profit / Loss before 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
extraordinary items and tax (5 + 6)
8 Extraordinary items - - - - -
9 Restated Profit / Loss before tax (7 372.55 693.76 (1.29) (105.91) (17.17) (4.98)
+ 8)
10 Tax expense:
(a) Current tax expense for current 75.95 141.45 -
year
(b) (Less): MAT credit (where - - - - -
applicable)
(c) Current tax expense relating to - - - - -
prior years
(d) Net current tax expense 75.95 141.45 - - - -
(e) Deferred tax 3.51 21.36 20.04 23.80 32.84 43.13
Total Tax Expense 79.46 162.81 20.04 23.80 32.84 43.13
11 Restated Profit / (Loss) from 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
continuing operations (9 +10)
12 Restated Profit / (Loss) for the year 293.09 530.95 (21.33) (129.71) (50.01) (48.11)

Notes: The above statement should be necessarily read with the basis of preparation and significant
accounting policies annexed to this statement.

127
Annexure III - Restated Standalone Summary Statement of Cash Flow

As on June 2016 2015 2014 2013 2012

PARTICULARS 30, 2016
` in Lacs
A. Cash flow from Operating Activities
Net profit as per Profit and loss account 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
ADJUSTMENTS FOR
Depreciation in books 30.39 119.17 115.10 112.79 112.55 112.33
Preliminary expenditure written off
Deferred Tax 3.51 21.36 20.04 23.80 32.84 43.13
Share Issue Expenses written off
Provision for Income tax & FBT 75.95 141.45 - - - -
Operating cash flows before adjusting for working
capital changes 402.94 812.93 113.81 6.88 95.38 107.35
Adjustment for Working Capital changes - - - -
Decrease/(Increase) in Sundry debtors (395.56) (401.30) 271.77 (266.51) 202.35 (233.73)
Decrease/(Increase) In other Current assets 92.77 (427.11) (11.88) (27.28) 157.40 76.92
Increase / (Decrease) in Current liabilities and (206.92)
provisions (1,045) 7.53 1,177.78 (100.73) 26.77
Operating cash flow after Adjusting for working (106.77)
Capital changes (1,060.81) 381.23 890.87 354.40 (22.69)
Net Cash Flow from operating activities – A (106.77) (1,060.81) 381.23 890.87 354.40 (22.69)
B. Cash Flow from Investing Activities
(11.04) (279.8
Purchase of Fixed Assets (31.94) 5) - (5.76) (11.87)
Capital Work in Progress - 12.88 (35.51) (123.53) (150.82) (146.23)
(11.04) (315.3
Net cash From Investing activities – B (19.06) 6) (123.53) (156.58) (158.10)
C. Cash flow from Financing Activities
Proceeds from Bank Loans - - (2.66) (276.65) (266.72)
Proceeds from issue of shares - 1,418.76 (762.19) 63.95 443.30
Net Cash Flow From Financing Activities – C - 1,418.76 - (764.85) (212.70) 176.58
Net Increase in cash and Cash equivalents (A + B (117.81)
+ C) 338.89 65.87 2.49 (14.88) (4.21)
Add: Cash and cash equivalents at the beginning of 404.15
the year 65.26 (0.61) (3.10) 11.78 15.99
Cash and cash equivalents at the end of the year 286.34 404.15 65.26 (0.61) (3.10) 11.78
(a) Cash on hand 3.81 1.52 1.75 0.11 0.17 0.13
(c) Balances with banks
(i) In current accounts 13.92 179.81 0.78 (0.72) (3.27) 11.65
(i) In deposit accounts 256.83 221.67 62.73 - - -
Interest accrued thereon 11.78 1.15 - - - -
Total 286.34 404.15 65.26 (0.61) (3.10) 11.78

Notes

For the For the year ended March 31

period
2016 2015 2014 2013 2012
PARTICULARS ended
June 30,
2016 ` in Lacs
(a) Cash on hand 3.81 1.52 1.75 0.11 0.17 0.13
(b) Balances with banks
(i) In current accounts 13.92 179.81 0.78 (0.72) (3.27) 11.65
(i) In deposit accounts 256.83 221.67 62.73 - - -
Interest accrued thereon 11.78 1.15 - - - -
Total 286.34 404.15 65.26 (0.61) (3.11) 11.78

128
The above statement should be necessarily read with the basis of preparation and significant accounting
policies annexed to this statement.

Annexure IV. Notes on Material Adjustments

1. The summary of results of restatement made in the audited Standalone financial statements for the
respective years and its impact on the profit/ (loss) of the Company is as follows

Particulars For For the Year ended March 31

the 2016 2015 2014 2013 2012
period
ended
June ` in Lacs
30,
2016
Net Profit/(Loss) as per audited financial statement 293.09 509.05 (17.30) (126.34) (24.25) (14.03)
Add / (Less) Gratuity Provision - 9.47 (3.29) (2.52) (2.12) (1.54)
Add / Less Sundry Balances Written back - (24.73) (39.60)
Add / Less Income tax adjustments - 9.30 0.38 - 1.81 7.58
Add / Less Deferred tax adjustments - 3.13 (1.12) (0.85) (0.72) (0.52)
Total Adjustments - 21.90 (4.03) (3.37) (25.76) (34.08)
Restated Profit / Loss for the years 293.09 530.95 (21.33) (129.71) (50.01) (48.11)

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

2. Details of adjustments pertaining to prior years

a. The Company had been following the Payment of Gratuity Act and no provision had been made in the
accounts. During the year ended March 31, 2016 Gratuity Provision had been provided based on
actuarial valuation and the liability in respect of pervious years had been provided which has been
restated and adjusted in the respective years to which they relate.

b. During the years ended March 31, 2013 and March 31, 2012 the company had written back the
creditors which were no longer expected to be settled. For the purpose of this statement, such write
back have been appropriately adjusted in the respective years to which they relate.

c. Minimum Alternate Tax and Deferred tax has been computed on adjustments made as detailed above
and has been adjusted in the restated statement of profit and loss for the year ended March 31,
2016,2015,2014,2013 and 2012.

3. Material regroupings

Appropriate adjustments have been made in the Restated Summary Financial Information, wherever required,
by a reclassification of the corresponding items of income, expenses, assets, liabilities and cash flows in order to
bring them in line with the groupings as per the audited financial statements of the Company as at and for the
year ended March 31, 2016, prepared in accordance with Schedule III of the Act and the requirements of the
Securities and Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2009 (as
amended). Accordingly, the Company has presented the Restated Summary Financial Information as at and for
the years ended March 31, 2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012
following the requirements of Schedule III of the Act.

4. Restatement adjustments made in the audited opening balance figures in the net surplus in the
statement of profit and loss for the fiscal 2011

Particulars ` In Lacs
Net Profit/(Loss) as per audited financial statement (301.19)
Adjustments
Sundry Balances written back 64.33
Net Profit/(Loss) as per restated financial statement (236.86)

129
Annexure V - Notes to restated Standalone summary Statements of Assets and Liabilities, Statement of Profit
and Loss and Cash Flows for the period ended June 30, 2016 and for the years ended March 31, 2016, March
31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012.

1 Corporate information
The Company was incorporated in November 21, 2005 as a Private Limited Company. The Company
has changed its name to GreenSignal Bio Pharma Private Limited on March 24, 2016. The company
has been converted into public limited company in the Extra Ordinary General Meeting held on March
24, 2016. The Company produces Life Saving Vaccine, namely, BCG Vaccine.
2 Significant accounting policies (Illustrative)
The significant accounting policies have been predominantly presented below in the order of the
Accounting Standards notified under the Companies (Accounting Standards) Rules, 2016 (as amended).
The order of presentation may be customised for each Company.
2.1 Basis of accounting and preparation of financial statements
The restated Standalone summary Statement of Assets and Liabilities of the Company as at June 30,
2016 and March 31, 2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012
and the related restated Standalone summary Statement of Profit and Loss and Cash Flows for the
period ended June 30, 2016 and for the years ended March 31, 2016, March 31, 2015, March 31, 2014,
March 31, 2013 and March 31, 2012 ( collectively referred to as the “Restated Standalone Summary
Financial Information’ ) have been prepared specifically for the purpose of inclusion in the Draft Red
Herring Prospectus (hereinafter referred to as ‘DRHP’ )/RHP/Prospectus to be filed by the Company
with the Securities and Exchange Board of India (SEBI) in connection with the proposed Initial Public
Offering ( hereinafter referred to as ‘ IPO’ )

The financial statements of the Company have been prepared in accordance with the Generally Accepted
Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards notified and
the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on
accrual basis under the historical cost convention. The accounting policies adopted in the preparation of
the financial statements are consistent with those followed in the previous year.
2.2 Use of estimates
The preparation of the financial statements in conformity with Indian GAAP requires the Management
to make estimates and assumptions considered in the reported amounts of assets and liabilities (including
contingent liabilities) and the reported income and expenses during the year. The Management believes
that the estimates used in preparation of the financial statements are prudent and reasonable. Future
results could differ due to these estimates and the differences between the actual results and the
estimates are recognised in the periods in which the results are known / materialise.
2.3 Inventories
Inventories are valued at cost except the finished goods which are being valued at cost or net market realisable
value whichever is lower. The stocks held at the factory are as verified and certified by the Management.
2.4 Cash and cash equivalents (for purposes of Cash Flow Statement)
Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances
(with an original maturity of three months or less from the date of acquisition), highly liquid investments
that are readily convertible into known amounts of cash and which are subject to insignificant risk of
changes in value.
2.5 Depreciation and amortisation
Depreciation on fixed assets is provided on straight line basis in accordance with the rates prescribed in
Schedule II of the Companies Act, 2013.
2.6 Revenue recognition
Sales represent gross value of sales excluding Sales Tax. Income and Expenditure are accounted on
accrual basis.
2.7 Other income
Interest income is accounted on accrual basis. Dividend income is accounted for when the right to
receive it is established.
2.8 Tangible fixed assets
Fixed Assets are stated at historical cost less accumulated depreciation and impairment loss, if any. Cost
comprises the purchase price and any attributable cost of bringing the assets to its working condition for its
intended use.
Capital work in progress

130
 Research & Development Expenditure where future benefits are expected to accrue for longer periods,
those costs are capitalized in the year in which they are incurred. These costs are amortised over the
tenure during which the benefits are expected to accrue. Unamortised costs are reviewed at each
Balance Sheet date to determine the amount, if any, which do not have any enduring benefit, such
identified amounts are written off in the year in which they are identified. The Research & Development
Expenditure outstanding at the beginning of every year is written off over a period of 3 years.
2.9 Intangible assets
Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of
an intangible asset comprises its purchase price, including any import duties and other taxes (other than those
subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the
asset ready for its intended use and net of any trade discounts and rebates. Subsequent expenditure on an
intangible asset after its purchase / completion is recognised as an expense when incurred unless it is probable
that such expenditure will enable the asset to generate future economic benefits in excess of its originally
assessed standards of performance and such expenditure can be measured and attributed to the asset reliably,
in which case such expenditure is added to the cost of the asset
2.10 Foreign currency transactions and translations
Foreign currency transactions are recorded at the rates prevailing on the date of transaction `and the
subsequent gain/ loss on realization is being dealt with in the Profit & Loss account. Monetary items
remaining unsettled, i.e., receivables and payables at the end of the year are converted at the closing /
year end rate and any exchange differences arising on such conversion are dealt with in the Profit &
Loss account. However there are no foreign currency items remaining outstanding against or in favour of
the company as at the end of the financial year.
2.11 Government grants, subsidies and export incentives
Government grants and subsidies are recognised when there is reasonable assurance that the Company
will comply with the conditions attached to them and the grants / subsidy will be received. Government
grants whose primary condition is that the Company should purchase, construct or otherwise acquire
capital assets are presented by deducting them from the carrying value of the assets. The grant is
recognised as income over the life of a depreciable asset by way of a reduced depreciation charge.

Export benefits are accounted for in the year of exports based on eligibility and when there is no
uncertainty in receiving the same.

Government grants in the nature of promoters' contribution like investment subsidy, where no repayment
is ordinarily expected in respect thereof, are treated as capital reserve. Government grants in the form of
non-monetary assets, given at a concessional rate, are recorded on the basis of their acquisition cost. In
case the non-monetary asset is given free of cost, the grant is recorded at a nominal value.

Other government grants and subsidies are recognised as income over the periods necessary to match
them with the costs for which they are intended to compensate, on a systematic basis.
2.12 Investments
Long-term investments (excluding investment properties), are carried individually at cost less provision
for diminution, other than temporary, in the value of such investments. Current investments are carried
individually, at the lower of cost and fair value. Cost of investments include acquisition charges such as
brokerage, fees and duties. Investment properties are carried individually at cost less accumulated
depreciation and impairment, if any. Investment properties are capitalised and depreciated (where
applicable) in accordance with the policy stated for Tangible Fixed Assets. Impairment of investment
property is determined in accordance with the policy stated for Impairment of Assets.
2.13 Employee benefits
Retirement benefits in the form of Provident fund and Employee state insurance are a defined contribution
scheme and the contributions are charged to the Profit and Loss account of the year when the contributions to
the respective funds are due. Gratuity has been provided on the basis of actuarial valuation report.
2.14 Borrowing costs
Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences
arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest
cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition
of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.
Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from
commencement of activities relating to construction / development of the qualifying asset upto the date
of capitalisation of such asset is added to the cost of the assets. Capitalisation of borrowing costs is
suspended and charged to the Statement of Profit and Loss during extended periods when active

131
 development activity on the qualifying assets is interrupted.
2.15 Segment reporting
The Company identifies primary segments based on the dominant source, nature of risks and returns and the
internal organisation and management structure. The operating segments are the segments for which separate
financial information is available and for which operating profit/loss amounts are evaluated regularly by the
executive Management in deciding how to allocate resources and in assessing performance.

The accounting policies adopted for segment reporting are in line with the accounting policies of the
Company. Segment revenue, segment expenses, segment assets and segment liabilities have been identified to
segments on the basis of their relationship to the operating activities of the segment. Inter-segment revenue is
accounted on the basis of transactions which are primarily determined based on market / fair value factors.
Revenue, expenses, assets and liabilities which relate to the Company as a whole and are not allocable to
segments on reasonable basis have been included under “unallocated revenue / expenses / assets / liabilities.
2.16 Leases
Where the Company as a lessor leases assets under finance leases, such amounts are recognised as
receivables at an amount equal to the net investment in the lease and the finance income is recognised
based on a constant rate of return on the outstanding net investment.

Assets leased by the Company in its capacity as lessee where substantially all the risks and rewards of
ownership vest in the Company are classified as finance leases. Such leases are capitalised at the inception
of the lease at the lower of the fair value and the present value of the minimum lease payments and a
liability is created for an equivalent amount. Each lease rental paid is allocated between the liability and the
interest cost so as to obtain a constant periodic rate of interest on the outstanding liability for each year.

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest
with the lessor are recognised as operating leases. Lease rentals under operating leases are recognised in
the Statement of Profit and Loss on a straight-line basis.
2.17 Earnings per share
In determining earnings per share, the Company considers the net profit after tax and includes the post
tax effect of any extra-ordinary / exceptional item. The number of shares used in computing basic
earnings per share is the weighted average number of shares outstanding during the period.

The number of shares used in computing diluted earnings per share comprises the weighted average
shares considered for deriving basic earnings per share, and also the weighted average number of equity
shares that could have been issued on the conversion of all dilutive potential equity shares.
2.18 Taxes on income
Current tax is the amount of tax payable on the taxable income for the year as determined in accordance
with the provisions of the Income Tax Act, 1961.

Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic
benefits in the form of adjustment to future income tax liability, is considered as an asset if there is
convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognised as
an asset in the Balance Sheet when it is probable that future economic benefit associated with it will
flow to the Company.

Deferred tax is recognised on timing differences, being the differences between the taxable income and
the accounting income that originate in one period and are capable of reversal in one or more subsequent
periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as
at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax
assets in respect of unabsorbed depreciation and carry forward of losses are recognised only if there is
virtual certainty that there will be sufficient future taxable income available to realise such assets.
Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable
certainty exists that sufficient future taxable income will be available against which these can be
realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by
the same governing tax laws and the Company has a legally enforceable right for such set off. Deferred
tax assets are reviewed at each Balance Sheet date for their realisability.
Current and deferred tax relating to items directly recognised in equity are recognised in equity and not
in the Statement of Profit and Loss.
2.19 Impairment of assets
The carrying values of assets / cash generating units at each Balance Sheet date are reviewed for
impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated

132
 and impairment is recognised, if the carrying amount of these assets exceeds their recoverable amount.
The recoverable amount is the greater of the net selling price and their value in use. Value in use is
arrived at by discounting the future cash flows to their present value based on an appropriate discount
factor. When there is indication that an impairment loss recognised for an asset in earlier accounting
periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the
Statement of Profit and Loss, except in case of revalued assets.
2.20 Provisions and contingencies
A provision is recognised when the Company has a present obligation as a result of past events and it is
probable that an outflow of resources will be required to settle the obligation in respect of which a
reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their
present value and are determined based on the best estimate required to settle the obligation at the
Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current
best estimates. Contingent liabilities are disclosed in the Notes.

3. Deferred Tax Liability ( Net)

Components of Deferred Tax Liability (Net) are as follows:

Timing Difference on account of For the As at March 31

period 2016 2015 2014 2013 2012
ended June
` in Lacs
30, 2016
Deferred tax (liability) / asset
Depreciation as per Companies Act 2013 30.39 119.18 115.10 112.79 112.55 112.33
Depreciation as per Income Tax Act, 1961 36.96 165.97 170.77 180.29 207.05 237.67
Difference representing Deferred Tax Liability 6.57 46.79 55.67 67.50 94.50 125.34
Provision for Gratuity - 4.04 5.02 3.29 2.52 2.12 1.54
Research & Development Expenses Written Off - 138.84 - - - -
Items constituting deferred tax liability 10.61 190.65 58.96 70.02 96.62 126.88
R & D Expenses capitalised - 125.96
Others - 0.07 - - - -
Items constituting deferred tax assets - 126.03 - - - -
Net deferred tax (liability) / asset 10.61 64.62 58.96 70.02 96.62 126.88
Deferred Tax for the year 3.51 21.36 20.04 23.80 32.84 43.13
Opening Balance of Deferred Tax (31-03-2015) 313.95 292.59 272.55 248.75 215.91 172.78
Closing Balance of Deferred Tax ( 31-03-2016) 317.46 313.95 292.59 272.55 248.75 215.91

4. Auditors Remuneration (excluding Service Tax wherever applicable)

For the For the year ended March 31

years
ended
PARTICULARS June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
As auditors - statutory audit 2.00 9.50 2.00 2.00 2.00 2.00
For taxation matters 0.50 0.50 0.50 0.50 0.50 0.50

5. Earnings Per Share

For the For the year ended March 31

period
ended
PARTICULARS 2016 2015 2014 2013 2012
June 30,
2016
` in Lacs
Restated Profit/ (Loss) restated after tax (` in 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
Lacs)
Weighted Number of Equity Shares(Nos.) 2,50,66,621 1,35,97,426 1,35,73,460 1,35,73,4601,35,73460 1,35,73,460

133
Basic and Diluted Earnings per Equity Share 1.17 3.90 (0.16) (0.96) (0.37) (0.35)
of Face Value ` 10/-

6. As at the Balance Sheet date as at June 30, 2016, March 31, 2016, March 31, 2015, March 31, 2014,
March 31, 2013 and March 31, 2012 the company does not have any dues outstanding to Micro, small
and Medium Enterprises as defined in the “The Micro, Small and Medium Enterprises Development
Act” and as such no interest is paid or payable or accrued or outstanding during the year to any
suppliers who are covered under the Micro, Small and Medium Enterprises Development Act, 2006.

7. The Employment term does not provide for Leave Encashment, Superannuation and hence no provision
has been made in the restated accounts for the period ended June 30, 2016 and for the years ended
March 31, 2016, March 31, 2015, March 31, 2014, March 31, 2013 and March 31, 2012.

8. Employee Benefits

i. Defined Contribution Plans

Contribution to Provident Fund administered by the Government.

The Company has recognised the following amounts in the Statement of Profit and Loss

For the Period For the year ended March 31

ended June 30, 2016 2015 2014 2013 2012
PARTICULARS
2016
` in Lacs
Provident Fund 0.90 4.43 0.98 0.34 0.60 0.51

Defined benefit plan

Gratuity

The Company earmarks liability towards unfunded Group Gratuity and Compensated absences and provides for
payment to vested employees as under:

a) On Normal retirement/ early retirement/ withdrawal/resignation:

As per the provisions of Payment of Gratuity Act, 1972 with vesting period of 5 years of service.

b) On death in service:

As per the provisions of Payment of Gratuity Act, 1972 without any vesting period. The most recent
actuarial valuation of plan assets and the present value of the defined benefit obligation for gratuity
were carried out as at June30, 2016 and March 31, 2016 by and independent actuary. The present
value of the defined benefit obligations and the related current service cost and past service cost, were
measured using the Projected Unit Credit Method The following table sets out the status of the gratuity
plan and the amounts recognised in the Company’ s financial statements as at June 30, 2016 and
March 31, 2016

For the For the year ended March 31

Period
ended
PARTICULARS June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
Gratuity 4.04 5.02 3.29 2.52 2.12 1.54

In accordance with the Accounting Standard 15 (Revised 2005), actuarial valuation has been done in respect of
defined benefit plan of gratuity based on the following assumptions:

134
 For the For the year ended March 31
period
ended
PARTICULARS June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
Discount rate 7.75% 8% 8% 8% 8% 8%
Salary Escalation rate 10% 10% 10% 10% 10% 10%

i. Change in present value of obligation

For the For the year ended March 31

Period
ended
PARTICULARS June 30, 2016 2015 2014 2013 2012
2016
` in Lacs
Opening present value of obligations 14.49 9.47 6.18 3.66 1.54
Interest Cost 0.28 0.76 0.49 0.29 0.12
Current Service Cost 1.51 3.96 2.81 2.16 1.77
Past Service Cost
Benefits Paid
Actuarial Losses (Gain) 2.25 0.29 (0.01) 0.06 0.22 1.54
Closing Present value of obligations 18.53 14.49 9.47 6.18 3.66 1.54

ii. Amount recognised in Balance Sheet

For the For the year ended March 31

Period
ended
PARTICULARS 2016 2015 2014 2013 2012
June 30,
2016
` in Lacs
Closing present value of obligations 18.53 14.49 9.47 6.18 3.66 1.54
Closing present value of plan assets - - - - -
Closing net liability recognised 18.53 14.49 9.47 6.18 3.66 1.54

Classification into Current / Non Current

The liability in respect of the plan comprises of the following current and non current portion

For For the year ended March 31

period 2016 2015 2014 2013 2012
ended
PARTICULARS
June 30,
2016
` in Lacs
Current 4.34 0.39 0.01 0.01 0.01 0.01
Non Current 14.19 14.10 9.46 6.17 3.65 1.53

iii. Expenses recognised in the Statement of Profit and Loss

For For the year ended March 31

period
ended
PARTICULARS 2016 2015 2014 2013 2012
June 30,
2016
` in Lacs
Current Service Cost 1.51 3.97 2.81 2.16 1.77 -
Interest Cost on benefit of obligations 0.28 0.76 0.49 0.29 0.12 -

135
 For For the year ended March 31
period
ended
PARTICULARS 2016 2015 2014 2013 2012
June 30,
2016
` in Lacs
Net actuarial Losses / (Gain) recognised in the current 2.25 0.29 (0.01) 0.06 0.22 1.54
cost
Past Service Cost - - - - -
Expenses recognised in the Statement of Profit and Loss 4.04 5.02 3.29 2,51 2.11

iv. Experience Adjustments

For the For the year ended March 31

Period
ended
PARTICULARS 2016 2015 2014 2013 2012
June 30,
2016
` in Lacs
Present value of defined benefit obligation 18.53 14.49 9.47 6.18 3.66 1.54
Fair value of plan assets - - - - -
(Deficit)/Surplus in the plan (18.53) (14.49) (9.47) (6.18) (3.66) (1.54)
Experience adjustment Gain / (Loss) on plan liabilities 2.25 (0.16) (0.01) 0.06 0.22 -
Actuarial Gain / (Loss) due to change on assumption - - - - -

9. Additional Information pursuant to provisions of Paragraph 5 (viii) of Schedule III.

a. Consumption of Raw Materials

For the For the year ended March 31

Period 2016 2015 2014 2013 2012
PARTICULARS ended June
30, 2016
` in Lacs
Glass Vials 12.63 65.76 52.89 12.57 43.22 56.69
Rubber Stopper 15.53 66.45 31.08 9.51 32.70 42.89
VVM 77.72 38.80 54.60 34.62 119.04 156.33

b. Value and % of Imported and Indigenous Raw Materials, Spare Parts and Components consumed:

For the Period For the year ended March 31

ended June 30,
PARTICULARS 2016 2015 2014 2013 2012
2016
` in Lacs
Raw Materials
Imported
Value 105.88 171.01 138.57 56.70 194.96 255.91
% to Total Consumption 78.01 29.80 86.58 73.38 73.39 73.46
Indigenous
Value 29.85 402.88 21.48 20.57 70.69 92.46
% to Total Consumption 21.99 70.20 13.42 26.62 26.61 26.54
Total
Value 135.73 573.89 160.05 77.27 265.65 348.37
% to Total Consumption 100.00 100.00 100.00 100.0 100.00 100.00
0

c. Value of Imports on CIF basis

` in lacs
For the Period For the Year ended March 31
Value of imports calculated on CIF ended June 2016 2015 2014 2013 2012
basis @: 30, 2016

136
 Raw materials 105.88 171.01 138.57 56.70 194.96 255.91
Total 105.88 171.01 138.57 56.70 194.96 255.91

d. Earnings in Foreign Exchange

` in lacs
For the 2016 2015 2014 2013 2012
Period
ended
June 30,
2016
Earnings in foreign exchange
Export of goods calculated on FOB basis 667.58 941.96 554.28 - - -

e. Expenditure in Foreign Exchange

` in lacs
For the For the Year ended March 31
Period 2016 2015 2014 2013 2012
ended June
30, 2016
Raw materials 105.88 171.01 138.57 56.70 194.96 255.91
Total 105.88 171.01 138.57 56.70 194.96 255.91

10. Details of Purchases, turnover and Inventory

a. Turnover
` in lacs
For the 2016 2015 2014 2013 2012
Period
ended June
30, 2016
BCG Vaccine 971.63 1849.37 591.37 329.13 1,044.72 990.41
BCG Onco 43.07 189.35 64.79 21.86 123.06 136.17

b. Inventories – Work in Process

` in lacs
Particulars As at June 2016 2015 2014 2013 2012
30, 2016
Inventories at the end of the year:
Work-in-progress 417.06 579.49 415.10 440.35 432.20 571.11

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure VI.

Restated Standalone Statement of Share Capital

As at As at March 31
June 30, 2016 2015 2014 2013 2012
Particulars
2016
` In Lacs
(a) Authorised
Equity shares of 4,00,00,000 of ` 10 4,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
each with voting rights (Previous
Year 2,00,00,000)
(b) Issued, Subscribed and Fully Paid Up
Equity shares of 3,83,67,275 of ` 10 3,836.73 1,534.69 1,357.35 1,357.35 1,357.35 1,357.35
each with voting rights (Previous
Year 1,53,46, 910)

137
 As at As at March 31
June 30, 2016 2015 2014 2013 2012
Particulars
2016
` In Lacs
Total 3,836.73 1,534.69 1,357.35 1,357.35 1,357.35 1,357.35

b. The Reconciliation of Number and Amount of Shares outstanding is as under

Particulars As at June 30, 2016 As at March 31

2016 2015
Number of ` In Lacs Number of ` In Lacs Number of ` In Lacs
shares Shares Shares
Opening Balance 1,53,46,910 1,534.69 1,35,73,460 1,357.35 1,35,73,460 1,357.35
Fresh issue - - 17,73,450 177.35 - -
Bonus 2,30,20,365 2,302.04 - - - -
Closing Balance 3,83,67,275 3,836.73 1,53,46,910 1534.70 1,35,73,460 1,357.35

Particulars As at March 31
2014 2013 2012
Number of ` In Number of ` In Number of ` In
shares Lacs Shares Lacs Shares Lacs
Opening 1,35,73,460 1,357.35 13,573,460 1,357.35 13,573,460 1,357.35
Balance
Fresh issue - - - - - -
Bonus - - - - - -
Closing Balance 1,35,73,460 1,357.35 1,35,73,460 1,357.35 13,573,460 1,357.35

Particc. Rights attached to Equity Shares:

The Company has issued one class of equity shares with voting rights having a par value of `10/- per share.

In the event of liquidation of the Company, the shareholders of equity shares will be entitled to receive
remaining assets of the Company after distribution of all preferential amounts. The distribution will be in
proportion to the number of equity shares held by the shareholders.

d. Details of Shares held by Shareholders holding more than 5% of the aggregate shares in the Company

Particulars As at June 30, 2016 As at March 31

2016 2015
Number of % of Number of % of Number of % of
shares holding Shares holding Shares holding
Dr. P. Murali 89,26,250 23.27 35,70,500 23.27 59,73,000 44.00
Mr. P. Sundaraparipooranan 2,14,87,250 56.00 85,94,900 56.00 44,01,450 32.43
M/S. Avon Cycles Limited 62,50,000 16.29 25,00,000 16.29 25,00,000 18.42

Particulars As at March 31
2014 2013 2012
Number of % of Number of % of Number of % of
shares holding Shares holding Shares holding
Dr. P. Murali 59,73,000 44.00 59,73,000 44.00 59,73,000 44.00
Mr. P. Sundaraparipooranan 44,01,450 32.43 44,01,450 32.43 44,01,450 32.43
M/S. Avon Cycles Limited 25,00,000 18.42 25,00,000 18.42 25,00,000 18.42

Aggregate number of shares allotted as fully paid up during last five years immediately preceding balance sheet
date pursuant to contracts without payment received in cash and by way of fully paid bonus shares

NIL.

Notes:

138
1) The figures disclosed above are based on the restated Standalone summary Statements of Assets and
Liabilities of the Company.

2) The above statement should be read with the notes to restated Standalone summary Statements of Assets
and Liabilities, Statement of Profit and Loss and Cash Flows appearing in Annexure IV.
Annexure VII

Restated Standalone Statement of Reserves and Surplus

As at March 31
Particulars As at June 30, 2016 2015 2014 2013 2012
2016
` in Lacs
(a) Capital reserve
Opening balance 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00
Add/Less: Additions/Utilised during the year - - - - -
(give details)
Closing balance 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00
(a) Revaluation reserve
Opening balance 166.23 166.23 - - - -
Add/Less: Additions/Utilised during the year - - 166.23
(give details)
Closing balance 166.23 166.23 166.23 - - -
(b) Securities premium account
Opening balance 2,897.12 1,655.70 1,655.70 1,655.70 1,655.70 1,655.70
Add : Premium on shares issued during the year 1,241.42 - - - -
Less : Utilised during the year 2,302.04 - - --
Closing balance 595.08 2,897.12 1,655.70 1,655.70 1,655.70 1,655.70
(c) Other reserves (specify the nature and
purpose of each reserve)-Subsidy Received
Opening balance 30.00 30.00 30.00 30.00 30.00 30.00
Add/ Less: Additions / transfers during the year - - - - -
Closing balance 30.00 30.00 30.00 30.00 30.00 30.00
(d) Surplus / (Deficit) in Statement of Profit
and Loss
Opening balance 44.93 (486.02) (464.69) (334.98) (284.97) (236.86)
Add: Profit / (Loss) for the year 293.09 530.95 (21.33) (129.71) (50.01) (48.11)
Closing balance 338.02 44.93 (486.02) (464.69) (334.98) (284.97)
Total 2129.33 4,138.28 2,365.91 2,221.01 2,350.72 2,400.73

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure VIII

Restated Standalone Statement of Long Term Borrowings

Particulars As at As at March 31
June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
Long Term Borrowings – From - - - 2.67 399.68
Banks
Total - - - 2.67 399.68

Notes:

139
The above statement should be necessarily read with the basis of preparation and significant accounting policies annexed to
this statement.

Annexure IX

Restated Standalone Statement of Short Term Borrowings

Particulars As at June 30, As at March 31, 2016

2016 2016 2015 2014 2013 2012
` in Lacs
(a) Loans repayable on
demand
From banks
Secured 387.61 558.07 392.32 398.45 655.90 535.54
Unsecured - - - - 2.06 2.06
387.61 558.07 392.32 398.45 657.96 537.60

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure-X

Restated Standalone Statement of Trade Payables

As at June 30 As at March 31
2016 2016 2015 2014 2013 2012
` in Lacs
Trade payables Other than Acceptances 107.22 89.46 33.76 25.57 1.38 32.27
107.22 89.46 33.76 25.57 1.38 32.27

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XI

Restated Standalone Statement of Other Current Liabilities

PARTICULARS As at June As at March 31

30, 2016 2016 2015 2014 2013 2012
` in Lacs
Other payables 100.00 143.00 1,424.26 1,382.01 9.88 -
a. Statutory remittances (Contributions to 13.82 25.04 10.18 20.14 4.16 14.43
PF and ESIC
b. Provision for Income Tax 207.63 131.68 (9.39) (9.39) (7.58) -
c. Advances from customers - - - 26.81 61.88
321.45 299.72 1,425.05 1,419.57 6.46 76.31

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XII

Restated Standalone Statement of Inventories

140
 As at June 30, As at March 31
Particulars 2016 2016 2015 2014 2013 2012
` in Lacs
(a) Raw materials 276.23 159.01 114.60 51.40 45.62 46.76
- - - - -
(b) Work-in-progress 417.06 579.49 415.10 440.35 432.20 571.11
- - - - -
Total 693.29 738.50 529.70 491.75 477.82 617.87

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XIII

Restated Standalone Statement of Trade Receivables

As at June 30, As at March 31

Particulars 2016 2016 2015 2014 2013 2012
` in Lacs
Trade receivables outstanding for a period
exceeding six months from the date they were
due for payment
Secured, considered good - -
Unsecured, considered good 48.26 52.27 56.05 47.55 50.33 50.79
Doubtful - - - - -
48.26 52.27 56.05 47.55 50.33 50.79
Less: Provision for doubtful trade receivables - - - - -
48.26 52.27 56.05 47.55 50.33 50.79
Other Trade receivables
Secured, considered good - -
Unsecured, considered good 819.62 420.05 14.97 295.24 25.95 227.84
Doubtful - - - - -
819.62 420.05 14.97 295.24 25.95 227.84
Less: Provision for doubtful trade receivables - - - - -
819.62 420.05 14.97 295.24 25.95 227.84
Total 867.88 472.32 71.02 342.79 76.28 278.63

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.
Annexure-XIV

Restated Standalone Statement of Cash and Cash Equivalents

PARTICULARS As at As at March 31
June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
(a) Cash on hand 3.81 1.52 1.75 0.11 0.17 0.13
(b) Balances with banks
(i) In current accounts 13.92 179.81 0.78 (0.72) (3.27) 11.65
(i) In deposit accounts 256.83 221.67 62.73 - - -
Interest accrued thereon 11.78 1.15 - - - -

141
Total 286.34 404.15 65.26 (0.61) (3.10) 11.78

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XV

Restated Standalone Statement of Short Term Loans and Advances

Particulars As at As at March 31
June 2016 2015 2014 2013 2012
30,
2016
` in Lacs
(b) Security deposits
Secured, considered good - -
Unsecured, considered good 26.47 25.95 24.16 22.30 19.63 14.13
Doubtful - - - - -
26.47 25.95 24.16 22.30 19.63 14.13
Less: Provision for doubtful deposits - - - - -
26.47 25.95 24.16 22.30 19.63 14.13
(c) Loans and advances to employees
Secured, considered good - -
Unsecured, considered good 1.07 0.79 0.37 4.55 3.62 7.45
Doubtful - - - - -
1.07 0.79 0.37 4.55 3.62 7.45
Less: Provision for doubtful loans and advances - - - - -
1.07 0.79 0.37 4.55 3.62 7.45
(e) Balances with government authorities
Unsecured, considered good
(i) TDS credit receivable 1.87 1.31 0.81 0.40 0.22 0.02
(ii) VAT credit receivable 2.47 0.21 11.33 12.34 12.85 13.89
(iii) Service Tax credit receivable
(g) Others (specify nature)
Secured, considered good
Unsecured, considered good 200.53 251.71 24.99 48.13 38.05 56.23
Doubtful - - - -
200.53 251.71 24.99 48.13 38.05 56.23
Less: Provision for other doubtful loans and advances - - - -
200.53 251.71 24.99 48.13 38.05 56.23

Total 232.41 279.97 61.66 87.72 74.37 91.72

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XVI

Restated Standalone Statement of Revenue from Operations

` in Lacs
For the For the Year ended March 31
period ended
Particulars
June 30, 2016 2015 2014 2013 2012
2016
Domestic Sale of products @ (Refer Note (i) below) 347.12 1,096.76 101.88 350.99 1,167.78 1,126.58

142
Export Sale of products @ (Refer Note (ii) below) 667.58 941.96 554.28 - - -
Other operating revenues # (Refer Note (iii) below)
1,014.70 2,038.72 656.16 350.99 1,167.78 1,126.58
Less:
Excise duty -
Total 1,014.70 2,038.72 656.16 350.99 1,167.78 1,126.58
Domestic Sale of products comprises
Manufactured goods
Product BCG VACCINE 304.05 907.41 39.06 329.13 1,044.72 990.41
Product BCG ONCO 43.07 189.35 62.82 21.86 123.06 136.17
Total - Domestic Sales 347.12 1,096.76 101.88 350.99 1,167.78 1,126.58
Export Sale of products comprises
Manufactured goods - -
Product BCG VACCINE 667.58 941.96 552.31 - - -
Product BCG ONCO - - 1.97 - - -
Total - Export Sale 667.58 941.96 554.28 - - -

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XVII

Restated Standalone Statement of Other Income

` in Lacs
For the For the Year ended March 31
Period
June 30,
2016
2016 2015 2014 2013 2012
- - - -
Dividend Income - 0.07 4.13 - - -
Interest Income 5.63 10.46 - 1.81 2.02 -
Scrap Sales 0.22 - - - - -
Total - Other non-operating income 5.85 10.53 4.13 1.81 2.02 -

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XVIII

Restated Standalone Statement of Cost of Materials Consumed

` in Lacsr teh
For the For the Year ended March 31
period
Particulars 2016 2015 2014 2013 2012
June 30,
2016
Opening stock 159.01 114.60 51.40 45.62 46.76 47.76
Add: Purchases 252.95 618.31 223.25 83.05 264.52 347.38
411.96 732.91 274.65 128.67 311.28 395.14
Less: Closing stock 276.23 159.01 114.60 51.40 45.62 46.76
Cost of material consumed 135.73 573.90 160.05 77.27 265.66 348.38
Material consumed comprises:
Glass Vials 12.63 65.76 52.89 12.57 43.22 56.69

143
 For the For the Year ended March 31
Particulars period 2016 2015 2014 2013 2012
June 30,
2016
Rubber Stoppers 15.53 66.45 31.08 9.51 32.70 42.89
VVM 77.72 38.80 54.60 34.62 119.04 156.33
Other items 29.85 402.88 21.48 20.57 70.70 92.47
Total 135.73 573.89 160.05 77.27 265.66 348.38

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XIX

Restated Standalone Statement of Changes in Inventories of Finished Goods, Work in Process and Stock in Trade

` in Lacs
For the For the year ended March 31
Particulars period 2016 2015 2014 2013 2012
ended
June 30,
2016
Inventories at the end of the year:
Finished goods -
Work-in-progress 417.06 579.49 415.10 440.35 432.20 571.12
Stock-in-trade - -
417.06 579.49 415.10 440.35 432.20 571.12
Inventories at the beginning of the year:
Finished goods -
Work-in-progress 579.49 415.10 440.35 432.20 571.11 648.69
Stock-in-trade - - -
579.49 415.10 440.35 432.20 571.11 648.69
Net (increase) / decrease 162.43 (164.39) 25.25 (8.15) 138.91 77.57

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XX

Restated Standalone Statement of Operations Cost

` in Lacs
For For the Year ended March 31
Particulars period 2016 2015 2014 2013 2012
June 30,
2016
Power and fuel 35.24 91.55 38.21 31.76 89.37 82.67
Repairs and maintenance - Buildings 2.95 22.36 6.24 - 2.20 0.58
Repairs and maintenance - Machinery 34.02 73.64 5.81 11.45 34.67 39.80
Insurance 0.25 4.24 3.93 2.79 3.21 3.33
Rates and taxes 2.03 9.12 10.12 4.33 1.15 15.97
Total 74.49 200.91 64.31 50.33 130.60 142.35

Notes:

144
The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XXI

Restated Standalone Statement of Employee Expenses

` in Lacs
For the For the year ended March 31
Particulars period 2016 2015 2014 2013 2012
ended
June30,
2016
Salaries and wages # 71.51 145.49 88.29 53.38 202.80 112.87
Contributions to provident and other funds 1.11 4.57 0.98 0.41 0.76 0.60
Provision for Gratuity 4.04 5.02 3.29 2.52 2.12 1.54
Staff welfare expenses ** 12.15 16.92 13.86 5.51 13.42 12.66
Total 88.81 172.00 106.42 61.82 219.10 127.67

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XXII

Restated Standalone Statement of Finance Cost

` in Lacs
For the For the years ended March 31
Particulars period 2016 2015 2014 2013 2012
ended
June30,
2016
(a) Interest expense on:
(i) Working Capital borrowings 11.42 60.42 70.60 114.72 156.75 208.84
(ii) Vehicles 0.27 0.63 - - - -
(iii) Others- Bank Charges 0.67 5.36 0.55 1.35 1.38 2.05
Total 12.36 66.41 71.15 116.07 158.13 210.89

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XXIII

Restated Standalone Statement of Other Expenses

` in Lacs
For the For the years ended March 31, 2016
Particulars period 2016 2015 2014 2013 2012
ended
June 30,
2016
Rent including lease rentals (Refer Note 30.8.d) 6.72 13.85 1.80 7.75 9.65 8.39
Communication * 1.67 6.07 3.56 2.45 4.41 -
Travelling and conveyance * 25.58 56.82 41.49 3.17 2.45 14.87

145
Postage, Printing and stationery* 5.90 13.64 7.03 1.34 6.08 4.39
Freight and forwarding including marketing cost 17.00 71.51 40.23 15.45 97.75 52.59
Professional Charges 41.65 12.48 3.20 1.47 0.35 5.05
Exchange Fluctuation 6.57 3.30 - - - -
Animal House Expenditure 29.44 54.30 14.10 - - -
Payments to auditors (Refer Note (i) below) 2.50 10.00 2.50 2.50 2.50 2.50
Internal Audit Fees - 0.25 - - - -
R & D Expenses - 138.84 - - - -
Security Charges 1.40 3.82 - - - -
Miscellaneous expenses 5.36 2.61 5.39 14.45 38.83 24.58
Total 143.79 387.49 119.30 48.58 162.02 112.37

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

Annexure XXIV

Restated Standalone Statement of Accounting Ratios

` in Lacs
For the For the years ended March 31
period ended 2016 2015 2014 2013 2012
June 30, 2016
A Restated Net Profit/Loss after 2,93,08,380 5,30,94,963 (21,33,366) (1,29,70,914) (50,00,582) (48,11,271)
tax attributable to Equity
Shareholders
B Number of Equity Shares 3,83,67,275 1,53,46,910 1,35,73,460 1,35,73,460 1,35,73,460 1,35,73,460
outstanding during the year
C Weighted Number of Equity 2,50,66,621 1,35,97,426 1,35,73,460 1,35,73,460 1,35,73,460 1,35,73,460
Shares outstanding during the
year
D Basic and Diluted Earnings per 1.17 3.90 (0.16) (0.96) (0.37) (0.35)
Share (EPS) of face value of `
10/- per share (A / C )
E Net worth 47,69,81,802 44,76,73,422 25,27,02,45 25,48,35,825 26,78,06,739 27,28,07,321
9
F Return on Net worth (A/E*100) 6.14 11.86 (0.84) (5.09) (1.87) (1.76)
G Net asset value per Equity Share 12.43 29.17 18.62 18.77 19.73 20.10
(E/B)

Notes:
The above statement should be necessarily read with the basis of preparation and significant accounting policies annexed to
this statement.

Annexure XXV

Capitalisation Statement

Particulars Pre IPO as at June 30, 2016 As adjusted for IPO

Debt
Short Term Debt (A) 3,87,61,306 3,87,61,306
Long Term Debt (B)
Total Debt (A + B) 3,87,61,306 3,87,61,306
Shareholder’s Fund
Equity Share Capital 3,83,67,275 3,83,67,275
Reserves & Surplus (Excluding 9,33,09,052 9,33,09,052
Revaluation Reserves)
Total Shareholder’s Funds (C ) 47,69,81,802 47,69,81,802

146
 Particulars Pre IPO as at June 30, 2016 As adjusted for IPO
Total Debt / Shareholder’s Fund 0.08 0.08
(A+B)/C

Notes:

1) The above has been computed on the basis of the restated Standalone summary statements of assets and
liabilities of the Company.

2) Since this is only Offer for Sale and no further issue of shares the corresponding figures (As adjusted for
issue) are also the same.

3) Long Term debts are borrowings other than short term borrowings and also includes current maturities of
long term debt included in other current liabilities

Annexure- XXVI
Tax Shelter Statement

For the For the year ended

period 2015 2015 2014 2013 2012
ended
June 30,
2016
` in Lacs
A Restated Net Profit/Loss before tax 372.55 693.76 (1.29) (105.91) (17.16) (4.99)

B Tax Rates including Surcharge and 33.06% 33.06% 33.99% 33.99% 33.99% 33.99%
education cess
C Tax thereon including Surcharge and
education cess
Tax on normal Profit / Loss 123.17 229.36 - - - -

D Permanent differences
Deductions allowed under IT Act (290.28) (629.14) - - - -

E Timing Differences
Difference between book depreciation and (6.57) (46.79) (55.67) (67.50) (94.50) (125.34)
depreciation under IT Act
Other timing differences (4.04) (17.83) (3.29) (2.52) (2.12) (1.54)
Total E (10.61) (64.62) (58.96) (70.02) (96.62) (126.88)

F Net Adjustments (300.89) (693.76) (58.96) (70.02) (96.62) (126.88)

G Tax Expenses / Saving thereon (F x B) (99.47) (229.36) (20.04) (23.80) (32.84) (43.13)

H Total Current Tax ( C + G ) 27.20 0 (20.04) (23.80) (32.84) (43.13)

I Tax as per Minimum Alternate Tax under 75.96 141.46 - - - -

Section 115JB of the Income Tax Act 1961

J Net tax expenses ( Higher of H and I) 75.96 141.46 - - - -

K MAT credit entitlement 75.96 141.46 - - - -

L Total Current Tax Expense 75.96 141.46 - - - -

147
Notes:

1. The aforesaid Tax Shelters Statement has been prepared as per the restated Standalone summary Statements
of Profits and Losses of the Company.

2. The above statement should be read with the notes to restated Standalone summary Statements of Assets
and Liabilities, Profits and Losses and Cash Flows appearing in Annexure IV.

Annexure XXVII

Related Party Transactions

List of Related parties and transactions as per requirements of Accounting Standard – 18, Related Party
Disclosure.

For the period ended June 30, 2016

A. Name of related party and description of relationship:

Name of Related Parties Description of Relationship

VMB Enterprises Private Limited Other Related Parties (entities in which shareholder /
their relatives have significant influence)

B. Related Party Transaction:

Particulars Amount ` In Lacs

Advance Received 100.00

C. Balances outstanding at the end of the year

As at June 30, 2016 100.00

For the year ended March 31, 2016

A. Name of related party and description of relationship:

Name of Related Parties Description of Relationship

VMB Enterprises Private Limited Other Related Parties (entities in which shareholder /
their relatives have significant influence)

B. Related Party Transaction:

Particulars Amount ` In Lacs

Advance Received 143.00

C. Balances outstanding at the end of the year

As at March 31, 2016 143.00

Notes:

The above statement should be necessarily read with the basis of preparation and significant accounting policies
annexed to this statement.

148
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS

You should read the following discussion of our financial condition and results of operations together with our
Restated Standalone Financial Information for the period ended June 30, 2016 and as of the fiscal years ended
March 31, 2016, 2015, 2014, 2013 and 2012 including the notes thereto and reports thereon, each included in
this Draft Red Herring Prospectus, and our assessment of the factors that may affect our prospects and
performance in future periods. Our restated financial information included in this Draft Red Herring Prospectus
is prepared in accordance with Indian GAAP, the Companies Act, 2013, as amended/Companies Act, 1956, as
applicable, and as restated in accordance with the SEBI ICDR Regulations, which differ in certain material
respects from IFRS, U.S. GAAP and GAAP in other countries. Accordingly, the degree to which our Restated
Standalone Financial Information in this Draft Red Herring Prospectus will provide meaningful information to a
prospective investor in countries other than India is entirely dependent on the reader’s level of familiarity with
Indian GAAP.

This discussion and analysis contains forward-looking statements that reflect our current views with respect to
future events and our financial performance. Our actual results may differ materially from those anticipated in
these forward-looking statements. As such, you should also read the sections titled “Forward Looking
Statements” and “Risk Factors” beginning on pages 13 and 14, respectively which discuss a number of factors
and contingencies that could affect our financial condition and results of operations. Our fiscal year ends on
March 31 of each year. Accordingly, all references to a particular fiscal year are to the 12 months ended March
31 of that year.

Overview

We are an Indian Vaccine Manufacturing Company with global operations. As on date we produce the
following products:

1. BCG Vaccine (Freeze Dried) I.P/B.P/E.P/U.S.P for immunization against Tuberculosis

2. BCG for Immunotherapy (Freeze Dried)BP for the treatment of Urinary Bladder Carcinoma.

The main objective of our Company is to provide the much needed vaccine against tuberculosis to the new born
children, thereby reducing the mortality and morbidity in children which occur due to the infectious disease and
also to provide much needed drug for immunotherapy against urinary bladder cancer to the individuals, thereby
reducing the mortality due to cancer. The motto of the Company is “Wellness for All”.

BCG Vaccine

For prevention of Tuberculosis, BCG Vaccination is accepted as one of the most important measures. It is
compulsory in 64 countries including India and is officially recommended in an additional 118 countries and
territories. BCG is most effective known adjuvant in animals and humans. It is also cheap, stable and safe.

BCG Vaccine should be routinely given to all infants at risk of early exposure to tuberculosis. This vaccine
should be given soon after the child is born. BCG administered early in life provides high level of protection
particularly against severe forms of childhood tuberculosis and tubercular meningitis. The vaccine can be given
simultaneously with DTP, DT, TT, Measles, Polio and Hepatitis B but at a separate site.

Interaction with other medicinal products and other form of interactions

Intradermal BCG Vaccination may be given concurrently with inactivated or live vaccines. Other vaccines to be
given at the same time as BCG vaccine should not be given into the same arm. If not given same time an
interval of mot less than four weeks should normally be allowed to lapse between the administrations of any two
live vaccines.

It is advisable not to give further vaccination in the arm used for BCG Vaccination for 3 months because of the
risk of regional lymphadenitis.

BCG for Immunotherapy BP:

Urinary Bladder Carcinoma is one of the most common cancers worldwide. Bladder Carcinoma is the fourth
most common cancer among men and eighth most common cancer among women. It’s disease in which
abnormal cells multiply without control in the bladder.
The major treatment mechanism for the cancer is

 Surgery – TURBT, Cystectomy

149
 Chemotherapy
 Radiotherapy
 Immunotherapy – Intravesical BCG Therapy

Benefits of Intravesical BCG Therapy

 Significant Reduction in tumor reoccurrence and progression rate

 Internationally accepted
 Used in Post TURBT

UROVAC is a live freeze dried preparation made from Bacillus Calmette Guerin Strain, which is an attenuated
stain of Mycobacterium bovis. The BCG which is propagated is also derived from Danish 1331 stain.

BCG for Immunotherapy has been widely accepted as the optimal treatment for Carcinoma in situ and high
grade superficial transitional Urinary Bladder Carcinoma.

UROVAC is not a Vaccine for prevention of cancer.

Interaction with other Medicinal Products and other forms of interactions:

Antimicrobial therapy (potential negative effect on actions of BCG), bone marrow depressants or
immunosuppressant or radiation (may impair immune response to BCG). The interval between discontinuation
of medications that cause Immunosuppression and restoration of the patient’s ability to respond BCG depends
on the intensity and type of Immunosuppression causing therapy used, the under lying disease and other factors;
estimates vary from 3 months to 1 year. Also may increase the risk of osteomyelitis or disseminated BCG
infections.

Our Company is focused on expanding its presence geographically. An important milestone in that process was
achieved during November 6, 2015, as our Company became a WHO Pre Qualified supplier.

The standalone net revenues from operations for the period ended June 30, 2016 was `1014.70 lacs and for the
years ended March 31, 2016,2015 and 2014 were `2038.72 Lacs, 656.72 Lacs and 350.99 Lacs respectively.
The following table sets forth certain information regarding our net revenue from operations for our geographic
segments on a standalone basis

(In ` Lacs)
Geographic Segments As at 2016 2015 2014
June 30,
2016
Domestic Sale of products 347.12 1,096.76 101.88 350.99
Export Sale of products 667.58 941.96 554.28 -
Total 1,014.70 2038.72 656.16 350.99

Significant Factors Affecting Our Results of Operations.

Sales volume of our Products, Launches of New Products and Pricing of our Products

Our products are marketed in India as well as in the international markets. The key growth driver for increase in
our results of operations has been the volume growth of our existing products internationally due to the
achievement of Pre Qualification from WHO.

Fiscal Benefits

Export incentives/benefits. The Government of India has framed several schemes to encourage exports. These
schemes grant incentives and other benefits to companies that export their products. We have received various
incentives and benefits under the duty drawback scheme, advance license scheme and focus market schemes for
exporting goods pursuant to the various applicable incentive schemes.

Macroeconomic Factors

Macroeconomic factors, both in the Indian and international contexts, such as economic instability, political
uncertainty, social upheavals or acts of God could influence our business and, as a result, our results of

150
operations. In addition, fluctuations in interest rates, exchange rates and inflation could have an effect on certain
key aspects of our operations, including on the costs of our raw materials, the prices at which we can sell our
pharmaceutical products, our finance costs required to fund our operations and profit margins.

Results of Operations

The following table shows a breakdown of our results of operations and each item as a percentage of total
income for the year ended March 31 and period ended June 30, 2016;

Particulars For the % 2016 % 2015 % 2014 %

Period
ended
June
30,
2016
` in Lacs
CONTINUING
OPERATIONS
Revenue from operations 1014.70 99.43 2,038.72 99.49 656.16 99.37 350.99 99.49
(gross)
Revenue from operations 1014.70 99.43 2,038.72 99.49 656.16 99.37 350.99 99.49
(net)
Other income 5.85 0.57 10.53 0.51 4.13 0.63 1.81 0.51
Total revenue (1+2) 1020.55 100 2,049.25 100.0 660.29 100.00 352.80 100.00
0
Expenses
(a) Cost of materials 135.73 13.30 573.90 28.01 160.05 24.24 77.27 21.90
consumed
(b) Changes in 162.43 15.92 -164.39 -8.02 25.25 3.82 -8.15 -2.31
inventories of finished
goods, work-in-progress
and stock-in-trade
(c) Operations Cost 74.49 7.30 200.91 9.80 64.31 9.74 50.33 14.27
(d) Employee benefits 88.81 8.70 172.00 8.39 106.42 16.12 61.82 17.52
expense
(e) Finance costs 12.36 1.21 66.41 3.24 71.15 10.78 116.07 32.90
(f) Depreciation and 30.39 2.98 119.17 5.82 115.10 17.43 112.79 31.97
amortisation expense
(g) Other expenses 143.79 14.09 387.49 18.91 119.30 18.07 48.58 13.77
Total expenses 648.00 63.50 1,355.49 66.15 661.58 100.20 458.71 130.02
Profit before 372.55 36.50 693.76 33.85 -1.29 -0.20 -105.91 -30.02
exceptional and
extraordinary items
and tax (3 - 4)
Exceptional items - - -
Profit before 372.55 36.50 693.76 33.85 -1.29 -0.20 -105.91 -30.02
extraordinary items and
tax (5 + 6)
Extraordinary items - - -
Profit before tax (7 + 372.55 36.50 693.76 33.85 -1.29 -0.20 -105.91 -30.02
8)
Tax expense:
(a) Current tax expense 75.95 7.44 141.45 6.90 - - -
for current year
(d) Net current tax 75.95 7.44 141.45 6.90 - - - -
expense
(e) Deferred tax 3.51 0.34 21.36 1.04 20.04 3.04 23.80 6.75
Total Tax Expense 79.46 7.79 162.81 7.94 20.04 3.04 23.80 6.75

151
 Profit / (Loss) from 293.09 28.72 530.95 25.91 -21.33 -3.23 -129.71 -36.77
continuing operations (9
+10)
Profit / (Loss) for the 293.09 28.72 530.95 25.91 -21.33 -3.23 -129.71 -36.77
year

Components of Income and Expenses

The components of our income and expenses are as set forth below:

Total Income

Our total income comprises revenue from sales of products and other income.

Revenue from Operations

Sale of Products

Sales of products comprise sales of finished goods in India and international markets.

Sales of finished goods are sales of BCG Vaccine and BCG for Immunotherapy, that we manufacture at our
manufacturing facility.

Other Revenue

Other income comprises of Interest income on deposits.

Expenses

Our expenses comprise Cost of Materials consumed, Changes in Inventories of Finished Goods, Work-in-
Progress and Raw Materials, Operations Cost, Employee Benefits Expenses, Depreciation, Finance Costs and
Other Expenses.

Cost of Materials Consumed

Cost of materials consumed comprises the cost of raw materials for manufacturing our products and the cost of
packing materials.

Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade

Changes in inventories of finished goods, work-in-progress and stock-in-trade comprise net increases or
decreases in inventory levels of finished goods and stock-in-trade and work-in-progress.

Operations Cost

Operations Cost comprises Power and Fuel, Repairs & Maintenance to Buildings, Repairs & Maintenance to
Machinery, Insurance and Rates & Taxes.

Employee Benefits Expense

Employee benefits expense comprise salaries, wages, bonus and allowances to our employees and full-time
directors, contributions to provident fund, employees’ state insurance and other welfare funds, and staff welfare
expenses such as food and transport costs.

Depreciation and Amortization

Depreciation is provided for using the straight line method over the useful lives of our tangible assets and
intangible assets estimated by management or at rates prescribed under Schedule XIV of the Companies Act,
1956 and under Schedule II of the Companies Act, 2013 as amended, whichever is higher.

Finance Costs

152
Finance costs comprise interest expenses and other borrowing costs.
Other Expenses

Other expenses primarily comprise rent, communication, travelling and conveyances, postage, printing &
stationery, freight and forwarding costs including marketing, legal and professional fees, Animal house
expenses, payment to auditors, and miscellaneous expenses.

Tax Expenses

Tax expenses comprise current tax and deferred tax. Current income tax is measured in amounts expected to be
paid to the tax authorities in accordance with the applicable tax law in the relevant jurisdiction. Deferred income
tax reflects the impact of timing differences between taxable income and accounting income over a given year.

Fiscal Year upto June 30, 2016 Compared to Fiscal Year 2016

Revenue from Operations

Our Revenue from operations have increased by 99.09 % on an annualised basis to ` 1014.70 Lacs for the
period ended June 30, 2016 from `2038.72 Lacs for the year ended March 31, 2016 primiarily as a result of
increase in exports due to achievement of Pre Qualified Supplier status by World Health Organisation.

Sale of Products

Our revenue from sale of products have increased by 99.09 % to `1014.70 Lacs for the period ended June 30,
2016 from `2038.72 Lacs for the year ended March 31, 2016 primiarily as a result of increase in sale of
products.

Other Income

Our other income increased by 122.22 % on an annualised basis to `5.85 Lacs for the period ended June 30,
2016 from `10.53 Lacs for the year ended March 31, 2016. This was primarily due to increase in Fixed
Deposit with banks for Earnst Money Deposit (EMD) for the sale of products.

Expenses

Our Expenses increased by 91.22 % on an annualised basis to `648.00 Lacs for the period ended June 30, 2016
from `1355.49 Lacs for the year ended March 31, 2016 primarily as a result of increase in materials consumed,
personnel costs and other expenses all of which were attributable to the growth of our operations.

Cost of materials consumed

Our cost of materials consumed decreased by 5.40 % to `135.73 Lacs for the period ended June 30, 2016 from
` 573.90 Lacs for the year ended March 31, 2016 primarily as a result of decrease in materials consumed which
were attributable to the growth of our operations.

Changes in Inventories of Finished Goods and Worki in Process

Our closing investories of work in process decreased by 495.23 % to `162.43 Lacs for the period ended June
30, 2016 from ` (164.39) Lacs for the year ended March 31, 2016 primarily as a result of increase in sales
volume during the year, enhanced inventory management.

Operations Cost

Our Operations Cost increased by 48.31 % to `74.49 Lacs for the period ended June 30, 2016 from `200.91
Lacs for the year ended March 31, 2016 primarily as a result of increase in power & fuel, and Repairs and
Maintenance to Machinery and are attributable to the increase in the operations of the company.

Employee Benefit Expense

Our employee benefit expense increased by 106.53 % to `88.81 Lacs for the period ended June 30, 2016 from
`172.00 Lacs for the year ended March 31, 2016 primarily as a result of increase in personnel costs.

153
Finance Cost

Our Finance Cost decreased on an annualised basis by (25.55) % to `12.36 Lacs for the period ended June 30,
2016 from `66.41 Lacs for the year ended March 31, 2016 primarily on account of reduction of working capital
loan due to increased sales revenues.

Depreciation

The Depreciation increased by 2.01% to `30.39 Lacs for the period ended June 30, 2016 from `119.17 Lacs
for the year ended March 31, 2016 primarily on account of increase in the fixed assets of the company.

Other Expenses

Other expenses increased on an annualised basis by 48.43 % to `143.79 Lacs for the period ended June 30,
2016 from `398.79 Lacs for the year ended March 31, 2016. This was primarily due to the following factors.

Increase of rent on an annualised by 94.08 % to Rs, 6.72 Lacs for the period ended June 30, 2016 from `13.85
Lacs for the year ended March 31, 2016 and the same is in line with the growth of our operations.

Increase of Communication by 10.05 % to `1.67 Lacs for the period ended June 30, 2016 from `6.07 Lacs for
the year ended March 31, 2016 and the same is in line with the growth of our operations.

Increase of Travelling and Conveyance by 80.08 % to `25.58 for the period ended June 30, 2016 from `56.82
Lacs for the year ended March 31, 2016 and the same is in line with the growth of our operations.

Increase of Postage, Printing and Stationery by 73.02 % to `5.90 Lacs for the period ended June 30, 2016 from
`13.64 Lacs for the year ended March 31, 2016 and the same is in line with the growth of our operations.

Decrease of Freight & Forwarding including marketing cost by 4.91 % to `17.00 Lacs for the period ended
June 30, 2016 from `71.51 Lacs for the year ended March 31, 2016 and the same is in line with the growth of
our operations.

Increase of Professional Charges by 1234.94 % to `41.65 Lacs for the period ended June 30, 2016 from `12.48
Lacs for the year ended March 31, 2016 and the same is in line with the growth of our operations.

Increase of Animal House Expenditure by 696.36 % to `6.57 Lacs for the period ended June 30, 2016 from `
3.30 Lacs for the year ended March 31, 2015 and the same is in line with the growth of our operations.

Profit / Loss before Tax

As a result of the foregoing facts, our profit before tax has increased by 114.80 % to ` 372.55 Lacs for the
period ended June 30, 2016 from `693.76 Lacs for the year ended March 31, 2016.

Tax Expenses

Our Current tax has increased by 114.78 % to `75.95 Lacs for the period ended June 30, 2016 from `141.45
Lacs for the year ended March 31, 2016 and the increase is due to the increase in profit of the company due to
increased operations.

Our deferred tax has decreased by 34.27% to `3.51 Lacs for the period ended June 30, 2016 from `21.36 Lacs
for the year ended March 31, 2016.

Net Profit / Loss after tax

As a result of the foregoing facts, our Net profit after tax has increased by 120.80 % to ` 293.09 Lacs for the
period ended June 30, 2016 from ` 530.95 Lacs for the year ended March 31, 2016.

Fiscal Year 2016 Compared to Fiscal Year 2015

Revenue from Operations

154
Our Revenue from operations have increased by 210.36 % to `2049.25 Lacs for the year ended March 31, 2016
from `660.29 Lacs for the year ended March 31, 2015 primarily as a result of increase in exports due to
achievement of Pre-Qualified Supplier status by World Health Organisation.

Sale of Products

Our revenue from sale of products have increased by 210.70 % to `2038.72 Lacs for the year ended March 31,
2016 from `656.16 Lacs for the year ended March 31, 2015 primarily as a result of increase in sale of products.

Other Income

Our other income increased by 154.96 % to `10.53 Lacs for the year ended March 31, 2016 from `4.13 Lacs for
the year ended March 31, 2015. This was primarily due to increase in Fixed Deposit with banks for Earnest
Money Deposit (EMD) for the sale of products.

Expenses

Our Expenses increased by 104.89 % to `1355.49 Lacs for the year ended March 31, 2016 from `661.58 Lacs
for the year ended March 31, 2015 primarily as a result of increase in materials consumed, personnel costs and
other expenses all of which were attributable to the growth of our operations.

Cost of materials consumed

Our cost of materials consumed increased by 258.58 % to `573.90 Lacs for the year ended March 31, 2016 from
`160.05 Lacs for the year ended March 31, 2015 primarily as a result of increase in materials consumed which
were attributable to the growth of our operations. The increase in the cost of materials consumed is in line with
our increased manufacturing volumes and higher cost of procurement for raw and packing materials.

Changes in Inventories of Finished Goods and Work in Process

Our closing inventories of work in process decreased by 751.05 % to ` (164.39) Lacs for the year ended March
31, 2016 from `25.25 Lacs for the year ended March 31, 2015 primarily as a result of increase in sales volume
during the year, enhanced inventory management.

Operations Cost

Our Operations Cost increased by 212.41 % to `200.91 Lacs for the year ended March 31, 2016 from `64.31
Lacs for the year ended March 31, 2015 primarily as a result of increase in power & fuel, and Repairs and
Maintenance to Machinery and are attributable to the increase in the operations of the company.

Employee Benefit Expense

Our employee benefit expense increased by 61.62 % to `172.00 Lacs for the year ended March 31, 2016 from
`106.42 Lacs for the year ended March 31, 2015 primarily as a result of increase in materials consumed,
personnel costs and other expenses all of which were attributable to the growth.

Finance Cost

Our Finance Cost decreased by (6.66) % to `66.41 Lacs for the year ended March 31, 2016 from `71.75 Lacs
for the year ended March 31, 2015 primarily on account of reduction of working capital loan due to increased
sales revenues.

Depreciation

The Depreciation increased by 3.54 % to `119.17 Lacs for the year ended March 31, 2016 from `115.10 Lacs
for the year ended March 31, 2015 primarily on account of increase in the fixed assets of the company.

Other Expenses

Other expenses increased by 224.80 % to `387.49 Lacs for the year ended March 31, 2016 from `119.30 Lacs
for the year ended March 31, 2015. This was primarily due to the following factors.

155
Increase of rent by 669.44 % to Rs, 13.85 Lacs for the year ended March 31, 2016 from `1.80 Lacs for the year
ended March 31, 2015 and the same is in line with the growth of our operations.

Increase of Communication by 70.51 % to `6.07 Lacs for the year ended March 31, 2016 from `3.56 Lacs for
the year ended March 31, 2015 and the same is in line with the growth of our operations.

Increase of Travelling and Conveyance by 36.95% to `56.82 for the year ended March 31, 2016 from `41.49
Lacs for the year ended March 31, 2015 and the same is in line with the growth of our operations.

Increase of Postage, Printing and Stationery by 94.03 % to `13.64 Lacs for the year ended March 31, 2016 from
`7.03 Lacs for the year ended March 31, 2015 and the same is in line with the growth of our operations.

Increase of Freight & Forwarding including marketing cost by 77.75 % to `71.51 Lacs for the year ended March
31, 2016 from `40.23 Lacs for the year ended March 31, 2015 and the same is in line with the growth of our
operations.

Increase of Professional Charges by 290.00 % to `12.48 Lacs for the year ended March 31, 2016 from `3.20
Lacs for the year ended March 31, 2015 and the same is in line with the growth of our operations.

Increase of Animal House Expenditure by 285.11 % to `54.30 Lacs for the year ended March 31, 2016 from
`14.10 Lacs for the year ended March 31, 2015 and the same is in line with the growth of our operations.

Profit / Loss before Tax

As a result of the foregoing facts, our profit before tax has increased by 695.05 % to `693.76 Lacs for the year
ended March 31, 2016 from ` (1.29) Lacs for the year ended March 31, 2015.

Tax Expenses

Our Current tax has increased by 141.45 % to `141.45 Lacs for the year ended March 31, 2016 from `Nil for
the year ended March 31, 2015 and the increase is due to the increase in profit of the company due to increased
operations.

Our deferred tax has increased by 6.59 % to ` 21.36 Lacs for the year ended March 31, 2016 from `20. 04 Lacs
for the year ended March 31, 2015.

Net Profit / Loss after tax

As a result of the foregoing facts, our Net profit after tax has increased by 552.28 % to `530.95 Lacs for the year
ended March 31, 2016 from `(21.33) Lacs for the year ended March 31, 2015.

Fiscal Year 2015 Compared to Fiscal Year 2014

Revenue from Operations

Our Revenue from operations have increased by 87.16 % to `660.29 Lacs for the year ended March 31, 2015
from `352.80 Lacs for the year ended March 31, 2014 primarily as a result of increase in exports.

Sale of Products

Our revenue from sale of products have increased by 86.95 % to `656.16 Lacs for the year ended March 31,
2015 from `350.99 Lacs for the year ended March 31, 2014 primarily as a result of increase in sale of products.

Other Income

Our other income increased by 128.18 % to `4.13 Lacs for the year ended March 31, 2015 from `1.81 Lacs for
the year ended March 31, 2014. This was primarily due to increase in Fixed Deposit with banks for Earnest
Money Deposit (EMD) for the sale of products.

Expenses

156
Our Expenses increased by 44.23 % to `661.58 Lacs for the year ended March 31, 2015 from `458.71 Lacs for
the year ended March 31, 2014 primarily as a result of increase in materials consumed, personnel costs and
other expenses all of which were attributable to the growth of our operations.

Cost of materials consumed

Our cost of materials consumed increased by 107.13 % to `160.05 Lacs for the year ended March 31, 2015 from
`77.27 Lacs for the year ended March 31, 2014 primarily as a result of increase in materials consumed which
were attributable to the growth of our operations. The increase in the cost of materials consumed is in line with
our increased manufacturing volumes and higher cost of procurement for raw and packing materials.

Changes in Inventories of Finished Goods and Work in Process

Our closing inventories of work in process increased by 409.82 % to `25.25 Lacs for the year ended March 31,
2015 from `(8.15) Lacs for the year ended March 31, 2014 primarily as a result of increase in work in process at
the year end.

Operations Cost

Our Operations Cost increased by 27.78 % to `64.31 Lacs for the year ended March 31, 2015 from `50.33 Lacs
for the year ended March 31, 2014 primarily as a result of increase in power & fuel, and Repairs and
Maintenance to Machinery and are attributable to the increase in the operations of the company.

Employee Benefit Expense

Our employee benefit expense increased by 72.14 % to `106.42 Lacs for the year ended March 31, 2015 from
`61.82 Lacs for the year ended March 31, 2014 primarily as a result of increase in materials consumed,
personnel costs and other expenses all of which were attributable to the growth.

Finance Cost

Our Finance Cost decreased by (38.70) % to `71.15 Lacs for the year ended March 31, 2015 from `116.07 Lacs
for the year ended March 31, 2014 primarily on account of reduction of working capital loan and due to
increased sales revenues.

Depreciation

The Depreciation increased by 2.05 % to `115.10 Lacs for the year ended March 31, 2015 from `112.79 Lacs
for the year ended March 31, 2014 primarily on account of increase in the fixed assets of the company.

Other Expenses

Other expenses increased by 145.57 % to `119.30 Lacs for the year ended March 31 March 31, 2015 from
`48.58 Lacs for the year ended March 31, 2014. This was primarily due to the following factors.

Decrease of rent by (76.77) % to Rs, 1.80 Lacs for the year ended March 31, 2015 from `7.75 Lacs for the year
ended March 31, 2014 and the same is in line with the growth of our operations.

Increase of Communication by 45.31 % to `3.56 Lacs for the year ended March 31, 2015 from `2.45 Lacs for
the year ended March 31, 2014 and the same is in line with the growth of our operations.

Increase of Travelling and Conveyance by 1208.83 % to `41.49 for the year ended March 31, 2015 from ` 3.17
Lacs for the year ended March 31, 2014 and the same is in line with the growth of our operations.

Increase of Postage, Printing and Stationery by 424.63 % to `7.03 Lacs for the year ended March 31, 2015 from
`1.34 Lacs for the year ended March 31, 2014 and the same is in line with the growth of our operations.

Increase of Freight & Forwarding including marketing cost by 160.39 % to `40.23 Lacs for the year ended
March 31, 2015 from Rs.15.45 Lacs for the year ended March 31, 2014 and the same is in line with the growth
of our operations.

Increase of Professional Charges by 117.69 % to `3.20 Lacs for the year ended March 31, 2015 from `1.47 Lacs
for the year ended March 31, 2014 and the same is in line with the growth of our operations.

157
Increase of Animal House Expenditure by 100.00 % to `14.10 Lacs for the year ended March 31, 2015 from
`Nil for the year ended March 31, 2014 and the same is in line with the growth of our operations.

Profit/Loss before Tax

As a result of the foregoing facts, our Loss before tax has decreased by (98.78) % to `(1.29) Lacs for the year
ended March 31, 2015 from `(105.91) Lacs for the year ended March 31, 2014.

Tax Expenses

Our deferred tax has decreased by (15.80) % to `20.04 Lacs for the year ended March 31, 2015 from `23.80
Lacs for the year ended March 31, 2014.

Net Profit/Loss

As a result of the foregoing facts, our Net losses after tax has decreased by (83.56) % to `(21.33) Lacs for the
year ended March 31, 2015 from `(129.71) Lacs for the year ended March 31, 2014

Liquidity and Capital Resources

Liquidity

We have historically met our working capital and other capital expenditure requirements primarily from cash
generated by operating activities, short-term and long-term bank borrowings. We believe that we have adequate
working capital for our present requirements and that our net cash generated from operating activities, together
with cash and cash equivalents will provide sufficient funds to satisfy our working capital requirements and
anticipated capital expenditures for the next 12 months following the date of this Draft Red Herring Prospectus.

We may, however, incur additional indebtedness to finance all or a portion of our capital expenditures or for any
other purposes depending on our capital requirements, market conditions and other factors.

Cash flows

The table below summarizes our cash flows for the periods indicated

For the As at March 31,

period 2016 2015 2014
ended
June
30,
PARTICULARS 2016
` in Lacs
Net Cash Flow from operating activities – A (106.77) (1,060.81) 381.23 890.87
Net cash From Investing activities – B (11.04) (19.06) (315.36) (123.53)
Net Cash Flow From Financing Activities – C - 1,418.76 - (764.85)
Net Increase in cash and Cash equivalents (A + B + C) (117.81) 338.89 65.87 2.49
Add: Cash and cash equivalents at the beginning of the year 404.15 65.26 (0.61) (3.10)
Cash and cash equivalents at the end of the year 286.34 404.15 65.26 (0.61)

Cash Flow from Operating activities

Net cash generated from our operating activities was ` (106.77) Lacs for the period ended June 30, 2016. Our
net profit before taxation was `372.55 Lacs for the period ended June 30, 2016, which was adjusted mainly for
depreciation of `. 30.39 Lacs. As a result, our operating profit before working capital changes was ` 402.94
Lacs for the period ended June 30, 2016. This was further adjusted primarily for an increase in our working
capital of ` (509.71) Lacs. As a result, cash generated from our operations was ` (106.77) Lacs. The increase
in our working capital was primarily attributable to increases in trade receivables, decrease in Loans and
Advances and other current assets of ` (395.56) Lacs, ` 92.77 Lacs respectively, decrease in trade payables and

158
other liabilities of ` (207.00) Lacs. As a result, our net cash generated from operating activities was ` (106.77)
Lacs for the period ended June 30, 2016.

Net cash generated from our operating activities was `(1060.81) Lacs for the Year ended March 31, 2016. Our net
profit before taxation was `693.76 Lacs for the year ended March 31, 2016, which was adjusted mainly for
depreciation of ``119.17 Lacs. As a result, our operating profit before working capital changes was `812.93 Lacs for
the year ended March 31, 2016. This was further adjusted primarily for an increase in our working capital of
`(1873.74) Lacs. As a result, cash generated from our operations was `(1060.81) Lacs. The increase in our working
capital was primarily attributable to increases in trade receivables, Loans and Advances and other current assets of
`(401.30) Lacs, `(427.11) Lacs respectively, decrease in trade payables and other liabilities of `(1045.00) Lacs. As a
result, our net cash generated from operating activities was `(1060.81) Lacs for the Year ended March 31, 2016.

Net cash generated from operating activities was `381.23 Lacs for the Year ended March 31, 2015. Our net
profit before taxation was `(1.29) Lacs for the Year ended March 31, 2015, which was adjusted mainly for
depreciation of `115.10 Lacs. As a result, our operating profit before working capital changes was ``113.81
Lacs for the Year ended March 31, 2015. This was further adjusted primarily for a decrease in our working
capital of `267.42 Lacs. The increase in our working capital was primarily attributable to decreases in trade
receivables of `271.77 Lacs and increase in Loans and advances and other current assets of `(11.88) Lacs,
increase in trade payables and other liabilities of `7.53 Lacs. Cash generated from our operations was `381.23
Lacs in the Year ended March 31, 2015,

Net cash generated from operating activities was `890.87 Lacs for the Year ended March 31, 2014. Our net
profit before taxation was `(105.91) Lacs for Year ended March 31, 2014, which was adjusted mainly for
depreciation of `112.79 Lacs. As a result, our operating profit before working capital changes was `6.88 Lacs
for the Year ended March 31, 2014. This was further adjusted primarily for an increase in our working capital of
`883.99 Lacs. As a result, cash generated from our operations was `890.87 Lacs for the Year ended March 31,
2014. This increase in our working capital was primarily attributable to increase in trade receivables, loans and
advances, of `(166.51) Lacs, `(27.28) Lacs respectively, which was offset by an increase in trade payables and
other liabilities of `1177.78 Lacs. Cash generated from our operations was `890.87 Lacs in the Year ended
March 31, 2014.

Cash Flow from Investing Activities

Net cash used for investing activities was `11.04 Lacs for the period ended June 30, 2016, which was primarily
attributable to our purchase of fixed assets amounting to `11.04 Lacs.

Net cash used for investing activities was `19.06 Lacs for the Year ended March 31, 2016, which was primarily
attributable to our purchase of fixed assets amounting to `31.94 Lacs and net decrease in expenditure on
Research & Development of `12.88 Lacs.

Net cash used from investing activities was `315.36 Lacs for the Year ended March 31, 2015, which was primarily
attributable to purchase of fixed assets amounting to `279.85 Lacs and net increase in expenditure on research &
development of `35.51 Lacs. Net cash used in investing activities was `123.53 Lacs for the Year ended March 31,
2014 which was primarily attributable towards our expenditure on research & Development of `123.53 Lacs.

Cash Flow from Financing Activities

There was no change in the Financing activities for the period ended June 30, 2016.

Net cash generated in financing activities was `1418.76 Lacs for the Year ended March 31, 2016, mainly
consisting of proceeds from fresh issue of equity capital. Net cash used in financing activities was ` 764.84
Lacs for the Year ended March 31, 2014, mainly consisting of proceeds from fresh issue of equity capital and
decrease in bank borrowings of `2.66 Lacs for the year ended March 31, 2014.

Borrowings

To fund our working capital and capital expenditure requirements, we enter into long-term and short-term credit
facilities. Our borrowings are in Indian Rupee.

The following table shows certain information about our borrowings as of March 31, 2014 and June 30, 2016.

159
 (`In Lacs)
For the period ended June 30, March 31, 2016
2016
Short Term Borrowings
Secured 387.61 558.07
-
Total Borrowings 387.61 558.07

The above borrowings are Cash Credit facilities from Union Bank of India, T. Nagar Branch.

Contractual Obligations

The following table summarizes our contractual and commitments as of June 30, 2016.

`In Lacs
Payment due by period
Total Less Than one Between 1 and Later than 5
year 5 Years Years
Short Term Borrowings 387.61 387.61 - -
Long Term Borrowings - - - -

`In Lacs
Payment due by period
Total Less Than one Between 1 and Later than 5
year 5 Years Years
Trade Payables 107.22 107.22 - -
Other Payables 100.00 100.00 - -

Contingent Liabilities

The Company does not have any contingent liabilities as on June 30, 2016.

Off Balance Sheet Arrangements

Except as set forth above, we do not have any other off-balance sheet arrangements, derivative instruments or
other relationships with unconsolidated entities that have been established for the purpose of facilitating off-
balance sheet arrangements.

Capital Expenditures

Historical Capital Expenditures

Historically, we have incurred capital expenditure in the normal course of our business in relation to the
expansion of our existing manufacturing facilities, research and development facilities and we expect to
continue to incur such capital expenditure in the future.

Capital expenditure represents additions to fixed assets (tangible and intangible) plus changes in capital work in
progress (i.e., expenses incurred in relation to capital assets but not capitalized) and advance payments on
account of capital expenditure.

Period ended June 30, 2016

During the period ended June 30, 2016, our capital expenditures were `11.04 Lacs and primarily comprised:
Tangible assets: capital expenditures incurred on tangible assets for the period ended June 30, 2016 were
`11.04 Lacs.Year ended March 31, 2016

During the year ended March 31, 2016, our capital expenditures were `31.94 Lacs and primarily comprised:

160
• Tangible assets: capital expenditures incurred on tangible assets, including capital work-in-progress, year
ended March 31, 2016 were `31.94 Lacs.

Year ended March 31, 2015

During the year ended March 31, 2015, our capital expenditures were `279.85 Lacs and primarily comprised:

• Tangible assets: capital expenditures incurred on tangible assets, including capital work-in-progress, year
ended March 31, 2016 were `279.85 Lacs.

Planned Capital Expenditure

We expect to fund our future capital expenditure plans through funds generated from our operations.

Unusual or Infrequent Events or Transactions and Significant Economic Changes

Except as described in this Draft Red Herring Prospectus, there have been no other events or transactions that, to
our knowledge, may be described as “unusual” or “infrequent”.

Known Trends or Uncertainties

Other than as described in this Draft Red Herring Prospectus, particularly in the chapters “Risk Factors” and
“Our Business” beginning on pages 14 and 82, respectively and in this section, respectively, to our knowledge,
there are no known trends or uncertainties or significant economic changes that are expected to have a material
adverse impact on our revenues or income from continuing operations.

Future Relationship between Cost and Income

Other than as described in the chapter “Risk Factors” on page 14 and this section, respectively, to our
knowledge there are no known factors that will have a material adverse impact on our operations and financial
condition.

Seasonality

Our results of operations have not, and are not expected to, generally exhibit seasonality.

Quantitative and Qualitative Disclosures about Market Risk

Risk Management

We are exposed to market risk as a result of various activities including manufacturing and borrowing from
changes in interest rates.

Commodities Risk

We are exposed to market risk with respect to commodity prices from the purchase of raw material components.
Prices for these raw material components can fluctuate over periods of time. We evaluate and manage our
commodity price risk exposure through our operating procedures and sourcing. Accordingly, significant
increases in the prices of our raw materials could affect our results of operations.

Interest Rate Risk

We are exposed to market risk with respect to changes in interest rates related to our borrowings. Interest rate
risk exists with respect to our indebtedness that bears interest at floating rates tied to certain benchmark rates as
well as borrowings where the interest rate is reset based on changes in interest rates set by RBI. If the interest
rates for our existing or future borrowings increase significantly, our cost of servicing such debt will increase.
Interest rate risk exists with respect to our indebtedness that bears interest at floating rates tied to certain
benchmark rates as well as borrowings where generally announced through credit policy measures issued twice
a year. Moreover, our interest rate risk is affected primarily by the short-term interest rates set by Indian banks.

Foreign Currency Exchange Rate Risk

161
Although our Company’s reporting currency is in Indian Rupees, we transact a significant portion of our
business in United States Dollars. Approximately 46.20% and 84.47% of our net revenue from sales of products
in the year ended March 31, 2016 and 2015, respectively, were derived from sales outside India. Therefore, our
exchange rate risk primarily arises from our foreign currency revenues, costs and other foreign currency assets
and liabilities to the extent that there is no natural hedge. We may be affected by significant fluctuations in the
exchange rates between the Indian rupee and other currencies.

Credit Risk

We are exposed to credit risk on monies owed to us by our customers. If our customers do not pay us promptly
or at all, we may have to make provisions for or write-off such amounts. For the period ended June 30, 2016, for
the year ended March 31, 2016 and the year ended March 31, 2015, our trade receivables were ` 876.88 Lacs,
`472.32 Lacs and `71.02 Lacs, respectively.

Critical Accounting Policies.

We have prepared Restated Standalone Financial Information contained elsewhere in this Draft Red Herring
Prospectus in accordance with Indian GAAP. Our significant accounting policies are more fully described in
Annexure V to our Restated Standalone Financial Information. The preparation of our Restated Standalone
Financial Information in conformity with Indian GAAP requires our management to make judgments, estimates
and assumptions as disclosed in Annexure V to our Restated Standalone Financial Information that affects the
reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent assets and liabilities
in the Restated Standalone Financial Information. The critical accounting policies that our management believes
to be the most significant are disclosed below.

Use of estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make
estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent
liabilities) and the reported income and expenses during the year. The Management believes that the estimates
used in preparation of the financial statements are prudent and reasonable. Future results could differ due to
these estimates and the differences between the actual results and the estimates are recognised in the periods in
which the results are known / materialise.

Inventories

Inventories are valued at cost except the finished goods which are being valued at cost or net market realisable
value whichever is lower. The stocks held at the factory are as verified and certified by the Management.

Cash and cash equivalents (for purposes of Cash Flow Statement)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with
an original maturity of three months or less from the date of acquisition), highly liquid investments that are
readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

Depreciation and amortisation

Depreciation on fixed assets is provided on straight line basis in accordance with the rates prescribed in
Schedule II of the Companies Act, 2013.

Revenue recognition

Sales represent gross value of sales excluding Sales Tax. Income and Expenditure are accounted on accrual
basis.

Other income

Interest income is accounted on accrual basis. Dividend income is accounted for when the right to receive it is
established.

Tangible fixed assets

162
Fixed Assets are stated at historical cost less accumulated depreciation and impairment loss, if any. Cost
comprises the purchase price and any attributable cost of bringing the assets to its working condition for its
intended use.

Capital work in progress

Research & Development Expenditure where future benefits are expected to accrue for longer periods, those
costs are capitalized in the year in which they are incurred. These costs are amortised over the tenure during
which the benefits are expected to accrue. Unamortised costs are reviewed at each Balance Sheet date to
determine the amount, if any, which do not have any enduring benefit, such identified amounts are written off in
the year in which they are identified. The Research & Development Expenditure outstanding at the beginning
of every year is written off over a period of 3 years.

Intangible assets

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an
intangible asset comprises its purchase price, including any import duties and other taxes (other than those
subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the
asset ready for its intended use and net of any trade discounts and rebates. Subsequent expenditure on an
intangible asset after its purchase / completion is recognised as an expense when incurred unless it is probable
that such expenditure will enable the asset to generate future economic benefits in excess of its originally
assessed standards of performance and such expenditure can be measured and attributed to the asset reliably, in
which case such expenditure is added to the cost of the asset

Foreign currency transactions and translations

Foreign currency transactions are recorded at the rates prevailing on the date of transaction `and the subsequent
gain/ loss on realization is being dealt with in the Profit & Loss account. Monetary items remaining unsettled,
i.e., receivables and payables at the end of the year are converted at the closing / year end rate and any exchange
differences arising on such conversion are dealt with in the Profit & Loss account. However there are no foreign
currency items remaining outstanding against or in favour of the company as at the end of the financial year.

Government grants, subsidies and export incentives

Government grants and subsidies are recognised when there is reasonable assurance that the Company will
comply with the conditions attached to them and the grants / subsidy will be received. Government grants whose
primary condition is that the Company should purchase, construct or otherwise acquire capital assets are
presented by deducting them from the carrying value of the assets. The grant is recognised as income over the
life of a depreciable asset by way of a reduced depreciation charge.

Export benefits are accounted for in the year of exports based on eligibility and when there is no uncertainty in
receiving the same.

Government grants in the nature of promoters' contribution like investment subsidy, where no repayment is
ordinarily expected in respect thereof, are treated as capital reserve. Government grants in the form of non-
monetary assets, given at a concessional rate, are recorded on the basis of their acquisition cost. In case the non-
monetary asset is given free of cost, the grant is recorded at a nominal value.

Other government grants and subsidies are recognised as income over the periods necessary to match them with
the costs for which they are intended to compensate, on a systematic basis.

Investments

Long-term investments (excluding investment properties), are carried individually at cost less provision for
diminution, other than temporary, in the value of such investments. Current investments are carried individually,
at the lower of cost and fair value. Cost of investments include acquisition charges such as brokerage, fees and
duties. Investment properties are carried individually at cost less accumulated depreciation and impairment, if
any. Investment properties are capitalised and depreciated (where applicable) in accordance with the policy
stated for Tangible Fixed Assets. Impairment of investment property is determined in accordance with the
policy stated for Impairment of Assets.

Employee benefits

163
Retirement benefits in the form of Provident fund and Employee state insurance are a defined contribution
scheme and the contributions are charged to the Profit and Loss account of the year when the contributions to
the respective funds are due. Gratuity has been provided on the basis of actuarial valuation report.

Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from
foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in
connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets
are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and
utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction /
development of the qualifying asset upto the date of capitalisation of such asset is added to the cost of the assets.
Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended
periods when active development activity on the qualifying assets is interrupted.

Segment reporting

The Company identifies primary segments based on the dominant source, nature of risks and returns and the
internal organisation and management structure. The operating segments are the segments for which separate
financial information is available and for which operating profit/loss amounts are evaluated regularly by the
executive Management in deciding how to allocate resources and in assessing performance.

The accounting policies adopted for segment reporting are in line with the accounting policies of the Company.
Segment revenue, segment expenses, segment assets and segment liabilities have been identified to segments on
the basis of their relationship to the operating activities of the segment. Inter-segment revenue is accounted on
the basis of transactions which are primarily determined based on market / fair value factors. Revenue,
expenses, assets and liabilities which relate to the Company as a whole and are not allocable to segments on
reasonable basis have been included under “unallocated revenue / expenses / assets / liabilities.

Leases

Where the Company as a lessor leases assets under finance leases, such amounts are recognised as receivables at
an amount equal to the net investment in the lease and the finance income is recognised based on a constant rate
of return on the outstanding net investment.

Assets leased by the Company in its capacity as lessee where substantially all the risks and rewards of
ownership vest in the Company are classified as finance leases. Such leases are capitalised at the inception of
the lease at the lower of the fair value and the present value of the minimum lease payments and a liability is
created for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost so
as to obtain a constant periodic rate of interest on the outstanding liability for each year.

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the
lessor are recognised as operating leases. Lease rentals under operating leases are recognised in the Statement of
Profit and Loss on a straight-line basis.

Earnings per share

In determining earnings per share, the Company considers the net profit after tax and includes the post tax effect
of any extra-ordinary / exceptional item. The number of shares used in computing basic earnings per share is the
weighted average number of shares outstanding during the period.

The number of shares used in computing diluted earnings per share comprises the weighted average shares
considered for deriving basic earnings per share, and also the weighted average number of equity shares that
could have been issued on the conversion of all dilutive potential equity shares.

Taxes on income

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the
provisions of the Income Tax Act, 1961.
Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in
the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence
that the Company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet
when it is probable that future economic benefit associated with it will flow to the Company.

164
Deferred tax is recognised on timing differences, being the differences between the taxable income and the
accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as at the reporting
date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets in respect of
unabsorbed depreciation and carry forward of losses are recognised only if there is virtual certainty that there
will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for
timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable
income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such
items relate to taxes on income levied by the same governing tax laws and the Company has a legally
enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their
realisability.
Current and deferred tax relating to items directly recognised in equity are recognised in equity and not in the
Statement of Profit and Loss.

Impairment of assets

The carrying values of assets / cash generating units at each Balance Sheet date are reviewed for impairment. If
any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is
recognised, if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is
the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash
flows to their present value based on an appropriate discount factor. When there is indication that an impairment
loss recognised for an asset in earlier accounting periods no longer exists or may have decreased, such reversal
of impairment loss is recognised in the Statement of Profit and Loss, except in case of revalued assets.

Provisions and contingencies

A provision is recognised when the Company has a present obligation as a result of past events and it is
probable that an outflow of resources will be required to settle the obligation in respect of which a reliable
estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and
are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are
reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent liabilities are
disclosed in the Notes.

165
 FINANCIAL INDEBTEDNESS

The following table shows certain information about our borrowings as of March 31, 2016 and June 30, 2016.

(`In Lacs)
For the period ended June 30, March 31, 2016
2016
Short Term Borrowings
Secured 387.61 558.07
-
Total Borrowings 387.61 558.07

The above borrowings are Cash Credit facilities from Union Bank of India, T. Nagar Branch.

Contractual Obligations

The following table summarizes our contractual and commitments as of June 30, 2016.

`In Lacs
Payment due by period
Total Less Than one Between 1 and Later than 5
year 5 Years Years
Short Term Borrowings 387.61 387.61 - -
Long Term Borrowings - - - -

`In Lacs
Payment due by period
Total Less Than one Between 1 and Later than 5
year 5 Years Years
Trade Payables 107.22 107.22 - -
Other Payables 100.00 100.00 - -

166
 SECTION –VI
OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Except, as stated below and mentioned elsewhere in this Draft Red Herring Prospectus there are no litigations
including, but not limited to suits, criminal proceedings, civil proceedings, statutory or legal proceedings,
including those for economic offences, tax liabilities, show cause notice or legal notices pending against our
Company, Directors, Promoters, Subsidiaries and Group Companies or against any other company whose
outcomes could have a material adverse effect on the business, operations or financial position of the Company
and there are no proceedings initiated for economic, civil or any other offences (including past cases where
penalties may or may not have been awarded and irrespective of whether they are specified under paragraph (a)
of Part I of Schedule V of the Companies Act, 2013) other than unclaimed liabilities of our Company, and no
disciplinary action has been taken by SEBI or any stock exchange against the Company, Directors, Promoters or
Group Entities.

Except as disclosed below there are no i) litigation or legal actions, pending or taken, by any Ministry or
department of the Government or a statutory authority against our Promoters during the last five years; (ii)
direction issued by such Ministry or Department or statutory authority upon conclusion of such litigation or
legal action; (iii) pending proceedings initiated against our Company for economic offences; (iv) default and
non-payment of statutory dues by our Company; (v) inquiries, inspections or investigations initiated or
conducted under the Companies Act, 2013 or any previous companies law in the last five years against our
Company and Subsidiaries including fines imposed or compounding of offences done in those five years; or (vi)
material frauds committed against our Company in the last five years.

Except as stated below there are no Outstanding Material Dues (as defined below) to creditors; or (ii)
outstanding dues to small scale undertakings and other creditors.

Our Board, in its meeting held on May 23, 2016 determined that outstanding dues to creditors in excess of 5%
of our Company’s Net Profit as per last audited financial statements shall be considered as material dues
(“Material Dues”) for the purpose of disclosure in this section.

Our Board, in its meeting held on May 23, 2016 determined that litigations involving an amount of more than
1% of our Company’s Net Profit as per last audited financial statements shall be considered as material
(“Material Litigation”).

Unless otherwise stated to contrary, the information provided is as of date of this Draft Red Herring Prospectus.

LITIGATION INVOLVING OUR COMPANY

Against our Company

Criminal Litigation

Nil

Civil Proceedings

Serum Institute of India Limited has filed a suit bearing reference no. Suit No. 2564/2010 along with Notice of
Motion No. 2696/2010 before Hon’ble High Court of Bombay against our Company stating that they are the
registered trademark owner of “ONCO BCG” They further stated that our company is also selling its product
under ‘BCG ONCO BP’ and that by using the similar mark for our products we have infringed their trademark.
They have prayed before the Hon’ble High Court that our company shall be restrained from using the mark
BCG ONCO BP. After hearing the parties Hon’ble High Court decided in favour of Serum India Institute
Limited and restrained us from using the said trade mark. Our Company filed an appeal before the division
bench against the said order however same was rejected. Against the said order our Company filed an SLP in
Supreme Court which was dismissed by Hon’ble Apex Court. The Hon’ble Supreme Court directed the single
judge of High Court to decide the matter afresh. Our Company has filed an application before IPAB for
rectification. Bombay High Court vide its order dated November 26, 2014 directed that parties would be at
liberty to mention the suit and have placed the same on board after the rectification application is disposed.

Taxation Matters

Nil

167
Proceedings against Our Company for economic offence/securities laws/ or any other law

Nil

Penalties in Last Five Years

Nil

Pending Notice against our Company

Nil

Past Notice to our Company

Nil

Disciplinary Action taken by SEBI or stock exchanges against Our Company

Nil

Defaults including non-payment or statutory dues to banks or financial institutions

Nil

Details of material fraud against the Company in last five years and action taken by the Companies.

Nil

LITIGATION FILED BY OUR COMPANY

Criminal Litigation

Nil

Civil Proceedings

Nil

Taxation Matters

Nil

Details of any enquiry, inspection or investigation initiated under Companies Act, 2013 or any previous
Company Law

Nil

LITIGATION INVOLVING DIRECTORS OF OUR COMPANY

Litigation against our Directors

Nil

Criminal Litigation

Nil

Civil Proceedings

Nil

Taxation Matters

168
Nil

Past Penalties imposed on our Directors

Nil

Proceedings initiated against our directors for Economic Offences/securities laws/ or any other law

Nil

Directors on list of wilful defaulters of RBI

Nil

Litigation by Directors of Our Company

Criminal Litigation

Nil

Civil Proceedings

Nil

Taxation Matters

Nil

LITIGATION INVOLVING PROMOTER OF OUR COMPANY

Outstanding Litigation against our Promoters

Criminal Litigation

Nil

Civil Proceedings

Nil

Taxation Matters

Nil

Past Penalties imposed on our Promoters

Nil

Proceedings initiated against our Promoters for Economic Offences/securities laws/ or any other law

Nil

Litigation /Legal Action pending or taken by Any Ministry or any statutory authority against any
Promoter in last five years

CBI inititated proceeding against our Promoter Mr. P. Sundaraparipooranan and Company along with Director,
BCG Vaccine Laboratory, Chennai and Pasteur Institute of Chennai vide RC 47/2208. The CBI in its
proceeding has stated that our promoter and company along with other accused has hatched conspiracy to cause
loss to Government of India. It states that accused person without any authorisation has entered into agreement
for supply of measles seeds and human diploid cell line for manufacture of measles and rubella vaccine. Our
Company filed a Cr. O.P. no. 4389/2009 before Hon’ble High Court of Chennai for quashing the said
proceedings. After hearing parties Hon’ble High Court quashed the proceedings vide its order dated April 30,
2009. Against the said order of Hon’ble High Court, CBI also filed a Special Leave Appeal no. 8555/2009

169
before Hon’ble Supreme Court of India. The matter has been dismissed by Hon’ble Supreme Court vide its
order dated February 22, 2016.

Penalties in Last Five Years

Nil

Litigation /defaults in respect of the companies/Firms/ventures/ with which our promoter was associated
in Past

Nil

Adverse finding against Promoter for violation of Securities laws or any other laws

Nil

Litigation by Our Promoters

Criminal Litigation

Nil

Civil Proceedings

Nil

Taxation Matters

Nil

LITIGATION INVOLVING OUR GROUP COMPANIES

Our Company does not have a group company.

LITIGATION INVOLVING OUR SUBSIDIARIES

Our Company does not have a subsidiary.

OTHER MATTERS

Nil

Details of any inquiry, inspection or investigation initiated under present or previous companies laws in
last five years against the Company or its subsidiaries

Nil

Outstanding Litigation against other companies/ any other person whose outcome could have an adverse
effect on our company

Nil

Material Developments since the Last Balance Sheet

Though there has been no material development since date of last balance sheet following happned between
March 31, 2016 and June 30, 2016:

1. Our Company has issued bonus shares in the ratio of 3:2 (3 shares for every 2 shares held) to existing
shareholders. The bonus issue was approved by our board of directors in their meeting held on April 2,
2016 and shareholders have approved the same in AGM held on May 2, 2016. The record date for the
same was April 25, 2016 to May 2, 2016. The shares were allotted on May 23, 2016. The bonus
shares were issued by capitalisation of the share premium account as on March 31, 2016 and EPS of
the same shall stand diluted to such extent.

170
2. Our Company was converted in to public limited company with effect from May 12, 2016 and a fresh
certificate of incorporation was issued by RoC, Chennai, Tamil Nadu.

Outstanding dues to small scale undertakings or any other creditors

Our Company owes an amount of ` 558.07 to Union Bank of India as on March 31, 2016 which is more than
5% of our Company’s Net Profit as per last audited financial statements . Also, our Company has trade
paybales and other payables of ` 89.46 lacs and ` 143.00 lacs respectively. For further details please refer to
Financial Indebtedness on page 166.

Our Company did not owe any small scale undertakings any amounts exceeding 5% of our Net Profit (` 26.55
lacs) as on March 31, 2016. Also, there is no small scale undertaking to which Company owes more than ` 1
lac for more than one month. Also there are no other individual creditors to which our Company owes more than
5% our Net Profit (` 26.55 lacs ) as on March 31, 2016.

The details pertaining to the net outstanding dues towards such creditors as on March 31, 2016, are available
on the website of our Company at www.gsbpl.com. The details in relation to other creditors and amount
payable to each creditor available on the website of our Company do not form a part of this Draft Red Herring
Prospectus.

171
 GOVERNMENT AND OTHER APPROVALS

Our Company has received the necessary consents, licenses, permissions, registrations and approvals from the
Government/RBI, various Government agencies and other statutory and/ or regulatory authorities required for
carrying on our present business activities and except as mentioned under this heading, no further material
approvals are required for carrying on our present business activities. Our Company undertakes to obtain all
material approvals and licenses and permissions required to operate our present business activities. Unless
otherwise stated, these approvals or licenses are valid as of the date of this Draft Red Herring Prospectus and
in case of licenses and approvals which have expired; we have either made an application for renewal or are in
the process of making an application for renewal. In order to operate our business of vaccine manufacturing,
and as on date we produce two vaccines BCG and BCG ONCO for Immunotherapy), we require various
approvals and/ or licenses under various laws, rules and regulations. For further details in connection with the
applicable regulatory and legal framework, pleas refer to “Regulations and Policies” on page 92 of this Draft
Red Herring Prospectus.

The Objects Clause of the Memorandum of Association enables our Company to undertake its present business
activities. The approvals required to be obtained by our Company include the following:

APPROVALS IN RELATION TO INCORPORATION

1. The Certificate of Incorporation dated November 21, 2005 issued by the Registrar of Companies,
Chennai, in the name of “Green Signal Bio Pharma Private Limited”.

2. The Certificate of Incorporation dated April 21, 2016, issued by the Registrar of Companies, Chennai,
in the name of “GreenSignal Bio Pharma Private Limited”.

3. Fresh Certificate of Incorporation Consequent upon Conversion from Private Company to Public
company issued on May 12, 2016 by the Registrar of Companies,Chennai in the name of “GreenSignal
Bio Pharma Limited”.

4. The Corporate Identity Number (CIN) of the Company is U24232TN2005PLC058068.

APPROVALS FOR THE ISSUE/OFFER

Corporate Approvals

1. Our Board has pursuant to its resolution passed at its meeting held on May 23, 2016 authorized the
Offer.

In- principle approvals from BSE and NSE

We have received in-principle approvals from the stock exchange for the listing of our Equity Shares pursuant to
letter dated [•] bearing reference no. [•].

Agreements with NSDL and CDSL

1. The Company has entered into an agreement dated May 4, 2016 with the Central Depository Services
(India) Limited (“CDSL”) and the Registrar and Transfer Agent, who in this case is, Bigshare Services
Private Limited for the dematerialization of its shares.

2. Similarly, the Company has also entered into an agreement dated May 12, 2016 with the National
Securities Depository Limited (“NSDL”) and the Registrar and Transfer Agent, who in this case is
Bigshare Services Private Limited for the dematerialization of its shares.

Lenders Agreement/NOC

Union Bank of India via Sanction letter dated February 18, 2016 has renewed/ enhanced credit facilities dated
December 31, 2015 in the name of our Company. A NOC dated June 17, 2016 has been obtained from the
Lender for the issue.

APPROVALS IN RELATION TO OUR BUSINESS OPERATIONS

172
Certificate of Importer-Exporter Code (“IEC”) dated January 10, 2006 bearing number 0405026544 is allotted
to the Company by Additional Director Generalof Foreign Trade, Ministry of Commerce and Industry.

License to work a factory dated January 23, 2008 issued by Department of Labour, Government of Tamil Nadu
under the Factories Act, 1948 bearing licenses no. 2699 and registration number TVR8727.

Manufacturing Unit Related Approvals:

Certificate (WHO GMP Certificate)approving the manufacturing facility to be compliant with the World Health
Organisation-Good Manufacturing Practices, dated March 31, 2015 issued by the Director of Drugs Control,
Chennai, Tamil Nadu, valid up to December 31, 2016.

Certificate to manufacture for sale Large volume Perenterals/Sera and Vaccine/specified in Schedules C and
C(1), excluding those specified in Schedule X of the Drugs and Cosmetics Rules, 1945 bearing License no.
TN00002462 to, dated December 23, 2013 issued by the Director of Drugs Controller, Chennai renewed upto,
December 22, 2018.

Health Clearance Certificate no. 3776/E2/2016 dated June 25, 2016 issued by Deparrtment of preventive health
and medicine under provisons of the Tamil Nadu Public Health Act, 1939. The said certifaicate is valid upto
March 31, 2017.

Marketing related Approvals

Certificate of pharmaceutical products to be placed on market dated March 30, 2015 issued by Department of
food safety and drugs administration. Same is valid upto March 30, 2016

Business Related Material Agreements:

Long Term Arrangement with LTA – 42105458 for BCG Vaccine dated November 23, 2015 for the period
2016-2018. As well as letter of confirmation for awarding of Long Term Agreement for the supply of BCG
vaccines to UNICEF dated November 9, 2015 from UNICEF for the period 2016-2018 as per the proposal
DAN-2015-501959 dated August 19, 2015.

Sales and Distribution Agreement entered between our Company and Cadila Healthcare Ltd dated June 29, 2011
initial term of the agreement being five years from the date of signing the agreement.

TAX RELATED APPROVALS

PAN Number Registration: We are registered with the Income Tax Department, Government of India bearing
Permanent Account Number (“PAN”) AACCG4791Mon June 4, 2016

TAN Registration: Issued by the Income Tax Department, Government of India having Number CHEG07968C
the Income Tax Act.

Central Sales tax Registration: Certificate of Registration having number having number 847294 issued by
Commercial tax Department.

VAT having number 33961403687 issued by Commercial Taxes Department

APPROVALS RELATED TO EMPLOYEES/ LABOUR:

Employees Provident Fund Registration: Company was allotted Code Number TN/54142 dated May 1, 2009
by Ministry of Labour and Employment, Government of India under the provisions of Employee’s Provident
Fund and Miscellaneous Act, 1952.

Registration for Employees State Insurance: Company is registered under the Employees State Insurance
Act, 1948 bearing registration number 51-90114-35 dated June 10, .2009 issued by the ESIC.

OTHER BUSINESS RELATED APPROVALS

WHO Prequalification no. l dis no. 4787/d1/3/2014 dated March 31, 2015 issued by office of Directors of
drugs control, Tamil Nadu Chennai.

173
ENVIRONMENTAL REGULATIONS

Consent to Establish: Consent Order no. 16082285794 dated has expired on March 31, 2016 and we have
applied for the same and same shall be received in due course

INTELLECTUAL PROPERTY RELATED APPROVALS:

The brand name/mark currently being used by our Company in relation to its business operations and the status
of registration of the trademark of the Brand name in India is set forth in table below:

Our Company uses UROVAC logo for business purpose however the same is registered under section 23(2),
Rule 62(1) of the Trademarks Act, 1999and Trademark Rules, 2002 class 5 type word mark dated January 23,
2013 valid till January 23, 2023.

We do not require any patents as the two products (namely the BCG vaccine and the ONCO-BCG Vaccine) are
generic drugs and hence do not require specific patents.

Other than the above we have not registered any intellectual property with regard to our business or products.,

REGISTRATIONS and APPROVALS REQUIRED FOR OVERSEAS SUPPLY AND DISTRIBUTION

OF OUR PRODUCTS:

United Nations:

Letter of acceptance of BCG vaccine for United Nation agencies by WHO dated November 6, 2015.

Nepal:

Letter of Recommendation for Import of Drugs dated April 24, 2016, bearing Reference No. 256780 and
registration No. 8764 for Product Name: BCG Vaccine issued by Ministry of Health and Population,
Department of Drug Administration, government of Nepal valid till March 24, 2018.

IV. APPROVALS AND REGISTRATIONS REQUIRED BUT NOT APPLIED FOR IN INDIA

Certain consents, license, registrations, permissions and approvals may have lapsed in their normal course or
may not have been applied for by our Company as on the date of filing of this Draft Red Herring Prospectus.
Our Company undertakes to obtain all consents, approvals, licenses, registrations and permissions required to
operate its business. Some of the materials consents, licenses, registrations, permission and approvals were
registered in the name of our partnership firm for which Fresh Approvals or Change of Name applications are
yet to be made by our Company include:

MATERIAL LICENSES / APPROVALS FOR WHICH THE COMPANY IS YET TO APPLY

Nil

Approvals applied for renewal/change of Name, but not received

Certain material approvals that are required to be obtained by our Company for undertaking its business have
elapsed in their normal course and our Company has either made an application to the relevant Central or State
government authorities for renewal of such approvals, licenses, registrations and permits or is in the process of
making such applications.

Also, our company has applied for various approval like Import Export Code, PF registration number , Consent
from state pollution control board etc.to be transferred in name of GreenSignal Bio Pharma Limited from Green
Signal Bio Pharma Private Limited.

174
 OTHER REGULATORY AND STATUTORY DISCLOSURES

Authority for the Offer

Our Board of Directors have approved the Offer pursuant to the resolution passed at their meeting held on May
23, 2016.

The Offer has been authorized by the Selling Shareholders by way of their respective letters as listed below:

Sl. No. Name of the Selling Number of Equity Shares Date of Consent Letter and Offer
Shareholder Offered Letter
1 P. Sundaraparipooranan 81,69,430 May 23, 2016
2 P. Murali 33,91,980 May 23, 2016
3 Avon Cycles Ltd 23,75,000 May 23, 2016
4 R. Srinivasan 19,000 May 23, 2016
5 Mallika Murali 6.24,150 May 23, 2016
TOTAL 1,45,79,560

Each of the Selling Shareholders has confirmed that the Equity Shares proposed to be offered and sold by it in
the Offer are eligible to be offered for sale in accordance with the SEBI ICDR Regulations, and that Equity
Shares offered and sold by it are free from any lien, charge, encumbrance or contractual transfer restrictions.
The Selling Shareholders have also confirmed that they are the legal and beneficial owners of the Equity Shares
being offered under the Offer.In-Principle Listing Approvals

1. We have received an in-principle approval from BSE for the listing of the Equity Shares pursuant to a
letter dated [•]

2. We have received an in-principle approval from NSE for the listing of the Equity Shares pursuant to a
letter dated [•]

Prohibition by SEBI or Other Government Authorities

Our Company, our Promoters, our Directors, and the Selling Shareholders, have not been debarred or prohibited
from accessing or operating in the capital markets or restrained from buying, selling or dealing in securities
under any order or direction passed by SEBI or any other regulatory or governmental authority.

The companies, with which our Promoters, our Directors or persons in control of our Company are or were
associated as promoters, directors or persons in control have not been debarred from accessing the capital
market under any order or direction passed by SEBI or any other regulatory or governmental authority.

None of our Directors are associated with the securities market. Other than as disclosed under the chapter
“Outstanding Litigation and Material Developments” on page 167 there has been no action taken by SEBI
against our Directors or any entity the Directors are involved in as promoters or directors.

None of the entities that our Directors are associated with are engaged in securities market related business and
are registered with SEBI.

Prohibition by RBI

Neither our Company, our Promoters, relatives of Promoters (as defined under Companies Act, 2013),
Directors, nor the Selling Shareholders have been identified as wilful defaulters by the RBI or any other
governmental authority. Except as disclosed in section entitled “Outstanding Litigation and Material
Developments” on page 167, there are no violations of securities laws committed by them in the past or are
pending against them.

Eligibility for the Offer

Our Company is eligible for the Issue in accordance with the Regulation 26(2) of the SEBI ICDR Regulations, which
states as follows:

175
(2) “An issuer not satisfying the condition stipulated in sub-regulation (1) may make an initial public offer if the issue
is made through the book-building process and the issuer undertakes to allot, at least seventy five percent of the net
offer to public, to qualified institutional buyers and to refund full subscription money if it fails to make the said
minimum allotment to qualified institutional buyers.”

We are an unlisted company not complying with the conditions specified in Regulation 26(1) of the SEBI ICDR
Regulations and are therefore required to meet the conditions detailed in Regulation 26(2) of the SEBI ICDR
Regulations.

 We are complying with Regulation 26(2) of the SEBI ICDR Regulations and at least 75% of the Issue is
proposed to be Allotted to QIBs and in the event we fail to do so, the full application monies shall be
refunded to the Bidders.

 We are complying with Regulation 43(2A) of the SEBI ICDR Regulations and Non-Institutional Bidders
and Retail Individual Bidders will be allocated not more than 15% and 10% of the Equity Shares in the issue,
respectively.

Hence, we are eligible to undertake the Issue under Regulation 26(2) of the SEBI ICDR Regulations.

Further in accordance with Regulation 26(4) of the SEBI ICDR Regulations, our Company shall ensure that the
number of prospective Allottees to whom the Equity Shares will be Allotted shall not be less than 1,000 failing which
the entire application monies shall be refunded forthwith.

Our Company is in compliance with conditions specified in Regulation 4(2) of the SEBI ICDR Regulations, to the
extent Applicable.

DISCLAIMER CLAUSE OF SEBI

AS REQUIRED, A COPY OF THE DRAFT RED HERRING PROSPECTUS HAS BEEN SUBMITTED
TO SEBI. IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF THE DRAFT RED
HERRING PROSPECTUS TO SEBI SHOULD NOT, IN ANY WAY, BE DEEMED OR CONSTRUED
THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY
RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE
PROJECT FOR WHICH THE OFFER IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS
OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE DRAFT RED HERRING
PROSPECTUS. THE BOOK RUNNING LEAD MANAGER, INDIAN OVERSEAS BANK HAS
CERTIFIED THAT THE DISCLOSURES MADE IN THE DRAFT RED HERRING PROSPECTUS
ARE GENERALLY ADEQUATE AND ARE IN CONFORMITY WITH THE SECURITIES AND
EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS)
REGULATIONS, 2009 IN FORCE FOR THE TIME BEING. THIS REQUIREMENT IS TO
FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING AN
INVESTMENT IN THE PROPOSED OFFER.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE COMPANY IS PRIMARILY

RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT
INFORMATION IN THE DRAFT RED HERRING PROSPECTUS, AND EACH SELLING
SHAREHOLDER IS SEVERALLY RESPONSIBLE FOR THE CORRECTNESS OF THE
STATEMENTS AND UNDERTAKINGS MADE BY IT IN THE DRAFT RED HERRING
PROSPECTUS ABOUT OR IN RELATION TO ITSELF AND THE EQUITY SHARES BEING SOLD
BY IT IN THE OFFER, THE BOOK RUNNING LEAD MANAGER ARE EXPECTED TO EXERCISE
DUE DILIGENCE TO ENSURE THAT THE COMPANY AND THE SELLING SHAREHOLDERS
DISCHARGE THEIR RESPECTIVE RESPONSIBILITIES ADEQUATELY IN THIS BEHALF AND
TOWARDS THIS PURPOSE, THE BOOK RUNNING LEAD MANAGER, INDIAN OVERSAES
BANK, HAVE FURNISHED TO SEBI, A DUE DILIGENCE CERTIFICATE DATED JULY 4, 2016
WHICH READS AS FOLLOWS:

WE, THE LEAD MERCHANT BANKER TO THE ABOVE MENTIONED FORTHCOMING OFFER,
STATE AND CONFIRM AS FOLLOWS:

176
1. WE HAVE EXAMINED VARIOUS DOCUMENTS INCLUDING THOSE RELATING TO
LITIGATION LIKE COMMERCIAL DISPUTES, PATENT DISPUTES, DISPUTES WITH
COLLABORATORS, ETC. AND OTHER MATERIAL DOCUMENTS IN CONNECTION
WITH THE FINALISATION OF THE DRAFT RED HERRING PROSPECTUS PERTAINING
TO THE SAID OFFER;

2. ON THE BASIS OF SUCH EXAMINATION AND THE DISCUSSIONS WITH THE

COMPANY, ITS DIRECTORS AND OTHER OFFICERS, OTHER AGENCIES, AND
INDEPENDENT VERIFICATION OF THE STATEMENTS CONCERNING THE OBJECTS
OF THE OFFER, PRICE JUSTIFICATION AND THE CONTENTS OF THE DOCUMENTS
AND OTHER PAPERS FURNISHED BY THE COMPANY, WE CONFIRM THAT:

(A) THE DRAFT RED HERRING PROSPECTUS FILED WITH THE SECURITIES AND
EXCHANGE BOARD OF INDIA IS IN CONFORMITY WITH THE DOCUMENTS,
MATERIALS AND PAPERS RELEVANT TO THE OFFER;

(B) ALL THE LEGAL REQUIREMENTS RELATING TO THE OFFER AS ALSO THE
REGULATIONS, GUIDELINES, INSTRUCTIONS, ETC. FRAMED/ISSUED BY THE
SECURITIES AND EXCHANGE BOARD OF INDIA, THE CENTRAL
GOVERNMENT AND ANY OTHER COMPETENT AUTHORITY IN THIS BEHALF
HAVE BEEN DULY COMPLIED WITH; AND

(C) THE DISCLOSURES MADE IN THE DRAFT RED HERRING PROSPECTUS ARE
TRUE, FAIR AND ADEQUATE TO ENABLE THE INVESTORS TO MAKE A WELL
INFORMED DECISION AS TO THE INVESTMENT IN THE PROPOSED OFFER
AND SUCH DISCLOSURES ARE IN ACCORDANCE WITH THE REQUIREMENTS
OF THE COMPANIES ACT, 1956 AS AMENDED AND REPLACED BY THE
COMPANIES ACT, 2013, TO THE EXTENT IN FORCE, THE SECURITIES AND
EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2009 (THE “SEBI REGULATIONS”) AND
OTHER APPLICABLE LEGAL REQUIREMENTS.

3. WE CONFIRM THAT BESIDES OURSELVES, ALL THE INTERMEDIARIES NAMED IN

THE DRAFT RED HERRING PROSPECTUS ARE REGISTERED WITH THE SECURITIES
AND EXCHANGE BOARD OF INDIA (“SEBI”) AND THAT TILL DATE SUCH
REGISTRATION IS VALID.

4. WE HAVE SATISFIED OURSELVES ABOUT THE CAPABILITY OF THE

UNDERWRITERS TO FULFIL THEIR UNDERWRITING COMMITMENTS. – NOTED FOR
COMPLIANCE

5. WE CERTIFY THAT WRITTEN CONSENT FROM THE PROMOTERS HAS BEEN

OBTAINED FOR INCLUSION OF THEIR EQUITY SHARES AS PART OF PROMOTER’S
CONTRIBUTION SUBJECT TO LOCK-IN AND THE EQUITY SHARES PROPOSED TO
FORM PART OF PROMOTER’S CONTRIBUTION SUBJECT TO LOCK-IN SHALL NOT
BE DISPOSED/SOLD/TRANSFERRED BY THE PROMOTERS DURING THE
PERIODSTARTING FROM THE DATE OF FILING THE DRAFT RED HERRING
PROSPECTUS WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA TILL THE
DATE OF COMMENCEMENT OF LOCK-IN PERIOD AS STATED IN THE DRAFT RED
HERRING PROSPECTUS.

6. WE CERTIFY THAT REGULATION 33 OF THE SECURITIES AND EXCHANGE BOARD

OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS,
2009, WHICH RELATES TO EQUITY SHARES INELIGIBLE FOR COMPUTATION OF
PROMOTERS’ CONTRIBUTION, HAS BEEN DULY COMPLIED WITH AND
APPROPRIATE DISCLOSURES AS TO COMPLIANCE WITH THE SAID REGULATION
HAVE BEEN MADE IN THE DRAFT RED HERRING PROSPECTUS-COMPLIED WITH
AND NOTED FOR COMPLIANCE

7. WE UNDERTAKE THAT SUB-REGULATION (4) OF REGULATION 32 AND CLAUSE (C)

AND (D) OF SUB-REGULATION (2) OF REGULATION 8 OF THE SECURITIES AND
EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2009 SHALL BE COMPLIED WITH. WE CONFIRM

177
 THAT ARRANGEMENTS HAVE BEEN MADE TO ENSURE THAT PROMOTERS’
CONTRIBUTION SHALL BE RECEIVED AT LEAST ONE DAY BEFORE THE OPENING
OF THE OFFER. WE UNDERTAKE THAT AUDITORS’ CERTIFICATE TO THIS EFFECT
SHALL BE DULY SUBMITTED TO SEBI. WE FURTHER CONFIRM THAT
ARRANGEMENTS HAVE BEEN MADE TO ENSURE THAT PROMOTERS’
CONTRIBUTION SHALL BE KEPT IN AN ESCROW ACCOUNT WITH A SCHEDULED
COMMERCIAL BANK AND SHALL BE RELEASED TO THE COMPANY ALONG WITH
THE PROCEEDS OF THE PUBLIC OFFER- NOT APPLICABLE

8. WE CERTIFY THAT THE PROPOSED ACTIVITIES OF THE COMPANY FOR WHICH

THE FUNDS ARE BEING RAISED IN THE PRESENT OFFER FALL WITHIN THE ‘MAIN
OBJECTS’ LISTED IN THE OBJECT CLAUSE OF THE MEMORANDUM OF
ASSOCIATION OR OTHER CHARTER OF THE COMPANY AND THAT THE ACTIVITIES
WHICH HAVE BEEN CARRIED OUT UNTIL NOW ARE VALID IN TERMS OF THE
OBJECT CLAUSE OF ITS MEMORANDUM OF ASSOCIATION-NOT APPLICABLE

9. WE CONFIRM THAT NECESSARY ARRANGEMENTS HAVE BEEN MADE TO

ENSURETHAT THE MONEYS RECEIVED PURSUANT TO THE OFFER ARE KEPT IN
ASEPARATE BANK ACCOUNT AS PER THE PROVISIONS OF SECTION 40 OF THE
COMPANIES ACT, 2013 AND THAT SUCH MONEYS SHALL BE RELEASED BY THE
SAID BANK ONLY AFTER PERMISSION IS OBTAINED FROM ALL THE STOCK
EXCHANGES MENTIONED IN THE DRAFT RED HERING PROSPECTUS. WE FURTHER
CONFIRM THAT THE AGREEMENT ENTERED INTO BETWEEN THE BANKERS TO
THE OFFER, THE SELLING SHAREHOLDERS AND THE COMPANY SPECIFICALLY
CONTAINS THISCONDITION. - NOTED FOR COMPLIANCE. ALL MONIES RECEIVED
OUT OF THE OFFER SHALL BE CREDITED/ TRANSFERRED TO A SEPARATE BANK
ACCOUNT AS REFERRED TO IN SUB-SECTION (3) OF SECTION 40 OF THE
COMPANIES ACT, 2013.

10. WE CERTIFY THAT A DISCLOSURE HAS BEEN MADE IN THE DRAFT RED HERRING
PROSPECTUS THAT THE INVESTORS SHALL BE GIVEN AN OPTION TO GET THE
SHARES IN DEMAT OR PHYSICAL MODE -NOT APPLICABLE. UNDER SECTION 29 OF
THE COMPANIES ACT, 2013, THE EQUITY SHARES IN THE OFFER ARE TO BE ISSUED
IN DEMATERIALISED FORM ONLY.

11. WE CERTIFY THAT ALL THE APPLICABLE DISCLOSURES MANDATED IN THE SEBI
REGULATIONS HAVE BEEN MADE IN ADDITION TO DISCLOSURES WHICH, IN OUR
VIEW, ARE FAIR AND ADEQUATE TO ENABLE THE INVESTOR TO MAKE A WELL
INFORMED DECISION.

12. WE CERTIFY THAT THE FOLLOWING DISCLOSURES HAVE BEEN MADE IN THE
DRAFT RED HERRING PROSPECTUS:

(A) AN UNDERTAKING FROM THE COMPANY THAT AT ANY GIVEN TIME,

THERE SHALL BE ONLY ONE DENOMINATION FOR THE EQUITY SHARES OF
THE COMPANY; AND

(B) AN UNDERTAKING FROM THE COMPANY THAT IT SHALL COMPLY WITH

SUCH DISCLOSURE AND ACCOUNTING NORMS SPECIFIED BY THE BOARD
FROM TIME TO TIME.

13. WE UNDERTAKE TO COMPLY WITH THE REGULATIONS PERTAINING TO

ADVERTISEMENT IN TERMS OF THE SEBI REGULATIONS WHILE MAKING THE
OFFER. - NOTED FOR COMPLIANCE

14. WE ENCLOSE A NOTE EXPLAINING HOW THE PROCESS OF DUE DILIGENCE HAS
BEEN EXERCISED BY US IN VIEW OF THE NATURE OF CURRENT BUSINESS
BACKGROUND OF THE COMPANY, SITUATION AT WHICH THE PROPOSED
BUSINESS STANDS, THE RISK FACTORS, PROMOTERS’ EXPERIENCE, ETC. 15. WE
ENCLOSE A CHECKLIST CONFIRMING REGULATION-WISE COMPLIANCE WITH
THE APPLICABLE PROVISIONS OF THE SEBI REGULATIONS, CONTAINING DETAILS
SUCH AS THE REGULATION NUMBER, ITS TEXT, THE STATUS OF COMPLIANCE,

178
 PAGE NUMBER OF THE DRAFT RED HERRING PROSPECTUS WHERE THE
REGULATION HAS BEEN COMPLIED WITH AND OUR COMMENTS, IF ANY.

15. WE ENCLOSE STATEMENT ON ‘PRICE INFORMATION OF PAST ISSUES HANDLED BY

MERCHANT BANKERS (WHO ARE RESPONSIBLE FOR PRICING THE OFFER)’, AS PER
FORMAT SPECIFIED BY THE SECURITIES AND EXCHANGE BOARD OF INDIA
THROUGH CIRCULAR.

16. WE CERTIFY THAT PROFITS FROM RELATED PARTY TRANSACTIONS HAVE ARISEN
FROM LEGITIMATE BUSINESS TRANSACTIONS. – COMPLIED WITH TO THE EXTENT
OF THE RELATED PARTY TRANSACTIONS CERTIFIED BY M/S. RAJ AND RAVI,
CHARTERED ACCOUNTANTS (FIRM REGISTRATION 10935S) PURSUANT TO ITS
CERTIFICATE DATED JULY 2, 2016.

17. WE CERTIFY THAT THE ENTITY IS ELIGIBLE UNDER 106Y (1) (A) OR (B) (AS THE
CASE MAY BE) TO THE LIST ON THE INSTITUTIONAL TRADING PLATFORM, UNDER
CHAPTER XC OF THE SEBI REGULATIONS (IF APPLICABLE) – NOT APPLICABLE

The filing of this Draft Red Herring Prospectus does not, however, absolve any person who has authorised the
issue of this Draft Red Herring Prospectus from any liabilities under Section 34 or Section 36 of Companies
Act, 2013 or from the requirement of obtaining such statutory and/or other clearances as may be required for the
purpose of the proposed Offer. SEBI further reserves the right to take up at any point of time, with BRLM any
irregularities or lapses in this Draft Red Herring Prospectus.

All legal requirements pertaining to the Offer will be complied with at the time of filing of the Red Herring
Prospectus with Registrar of Companies in terms of Section 32 of the Companies Act, 2013. All legal
requirements pertaining to the Offer will be complied with at the time of registration of the Prospectus with
Registrar of Companies in terms of Sections 32 and 33 of the Companies Act, 2013, as applicable.

CAUTION – DISCLAIMER CLAUSE OF OUR COMPANY, THE SELLING SHAREHOLDER AND

THE BRLM

Our Company, the Directors, the Selling Shareholders and BRLM accept no responsibility for statements made
otherwise than in this Draft Red Herring Prospectus or in the advertisements or any other material issued by or
at our Company’s instance and anyone placing reliance on any other source of information, including our
Company’s website www.gsbpl.com, would be doing so at his or her own risk.

The Selling Shareholders assume responsibility only for the statements and undertakings made by it in this Draft
Red Herring Prospectus about or in relation to itself and the Equity Shares being sold by it in the Offer, provided
however that Selling Shareholders assume no responsibility for any of the statements or undertakings made by
the Company or any other Selling Shareholder or any expert or any other person in this Draft Red Herring
Prospectus.

BRLM accept no responsibility, save to the limited extent as provided in the Offer Agreement and Underwriting
Agreement to be entered into amongst the Underwriters, the Selling Shareholders and our Company.

All information shall be made available by our Company, the Selling Shareholders and BRLM to the public and
Bidders at large and no selective or additional information would be available for a section of the investors in
any manner whatsoever including at road show presentations, in research or sales reports, at bidding centres or
elsewhere.

None among our Company, the Selling Shareholders or any member of the Syndicate is liable for any failure in
downloading the Bids due to faults in any software/hardware system or otherwise.

Bidders will be required to confirm and will be deemed to have represented to our Company, the Selling
Shareholders, Underwriters and their respective directors, officers, agents, affiliates, and representatives that
they are eligible under all applicable laws, rules, regulations, guidelines and approvals to acquire the Equity
Shares of our Company and will not issue, sell, pledge, or transfer the Equity Shares of our Company to any
person who is not eligible under any applicable laws, rules, regulations, guidelines and approvals to acquire the
Equity Shares of our Company. Our Company, the Selling Shareholders, Underwriters and their respective
directors, officers, agents, affiliates, and representatives accept no responsibility or liability for advising any
Bidder on whether such Bidder is eligible to acquire the Equity Shares of our Company.

179
The BRLM and their respective associates and affiliates may engage in transactions with, and perform services
for, our Company, the Selling Shareholders and their respective group companies, affiliates or associates or
third parties in the ordinary course of business and have engaged, or may in the future engage, in commercial
banking and investment banking transactions with our Company, the Selling Shareholders and their respective
group companies, affiliates or associates or third parties, for which they have received, and may in the future
receive, compensation.

PRICE INFORMATION OF PAST ISSUES HANDLED BY THE BRLM

Issue Name Issue Issue Listing Opening +/-%change in +/- change in +/- change in
S. Size price(Rs.) date price on closing closing price, closing price
No. (`In listing price,(+/- (+/- % change (+/- % change
lac.) date change in in closing in closing
(Rs.) closing benchmark)- benchmark)-
benchmark)- 90th Calendar 180th calendar
30th calendar days from days from
days from listing listing
listing
1 Veto 250.00 50.00 December 50.45 0.09 1.58 3.96
Switchgears 13, 2012
and Cables
Limited

Notes:
1. All data secured from NSEINDIA.COM –EMERGE
2. Bench mark index considered is NSE SME
3. 30th, 90th,180th calendar day from listed day have been taken as listing day plus 29,89 and 179 calendar days except wherever
30th,90th, 180th calendar is either a holiday or share not traded in which case we have considered the closing date of next traded
day.
SUMMARY STATEMENT OF DISCLOSURE

1 Total Total No of IPOs trading at No of IPOs trading at No of IPOs trading at No of IPOs trading at
no funds Discount -30th Premium 30th discount -180th calendar premium 180th calendar
IPOs Raised calendar days calendar days days from listing days from listing
(`In From listing From listing
lacs.)
Over Between Less Over Between Less Over Between Less Over Between Less
50% 25-50% than 50% 25-50% than 50% 25-50% than 50% 25-50% than
25% 25% 25% 25%
2012- 1 250.00 - - - - - 1 - - - - - 1
13

TRACK RECORD OF PAST ISSUES HANDLED BY THE BRLM

For details regarding the track record of the BRLM’s as specified in circular no. CIR/MIRSD/1/2012 dated January 10,2012 issued by SEBI,
kindly refer to the website of the BRLM as set forth in the table below

S. No. Name of BRLM Website

1 Indian Overseas Bank www.iob.in

DISCLAIMER WITH RESPECT TO JURISDICTION

This Offer is being made in India to persons resident in India (including Indian nationals resident in India who
are not minors, HUFs, companies, corporate bodies and societies registered under the applicable laws in India
and authorised to invest in shares, Indian Mutual Funds registered with SEBI, Indian financial institutions,
commercial banks, regional rural banks, co-operative banks (subject to RBI permission), or trusts under
applicable trust law and who are authorised under their constitution to hold and invest in shares, permitted
insurance companies and pension funds, insurance funds set up and managed by the army and navy and
insurance funds set up and managed by the Department of Posts, India) and to FPIs, Eligible NRIs and other
eligible foreign investors. This Draft Red Herring Prospectus does not, however, constitute an invitation to
purchase shares offered hereby in any jurisdiction other than India to any person to whom it is unlawful to make
an offer or invitation in such jurisdiction. Any person into whose possession this Draft Red Herring Prospectus

180
comes is required to inform himself or herself about, and to observe, any such restrictions. Any dispute arising
out of this Offer will be subject to the jurisdiction of appropriate court(s) in Chennai only.

No action has been, or will be, taken to permit a public offering in any jurisdiction where action would be
required for that purpose, except that this Draft Red Herring Prospectus has been filed with SEBI for its
observations and SEBI shall give its observations in due course. Accordingly, the Equity Shares represented
thereby may not be offered or sold, directly or indirectly, and this Draft Red Herring Prospectus may not be
distributed, in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction.
Neither the delivery of this Draft Red Herring Prospectus nor any sale hereunder shall, under any circumstances,
create any implication that there has been no change in the affairs of our Company since the date hereof or that
the information contained herein is correct as of any time subsequent to this date.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as
amended (the “U.S. Securities Act”) or any state securities laws in the United States and may not be
offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in
Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the registration
requirements of the U.S. Securities Act and applicable state securities laws in the United States.

Accordingly, the Equity Shares are being offered and sold outside the United States in offshore
transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the
jurisdiction where those offers and sales occur.

DISCLAIMER CLAUSE OF NSE

As required, a copy of this Draft Red Herring Prospectus has been submitted to NSE. The disclaimer clause as
intimated by BSE to our Company, post scrutiny of this Draft Red Herring Prospectus, shall be included in the
Red Herring Prospectus prior to the filing with the Registrar of Companies.

DISCLAIMER CLAUSE OF BSE

As required, a copy of this Draft Red Herring Prospectus has been submitted to BSE. The disclaimer clause as
intimated by BSE to our Company, post scrutiny of this Draft Red Herring Prospectus, shall be included in the
Red Herring Prospectus prior to the filing with the Registrar of Companies.

FILING

A copy of this Draft Red Herring Prospectus has been filed with SEBI at Overseas Towers, 7th Floor, 756-L,
Anna Salai, Chennai

A copy of the Red Herring Prospectus, along with the documents required to be filed would be delivered for
registration to the Registrar of Companies in accordance with Section 32 of the Companies Act, 2013 and a
copy of the Prospectus to be filed under Section 26 of the Companies Act would be delivered for registration
with the Registrar of Companies at Block No.6, B Wing, 2 nd Floor, Shastri Bhavan, 26 Haddows Road, Chennai
600 034.

LISTING

Applications have been made to the Stock Exchanges for permission to deal in and for an official quotation of
the Equity Shares. [●], will be the Designated Stock Exchange with which the Basis of Allotment will be
finalised.

If the permissions to deal in, and for an official quotation of, the Equity Shares are not granted by any of the
Stock Exchanges mentioned above, our Company and the Selling Shareholders will forthwith repay, all moneys
received from the applicants in pursuance of the Red Herring Prospectus. If such money is not repaid within the
prescribed time, then our Company, the Selling Shareholders and every officer in default shall be liable to repay
the money, with interest, as prescribed under applicable law.

Our Company shall ensure that all steps for the completion of the necessary formalities for listing and
commencement of trading at all Stock Exchanges mentioned above are taken within six Working Days of the
Bid/Offer Closing Date. Further, the Selling Shareholders confirm that they shall provide assistance to the
Company and the BRLM, as may be reasonably required and necessary, for the completion of the necessary
formalities for listing and commencement of trading at all the Stock Exchanges where the Equity Shares are
proposed to be listed within six Working Days of the Bid/Offer Closing Date.

181
CONSENTS

Consents in writing of: (a) our Directors, Promoter, our Company Secretary and Compliance Officer, CFO,
Statutory Auditors, Indian Legal Counsel to Offer, Banker/Lenders to our Company, Selling Shareholders,
Advisor, IRR Advisory Services Pvt Ltd; and (b) the BRLM, the Syndicate Members, the Escrow Collection
Banks and the Registrar and Share Transfer Agent to the Offer to act in their respective capacities, will be
obtained and filed along with a copy of the Red Herring Prospectus with the Registrar of Companies as required
under the Companies Act, 2013 and such consents shall not be withdrawn up to the time of delivery of the Red
Herring Prospectus for registration with the Registrar of Companies.

In accordance with the Companies Act, 2013 and the SEBI ICDR Regulations, M/s. RAJ AND RAVI,
Chartered Accountants, our Company’s Statutory Auditors, have given their written consent to the inclusion of
their examination reports dated July 2, 2016 on the restated financial statements and statement of tax benefits
included in this Draft Red Herring Prospectus and such consent shall not be withdrawn up to the time of
delivery of this Draft Red Herring Prospectus for filing with SEBI.

EXPERTS

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent from our Statutory Auditors namely, RAJ AND RAVI, Chartered
Accountants, to include their name as an expert under section 26(1)(a)(v) of the Companies Act, 2013 in this
Draft Red Herring Prospectus in respect of each of the reports dated July 2, 2016 on the Restated Financial
Information and the statement of tax benefits July 2, 2016 included in this Draft Red Herring Prospectus and
such consents have not been withdrawn as on the date of this Draft Red Herring Prospectus. However, the term
“expert” shall not be construed to mean an “expert” as defined under the U.S. Securities Act.

OFFER EXPENSES

The expenses of this Offer include, among others, underwriting and management fees, selling commissions,
printing and distribution expenses, legal fees, statutory advertisement expenses, registrar and depository fees
and listing fees. The Offer expenses except the listing fees will be reimbursed by the Selling Shareholders. For
further details of Offer expenses, please refer to the chapter “Objects of the Offer” on page 57.

All expenses except listing fees, in relation to the Offer shall be shared between each of the Selling
Shareholders in proportion to the Equity Shares being offered for sale in the Offer. In case incurs any expenses
in relation to issue same shall be reimubursed by the Selling Sharholder to Company.

FEES PAYABLE TO THE SYNDICATE

The total fees payable to the Syndicate (including underwriting commission and selling commission and
reimbursement of their out-of-pocket expense) will be as per the engagement letter dated [●].

For details of the Offer expenses, please refer to “Objects of the Offer” on page 57.

COMMISSION PAYABLE TO THE SCSBs, REGISTERED BROKERS, RTAs AND CDPs

For details of commission payable to the SCSBs, Registered Brokers, RTAs and CDPs, please refer to “Objects
of the Offer” on page 57.

UNDERWRITING COMMISSION, BROKERAGE AND SELLING COMMISSION ON PREVIOUS

ISSUES

Since this is an initial public offering of our Company, no sum has been paid or is payable as commission or
brokerage for subscribing to or procuring or agreeing to procure subscription for any Equity Shares since
inception of our Company.

PARTICULARS REGARDING PUBLIC OR RIGHTS ISSUES BY OUR COMPANY DURING THE

LAST FIVE YEARS

182
Our Company has not made any public or rights issues during the five years preceding the date of this Draft Red
Herring Prospectus.

PREVIOUS ISSUES OF THE EQUITY SHARES OTHERWISE THAN CASH

Except as disclosed in “Capital Structure” on page 48, our Company has not issued any Equity Shares for
consideration otherwise than for cash.

COMMISSION AND BROKERAGE PAID ON PREVIOUS ISSUES OF THE EQUITY SHARES

Since this is the initial public offering of Equity Shares, no sum has been paid or has been payable as
commission or brokerage for subscribing to or procuring or agreeing to procure subscription for any of the
Equity Shares since our Company’s inception.

Previous capital issue during the previous three years by listed Group Companies and Subsidiary of our
Company

We don’t have any group company or subsidiary.

Performance vis-à-vis objects – Public or Rights Issue of our Company or listed Group Companies or
both, Subsidiary and associates of our Company

Our Company has not undertaken any previous public or rights issue.

OUTSTANDING DEBENTURES OR BONDS

As on date, there are no outstanding debentures or bonds of our Company.

OUTSTANDING PREFERENCE SHARES

As on date, there are no outstanding preference shares of our Company.

STOCK MARKET DATA FOR THE EQUITY SHARES

This being an initial public offer of our Company, no stock market data is available

MECHANISM FOR REDRESSAL OF INVESTOR GRIEVANCES

Bidders may contact the BRLM for complaints, information or clarifications pertaining to the Offer.

The agreement between the Registrar and Share Transfer Agent to the Offer, our Company and the Selling
Shareholders provides for retention of records with the Registrar and Share Transfer Agent to the Offer for a
period of at least three years from the last date of despatch of the letters of allotment, demat credit and refund
orders to enable the investors to approach the Registrar and Share Transfer Agent to the Offer for redressal of
their grievances.

All grievances other than those of Anchor Investors may be addressed to the Registrar and Share Transfer Agent
to the Offer with a copy to the relevant Designated Intermediary with whom the Bid cum Application Form was
submitted. The Bidder should give full details such as name of the sole or first Bidder, Bid cum Application
Form number, Bidder DP ID, Client ID, PAN, date of the Bid cum Application Form, address of the Bidder,
number of the Equity Shares applied for and the name and address of the Designated Intermediary where the
Bid cum Application Form was submitted by the Bidder.

Further, the investor shall also enclose the Acknowledgement Slip from the Designated Intermediaries in
addition to the documents or information mentioned hereinabove.

All grievances of the Anchor Investors may be addressed to the Registrar and Share Transfer Agent to the Offer,
giving full details such as name of the sole or first Bidder, Anchor Investor Application Form number, Bidders
DP ID, Client ID, PAN, date of the Anchor Investor Application Form, address of the Bidder, number of the
Equity Shares applied for, Bid Amount paid on submission of the Anchor Investor Application Form and the
name and address of the Book Running Lead Manager where the Anchor Investor Application Form was
submitted by the Anchor Investor.

183
DISPOSAL OF INVESTOR GRIEVANCES BY OUR COMPANY

Our Company estimates that the average time required by our Company or Registrar and Share Transfer Agent
to the Offer or SCSB, for the redressal of routine investor grievances shall be 10 Working Days from the date of
receipt of the complaint. In case of non-routine complaints and complaints where external agencies are involved,
our Company will seek to redress these complaints as expeditiously as possible.

Our Company has also appointed Ms S Rathna Prabha, Company Secretary of our Company, as the Compliance
Officer for this Offer and she may be contacted in case of any pre-Offer or post-Offer related concerns at the
following address:

Old No.5, New No.13/A3,

Sai Nikethan, Circular Road,
United India Colony,
Kodambakkam, Chennai 600 024.
Tamil Nadu, India.
Telephone No: +91 044 2472 2244
Fax No: +91 044 24722233
E Mail: [email protected]

Our Company has not received any investor complaint during the three years preceding the date of filing of this
Draft Red Herring Prospectus.

CHANGES IN AUDITORS

Our Company has not changed its Auditors since in last three years.

CAPITALISATION OF RESERVES OR PROFITS

Our Company has not capitalised its reserves or profits at any time during the last five years, except as stated in
the section entitled “Capital Structure” on 48.

REVALUATION OF ASSETS

Our Company has not revalued its assets, except as disclosed below:

The Company has revalued the land held by it to an extent of 34.01 acres in Kunnavalam Village, Thiruvallur
District during the financial year 2014-15. The land was revalued to ` 459.20 lacs as per the prevailing
guideline value. The revaluation was done for administrative purposes and the same was reflected in the
financial statements for the year ended March 31, 2015.

Change in Accounting Policies

There has been no change in accounting policies of the Company since incorporation of the Company.

184
 SECTION VII – OFFER INFORMATION
TERMS OF THE OFFER

The Equity Shares being offered pursuant to the Offer shall be subject to the provisions of the Companies Act,
2013, the Memorandum and Articles of Association, the terms of the Red Herring Prospectus and the
Prospectus, Bid cum Application Form, the Revision Form, the CAN, the Allotment Advice and other terms and
conditions as may be incorporated in the Allotment Advices and other documents/ certificates that may be
executed in respect of the Offer. The Equity Shares shall also be subject to laws, guidelines, notifications and
regulations relating to the issue of capital and listing and trading of securities issued from time to time by SEBI,
the Government, Stock Exchanges, Registrar of Companies, RBI and/or other authorities, as in force on the date
of the Offer and to the extent applicable, or such other conditions as may be prescribed by SEBI, RBI, the
Government of India the Stock Exchanges, the Registrar of Companies and/or any other authorities while
granting its approval for the Offer.

Offer for Sale

The Offer comprises an Offer for Sale by the Selling Shareholders. All expenses in relation to the Offer other
than listing fees (which will be borne by our Company) shall be borne by (i) P. Sundaraparipooranan; (ii) P.
Murali (iii) Avon Cycles Limited; (iv) R. Srinivasan and (v) Mallika Murali in proportion to the Equity Shares
contributed to the Offer in accordance with applicable law. However, for ease of operations, expenses of the
Selling Shareholders may, at the outset, be borne by our Company, if required, on behalf of Selling Shareholders
agrees that it will reimburse our Company all such expenses.

Ranking of the Equity Shares

The Equity Shares being offered pursuant to the Offer shall be subject to the provisions of Companies Act and
Memorandum and Articles of Association and shall rank pari-passu with the existing Equity Shares of our
Company including rights in respect of dividend. Allottees in receipt of Allotment of the Equity Shares under
this Offer will be entitled to dividends and other corporate benefits, if any, declared by our Company after the
date of Allotment. For further details, see section “Main Provisions of the Articles of Association” on page
237.

Mode of Payment of Dividend

Our Company shall pay dividends, if declared, to its shareholders in accordance with the provisions of
Companies Act, Memorandum and Articles of Association and provisions of the Listing Regulations. For
further details in relation to dividends, see sections entitled “Dividend Policy” and “Main Provisions of the
Articles of Association” on pages 123 and 237, respectively.

Face Value and Offer Price

The face value of the Equity Shares is ₹ 10 each and the Offer Price at the lower end of the Price Band is ` [●]
per Equity Share and at the higher end of the Price Band is ` [●] per Equity Share. The Anchor Investor
Allocation Price is ` [●] per Equity Share.

The Price Band and the minimum Bid Lot size for the Offer will be decided by our Company and the Selling
Shareholders in consultation with BRLM and advertised in one the English newspaper, one Hindi newspaper,
and one Tamil newspaper with wide circulation, at least five Working Days prior to the Bid/Offer Opening
Date. The Price Band, along with the relevant financial ratios calculated at the Floor Price and at the Cap Price,
shall be prefilled in the Bid cum Application Form available at the websites of the Stock Exchanges.

At any given point of time there shall be only one denomination for the Equity Shares.

Compliance with the disclosure and accounting norms

Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Rights of the Equity Shareholder

Subject to applicable laws, the equity shareholders shall have the following rights:

185
 right to receive dividends, if declared;
 right to attend general meetings and exercise voting powers, unless prohibited by law or due to an
order/judgment of a court, tribunal or regulatory/judicial/statutory authority;
 right to vote on a poll either in person or by proxy;
 right to receive offers for rights shares and be allotted bonus shares, if announced;
 right to receive surplus on liquidation, subject to any statutory and preferential claim being satisfied;
 right of free transferability subject to applicable law, including any RBI rules and regulations; and
 such other rights, as may be available to a shareholder of a listed public company under the Companies
Act, the

Listing Regulations and our Company’s Memorandum and Articles of Association.

For a detailed description of the main provisions of the Articles of Association relating to voting rights,
dividend, forfeiture and lien and/or consolidation/splitting, see section entitled “Main Provisions of the Articles
of Association” on page 237.

Market Lot and Trading Lot

In terms of Section 29 of Companies Act, 2013, the Equity Shares shall be allotted only in dematerialised form.
As per the SEBI ICDR Regulations, the trading of the Equity Shares shall only be in dematerialised form. In this
context, two agreements have been signed among our Company, the respective Depositories and the Registrar
and Share Transfer Agent to the Offer:

1. Tripartite agreement dated May 12, 2016 between our Company, NSDL and the Registrar and Share
Transfer Agent to the Offer.

2. Tripartite agreement dated May 4, 2016 between our Company, CDSL and the Registrar and Share
Transfer Agent to the Offer.

Since trading of the Equity Shares is in dematerialised form, the tradable lot is one Equity Share. Allotment in
this Offer will be only in electronic form in multiples of one Equity Share subject to a minimum Allotment of
[] Equity Shares.

Joint Holders

Where two or more persons are registered as the holders of the Equity Shares, they shall be entitled to hold the
same as joint tenants with benefits of survivorship.

Jurisdiction

Exclusive jurisdiction for the purpose of this Offer is with the competent courts/authorities in Chennai.

Compliance with SEBI ICDR Regulations

Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Nomination Facility to Investor

In accordance with Section 72 of the Companies Act, the sole Bidder, or the first Bidder along with other joint
Bidders, may nominate any one person in whom, in the event of the death of sole Bidder or in case of joint
Bidders, death of all the Bidders, as the case may be, the Equity Shares Allotted, if any, shall vest. A person,
being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall be entitled
to the same advantages to which he or she would be entitled if he or she were the registered holder of the
Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the
prescribed manner, any person to become entitled to the Equity Share(s) in the event of his or her death during
the minority. A nomination shall stand rescinded upon a sale/ transfer /alienation of the Equity Share(s) by the
person nominating. A buyer will be entitled to make a fresh nomination in the prescribed manner. Fresh
nomination can be made only on the prescribed form available on request at our Registered Office or to the
registrar and transfer agents of our Company.

186
Any person who becomes a nominee by virtue of Section 72 of the Companies Act, shall upon the production
of such evidence as may be required by the Board, elect either:

 To register himself or herself as the holder of the Equity Shares; or

 To make such transfer of the Equity Shares, as the deceased holder could have made.

Further, the Board may at any time give notice requiring any nominee to choose either to be registered himself
or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of ninety days,
the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable in respect of the
Equity Shares, until the requirements of the notice have been complied with.

Since the Allotment of the Equity Shares in the Offer will be made only in dematerialised form, there is no
need to make a separate nomination with our Company. Nominations registered with respective depository
participant of the applicant would prevail. If the investors require changing their nomination, they are
requested to inform their respective depository participant.

Withdrawal of the Offer

Our Company in consultation with the Selling Shareholders and the BRLM, reserve the right not to proceed
with the Offer after the Bid/Offer Opening Date but before the Allotment. In such an event, our Company would
issue a public notice in the newspapers in which the pre-Offer advertisements were published, within two days
of the Bid/Offer Closing Date or such other time as may be prescribed by SEBI, providing reasons for not
proceeding with the Offer. The BRLM through the Registrar and Share Transfer Agent to the Offer, shall notify
the SCSBs to unblock the ASBA Accounts (other than Anchor Investors) within one Working Day from the date
of receipt of such notification. Our Company shall also inform the same to the Stock Exchanges on which
Equity Shares are proposed to be listed. The notice of withdrawal will be issued in the same newspapers where
the pre-Offer advertisements have appeared.

If our Company in consultation with the Selling Shareholders withdraws the Offer after the Bid/Offer Closing
Date and thereafter determines that it will proceed with an issue/offer for sale of the Equity Shares, our
Company shall file a fresh draft red herring prospectus with SEBI. Notwithstanding the foregoing, this Offer is
also subject to obtaining the final listing and trading approvals of the Stock Exchanges, which our Company
shall apply for after Allotment within six Working Days of the Bid/Offer Closing Date, and the final RoC
approval of the Prospectus after it is filed with the RoC.

The period of operation of subscription list of the Offer

Bid/Offer opens on [•]1

Bid/Offer closes on [•]2
1
Our Company and the Selling Shareholders may, in consultation with the BRLM, consider participation by
Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period
shall be one Working Day prior to the Bid/Offer Opening Date.
2
Our Company and the Selling Shareholders may, in consultation with BRLM, consider closing the Bid/Offer
Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR
Regulations.

An indicative timetable in respect of the Offer is set out below:

Event Indicative Date

Bid/ Offer Closing Date On or about [●]
Finalisation of Basis of Allotment with the Designated Stock Exchange On or about [●]
Initiation of refunds/ un-blocking of ASBA Accounts On or about [●]
Credit of Equity Shares to demat accounts of Allottees On or about [●]
Commencement of trading of the Equity Shares on the Stock Exchanges On or about [●]

The above timetable, other than the Bid/Offer Closing Date, is indicative and does not constitute any
obligation on our Company or the Selling Shareholders or the BRLM.

Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the
listing and the commencement of trading of the Equity Shares on the Stock Exchanges are taken within six

187
Working Days of the Bid/Offer Closing Date, the timetable may change due to various factors, such as
extension of the Bid/Offer Period by our Company and the Selling Shareholders, revision of the Price Band
or any delay in receiving the final listing and trading approval from the Stock Exchanges. The
commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchanges
and in accordance with the applicable laws. The Selling Shareholders severally, and not jointly, undertake
to provide such reasonable support and extend reasonable cooperation as may be requested by our
Company, to the extent such support and cooperation is required from such party to facilitate the process
of listing and commencement of trading of the Equity Shares on the Stock Exchanges within six Working
Days from the Bid/Offer Closing Date.

Except in relation to the Bids received from the Anchor Investors, Bids and any revision in Bids shall be
accepted only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time (“IST”) during the Bid/Offer Period
(except the Bid/Offer Closing Date) at the Bidding Centres.

On the Bid/Offer Closing Date, the Bids and any revision in the Bids shall be accepted only between 10.00 a.m.
and 3.00 p.m. IST and shall be uploaded until (i) 4.00 p.m. IST in case of Bids by QIBs and Non-Institutional
Bidders, and (ii) until 5.00 p.m. IST or such extended time as permitted by the Stock Exchanges, in case of Bids
by Retail Individual Bidders after taking into account the total number of applications received up to the closure
of timings and reported by the BRLM to the Stock Exchanges.

It is clarified that Bids not uploaded on the electronic bidding system or in respect of which the full Bid Amount
is not blocked by SCSBs would be rejected.

Due to limitation of time available for uploading the Bids on the Bid/Offer Closing Date, Bidders are advised to
submit their Bids one day prior to the Bid/Offer Closing Date and, in any case, no later than 1.00 p.m. IST on
the Bid/Offer Closing Date. Any time mentioned in this Draft Red Herring Prospectus is IST. Bidders are
cautioned that, in the event a large number of Bids are received on the Bid/Offer Closing Date, as is typically
experienced in public offerings, some Bids may not get uploaded due to lack of sufficient time. Such Bids that
cannot be uploaded will not be considered for allocation under this Offer. Bids will be accepted only between
Monday to Friday (excluding any public holiday). None among our Company, the Selling Shareholders or any
member of the Syndicate is liable for any failure in uploading the Bids due to faults in any software/hardware
system or otherwise.

On Bid/Offer Closing Date, extension of time may be granted by Stock Exchanges only for uploading Bids
received by Retail Individual Bidders after taking into account the total number of Bids received and as reported
by the BRLM to the Stock Exchanges.

In case of discrepancy in the data entered in the electronic book vis-a-vis the data contained in the physical or
electronic Bid cum Application Form, for a particular Bidder, the Registrar and Share Transfer Agent to the
Offer shall ask for rectified data.

Our Company and the Selling Shareholders in consultation with the BRLM, reserves the right to revise the Price
Band during the Bid/Offer Period, provided that the Cap Price shall be less than or equal to 120% of the Floor
Price and the Floor Price shall not be less than the face value of the Equity Shares. The revision in the Price
Band shall not exceed 20% on either side i.e. the Floor Price can move up or down to the extent of 20% of the
Floor Price and the Cap Price will be revised accordingly.

In case of revision in the Price Band, the Bid/Offer Period shall be extended for at least three additional
Working Days after such revision, subject to the Bid/Offer Period not exceeding 10 Working Days. Any
revision in Price Band, and the revised Bid/Offer Period, if applicable, shall be widely disseminated by
notification to the Stock Exchanges, by issuing a press release and also by indicating the change on the
websites of the BRLM and the terminals of the other members of the Syndicate.

Minimum Subscription

The requirement of minimum subscription is not applicable to the Offer in accordance with the SEBI ICDR
Regulations. However, In accordance with Regulation 26(4) of the SEBI ICDR Regulations, our Company shall
ensure that the number of prospective Allottees to whom the Equity Shares will be Allotted will be not less than
1,000. It shall also be ensured that the minimum allotment to public shall be atleast twenty five percent of the
post issue capital of the company, as specified under Regulation 19(2) (b) (i) of Securities Contracts
(Regulation) Rules, 1957

188
ARRANGEMENT FOR DISPOSAL OF ODD LOT

Since the Equity Shares will be traded in dematerialized form only, the marketable lot for the Equity Shares
will be one and hence, no arrangements for disposal of odd lots are required.

RESTRICTION ON TRANSFER OF EQUITY SHARES

Except for lock-in of pre-Offer equity shareholding, Promoters minimum contribution and lock-in of Equity
Shares Allotted to Anchor Investor, as detailed in the chapter “Capital Structure - Build-up of Promoters’
Shareholding, Promoters’ contribution and Lock-in” on page 50, and except as provided in the Articles of
Association, there are no restrictions on transfers of Equity Shares. There are no restrictions on transmission of
Equity Shares and on their consolidation/ splitting except as provided in the Articles of Association. Please
refer to “Main Provisions of the Articles of Association” on page 237.

OPTION TO RECEIVE EQUITY SHARES IN DEMATERIALIZED FORM

In accordance with the SEBI ICDR Regulations, Allotment of Equity Shares to successful Bidders will only be
in the dematerialized form. Bidders will not have the option of Allotment of the Equity Shares in physical
form. The Equity Shares on Allotment will be traded only on the dematerialized segment of the Stock
Exchanges. Allottees shall have the option to re-materialise the Equity Shares, if they so desire, as per the
provisions of the Companies Act, 2013 and the Depositories Act.

189
 OFFER STRUCTURE

Initial public offering of up to 1,457,9560 Equity Shares of face value of ` 10 each for cash at a price of `
[●] per Equity Share through an offer for sale, aggregating up to ` [●] lacs, through the Book Building
Process.The Offer will constitute up to 38% of the total post-Offer paid-up equity capital of our Company. The
Offer is being made through the Book Building Process:

Particulars QIBs@ Non-Institutional Retail Individual

Investors Investors
Number of Equity Shares At least 1,09,34,670 Equity Not more than 21,86,934 Not more than 14,57,956
available for Shares Equity Shares available for Equity Shares available
allocation/Allotment* allocation for allocation

Percentage of the Offer Not less than 75% of Net Not more than 15% of Not more than 10% of
Size available for Offer Size shall be the Net Offer. the Net Offer.
allocation/ Allotment allocated to QIBs.

However, up to 5% of the
Net QIB Portion shall be
available for allocation
proportionately to Mutual
Funds only.

Up to 60% of the QIB

Portion may be available
for allocation to Anchor
Investors and one- third of
the Anchor Investor Portion
shall be available for
allocation to domestic
Mutual Funds.**
Basis of allocation/ Proportionate as follows: Proportionate. Not less than the
Allotment, if respective minimum Bid Lot
category is (a) 2,18,693 Equity Shares, (subject to availability of
oversubscribed constituting 5% of the Net Equity Shares), and the
QIB Portion (excluding remaining Equity Shares,
Anchor Investor Portion), if any, shall be allotted
shall be available for on a proportionate
allocation on a proportionate #
basis .
basis to Mutual Funds;

(b) 41,55,175 Equity Shares

shall be allotted on a
proportionate basis to all
QIBs (except to Anchor
Investors) including Mutual
Funds receiving allocation as
per (a) above.
Minimum Bid Such number of Equity Such number of Equity [●] Equity Shares and in
Shares and in multiples of Shares that the Bid multiples of [●] Equity
[●] Equity Shares thereafter Amount exceeds ` Shares thereafter.
such that the Bid Amount 200,000 and in multiples
exceeds ` 200,000. of [●] Equity Shares
thereafter.
Maximum Bid Not exceeding the size of Not exceeding the size of Such number of Equity
the Net Offer subject to the Net Offer subject to Shares in multiples of
Regulations as applicable to regulations as applicable [●] so as to ensure that
the Bidder. to the Bidder. the Bid Amount does not

190
 Particulars QIBs@ Non-Institutional Retail Individual
Investors Investors
exceed ` 200,000.
Mode of bidding Through ASBA only. Through ASBA only. Through ASBA only.
Mode of Allotment Compulsorily in Compulsorily in
Compulsorily in
dematerialized form. dematerialized form. dematerialized form.
Bid Lot [●] Equity Shares in [●] Equity Shares in [●] Equity Shares in
multiples of [●] Equity multiples of [●] Equity multiples of [●] Equity
Shares thereafter. Shares thereafter. Shares thereafter.
Allotment Lot [●] Equity Shares and in [●] Equity Shares and in [●] Equity Shares and in
multiples of one Equity multiples of one Equity multiples of one Equity
Shares thereafter. Shares thereafter. Shares.
Trading Lot One Equity Share. One Equity Share. One Equity Share.
Who can Apply*** Public financial institutions Resident Indian
Resident Indian
as specified in Section 2(72) individuals, Eligible
individuals, Eligible
of the Companies Act, 2013, NRIs, HUFs (in the NRIs and HUFs (in the
Scheduled Commercial name of Karta),
name of Karta).
Banks, Mutual Fund companies, corporate
registered with SEBI, FPIs bodies, scientific
other than Category III Institutions societies and
Foreign Portfolio Investors, trusts, Category III FPIs
VCFs, FVCIs, Multilateral .
and Bilateral Development
Financial Institutions, state
Industrial Development
Corporation, Insurance
Company registered with
IRDA, provident fund
(subject to applicable law)
with minimum corpus of ₹
2500 lacs, pension fund with
minimum corpus of ₹2500
lacs, in accordance with
applicable law and National
Investment Fund set up by
the Government of India,
insurance funds set up and
managed by army, navy or
air force of
the Union of India and
insurance funds set up and
managed by the
Department of Posts, India
Terms of Payment## Full Bid Amount shall be Full Bid Amount shall be Full Bid Amount shall be
payable at the time of payable at the time of payable at the time of
submission of the Bid cum submission of the Bid submission of the Bid
Application Form through cum Application Form cum Application Form
the ASBA Process (other through the ASBA through ASBA.
than for Anchor Investors). Process.
@ Our Company and the Selling Shareholders may, in consultation with the BRLM, allocate up to 60% of
the QIBPortion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall
be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at
or above the price at which allocation is being done to other Anchor Investors. For details, please refer to
the chapter “Offer Procedure” on page 193.
* Subject to valid Bids being received at or above the Offer Price pursuant to the Net Offer is being made for
at least 25% of the post-Offer paid-up Equity Share capital of our Company. The Offer is being made
through the Book Building Process, wherein not less than 75% of the Net Offer will be available for
allocation to QIBs on a proportionate basis, provided that our Company and the Selling Shareholders
may, in consultation with the BRLM, allocate up to 60% of the QIB Portion to Anchor Investors at the
Anchor Investor Offer Price to the Anchor Investor, on a discretionary basis subject to valid bids being

191
 received at Anchor Investor Offer Price. Further, not more than 15% of the Net Offer will be available for
allocation on a proportionate basis to Non-Institutional Investors, subject to valid Bids being received at
or above the Offer Price and not more than 10% of the Net Offer will be available for allocation to Retail
Individual Investors in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or
above the Offer Price. Allotment of Equity Shares to each of the Retail Individual Investors shall not be less
than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining
available Equity Shares, if any, shall be allotted on a proportionate basis. Any unsubscribed portion in any
reserved category, if any shall be added to the Net Offer. In case of under-subscription, if any, in Non-
Institutional and Retail Individual categories, the under subscription would be allowed to be met with spill
over inter-se from any other categories, at the discretion of our Company and Selling Shareholders in
consultation with the BRLM and subject to applicable provisions of SEBI ICDR Regulations. However,
under-subscription in the Net QIB Portion would not be allowed to be met with spill-over from any other
category.

** Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Bid cum
Application Forms. In case the Anchor Investor Offer Price is lower than the Offer Price, the balance
amount will be payable as per pay-in date mentioned in the revised CAN.

*** In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder
whose name should also appear as the first holder of the beneficiary account held in joint names. The
signature of only such First Bidder would be required in the Bid cum Application Form and such First
Bidder would be deemed to have signed on behalf of the joint holders.

Bidders will be required to confirm and will be deemed to have represented to our Company, the BRLM,
their respective directors, officers, agents, affiliates and representatives that they are eligible under
applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares in this Offer.
# In case of oversubscription in Retail Portion, maximum number of Retail Individual Investors who can
be Allotted the minimum Bid Lot will be computed by dividing the total number of Equity Shares available
for Allotment to Retail Individual Investors by the minimum Bid Lot (“Retail – Bid Lot Allottees”). The
Allotment to Retail Individual Investors will then be made in the following manner:

i. In the event the number of Retail Individual Investors who have submitted valid Bids in the Net Offer
is equal to or less than Retail – Bid Lot Allottees, (i) all such Retail Individual Investors shall be
Allotted the minimum Bid Lot; and (ii) the balance Equity Shares, if any, remaining in the Retail
Portion shall be Allotted on a proportionate basis to those Retail Individual Investors who have
applied for more than the minimum Bid Lot, for the balance demand of the Equity Shares Bid by them
(i.e. the difference between the Equity Shares Bid and the minimum Bid Lot).
ii. In the event number of Retail Individual Investors who have submitted valid Bids in the Net Offer is
more than the Retail – Bid Lot Allottees, those Retail Individual Investors, who will be Allotted the
minimum Bid Lot shall be determined the basis of draw of lots. In the event of a draw of lots,
Allotment will only be made to such Retail Individual Investors who are successful pursuant to such
draw of lots.
## In case of ASBA Bidders, the SCSB shall be authorised to block such funds in the bank account of the ASBA
Bidder that is specified in the Bid cum Application Form.

Under subscription, if any, in any category, except in the QIB Portion, would be met with spill-over from other
categories at the discretion of our Company and the Selling Shareholders in consultation with BRLM and the
Designated Stock Exchange.

Retail discount

Retail discount, if any, of [●]% to the Floor Price will be offered to Retail Individual Investors. The rupee
amount of the Retail Discount will be decided by our Company and the Selling Shareholders in consultation
with the BRLM and will be advertised at least five Working Days prior to the Bid/ Offer Opening Date.

192
 OFFER PROCEDURE

All Bidders should review the General Information Document for Investing in Public Issues prepared and
issued in accordance with the circular (CIR/ CFD/ DIL/ 12/ 2013) dated October 23, 2013 notified by SEBI
(“General Information Document”) included below under “ – Part B - General Information Document”,
which highlights the key rules, processes and procedures applicable to public issues in general in accordance
with the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, the Securities
Contracts (Regulation) Rules, 1957 and the SEBI ICDR Regulations. The General Information Document has
been updated to include reference to the Securities and Exchange Board of India (Foreign Portfolio Investors)
Regulations, 2014 and certain notified provisions of the Companies Act, 2013, to the extent applicable to a
public issue, read with the rules thereto. The General Information Document is also available on the websites of
the Stock Exchanges and the BRLM. Please refer to the relevant portions of the General Information Document
which are applicable to this Offer.

Our Company, the Selling Shareholders and the BRLM do not accept any responsibility for the completeness
and accuracy of the information stated in this chapter and the General Information Document. Bidders are
advised to make their independent investigations and ensure that their Bids do not exceed the investment limits or
maximum number of Equity Shares that can be held by them under applicable law or as specified in the Red
Herring Prospectus and the Prospectus.

PART A

Book Building Procedure

The Issue is being made through the Book Building Process wherein not less than 75% of the Issue shall be
allocated to QIBs on a proportionate basis, provided that our Company, in consultation with the BRLM, may
allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis and in accordance with
the SEBI ICDR Regulations, subject to valid Bids being received from domestic Mutual Funds at or above the
Anchor Investor Allocation Price. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be
available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB
Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor
Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further,
not more than 15% of the Issue shall be available for allocation on a proportionate basis to Non Institutional
Bidders and not more than 10% of the Issue shall be available for allocation to Retail Individual Bidders in
accordance with the SEBI ICDRRegulations, subject to valid Bids being received at or above the Issue Price.

Investors should note that the Equity Shares will be Allotted to all successful Bidders only in
dematerialised form.

Investors should note that the Equity Shares will be Allotted to all successful Bidders only in
dematerialised form. The Bid cum Application Forms which do not have the details of the Bidders’
depository account, including DP ID, Client ID and PAN, shall be treated as incomplete and will be
rejected. Bidders will not have the option of being Allotted Equity Shares in physical form.

Bid cum Application Form

Copies of the Bid cum Application Form and the abridged prospectus will be available at the offices of the
BRLM, the Designated Intermediaries at Bidding Centres, and Registered Office of our Company. An electronic
copy of the Bid cum Application Form will also be available for download on the websites of the BRLM,
SCSBs, the NSE (www.nseindia.com), the BSE (www.bseindia.com), the terminals of the Registered Brokers,
the RTAs and the CDPs at least one day prior to the Bid/Offer Opening Date.

All Bidders (other than Anchor Investors) shall mandatorily participate in the Offer only through the ASBA
process. Anchor Investors are not permitted to participate in the Offer through the ASBA process.

ASBA Bidders must provide bank account details and authorisation to block funds in the relevant space
provided in the Bid cum Application Form and the Bid cum Application Forms that do not contain such details
are liable to be rejected.

ASBA Bidders shall ensure that the Bids are made on Bid cum Application Forms bearing the stamp of the
Designated Intermediary, submitted at the Collection Centres only (except in case of electronic Bid cum
Application Forms) and the Bid cum Application Forms not bearing such specified stamp are liable to be
rejected.

193
Copies of the Anchor Investor Application Form and the abridged prospectus will be available at the office of
the BRLM.

The prescribed colour of the Bid cum Application Form for the various categories is as follows:

Category Colour of Bid cum Application Form*

Resident Indians and Eligible NRIs applying on a non-
repatriation basis White
Non-Residents including Eligible NRIs, FIIs, FPI or Blue
other eligible non resident investor on repatriation
basis
Anchor Investors** White
* Excluding electronic Bid cum Application Form
** Anchor Investor Application Form will be made available at the office of the BRLM

Who can bid?

In addition to the category of Bidders set forth under section entitled “General Information Document for
Investing in Public Issues - Category of Investors Eligible to Participate in an Issue” on page 206, the
following persons are also eligible to invest in the Equity Shares under all applicable laws, regulations and
guidelines, including:

 Scientific and/or industrial research organisations authorised in India to invest in the Equity Shares;
and

 Any other persons eligible to Bid in this Offer under the laws, rules, regulations, guidelines and
policies applicable to them.

Participation by Associates and Affiliates of BRLM and Syndicate Members

The BRLM and the Syndicate member(s) shall not be entitled to purchase in this Offer in any manner except
towards fulfilling their underwriting obligations. Associates and affiliates of the BRLM and the Syndicate
member(s) may subscribe to or acquire Equity Shares in the Offer, including in the Net QIB Portion or Non-
Institutional Portion as may be applicable to such Bidder, where the allocation is on a proportionate basis. Such
bidding and subscription may be on their own account or on behalf of their clients. All categories of investors,
including associates or affiliates of the BRLM and Syndicate Members, shall be treated equally for the purpose
of allocation to be made on a proportionate basis

The BRLM and any persons related to the BRLM (other than Mutual Funds sponsored by entities related to the
BRLM) or our Promoters and the Promoter Group cannot apply in the Offer under the Anchor Investor Portion

Bids by Mutual Funds

With respect to Bids by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged
along with the Bid cum Application Form. Failing this, our Company and the Selling Shareholders reserve the
right to reject any Bid without assigning any reason thereof.

Bids made by asset management companies or custodians of Mutual Funds shall specifically state names of the
concerned schemes for which such Bids are made.

In case of a Mutual Fund, a separate Bid can be made in respect of each scheme of the Mutual Fund
registered with SEBI and such Bids in respect of more than one scheme of the Mutual Fund will not be
treated as multiple Bids provided that the Bids clearly indicate the scheme concerned for which the Bid
has been made

No Mutual Fund scheme shall invest more than 10% of its net asset value in equity shares or equity
related instruments of any single company provided that the limit of 10% shall not be applicable for
investments in case of index funds or sector or industry specific schemes. No Mutual Fund under all its
schemes should own more than 10% of any company’s paid-up share capital carrying voting rights.

Bids by Eligible NRIs

194
NRIs may obtain copies of Bid cum Application Form from the offices of the the BRLM and the
DesignatedIntermediaries. Eligible NRI Bidders bidding on a repatriation basis by using the Non-Resident
Forms should authorize their SCSB to block their Non-Resident External (“NRE”) accounts, or Foreign
Currency Non-Resident (“FCNR”) ASBA Accounts, and eligible NRI Bidders bidding on a non-repatriation
basis by using Resident Forms should authorize their SCSB to block their Non-Resident Ordinary (“NRO”)
accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form.

Eligible NRIs Bidding on non-repatriation basis are advised to use the Bid cum Application Form for residents
(white in colour). Eligible NRIs Bidding on a repatriation basis are advised to use the Bid cum Application
Form meant for Non-Residents (blue in colour). Company shall be disclosing the name and address of at least
one place in India from where individual Eligible NRIs can obtain the Bid cum Application forms in the Red
Herring Prospectus.

Bids by FPIs and FIIs

On January 7, 2014, SEBI notified the SEBI FPI Regulations pursuant to which the existing classes of portfolio
Bidders namely ‘foreign institutional investors’ and ‘qualified foreign investors’ will be subsumed under a new
category namely ‘foreign portfolio investors’ or ‘FPIs’. RBI on March 13, 2014 amended the FEMA
Regulations and laid down conditions and requirements with respect to investment by FPIs in Indian companies.

In terms of the SEBI FPI Regulations, an FII which holds a valid certificate of registration from SEBI shall be
deemed to be a registered FPI until the expiry of the block of three years for which fees have been paid as per
the SEBI FII Regulations. Accordingly, such FIIs can participate in the Offer in accordance with Schedule 2 of
the FEMA Regulations. An FII shall not be eligible to invest as an FII after registering as an FPI under the SEBI
FPI Regulations.

In terms of the SEBI FPI Regulations, the issue of Equity Shares to a single FPI or an investor group (which
means the same set of ultimate beneficial owner(s) investing through multiple entities) is not permitted to
exceed 10% of our post-Offer Equity Share capital. Further, in terms of the FEMA Regulations, the total
holding by each FPI shall be below 10% of the total paid-up Equity Share capital of our Company and the total
holdings of all FPIs put together shall not exceed 24% of the paid-up Equity Share capital of our Company. The
aggregate limit of 24% may be increased up to the sectoral cap by way of a resolution passed by the Board of
Directors followed by a special resolution passed by the Shareholders of our Company and subject to prior
intimation to RBI. In terms of the FEMA Regulations, for calculating the aggregate holding of FPIs in a
company, holding of all registered FPIs as well as holding of FIIs (being deemed FPIs) shall be included
The existing individual and aggregate investment limits for an FII or sub account in our Company is 10% and
24% of the total paid-up Equity Share capital of our Company, respectively.

FPIs are permitted to participate in the Offer subject to compliance with conditions and restrictions which may
be specified by the Government from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of
Regulation 22 of the SEBI FPI Regulations, an FPI, other than Category III Foreign Portfolio Investors and
unregulated broad based funds, which are classified as Category II Foreign Portfolio Investors by virtue of their
investment manager being appropriately regulated, may issue or otherwise deal in offshore derivative
instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is
issued overseas by a FPI against securities held by it that are listed or proposed to be listed on any recognised
stock exchange in India, as its underlying) directly or indirectly, only if (i) such offshore derivative instruments
are issued only to persons who are regulated by an appropriate regulatory authority; and (ii) such offshore
derivative instruments are issued after compliance with ‘know your client’ norms. An FPI is also required to
nsure that no further issue or transfer of any offshore derivative instrument is made by, or on behalf of, it to any
persons that are not regulated by an appropriate foreign regulatory authority.

Bids by SEBI registered VCFs, AIFs

The SEBI AIF Regulations inter-alia prescribe the investment restrictions on the AIFs registered with SEBI.
Further, the SEBI AIF Regulations prescribe, among others, the investment restrictions on AIFs.

The holding by any individual VCF registered with SEBI in one venture capital undertaking should not exceed
25% of the corpus of the VCF. Further, VCFs can invest only up to 33.33% of the investible funds by way of
subscription to an initial public offering.

195
The category I and II AIFs cannot invest more than 25% of the corpus in one investee company. A category III
AIF cannot invest more than 10% of the corpus in one investee company. A venture capital fund registered as a
category I AIF, as defined in the SEBI AIF Regulations, cannot invest more than 1/3rd of its corpus by way of
subscription to an initial public offering of a venture capital undertaking. Additionally, the VCFs which have
not re-registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the VCF
Regulation until the existing fund or scheme managed by the fund is wound up and such funds shall not launch
any new scheme after the notification of the SEBI AIF Regulations.

There is no reservation for Eligible NRIs, FPIs and FVCIs and all Bidders will be treated on the same basis with
other categories for the purpose of allocation, subject to applicable law.

Bids by Limited Liability Partnerships

In case of Bids made by limited liability partnerships registered under the Limited Liability Partnership Act,
2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008,
must be attached to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders
reserve the right to reject any Bid without assigning any reason thereof.

Bids by Banking Companies

In case of Bids made by banking companies registered with the RBI, certified copies of: (i) the certificate of
registration issued by the RBI, and (ii) the approval of such banking company’s investment committee are
required to be attached to the Bid cum Application Form, failing which our Company reserves the right to
reject any Bid by a banking company without assigning any reason therefore.

The investment limit for banking companies in non-financial services companies as per the Banking
Regulation Act, 1949, as amended (the “Banking Regulation Act”), and the Master Circular dated July 1, 2015
– Para-banking Activities, is 10% of the paid-up share capital of the investee company or 10% of the banks’
own paid-up share capital and reserves, whichever is less. Further, the investment in a non-financial services
company by a banking company together with its subsidiaries, associates, joint ventures, entities directly or
indirectly controlled by the bank and mutual funds managed by asset management companies controlled by the
banking company cannot exceed 20% of the investee company’s paid-up share capital. A banking company
may hold up to 30% of the paid-up share capital of the investee company with the prior approval of the RBI
provided that the investee company is engaged in non-financial activities in which banking companies are
permitted to engage under the Banking Regulation Act.

Bids by SCSBs

SCSBs participating in the Offer are required to comply with the terms of the SEBI circulars dated September
13, 2012 and January 2, 2013. Such SCSBs are required to ensure that for making applications on their own
account using ASBA, they should have a separate account in their own name with any other SEBI registered
SCSBs. Further, such account shall be used solely for the purpose of making application in public issues and
clear demarcated funds should be available in such account for ASBA applications.

Bids by Insurance Companies

In case of Bids made by Insurance Companies, a certified copy of certificate of registration issued by IRDA
must be attached to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders
reserve the right to reject any Bid without assigning any reason thereof.

The exposure norms for insurers, prescribed under the Insurance Regulatory and Development Authority
(Investment) Regulations, 2000 are broadly set forth below:

a. equity shares of a company: the lower of 10% of the outstanding Equity Shares (face value) or 10% of
the respective fund in case of life insurer or 10% of investment assets in case of general insurer or
reinsurer;
b. the entire group of the investee company: not more than 15% of the respective fund in case of a life
insurer or 15% of investment assets in case of a general insurer or reinsurer or 15% of the investment
assets in all companies belonging to the group, whichever is lower; and
c. the industry sector in which the investee company belong to: not more than 15% of the fund of a life
insurer or a general insurer or a reinsurer or 15% of the investment asset, whichever is lower.

196
The maximum exposure limit, in the case of an investment in equity shares, cannot exceed the lower of an
amount of 10% of the investment assets of a life insurer or general insurer and the amount calculated under
points (a), (b) and (c) above, as the case may be.

Insurance companies participating in this Offer shall comply with all applicable regulations, guidelines and
circulars issued by IRDA from time to time.

Bids by Provident Funds/Pension Funds

In case of Bids made by provident funds/ pension funds, subject to applicable laws, with minimum corpus of `
2500 lacs, a certified copy of certificate from a chartered accountant certifying the corpus of the provident
fund/ pension fund must be attached to the Bid cum Application Form. Failing this, our Company and the
Selling Shareholders reserve the right to reject any Bid, without assigning any reason thereof.

Bids under Power of Attorney

In case of Bids made pursuant to a power of attorney or by limited companies, corporate bodies, registered
societies, Mutual Funds, insurance companies and provident funds with a minimum corpus of ` 2500 lacs
and pension funds with a minimum corpus of ` 2500 lacs (in each case, subject to applicable law and in
accordance with their respective constitutional documents), a certified copy of the power of attorney or the
relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of
association and articles of association and/ or bye laws, as applicable must be lodged along with the Bid cum
Application Form. Failing this, our Company and the Selling Shareholders reserve the right to accept or reject
any such Bid without assigning any reasons therefore.

Bids by Anchor Investors

For details in relation to Bids by Anchor Investors, see the section entitled “ General Information Document
for Investing in Public Issues” on page 203.

The above information is given for the benefit of the Bidders. Our Company, the Selling Shareholders, and the
BRLM are not liable for any amendments or modification or changes in applicable laws or regulations, which
may occur after the date of this Draft Red Herring Prospectus. Bidders are advised to make their independent
investigations and ensure that any single Bid from them does not exceed the applicable investment limits or
maximum number of the Equity Shares that can be held by them under applicable law or regulation or as
specified in this Draft Red Herring Prospectus.

General Instructions

Do’s:

1) Check if you are eligible to apply as per the terms of the Red Herring Prospectus and under applicable
law, rules, regulations, guidelines and approvals;
2) Ensure that you have Bid within the Price Band;
3) Read all the instructions carefully and complete the Bid cum Application Form in the prescribed form;
4) Ensure that the details about the PAN, DP ID and Client ID are correct and the Bidders depository
account is active, as Allotment of the Equity Shares will be in the dematerialised form only;
5) Ensure that your Bid cum Application Form bearing the stamp of a Designated Intermediary is submitted
to the Designated Intermediary at the Bidding Centre;
6) If the first applicant is not the account holder, ensure that the Bid cum Application Form is signed by the
account holder. Ensure that you have mentioned the correct bank account number in the Bid cum
Application Form;
7) Ensure that the signature of the First Bidder in case of joint Bids, is included in the Bid cum Application
Forms;
8) Ensure that the name(s) given in the Bid cum Application Form is/are exactly the same as the name(s) in
which the beneficiary account is held with the Depository Participant. In case of joint Bids, the Bid cum
Application Form should contain only the name of the First Bidder whose name should also appear as the
first holder of the beneficiary account held in joint names;
9) Ensure that you request for and receive a stamped acknowledgement of the Bid cum Application Form for
all your Bid options;
10) Ensure that you have funds equal to the Bid Amount in the ASBA Account maintained with the SCSB
before submitting the Bid cum Application Form under the ASBA process to the respective member of

197
 the Syndicate (in the Specified Locations), the SCSBs, the Registered Broker (at the Broker Centres), the
RTA (at the Designated RTA Locations) or CDP (at the Designated CDP Locations);
11) Submit revised Bids to the same Designated Intermediary, through whom the original Bid was placed and
obtain a revised acknowledgment;
12) Except for Bids (i) on behalf of the Central or State Governments and the officials appointed by the
courts, who, in terms of a SEBI circular dated June 30, 2008, may be exempt from specifying their PAN
for transacting in the securities market, and (ii) Bids by persons resident in the state of Sikkim, who, in
terms of a SEBI circular dated July 20, 2006, may be exempted from specifying their PAN for transacting
in the securities market, all Bidders should mention their PAN allotted under the IT Act. The exemption
for the Central or the State Government and officials appointed by the courts and for investors residing in
the State of Sikkim is subject to (a) the Demographic Details received from the respective depositories
confirming the exemption granted to the beneficiary owner by a suitable description in the PAN field and
the beneficiary account remaining in “active status”; and (b) in the case of residents of Sikkim, the
address as per the Demographic Details evidencing the same. All other applications in which PAN is not
mentioned will be rejected;
13) Ensure that the Demographic Details are updated, true and correct in all respects;
14) Ensure that thumb impressions and signatures other than in the languages specified in the Eighth Schedule
to the Constitution of India are attested by a Magistrate or a Notary Public or a Special Executive
Magistrate under official seal;
15) Ensure that the category and the investor status is indicated;
16) Ensure that in case of Bids under power of attorney or by limited companies, corporates, trust etc.,
relevant documents are submitted;
17) Ensure that Bids submitted by any person outside India should be in compliance with applicable foreign
and Indian laws;
18) Bidders should note that in case the DP ID, Client ID and the PAN mentioned in their Bid cum
Application Form and entered into the online IPO system of the Stock Exchanges by the relevant
Designated Intermediary, as the case may be, do not match with the DP ID, Client ID and PAN available
in the Depository database, then such Bids are liable to be rejected. Where the Bid cum Application Form
is submitted in joint names, ensure that the beneficiary account is also held in the same joint names and
such names are in the same sequence in which they appear in the Bid complication Form;
19) Ensure that the Bid cum Application Forms are delivered by the Bidders within the time prescribed as per
the Bid cum Application Form and the Red Herring Prospectus;
20) Ensure that you have mentioned the correct ASBA Account number in the Bid cum Application Form;
21) Ensure that you have correctly signed the authorisation/undertaking box in the Bid cum Application
Form, or have otherwise provided an authorisation to the SCSB via the electronic mode, for blocking
funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form at
the time of submission of the Bid;
22) Ensure that you receive an acknowledgement from the concerned Designated Intermediary, for the
submission of your Bid cum Application Form; and
23) The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are no
complied with.

Don’ts:

1) Do not Bid for lower than the minimum Bid size;

2) Do not Bid/revise Bid Amount to less than the Floor Price or higher than the Cap Price;
3) Do not pay the Bid Amount in cash, by money order, cheques or demand drafts or by postal order or by
stock invest;
4) Do not send Bid cum Application Forms by post; instead submit the same to the Designated Intermediary
only;
5) Do not submit the Bid cum Application Forms to any non-SCSB bank, our Company or the Selling
Shareholders;
6) Do not Bid on a Bid cum Application Form that does not have the stamp of the relevant Designated
Intermediary;
7) Do not Bid at Cut-off Price (for Bids by QIBs and Non-Institutional Investors);
8) Instruct your respective Banks to release the funds blocked in the ASBA Account under the ASBA
process;
9) Do not Bid for a Bid Amount exceeding ₹200,000 (for Bids by Retail Individual Bidders);
10) Do not fill up the Bid cum Application Form such that the Equity Shares Bid for exceeds the Offer size
and/or investment limit or maximum number of the Equity Shares that can be held under the applicable
laws or regulations or maximum amount permissible under the applicable regulations or under the terms
of the Red Herring Prospectus;
11) Do not submit the General Index Register number instead of the PAN;

198
12) Do not submit the Bid without ensuring that funds equivalent to the entire Bid Amount are blocked in the
relevant ASBA Account;
13) Do not submit Bids on plain paper or on incomplete or illegible Bid cum Application Forms or on Bid
cum Application Forms in a colour prescribed for another category of Bidder;
14) Do not submit a Bid in case you are not eligible to acquire Equity Shares under applicable law or your
relevant constitutional documents or otherwise;
15) Do not Bid if you are not competent to contract under the Indian Contract Act, 1872 (other than minors
having valid depository accounts as per Demographic Details provided by the depository);
16) Do not submit more than five Bid cum Application Forms per ASBA Account;
17) Anchor Investors should not bid through the ASBA process. The Bid cum Application Form is liable to be
rejected if the above instructions, as applicable, are not complied with.

Payment Instructions

All Bidders (other than Anchor Investors) are required to use the ASBA facility to make payment. Anchor
Investors making payment through cheques are requested to use CTS cheques and that Anchor Investor
Application Forms accompanied by non-CTS cheques are liable to be rejected.

Payment into Escrow Account for Anchor Investors

Our Company in consultation with the BRLM, in its absolute discretion, will decide the list of Anchor Investors
to whom the Allotment Advice will be sent, pursuant to which the details of the Equity Shares allocated to them
in their respective names will be notified to such Anchor Investors. For Anchor Investors, the payment
instruments for payment into the Escrow Account should be drawn in favour of:

(a) In case of resident Anchor Investors: “[●]”

(b) In case of Non Resident Anchor Investor: “[●]”

Anchor Investors should note that the escrow mechanism is not prescribed by SEBI and has been
established as an arrangement between our Company, the Selling Shareholders, the Syndicate, the
Escrow Collection Banks and the Registrar and Share Transfer Agent to the Offer to facilitate collections
from the Anchor Investors.

Pre-Offer Advertisement

Subject to section 30 of the Companies Act, 2013, our Company shall, after registering the Red Herring
Prospectus with the RoC, published a pre-Offer advertisement, in the form prescribed by the SEBI ICDR
Regulations in [•]edition of [•] (English national); (ii) [•]edition of [•] (Hindi national), each with wide
circulation, and [•] edition of the Tamil newspaper, [•], a regional newspaper with wide circulation at the place
where the Registered Office is located. In the pre-Offer advertisement, we shall state the Bid Opening Date,
the Bid Closing Date and the QIB Bid Closing Date. This advertisement, subject to the provisions of Section
30 of the Companies Act, 2013, shall be in the format prescribed in Part A of Schedule XIII of the SEBI ICDR
Regulations.

Signing of the Underwriting Agreement and the RoC Filing

a. Our Company, the Selling Shareholders, Registrar to the Offer and the Syndicate intends to enter into
an Underwriting Agreement after the finalization of the Offer Price.

b. After signing the Underwriting Agreement, an updated Red Herring Prospectus would be filed with
the RoC in accordance with the applicable law, which then would be termed as the ‘Prospectus’. This
Draft Red Herring Prospectus contains details of the Offer Price, the Anchor Investor Offer Price,
Offer size, and underwriting arrangements and will be complete in all material respects.

IMPERSONATION

Attention of the applicants is specifically drawn to the provisions of sub-section (1) of section 38 of the
Companies Act, 2013, which is reproduced below:

“Any person who:

199
a. makes or abets making of an application in a fictitious name to a company for acquiring, or
subscribing for, its securities; or
b. makes or abets making of multiple applications to a company in different names or in different
combinations of his name or surname for acquiring or subscribing for its securities; or
c. otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to
him, or to any other person in a fictitious name, shall be liable for action under section 447.”

Section 447 of Companies Act, 2013 deals with ‘Fraud’ and prescribed a punishment of “imprisonment for a
term which shall not be less than six months but which may extend to ten years and shall also be liable to fine
which shall not be less than the amount involved in the fraud, but which may extend to three times the amount
involved in the fraud”.

UNDERTAKINGS BY OUR COMPANY

Our Company undertakes that:

 if our Company or Selling Shareholders do not proceed with the Offer, the reason thereof shall be
given as a public notice to be issued by our Company within two days of the Bid/ Offer Closing Date.
The public notice shall be issued in the same newspapers where the pre-Offer advertisements were
published. The stock exchanges on which the Equity Shares are proposed to be listed shall also be
informed promptly;

 if our Company and the Selling Shareholders withdraw the Offer after the Bid/ Offer Closing Date,
our Company shall be required to file a fresh offer document with the RoC/ SEBI, in the event our
Company and/or the Selling Shareholders subsequently decides to proceed with the Offer;

 the complaints received in respect of the Offer shall be attended to by our Company expeditiously and
satisfactorily;

 all steps for completion of the necessary formalities for listing and commencement of trading at all the
Stock Exchanges where the Equity Shares are proposed to be listed are taken within six Working
Days of the Bid/Offer Closing Date;;

 the funds required for making refunds to unsuccessful applicants as per the mode(s) disclosed shall be
made available to the Registrar to the Offer by our Company;

 Allotment will be made or the application money will be refunded within six Working Days from the
Bid/Offer Closing Date or such lesser time as specified by SEBI or the application money will be
refunded to the Bidders forthwith, failing which interest will be due to be paid to the Bidders at the
rate of 15% per annum for the delayed period;;

 where refunds are made through electronic transfer of funds, a suitable communication shall be sent to
the applicant within six Working Days from the Bid/Offer Closing Date, giving details of the bank
where refunds shall be credited along with amount and expected date of electronic credit of refund;

 adequate arrangements shall be made to collect all Bid cum Application Forms;
 the certificates of the securities/refund orders to Eligible NRIs shall be despatched within specified
time.
 no further Offer of the Equity Shares shall be made till the Equity Shares offered through the Red
Herring Prospectus are listed or until the Bid monies are refunded on account of non-listing,
undersubscription, etc.; and

 the Selling Shareholders shall not have recourse to the Offer Proceeds until the final approval for
listing and trading of the Equity Shares from all the Stock Exchanges where listing is sought have
been received.

UNDERTAKINGS BY SELLING SHAREHOLDERS

Each Selling Shareholder jointly and severally undertakes that

200
 the Equity Shares being sold by it pursuant to the Offer, have been held by it for a period of at least
one year prior to the date of filing the Draft Red Herring Prospectus with SEBI, are fully paid-up and
are in dematerialized form;

 it is the legal and beneficial owner of, and has full title to, the Equity Shares being sold in the Offer;

 the Equity Shares being sold by it pursuant to the Offer are free and clear of any liens or
encumbrances and shall be transferred to the eligible investors within the time specified under
applicable law;

 it shall provide all reasonable co-operation as requested by our Company in relation to the completion
of allotment and dispatch of the allotment advice and CAN, if required, and refund orders to the
extent of the Equity Shares offered by it pursuant to the Offer;

 they shall deposit their Equity Shares in an escrow account opened with the Registrar and Share
Transfer Agent to the Offer at least one Working Day prior to the date of the Red Herring Prospectus
or as disclosed in the Red Herring Prospectus;

 it shall provide such reasonable support and extend such reasonable cooperation as may be required
by our Company and the BRLM in redressal of such investor grievances that pertain to the Equity
Shares held by it and being offered pursuant to the Offer;

 funds required for making refunds to unsuccessful applicants as per the mode(s) disclosed in the Red
Herring Prospectus and this Draft Red Herring Prospectus shall be made available to the Registrar to
the Offer by the Selling Shareholders;

 it shall provide such reasonable support and extend such reasonable co-operation as may be required
by Company in sending a suitable communication, where refunds are made through electronic
transfer of funds, to the applicant within 15 days from the Bid/ Offer Closing Date, giving details of
the bank where refunds shall be credited along with amount and expected date of electronic credit of
refund;

 it shall not have recourse to the proceeds of the Offer until final approval for trading of the Equity
Shares from all Stock Exchanges where listing is sought has been received;

 subject to the Offer Agreement, they shall not offer, lend, pledge, encumber, sell, contract to sell or
otherwise transfer or dispose off, directly or indirectly, any of the Equity Shares held by them;

 it shall not further transfer the Equity Shares being sold by it pursuant to the Offer except in the Offer
during the period commencing from submission of the Draft Red Herring Prospectus with SEBI until
the final trading approvals from all the Stock Exchanges have been obtained for the Equity Shares
Allotted/ to be Allotted pursuant to the Offer and shall not sell, dispose of in any manner or create any
lien, charge or encumbrance on the Equity Shares offered by it in the Offer;

 they shall take all steps and provide all assistance to the Company and the BRLM, as may be required
and necessary by the Selling Shareholders, for the completion of the necessary formalities for listing
and commencement of trading at all the stock exchanges where the Equity Shares are proposed to be
listed within six Working Days from the Bid/Offer Closing Date of the Offer, failing which they shall
forthwith repay without interest all monies received from Bidders to the extent of the Investor Offered
Shares. In case of delay, interest as per applicable law shall be paid by them to the extent of the
Investor Offered Shares;

 they shall sign, and cause their authorized signatories (by way of powers of attorney or otherwise) to
sign the offer documents and agreements in relation to the Offer, and confirm that their duly
authorized signatories who have signed a declaration, that the statements made by them in the offer
documents about or in relation to them as well as any Offer related materials are true and correct as of
the date of this Draft Red Herring Prospectus and as will be included in the Red Herring Prospectus
and Prospectus, or such Offer related material, as the case may be;

 they shall disclose and furnish to the BRLM all information relating to any pending litigation,
arbitration, complaint or notice that may affect the ownership or title to the Equity Shares or their
ability to offer the Equity Shares in the Offer for Sale;

201
 they shall not offer, lend, pledge, charge, transfer or otherwise encumber, sell, any of the Equity
Shares held by them except the Equity Shares being offered by them in the Offer for Sale until such
time that the lock-in remains effective save and except as may be permitted under the SEBI ICDR
Regulations;

 they shall give appropriate instructions for dispatch of the refund orders or Allotment Advice to
successful Bidders within the time specified under applicable law.

 it shall take all such steps as may be required to ensure that the Equity Shares being sold by it
pursuant to the Offer are available for transfer in the Offer within the time specified under applicable
law; and

Utilisation of Offer Proceeds

The Selling Shareholders along with our Company declare that all monies received out of the Offer shall be
credited/ transferred to a separate bank account other than the bank account referred to in sub-section (3) of
section 40 of the Companies Act, 2013.

202
 PART B

GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUES

This General Information Document highlights the key rules, processes and procedures applicable to public
issues in accordance with the provisions of the Companies Act, 2013 (to the extent notified and in effect), the
Companies Act, 1956 (without reference to the provisions thereof that have ceased to have effect upon the
notification of the Companies Act, 2013), the Securities Contracts (Regulation) Act, 1956, the Securities
Contracts (Regulation) Rules, 1957 and the Securities and Exchange Board of India (Issue of Capital and
Disclosure Requirements) Regulations, 2009. Bidders/ Applicants should not construe the contents of this
General Information Document as legal advice and should consult their own legal counsel and other advisors in
relation to the legal matters concerning the Offer. For taking an investment decision, the Bidders/ Applicants
should rely on their own examination of the Company and the Offer, and should carefully read the Red Herring
Prospectus/ Prospectus before investing in the Offer.

SECTION 1: PURPOSE OF THE GENERAL INFORMATION DOCUMENT (GID)

This document is applicable to the public issues undertaken through the Book-Building process as well as to the
Fixed Price Issues. The purpose of the “General Information Document for Investing in Public Issues” is to
provide general guidance to potential Bidders/ Applicants in IPOs and FPOs, on the processes and procedures
governing IPOs and FPOs, undertaken in accordance with the provisions of the Securities and Exchange Board
of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (the “SEBI ICDR Regulations”).

Bidders/ Applicants should note that investment in equity and equity related securities involves risk and
Bidder/Applicant should not invest any funds in the Offer unless they can afford to take the risk of losing their
investment. The specific terms relating to securities and/ or for subscribing to securities in an Offer and the
relevant information about the Company undertaking the Offer are set out in the Red Herring Prospectus
(“RHP”)/ Prospectus filed by the Company with the Registrar of Companies (“RoC”). Bidders/ Applicants
should carefully read the entire RHP/ Prospectus and the Bid cum Application Form/ Application Form and the
Abridged Prospectus of the Company in which they are proposing to invest through the Offer. In case of any
difference in interpretation or conflict and/ or overlap between the disclosure included in this document and the
RHP/ Prospectus, the disclosures in the RHP/ Prospectus shall prevail. The RHP/ Prospectus of the Company is
available on the websites of stock exchanges, on the website(s) of the BRLM(s) to the Offer and on the website of
Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in.For the definitions of capitalized terms
and abbreviations used herein Bidders/ Applicants may refer to “Glossary and Abbreviations”.

SECTION 2: BRIEF INTRODUCTION TO IPO/FPOs

2.1 Initial Public Offer (IPO)

An IPO means an offer of specified securities by an unlisted Company to the public for subscription
and may include an Offer for Sale of specified securities to the public by any existing holder of such
securities in an unlisted Company.

For undertaking an IPO, a Company is inter alia required to comply with the eligibility requirements
of in terms of either Regulation 26(1) or Regulation 26(2) of the SEBI ICDR Regulations. For details
of compliance with the eligibility requirements by the Company, Bidders/ Applicants may refer to the
RHP/ Prospectus.

2.2 Further Public Offer (FPO)

An FPO means an offer of specified securities by a listed Company to the public for subscription and
may include Offer for Sale of specified securities to the public by any existing holder of such
securities in a listed company.

For undertaking an FPO, the company is inter alia required to comply with the eligibility requirements
in terms of Regulation 26 or Regulation 27 of the SEBI ICDR Regulations. For details of compliance
with the eligibility requirements by the company, Bidders/ Applicants may refer to the RHP/
Prospectus.

203
2.3 Other Eligibility Requirements

In addition to the eligibility requirements specified in paragraphs 2.1 and 2.2, an company proposing
to undertake an IPO or an FPO is required to comply with various other requirements as specified in
the SEBI ICDR Regulations, the Companies Act, 2013 (to the extent notified and in effect), the
Companies Act, 1956 (without reference to the provisions thereof that have ceased to have effect
upon the notification of the Companies Act, 2013), the Securities Contracts (Regulation) Rules, 1957
(the “SCRR”), industry-specific regulations, if any, and other applicable laws for the time being in
force.

For details in relation to the above Bidders/ Applicants may refer to the RHP/ Prospectus.

2.4 Types of Public Issues – Fixed Price Issues and Book Built Issues

In accordance with the provisions of the SEBI ICDR Regulations, a company can either determine the
Offer Price through the Book Building Process (“Book Built Issue”) or undertake a Fixed Price Issue
(“Fixed Price Issue”). A company may mention Floor Price or Price Band in the RHP (in case of a
Book Built Issue) and a Price or Price Band in the Draft Prospectus (in case of a fixed price issue)
/draft red herring prospectus and determine the price at a later date before registering the Prospectus
with the Registrar of Companies.

The cap on the Price Band should be less than or equal to 120% of the Floor Price. The company shall
announce the Price or the Floor Price or the Price Band through advertisement in all newspapers in
which the pre-Offer advertisement was given at least five Working Days before the Bid/ Offer
Opening Date, in case of an IPO and at least one Working Day before the Bid/ Offer Opening Date, in
case of an FPO.

The Floor Price or the Offer price cannot be lesser than the face value of the securities. Bidders/
Applicants should refer to the RHP/ Prospectus or Offer advertisements to check whether the Offer is
a Book Built Issue or a Fixed Price Issue.

2.5 ISSUE PERIOD

The Offer shall be kept open for a minimum of three Working Days (for all category of Bidders/
Applicants) and not more than ten Working Days. Bidders/ Applicants are advised to refer to ‘ the Bid
cum Application Form and Abridged Prospectus or RHP/ Prospectus for details of the Bid/ Offer
Period. Details of Bid/ Offer Period shall also be o available on the website of Stock Exchange(s).

In case of a Book Built Offer, the company may close the Bid/ Offer Period for QIBs one Working
Day prior to the Bid/ Offer Closing Date if disclosures to that effect are made in the RHP. In case of
revision of the Floor Price or Price Band in Book Built Issues the Bid/ Offer Period may be extended
by at least three Working Days, subject to the total Bid/ Offer Period not exceeding 10 Working Days.
For details of any revision of the Floor Price or Price Band, Bidders/ Applicants may check the
announcements made by the Company on the websites of the Stock Exchanges and the BRLM(s), and
the advertisement in the newspaper(s) issued in this regard.

1.1 FLOW CHART OF TIMELINES

A flow chart of process flow in Fixed Price and Book Built Issues is as follows. Bidders/
Applicants may note that this is not applicable for Fast Track FPOs.:

 In case of Offer other than Book Build Issue (Fixed Price Issue) the process at the
following of the below mentioned steps shall be read as:

i. Step 7 : Determination of Offer Date and Price

ii. Step 10: Applicant submits Bid cum Application Form with Designated
Branch of SCSB.

204
205
 SECTION 3: CATEGORY OF INVESTORS ELIGIBLE TO PARTICIPATE IN AN ISSUE

Each Bidder/Applicant should check whether it is eligible to apply under applicable law. Furthermore,
certain categories of Bidders/Applicants, such as NRIs, FIIs, FPIs and FVCIs may not be allowed to Bid/Apply
in the Offer or to hold Equity Shares, in excess of certain limits specified under applicable law.
Bidders/Applicants are requested to refer to the RHP/Prospectus for more details.

1. Indian nationals resident in India who are competent to contract under the Indian Contract Act, 1872,
in single or joint names (not more than three);
2. Bids/ Applications belonging to an account for the benefit of a minor (under guardianship);
3. Hindu Undivided Families or HUFs, in the individual name of the Karta. The Bidder/ Applicant
should specify that the Bid is being made in the name of the HUF in the Bid cum Application Form/
4. Application Form as follows: “Name of sole or first Bidder/ Applicant: XYZ Hindu Undivided Family
applying through XYZ, where XYZ is the name of the Karta”. Bids/ Applications by HUFs may be
considered at par with Bids/ Applications from individuals;
5. Companies, corporate bodies and societies registered under applicable law in India and authorised to
invest in equity shares;
6. QIBs;
7. Indian Financial Institutions, regional rural banks, co-operative banks (subject to RBI regulations and
the SEBI ICDR Regulations and other laws, as applicable);
8. NRIs on a repatriation basis or on a non-repatriation basis, subject to applicable law;
9. FIIs and sub-accounts registered with SEBI, other than a sub-account which is a foreign corporate or
foreign individual, bidding under the QIBs category;
10. Sub-accounts of FIIs registered with SEBI, which are foreign corporates or foreign individuals
Bidding only under the Non Institutional Investors (“NIIs”) category;
11. FPIs other than Category III foreign portfolio investors, Bidding under the QIBs category;
12. FPIs which are Category III foreign portfolio investors, Bidding under the NIIs category;
13. Trusts/ societies registered under the Societies Registration Act, 1860, or under any other law relating
to trusts/ societies and who are authorised under their respective constitutions to hold and invest in
equity shares;
14. Limited liability partnerships registered under the Limited Liability Partnership Act, 2008; and
15. Any other person eligible to Bid/ Apply in the Offer, under the laws, rules, regulations, guidelines and
policies applicable to them and under Indian laws.

As per existing regulations OCBs are not allowed to invest in the Offer.

SECTION 4: APPLYING IN THE ISSUE

Book Built Issue: Bidders should only use the specified ASBA Form (or in case of Anchor Investors, the
Anchor Investor Application Form) either bearing the stamp of a member of the Syndicate or any other
Designated Intermediary, as available or downloaded from the websites of the Stock Exchanges. Bid cum
Application Forms are available with the Book Running Lead Manager, the Designated Intermediaries at the
Bidding Centres and at the registered office of the Issuer. Electronic Bid cum Application Forms will be
available on the websites of the Stock Exchanges at least one day prior to the Bid/Offer Opening Date. For
further details, regarding availability of Bid cum Application Forms, Bidders may refer to the RHP/Prospectus.

Fixed Price Issue:

Applicants should only use the specified cum Application Form bearing the stamp of an SCSB as available or
downloaded from the websites of the Stock Exchanges. Application Forms are available with the Designated
Branches of the SCSBs and at the Registered and Corporate Office of the Issuer. For further details, regarding
availability of Application Forms, Applicants may refer to the Prospectus.

Bidders/Applicants should ensure that they apply in the appropriate category.

Securities Issued in an IPO can only be in dematerialized form in compliance with section 29 of the Companies
Act, 2013. Bidders/ Applicants will not have the option of getting the allotment of specified securities in
physical form. However, they may get the specified securities rematerialized subsequent to allotment.

Category Colour of Bid cum Application Form

Resident Indians and Eligible NRIs applying on a non-
repatriation basis White
Non-Residents including Eligible NRIs, FIIs, FPI or Blue

206
other eligible non resident investor
Anchor Investors As specified by Issuer

Securities issued in an IPO can only be in dematerialized form in accordance with Section 29 of the Companies
Act, 2013. Bidders/Applicants will not have the option of getting the Allotment of specified securities in
physical form. However, they may get the specified securities rematerialised subsequent to Allotment.

4.1 INSTRUCTIONS FOR FILING THE BID CUM APPLICATION FORM /APPLICATION
FORM

Bidders/Applicants may note that forms not filled completely or correctly as per instructions provided in this
GID, the RHP and the Bid cum Application Form/Application Form are liable to be rejected.

Instructions to fill each field of the Bid cum Application Form can be found on the reverse side of the Bid cum
Application Form. Specific instructions for filling various fields of the Resident Bid cum Application Form is
provided below.

The samples of the Bid cum Application Form is reproduced below:

207
 BID CUM APPLICATION FORM FOR RESIDENTS

Kindly note that this will be included prior to filing of the RHP.

208
BID CUM APPLICATION FORM FOR NON RESIDENTS

Kindly note that this will be included prior to filing of the RHP.

209
4.1.1 FIELD NUMBER 1: NAME AND CONTACT DETAILS OF THE SOLE/FIRST BIDDER/
APPLICANT

a. Bidders/ Applicants should ensure that the name provided in this field is exactly the same as
the name in which the Depository Account is held.

b. Mandatory Fields Mandatory Fields: Bidders/Applicants should note that the name and
address fields are compulsory and e-mail and/or telephone number/mobile number fields are
optional. Bidders/Applicants should note that the contact details mentioned in the Bid cum
Application Form/Application Form may be used to dispatch communications (including
letters notifying the unblocking of the bank accounts of Bidders/Applicants) in case the
communication sent to the address available with the Depositories are returned undelivered
or are not available. The contact details provided in the Bid cum Application Form may be
used by the Issuer, the Designated Intermediaries and the Registrar to the Offer only for
correspondence(s) related to an Offer and for no other purposes.

c. Joint Bids/ Applications: In the case of Joint Bids/Applications, the Bids/Applications

should be made in the name of the Bidder/Applicant whose name appears first in the
Depository account. The name so entered should be the same as it appears in the Depository
records. The signature of only such first Bidder/Applicant would be required in the Bid cum
Application Form/Application Form and such first Bidder/Applicant would be deemed to
have signed on behalf of the joint holders. All communications may be addressed to such
Bidder/Applicant and may be dispatched to his or her address as per the Demographic Details
received from the Depositories.

d. Impersonation: Attention of the Bidders/ Applicants is specifically drawn to the provisions

of subsection (1) of section 38 of the Companies Act, 2013 which is reproduced below:
“Any person who:

i. makes or abets making of an application in a fictitious name to a company for

acquiring, or subscribing for, its securities; or
ii. makes or abets making of multiple applications to a company in different names
or in different combinations of his name or surname for acquiring or subscribing
for its securities; or
iii. otherwise induces directly or indirectly a company to allot, or register any transfer
of, securities to him, or to any other person in a fictitious name, shall be liable for
action under section 447.
iv. The liability prescribed under section 447 of the Companies Act, 2013 includes
imprisonment for a term which shall not be less than six months extending up to
10 years (provided that where the fraud involves public interest, such term shall
not be less than three years) and fine of an amount not less than the amount
involved in the fraud, extending up to three times of such amount.”

e. Nomination Facility to Bidder/ Applicant: Nomination facility is available in accordance

with the provisions of section 72 of the Companies Act, 2013. In case of allotment of the
Equity Shares in dematerialized form, there is no need to make a separate nomination as the
nomination registered with the Depository may prevail. For changing nominations, the
Bidders/ Applicants should inform their respective DP.

4.1.2 FIELD NUMBER 2: PAN NUMBER OF SOLE/FIRST BIDDER/ APPLICANT

a. PAN (of the sole/ First Bidder/ Applicant) provided in the Bid cum Application Form/
Application Form should be exactly the same as the PAN of the person(s) in whose name the
relevant beneficiary account is held as per the Depositories’ records.

b. PAN is the sole identification number for participants transacting in the securities market
irrespective of the amount of transaction except for Bids/ Applications on behalf of the
Central or State Government, Bids/ Applications by officials appointed by the courts and
Bids/ Applications by Bidders/ Applicants residing in Sikkim (“PAN Exempted Bidders/
Applicants”). Consequently, all Bidders/ Applicants, other than the PAN Exempted Bidders/
Applicants, are required to disclose their PAN in the Bid cum Application Form/ Application

210
 Form, irrespective of the Bid/ Application Amount. A Bid cum Application Form/
Application Form without PAN, except in case of Exempted Bidders/ Applicants, is liable to
be rejected. Bids/ Applications by the Bidders/ Applicants whose PAN is not available as per
the Demographic Details available in their Depository records, are liable to be rejected.

c. The exemption for the PAN Exempted Bidders/ Applicants is subject to (a) the Demographic
Details received from the respective Depositories confirming the exemption granted to the
beneficiary owner by a suitable description in the PAN field and the beneficiary account
remaining in “active status”; and (b)in the case of residents of Sikkim, the address as per the
Demographic Details evidencing the same.

d. Bid cum Application Forms/ Application Forms which provide the General Index Register
Number instead of PAN may be rejected.

e. Bids/ Applications by Bidders whose demat accounts have been ‘suspended for credit’ are
liable to be rejected pursuant to the circular issued by SEBI on July 29, 2010, bearing
number CIR/ MRD/ DP/ 22/ 2010. Such accounts are classified as “Inactive demat
accounts” and demographic details are not provided by depositories.

4.1.3 FIELD NUMBER 3: BIDDERS/APPLICANTS DEPOSITORY ACCOUNT DETAILS

a. Bidders/ Applicants should ensure that DP ID and the Client ID are correctly filled in the Bid
cum Application Form/ Application Form. The DP ID and Client ID provided in the Bid cum
Application Form/ Application Form should match with the DP ID and Client ID available in
the Depository database, otherwise, the Bid cum Application Form/ Application Form is
liable to be rejected.

b. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum
Application Form/ Application Form is active.

c. Bidders/Applicants should note that on the basis of the DP ID and Client ID as provided in
the Bid cum Application Form/Application Form, the Bidder/Applicant may be deemed to
have authorized the Depositories to provide to the Registrar to the Offer, any requested
Demographic Details of the Bidder/Applicant as available on the records of the depositories.
These Demographic Details may be used, among other things, for unblocking of ASBA.
Account or for other correspondence(s) related to an Offer.

d. Bidders/ Applicants are, advised to update any changes to their Demographic Details as
available in the records of the Depository Participant to ensure accuracy of records. Any
delay resulting from failure to update the Demographic Details would be at the Bidders/
Applicants’ sole risk.

4.1.4 FIELD NUMBER 4: BID OPTIONS

a. Price or Floor Price or Price Band, minimum Bid Lot and Discount (if applicable) may be
disclosed in the Prospectus/ RHP by the Company. The Company is required to announce the
Floor Price or Price Band, minimum Bid Lot and Discount (if applicable) by way of an
advertisement in at least one English, one Hindi and one regional newspaper, with wide
circulation, at least five Working Days before Bid/Offer Opening Date in case of an IPO, and
at least one Working Day before Bid/ Offer Opening Date in case of an FPO.

b. The Bidders may Bid at or above Floor Price or within the Price Band for IPOs / FPOs
undertaken through the Book Building Process. In the case of Alternate Book Building
Process for an FPO, the Bidders may Bid at Floor Price or any price above the Floor Price
(For further details bidders may refer to (section 5.6 (e)).

c. Cut-Off Price: Retail Individual Investors or Employees or Retail Individual Shareholders

can Bid at the Cut-off Price indicating their agreement to Bid for and purchase the Equity
Shares at the Offer Price as determined at the end of the Book Building Process. Bidding at
the Cut-off Price is prohibited for QIBs and NIIs and such Bids from QIBs and NIIs may be
rejected.

211
 d. Minimum Application Value and Bid Lot: The Company and the Selling Shareholders in
consultation with the BRLM may decide the minimum number of Equity Shares for each Bid
to ensure that the minimum application value is within the range of ` 10,000 to ` 15,000.
The minimum Bid Lot is accordingly determined by an Company on basis of such minimum
application value.

e. Allotment: The allotment of specified securities to each RII shall not be less than the
minimum Bid Lot, subject to availability of shares in the RII category, and the remaining
available shares, if any, shall be allotted on a proportionate basis. For details of the Bid Lot,
bidders may refer to the RHP/ Prospectus or the advertisement regarding the Price Band
published by the Company.

4.1.4.1 MAXIMUM AND MINIMUM BID SIZE

a. The Bidder may Bid for the desired number of Equity Shares at a specific price. Bids by
Retail Individual Investors and Employees must be for such number of shares so as to ensure
that the Bid Amount less Discount (as applicable), payable by the Bidder does not exceed `
200,000.

b. In case the Bid Amount exceeds ` 200,000 due to revision of the Bid or any other reason,
the Bid may be considered for allocation under the Non-Institutional Category, with it not
being eligible for Discount then such Bid may be rejected if it is at the Cut-off Price.

c. Bids by QIBs and NIIs must be for such minimum number of shares such that the Bid
Amount exceeds ` 200,000 and in multiples of such number of Equity Shares thereafter, as
may be disclosed in the Bid cum Application Form and the RHP/ Prospectus, or as advertised
by the Company, as the case may be. Non-Institutional Investors and QIBs are not allowed to
Bid at ‘Cut-off Price’.
d. For NRIs, a Bid Amount of up to ₹200,000 may be considered under the Retail Portion for
the purposes of allocation and a Bid Amount exceeding ₹200,000 may be considered under
the Non-Institutional Category for the purposes of allocation.

e. RII may revise their bids till closure of the bidding period or withdraw their bids until
finalization of allotment. QIBs and NII’s cannot withdraw or lower their Bids (in terms of
quantity of Equity Shares or the Bid Amount) at any stage after bidding and are required to
pay the Bid Amount upon submission of the Bid.

f. In case the Bid Amount reduces to ` 200,000 or less due to a revision of the Price Band,
Bids by the Non-Institutional Investors who are eligible for allocation in the Retail Portion
would be considered for allocation under the Retail Portion.

g. For Anchor Investors, if applicable, the Bid Amount shall be least 10 crores. One-third of
the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid
Bids being received from domestic Mutual Funds at or above the price at which allocation is
being done to other Anchor Investors. Bids by various schemes of a Mutual Fund shall be
aggregated to determine the Bid Amount. A Bid cannot be submitted for more than 60% of
the QIB Category under the Anchor Investor Portion. Anchor Investors cannot withdraw
their Bids or lower the size of their Bids (in terms of quantity of Equity Shares or the Bid
Amount) at any stage after the Anchor Investor Bid/Offer Period and are required to pay the
Bid Amount at the time of submission of the Bid. In case the Anchor Investor Offer Price is
lower than the Offer Price, the balance amount shall be payable as per the pay-in-date
mentioned in the revised CAN. In case the Offer Price is lower than the Anchor Investor
Offer Price, the amount in excess of the Offer Price paid by the Anchor Investors shall not be
refunded to them. Bids by various schemes of a Mutual Fund shall be aggregated to
determine the Bid Amount. A Bid cannot be submitted for more than 60% of the QIB Portion
under the Anchor Investor Portion. Anchor Investors cannot withdraw their Bids or lower the
size of their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after
the Anchor Investor Bid/ Offer Period and are required to pay the Bid Amount at the time of
submission of the Bid. In case the Anchor Investor Offer Price is lower than the Offer Price,
the balance amount shall be payable as per the pay-in-date mentioned in the revised CAN. In
case the Offer Price is lower than the Anchor Investor Offer Price, the amount in excess of
the Offer Price paid by the Anchor Investors shall not be refunded to them.

212
 h. A Bid cannot be submitted for more than the Offer size.

i. The maximum Bid by any Bidder including QIB Bidder should not exceed the investment
limits prescribed for them under the applicable laws.

j. The price and quantity options submitted by the Bidder in the Bid cum Application Form
may be treated as optional bids from the Bidder and may not be cumulated. After
determination of the Offer Price, the number of Equity Shares Bid for by a Bidder at or
above the Offer Price may be considered for allotment and the rest of the Bid(s), irrespective
of the Bid Amount may automatically become invalid. This is not applicable in case of FPOs
undertaken through Alternate Book Building Process (For details of bidders may refer to
(section 5.6 (e))

4.1.4.2 MULTIPLE BIDS

a. Bidder should submit only one Bid cum Application Form. Bidder shall have the option to
make a maximum of Bids at three different price levels in the Bid cum Application Form and
such options are not considered as multiple bids.

Submission of a second Bid cum Application Form to either the same or to another
Designated Intermediary and duplicate copies of Bid cum Application Forms bearing the
same application number shall be treated as multiple Bids and are liable to be rejected.

b. Bidders are requested to note the following procedures may be followed by the Registrar to
the Offer to detect multiple bids:

i. All Bids may be checked for common PAN as per the records of the Depository. For
Bidders other than Mutual Funds and FII sub-accounts, Bids bearing the same PAN
may be treated as multiple Bids by a Bidder and may be rejected.

ii. For Bids from Mutual Funds and FII sub-accounts, submitted under the same PAN,
as well as Bids on behalf of the PAN Exempted Bidders, the Bid cum Application
Forms may be checked for common DP ID and Client ID. Such Bids which have the
same DP ID and Client ID may be treated as multiple Bids and are liable to be
rejected.

c. The following bids may not be treated as Multiple Bids:

i. Bids by Reserved Categories if any, bidding in their respective Reservation Portion

as well as bids made by them in the Net Offer portion in public category.
ii. Separate Bids by Mutual Funds in respect of more than one scheme of the Mutual
Fund provided that the Bids clearly indicate the scheme for which the Bid has been
made.
iii. Bids by Mutual Funds, and sub-accounts of FIIs (or FIIs and its sub-accounts)
submitted with the same PAN but with different beneficiary account numbers,
Client IDs and DP IDs.
iv. Bids by Anchor Investors under the Anchor Investor Portion and the QIB Portion.

4.1.5 FIELD NUMBER 5: CATEGORY OF BIDDERS

a. The categories of Bidders identified as per the SEBI ICDR Regulations, 2009 for the purpose
of Bidding, allocation and allotment in the Offer are RIIs, NIIs and QIBs.

b. Up to 60% of the QIB Portion can be allocated by the Company, on a discretionary basis
subject to the criteria of minimum and maximum number of anchor investors based on
allocation size, to the Anchor Investors, in accordance with SEBI ICDR Regulations, 2009,
with one-third of the Anchor Investor Portion reserved for domestic Mutual Funds subject to
valid Bids being received at or above the Offer Price. For details regarding allocation to
Anchor Investors, bidders may refer to the RHP/ Prospectus.

c. A Company can make reservation for certain categories of Bidders/ Applicants as permitted
under the SEBI ICDR Regulations, 2009. For details of any reservations made in the Offer,
Bidders/ Applicants may refer to the RHP/ Prospectus.

213
 d. The SEBI ICDR Regulations, 2009, specify the allocation or allotment that may be made to
various categories of Bidders in the Issue depending upon compliance with the eligibility
conditions. Details pertaining to allocation are disclosed on reverse side of the Revision
Form. For Offer specific details in relation to allocation Bidder/ Applicant may refer to the
RHP/ Prospectus.

4.1.6 FIELD NUMBER 6: INVESTOR STATUS

a. Each Bidder/ Applicant should check whether it is eligible to apply under applicable law and
ensure that any prospective allotment to it in the Offer is in compliance with the investment
restrictions under applicable law.

b. Certain categories of Bidders/ Applicants, such as NRIs, FIIs, FPIs, QFIs and FVCIs are not
be allowed to Bid/ Apply in the Offer. Bidders/ Applicants are requested to refer to the RHP/
Prospectus for more details.

c. Bidders/Applicants should check whether they are eligible to apply on non-repatriation basis
or repatriation basis and should accordingly provide the investor status. Details regarding
investor status are different in the Resident Bid cum Application Form and Non-Resident Bid
cum Application Form.

d. Bidders/Applicants should ensure that their investor status is updated in the Depository
records.

4.1.7 FIELD NUMBER 7: PAYMENT DETAILS

a. The full Bid Amount (net of any Discount, as applicable) shall be blocked based on the
authorisation provided in the Bid cum Application Form. If the Discount is applicable in the
Offer, the RIIs should indicate the full Bid Amount in the Bid cum Application Form and the
funds shall be blocked for Bid Amount net of Discount. Only in cases where the
RHP/Prospectus indicates that part payment may be made, such an option can be exercised
by the Bidder. In case of Bidders specifying more than one Bid Option in the Bid cum
Application Form, the total Bid Amount may be calculated for the highest of three options at
net price, i.e. Bid price less Discount offered, if any.

b. Bidders who Bid at Cut-off Price shall deposit the Bid Amount based on the Cap Price.

c. All Bidders (except Anchor Investors) can participate in the Offer only through the ASBA
mechanism.

d. Bid Amount cannot be paid in cash, through money order or through postal order.

4.1.7.1 INSTRUCTIONS FOR ANCHOR INVESTOR

(a) Anchor Investors may submit their Bids with a Book Running Lead Manager.

(b) Payments should be made either by RTGS, NEFT or cheque/ demand draft drawn on any
bank (including a co-operative bank), which is situated at, and is a member of or sub-member
of the bankers’ clearing house located at the centre where the Anchor Investor Application
Form is submitted. Cheques/bank drafts drawn on banks not participating in the clearing
process may not be accepted and applications accompanied by such cheques or bank drafts
are liable to be rejected.

(c) If the cheque or demand draft accompanying the Bid cum Application Form is not made
favouring the Escrow Account, the Bid is liable to be rejected.

(d) The Escrow Collection Banks shall maintain the monies in the Escrow Account for and on
behalf of the Anchor Investors until the Designated Date.

(e) Anchor Investors are advised to provide the number of the Anchor Investor Application
Form and PAN on the reverse of the cheque or bank draft to avoid any possible misuse of
instruments submitted.

214
4.1.7.2 Payment instructions for Bidders (other than Anchor Investors)

(a) Bidders may submit the Bid cum Application Form either

i. in physical mode to the Designated Branch of an SCSB where the

Bidders/Applicants have ASBA Account, or

ii. in electronic mode through the internet banking facility offered by an SCSB
authorizing blocking of funds that are available in the ASBA account specified in
the Bid cum Application Form, or

iii. in physical mode to any Designated Intermediary.

(b) Bidders must specify the Bank Account number in the Bid cum Application Form. The Bid
cum Application Form submitted by Bidder and which is accompanied by cash, demand
draft, money order, postal order or any mode of payment other than blocked amounts in the
ASBA Account maintained with an SCSB, may not be accepted.

(c) Bidders should ensure that the Bid cum Application Form is also signed by the ASBA
Account holder(s) if the Bidder is not the ASBA Account holder;

(d) Bidders shall note that for the purpose of blocking funds under ASBA facility clearly
demarcated funds shall be available in the account.

(e) From one ASBA Account, a maximum of five Bids cum Application Forms can be
submitted.

(f) Bidders bidding through a member of the Syndicate should ensure that the Bid cum
Application Form is submitted to a member of the Syndicate only at the Specified Locations.

Bidders should also note that Bid cum Application Forms submitted to the Syndicate at the
Specified Locations may not be accepted by the member of the Syndicate if the SCSB where
the ASBA Account, as specified in the Bid cum Application Form, is maintained has not
named at least one branch at that location for the members of the Syndicate to deposit Bid
cum Application Forms (a list of such branches is available on the website of SEBI at
http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries).

(g) Bidders bidding through a Registered Broker, RTA or CDP should note that Bid cum
Application Forms submitted to them may not be accepted, if the SCSB where the ASBA
Account, as specified in the Bid cum Application Form, is maintained has not named at least
one branch at that location for the Registered Brokers, RTA or CDP, as the case may be, to
deposit Bid cum Application Forms.

(h) Bidders bidding directly through the SCSBs should ensure that the Bid cum Application
Form is submitted to a Designated Branch of a SCSB where the ASBA Account is
maintained.

(i) Upon receipt of the Bid cum Application Form, the Designated Branch of the SCSB may
verify if sufficient funds equal to the Bid Amount are available in the ASBA Account, as
mentioned in the Bid cum Application Form.

(j) If sufficient funds are available in the ASBA Account, the SCSB may block an amount
equivalent to the Bid Amount mentioned in the Bid cum Application Form and for
application directly submitted to SCSB by investor, may enter each Bid option into the
electronic bidding system as a separate Bid.

(k) If sufficient funds are not available in the ASBA Account, the Designated Branch of the
SCSB may not upload such Bids on the Stock Exchange platform and such bids are liable to
be rejected.

(l) Upon submission of a completed Bid cum Application Form each Bidder may be deemed to
have agreed to block the entire Bid Amount and authorized the Designated Branch of the

215
 SCSB to block the Bid Amount specified in the Bid cum Application Form in the ASBA
Account maintained with the SCSBs.

(m) The Bid Amount may remain blocked in the aforesaid ASBA Account until finalisation of
the Basis of Allotment and consequent transfer of the Bid Amount against the Allotted
Equity Shares to the Public Issue Account, or until withdrawal or failure of the Offer, or until
withdrawal or rejection of the Bid, as the case may be.

(n) SCSBs bidding in the Offer must apply through an Account maintained with any other
SCSB; else their Bids are liable to be rejected.

4.1.7.2.1 Unblocking of ASBA Account

(a) Once the Basis of Allotment is approved by the Designated Stock Exchange, the Registrar to
the Offer may provide the following details to the controlling branches of each SCSB, along
with instructions to unblock the relevant bank accounts and for successful applications
transfer the requisite money to the Public Issue Account designated for this purpose, within
the specified timelines: (i) the number of Equity Shares to be Allotted against each Bid, (ii)
the amount to be transferred from the relevant bank account to the Public Issue Account, for
each Bid, (iii) the date by which funds referred to in (ii) above may be transferred to the
Public Issue Account, and (iv) details of rejected Bids, if any, along with reasons for
rejection and details of withdrawn or unsuccessful Bids, if any, to enable the SCSBs to
unblock the respective bank accounts.

(b) On the basis of instructions from the Registrar to the Offer, the SCSBs may transfer the
requisite amount against each successful Bidder to the Public Issue Account and may
unblock the excess amount, if any, in the ASBA Account.

(c) In the event of withdrawal or rejection of the Bid cum Application Form and for unsuccessful
Bids, the Registrar to the Offer may give instructions to the SCSB to unblock the Bid
Amount in the relevant ASBA Account within six Working Days of the Bid/Offer Closing
Date.

4.1.7.3 DISCOUNT (if Applicable)

(a) The Discount is stated in absolute rupee terms.

(b) Bidders applying under RII category, Retail Individual Shareholder and employees are only
eligible for discount. For Discounts offered in the Offer, Bidders may refer to the
RHP/Prospectus.

(c) The Bidders entitled to the applicable Discount in the Offer may block an amount i.e. the Bid
Amount less discount (if applicable).

(d) Bidder may note that in case the net amount blocked (post Discount) is more than two Lacs
Rupees, the Bidding system automatically considers such applications for allocation under
Non-Institutional Category. These applications are neither eligible for Discount nor fall under
RII category.

4.1.8 FIELD NUMBER 8: SIGNATURES AND OTHER AUTHORISATIONS

(a) Only the First Bidder/ Applicant is required to sign the Bid cum Application Form/
Application Form. Bidders/ Applicants should ensure that signatures are in one of the
languages specified in the Eighth Schedule to the Constitution of India.

(b) If the ASBA Account is held by a person or persons other than the Bidder/Applicant., then the
Signature of the ASBA Account holder(s) is also required.

(c) The signature has to be correctly affixed in the authorisation/undertaking box in the Bid cum
Application Form/Application Form, or an authorisation has to be provided to the SCSB via
the electronic mode, for blocking funds in the ASBA Account equivalent to the Bid Amount

216
 mentioned in the Bid cum Application Form/Application Form.

4.1.9 ACKNOWLEDGEMENTS AND FUTURE COMMUNICATION

(a) Bidders should ensure that they receive the Acknowledgment Slip duly signed and stamped
by a member of the Designated Intermediary, as applicable, for submission of the Bid cum
Application Form.

(b) All communications in connection with Bids/ Applications made in the Offer should be
addressed as under:
i. In case of queries related to Allotment, non-receipt of Allotment Advice, credit of
allotted equity shares, refund orders, the Bidders/ Applicants should contact the
Registrar to the Offer.
ii. In case of ASBA Bids submitted to the Designated Branches of the SCSBs, the
Bidders/ Applicants should contact the relevant Designated Branch of the SCSB.
iii. In case of queries relating to uploading of Syndicate ASBA Bids, the Bidders/
Applicants should contact the relevant Syndicate Member.
iv. In case of queries relating to uploading of Bids by a Registered Broker, the Bidders/
Applicants should contact the relevant Registered Broker.
v. In case of Bids submitted to the RTA, the Bidders/Applicants should contact the
relevant RTA.
vi. In case of Bids submitted to the DP, the Bidders/Applicants should contact the
relevant DP.
vii. Bidder/ Applicant may contact the Company Secretary and Compliance Officer or
BRLM in case of any other complaints in relation to the Offer.

(c) The following details (as applicable) should be quoted while making any queries :
i. full name of the sole or First Bidder/ Applicant, Bid cum Application Form number,
Applicants’/ Bidders’ DP ID, Client ID, PAN, number of Equity Shares applied for,
amount paid on application.
ii. name and address of the member of the Designated Intermediaries, where the Bid
was submitted or
iii. In case of Bids other than from Anchor Investors, ASBA Account number in which
the amount equivalent to the Bid Amount was blocked.
iv. In case of Anchor Investor bids cheque or draft number and the name of the issuing
bank thereof.

For further details, Bidder/ Applicant may refer to the RHP/ Prospectus and the Bid cum Application
Form.

4.2 INSTRUCTION FOR FILING THE REVISED FORM

(a) During the Bid/Offer Period, any Bidder/Applicant (other than QIBs and NIIs, who can only
revise their bid upwards) who has registered his or her interest in the Equity Shares at a
particular price level is free to revise his or her Bid within the Price Band using the Revision
Form, which is a part of the Bid cum Application Form.

(b) RII may revise their bids or withdraw their Bids till the Bid/Offer Close Date.

(c) Revisions can be made in both the desired number of Equity Shares and the Bid Amount by
using the Revision Form.

(d) The Bidder/Applicant can make this revision any number of times during the Bid/Offer
Period. However, for any revision(s) in the Bid, the Bidders/Applicants will have to use the
services of the same Designated Intermediary through which such Bidder/Applicant had
placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision
Form and the Bid(s) must be made only in such Revision Form or copies thereof.

217
 REVISION FORM:
[Kindly note that same will be incorporated before filing of RHP]

Instructions to fill each field of the Revision Form can be found on the reverse side of the Revision Form.
Other than instructions already highlighted at paragraph 4.1 above, point wise instructions regarding filling up
various fields of the Revision Form are provided below:

4.2.1 FIELDS 1,2 AND 3: NAME AND CONTACT DETAILS OF SOLE/FIRST BIDDER/
APPLICANT, PAN OF SOLE/ FIRST BIDDER/ APPLICANT & DEPOSITORY ACCOUNT
DETAILS OF THE BIDDER/ APPLICANT

Bidders/Applicants should refer to instructions contained in paragraphs 4.1.1, 4.1.2 and 4.1.3.

4.2.2 FIELD 4& 5: BID OPTIONS REVISION FROM AND TO

a. Apart from mentioning the revised options in the Revision Form, the Bidder/ Applicant must
also mention the details of all the bid options given in his or her Bid cum Application Form
or earlier Revision Form. For example, if a Bidder/ Applicant has Bid for three options in the
Bid cum Application Form and such Bidder/ Applicant is changing only one of the options in
the Revision Form, the Bidder/Applicant must still fill the details of the other two options
that are not being revised, in the Revision Form. The members of the Syndicate, the
Registered Brokers and the Designated Branches of the SCSBs may not accept incomplete or
inaccurate Revision Forms.
b. In case of revision, Bid options should be provided by Bidders/ Applicants in the same order
as provided in the Bid cum Application Form.
c. In case of revision of Bids by RIIs, Employees and Retail Individual Shareholders, such
Bidders/ Applicants should ensure that the Bid Amount, subsequent to revision, does not
exceed ` 200,000. In case the Bid Amount exceeds ` 200,000 due to revision of the Bid or
for any other reason, the Bid may be considered, subject to eligibility, for allocation under
the Non-Institutional Category, not being eligible for Discount (if applicable) and such Bid
may be rejected if it is at the Cut-off Price. The Cut-off Price option is given only to the RIIs,
Employees and Retail Individual Shareholders indicating their agreement to Bid for and
purchase the Equity Shares at the Offer Price as determined at the end of the Book Building
Process.
d. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds `
200,000, the Bid will be considered for allocation under the Non-Institutional Portion in
terms of the RHP/ Prospectus. If, however, the RII does not either revise the Bid or make
additional payment and the Offer Price is higher than the cap of the Price Band prior to
revision, the number of Equity Shares Bid for shall be adjusted downwards for the purpose of
allocation, such that no additional payment would be required from the RII and the RII is
deemed to have approved such revised Bid at Cut-off Price.
e. In case of a downward revision in the Price Band, RIIs, who have bid at the Cut-off Price
could either revise their Bid or the excess amount paid at the time of Bidding may be
unblocked in case of Bidders.

4.2.3 FIELD 6: PAYMENT DETAILS

(a) All Bidders/Applicants are required to make payment of the full Bid Amount (less Discount
(if applicable) along with the Bid Revision Form. In case of Bidders/Applicants specifying
more than one Bid Option in the Bid cum Application Form, the total Bid Amount may be
calculated for the highest of three options at net price, i.e. Bid price less discount offered, if
any.

(b) Bidder/Applicant may Offer instructions to block the revised amount based on cap of the
revised Price Band (adjusted for the Discount (if applicable) in the ASBA Account, to the
same Designated Intermediary through whom such Bidder/Applicant had placed the original
Bid to enable the relevant SCSB to block the additional Bid Amount, if any.

(c) In case the total amount (i.e., original Bid Amount less discount (if applicable) plus
additional payment) exceeds ₹200,000, the Bid may be considered for allocation under the
Non-Institutional Category in terms of the RHP/Prospectus. If, however, the
Bidder/Applicant does not either revise the Bid or make additional payment and the Offer
Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares

218
 Bid for may be adjusted downwards for the purpose of Allotment, such that additional
amount is required blocked and the Bidder/Applicant is deemed to have approved such
revised Bid at the Cut-off Price.

(d) In case of a downward revision in the Price Band, RIIs, Employees and Retail Individual
Shareholders, who have bid at the Cut-off Price, could either revise their Bid or the excess
amount paid at the time of Bidding may be unblocked.

4.2.4 FIELDS 7: SIGNATURES AND ACKNOWLEDGEMENTS

Bidders/ Applicants may refer to instructions contained at paragraphs 4.1.8 and 4.1.9 for this purpose.

4.3 INSTRUCTIONS FOR FILING APPLICAITON FORM IN ISSUES MADE OTHER THAN
THE THROUGH BOOK BUILDING PROCESS (FIXED PRICE ISSUE)

4.3.1 FIELDS 1,2,3 NAME AND CONTACT DETAILS OF SOLE/FIRST BIDDER/ APPLICANT,
PAN OF THE SOLE/FIRST BIDDER/ APPLICANT & DEPOSITORY ACCOUNT DETAILS
OF THE BIDDER/APPLICANT

Applicants should refer to instructions contained in paragraph 4.1.1, 4.1.2 and 4.1.3.

4.3.2 FIELD NUMBER 4: PRICE, APPLICATION QUANTITY & AMOUNT

a. The Company may mention Price or Price band in the draft Prospectus. However a
prospectus registered with RoC contains one price or coupon rate (as applicable).

b. Minimum Application Value and Bid Lot: The Company and the Selling Shareholders in
consultation with the Book Running Lead Manager to the Issue (BRLM) may decide the minimum
number of Equity Shares for each Bid to ensure that the minimum application value is within the
range of ` 10,000 to ` 15,000. The minimum Lot size is accordingly determined by a Company on
basis of such minimum application value.

c. Applications by RIIs, Employees and Retail Individual Shareholders, must be for such
number of shares so as to ensure that the application amount payable does not exceed `
200,000.

d. Applications by Other Investors must be for such minimum number of shares such that the
application amount exceeds ` 200,000 and in multiples of such number of Equity Shares
thereafter, as may be disclosed in the application form and the Prospectus, or as advertised by
the Company, as the case may be.

e. An application cannot be submitted for more than the Offer size.

f. The maximum application by any Applicant should not exceed the investment limits
prescribed for them under the applicable laws.

g. Multiple Applications: An Applicant should submit only one Application Form. Submission
of a second Application Form to either the same or to Collection Bank(s) or SCSB and
duplicate copies of Application Forms bearing the same application number shall be treated
as multiple applications and are liable to be rejected.

h. Applicants are requested to note the following procedures may be followed by the Registrar
to the Offer to detect multiple applications:

i. All applications may be checked for common PAN as per the records of the Depository.
For Applicants other than Mutual Funds and FII sub-accounts, Bids bearing the same PAN
may be treated as multiple applications by a Bidder/Applicant and may be rejected.

ii. For applications from Mutual Funds and FII sub-accounts, submitted under the same PAN,
as well as Bids on behalf of the PAN Exempted Applicants, the Application Forms may be
checked for common DP ID and Client ID. In any such applications which have the same DP
ID and Client ID, these may be treated as multiple applications and may be rejected.

219
 i. The following applications may not be treated as multiple Bids:

i. Applications by Reserved Categories, if any in their respective reservation portion,

if any, as well as that made by them in the Net Offer portion in public category.
ii. Separate applications by Mutual Funds in respect of more than one scheme of the
Mutual Fund provided that the Applications clearly indicate the scheme for which
the Bid has been made.
iii. Applications by Mutual Funds, and sub-accounts of FIIs (or FIIs and its sub-
accounts) submitted with the same PAN but with different beneficiary account
numbers, Client IDs and DP IDs.

4.3.3 FIELD NUMBER 5: CATEGORY OF APPLICANTS

a. The categories of applicants identified as per the SEBI ICDR Regulations, 2009 for the
purpose of Bidding, allocation and allotment in the Offer are RIIs, individual applicants other
than RII’s and Other Investors (including corporate bodies or institutions, irrespective of the
number of specified securities applied for).

b. An Company can make reservation for certain categories of Applicants permitted under the
SEBI ICDR Regulations, 2009. For details of any reservations made in the Offer, applicants
may refer to the Prospectus.

c. The SEBI ICDR Regulations, 2009 specify the allocation or allotment that may be made to
various categories of applicants in an Offer depending upon compliance with the eligibility
conditions. Details pertaining to allocation are disclosed on reverse side of the Revision
Form. For Offer specific details in relation to allocation applicant may refer to the
Prospectus.

4.3.4 FIELD NUMBER 6: INVESTOR STATUS

Applicants should refer to instructions contained in paragraphs 4.1.6.

4.3.5 FIELD NUMBER 7: PAYMENT DETAILS

(a) All Applicants (other than Anchor Investors) are required to make use ASBA for applying in
the Issue

(b) Application Amount cannot be paid in cash, through money order, cheque or through postal
order or through stock invest.

4.3.5.2 PAYMENT INSTRUCTIONS FOR APPLICANTS

(a) Applicants may submit the Application Form in physical mode to the Designated
Intermediaries.

(b) Applicants must specify the Bank Account number in the Application Form. The Application
Form submitted by an Applicant and which is accompanied by cash, demand draft, money
order, postal order or any mode of payment other than blocked amounts in the ASBA
Account maintained with an SCSB, will not be accepted.

(c) Applicants should ensure that the Application Form is also signed by the ASBA Account
holder(s) if the Applicant is not the ASBA Account holder;

(d) Applicants shall note that for the purpose of blocking funds under ASBA facility clearly
demarcated funds shall be available in the account.

(e) From one ASBA Account, a maximum of five Bids cum Application Forms can be
submitted. (f) Applicants bidding directly through the SCSBs should ensure that the
Application Form is submitted to a Designated Branch of a SCSB where the ASBA Account
is maintained.

220
 (g) Upon receipt of the Application Form, the Designated Branch of the SCSB may verify if
sufficient funds equal to the Application Amount are available in the ASBA Account, as
mentioned in the Application Form.

(h) If sufficient funds are available in the ASBA Account, the SCSB may block an amount
equivalent to the Application Amount mentioned in the Application Form and may upload
the details on the Stock Exchange Platform.

(i) If sufficient funds are not available in the ASBA Account, the Designated Branch of the
SCSB may not upload such Applications on the Stock Exchange platform and such
Applications are liable to be rejected.

(j) Upon submission of a completed Application Form each Applicant may be deemed to have
agreed to block the entire Application Amount and authorized the Designated Branch of the
SCSB to block the Application Amount specified in the Application Form in the ASBA
Account maintained with the SCSBs.

(k) The Application Amount may remain blocked in the aforesaid ASBA Account until
finalisation of the Basis of Allotment and consequent transfer of the Application Amount
against the Allotted Equity Shares to the Public Issue Account, or until withdrawal or failure
of the Offer, or until withdrawal or rejection of the Application, as the case may be.

(l) SCSBs applying in the Offer must apply through an ASBA Account maintained with any
other SCSB; else their Applications are liable to be rejected.

4.3.5.2.1 UNBLOCKING OF ASBA ACCOUNT

a. Once the Basis of Allotment is approved by the Designated Stock Exchange, the Registrar to
the Issue may provide the following details to the controlling branches of each SCSB, along
with instructions to unblock the relevant bank accounts and for successful applications
transfer the requisite money to the Public Issue Account designated for this purpose, within
the specified timelines: (i) the number of Equity Shares to be Allotted against each
Application, (ii) the amount to be transferred from the relevant bank account to the Public
Issue Account, for each Application, (iii) the date by which funds referred to in (ii) above
may be transferred to the Public Issue Account, and (iv) details of rejected ASBA
Applications, if any, along with reasons for rejection and details of withdrawn or
unsuccessful Applications, if any, to enable the SCSBs to unblock the respective bank
accounts.

b. On the basis of instructions from the Registrar to the Offer, the SCSBs may transfer the
requisite amount against each successful ASBA Application to the Public Issue Account and
may unblock the excess amount, if any, in the ASBA Account.

c. In the event of withdrawal or rejection of the Application Form and for unsuccessful
Applications, the Registrar to the Offer may give instructions to the SCSB to unblock the
Application Amount in the relevant ASBA Account within 12 Working Days of the Offer
Closing Date.

4.3.5.3 DISCOUNT (IF APPLICABLE)

a. The Discount is stated in absolute rupee terms.

b. RIIs, Employees and Retail Individual Shareholders are only eligible for discount. For
Discounts offered in the Offer, applicants may refer to the Prospectus.

c. The Applicants entitled to the applicable Discount in the Offer may make payment for an
amount i.e. the Application Amount less Discount (if applicable).

4.3.6 FIELD NUMBER 8: SIGNATURES AND OTHER AUTHORISATIONS &

ACKNOWLEDGEMENTS AND FUTURE COMMUNICATION

Applicants should refer to instructions contained in paragraphs 4.1.8 & 4.1.9.

221
4.4 SUBMISSION OF BID CUM APPLICATION FORM/REVISION FORM/APPLICATION
FORM

4.4.1 Bidders/Applicants may submit completed Bid cum application form/Revision Form in the
following manner:-

Mode of Investor Submission of Bid cum Application Form

Anchor Investor 1) To the Book Running Lead Manager at the Specified Locations
Application Form mentioned in the Bid cum Application Form
All Applications (a) To members of the Syndicate in the Specified Locations or
(other than Anchor Registered Brokers at the Broker Centres or the RTA at the
Investors) Designated RTA Location or the DP at the Designated DP Location

(b) To the Designated Branches of the SCSBs where the ASBA

Account is maintained

(a) Bidders/Applicants should submit the Revision Form to the same Designated Intermediary
through which such Bidder/Applicant had placed the original Bid.

(b) Upon submission of the Bid cum Application Form, the Bidder/Applicant will be deemed to
have authorized the Issuer to make the necessary changes in the RHP and the Bid cum
Application Form as would be required for filing Prospectus with the RoC and as would be
required by the RoC after such filing, without prior or subsequent notice of such changes to
the relevant Bidder/Applicant.

(c) Upon determination of the Offer Price and filing of the Prospectus with the RoC, the Bid cum
Application Form will be considered as the application form.

SECTION 5: ISSUE PROCEDURE IN BOOK BUILT ISSUE

Book Building, in the context of the Offer, refers to the process of collection of Bids within the Price Band or
above the Floor Price and determining the Offer Price based on the Bids received as detailed in Schedule XI of
SEBI ICDR Regulations, 2009. The Offer Price is finalised after the Bid/Offer Closing Date. Valid Bids
received at or above the Offer Price are considered for allocation in the Offer, subject to applicable regulations
and other terms and conditions.

5.1 SUBMISSION OF BIDS

(a) During the Bid/Offer Period, Bidders/Applicants may approach any of the Designated
Intermediaries to register their Bids. Anchor Investors who are interested in subscribing for
the Equity Shares should approach the Book Running Lead Manager, to register their Bid.

(b) In case of Bidders/Applicants (excluding NIIs and QIBs) Bidding at Cut-off Price, the
Bidders/Applicants may instruct the SCSBs to block Bid Amount based on the Cap Price less
Discount (if applicable).

(c) For Details of the timing on acceptance and upload of Bids in the Stock Exchanges Platform
Bidders/Applicants are requested to refer to the RHP.

5.2 ELECTRONIC REGISTRATION OF BIDS

(a) The Designated Intermediary may register the Bids using the on-line facilities of the Stock
Exchanges. The Designated Intermediaries can also set up facilities for off-line electronic
registration of Bids, subject to the condition that they may subsequently upload the off-line
data file into the on-line facilities for Book Building on a regular basis before the closure of
the issue.

(b) On the Bid/Offer Closing Date, the Designated Intermediaries may upload the Bids till such
time as may be permitted by the Stock Exchanges.

(c) Only Bids that are uploaded on the Stock Exchanges Platform are considered for
allocation/Allotment. The Designated Intermediaries are given till 1:00 pm on the day
following the Bid/Offer Closing Date to modify select fields uploaded in the Stock Exchange
Platform during the Bid/Offer Period after which the Stock Exchange(s) send the bid
information to the Registrar to the Issue for further processing.

222
5.3 BUILD UP OF THE BOOK

(a) Bids received from various Bidders/Applicants through the Designated Intermediaries may be
electronically uploaded on the Bidding Platform of the Stock Exchanges’ on a regular basis.
The book gets built up at various price levels. This information may be available with the
BRLM at the end of the Bid/Offer Period.

(b) Based on the aggregate demand and price for Bids registered on the Stock Exchanges
Platform, a graphical representation of consolidated demand and price as available on the
websites of the Stock Exchanges may be made available at the Bidding centres during the
Bid/Offer Period.

5.4 WITHDRAWAL OF BIDS

(a) RIIs can withdraw their Bids until Bid/Offer Closing Date. In case a RII wishes to withdraw
the Bid during the Bid/Offer Period, the same can be done by submitting a request for the
same to the concerned Designated Intermediary who shall do the requisite, including
unblocking of the funds by the SCSB in the ASBA Account.

(b) The Registrar to the Offer shall give instruction to the SCSB for unblocking the ASBA
Account on the Designated Date. QIBs and NIIs can neither withdraw nor lower the size of
their Bids at any stage.

5.5 REJECTION & RESPONSIBILITY FOR UPLOAD OF BIDS

(a) The Designated Intermediaries are individually responsible for the acts, mistakes or errors or
omission in relation to:
i. the Bids accepted by the Designated Intermediaries,
ii. the Bids uploaded by the Designated Intermediaries, and
iii. the Bid cum application forms accepted but not uploaded by the Designated
Intermediaries.
(b) The BRLM and their affiliate Syndicate Members, as the case may be, may reject Bids if all
the information required is not provided and the Bid cum Application Form is incomplete in
any respect.

(c) The SCSBs shall have no right to reject Bids, except in case of unavailability of adequate
funds in the ASBA account or on technical grounds. (d) In case of QIB Bidders, only the (i)
SCSBs (for Bids other than the Bids by Anchor Investors); and (ii) BRLM and their affiliate
Syndicate Members (only in the Specified Locations) have the right to reject bids. However,
such rejection shall be made at the time of receiving the Bid and only after assigning a reason
for such rejection in writing.
(e) All bids by QIBs, NIIs & RIIs Bids can be rejected on technical grounds listed herein.

5.5.1 GROUNDS FOR TECHNICAL REJECTIONS

Bid cum Application Forms/Application Form can be rejected on the below mentioned technical
grounds either at the time of their submission to any of the Designated Intermediaries, or at the time of
finalisation of the Basis of Allotment. Bidders/Applicants are advised to note that the
Bids/Applications are liable to be rejected, inter-alia, on the following grounds, which have been
detailed at various placed in this GID:-

(a) Bid/Application by persons not competent to contract under the Indian Contract Act, 1872, as
amended, (other than minors having valid Depository Account as per Demographic Details
provided by Depositories);

(b) Bids/Applications by OCBs, ; and

(c) In case of partnership firms, Bid/Application for Equity Shares made in the name of the firm.
However, a limited liability partnership can apply in its own name;

(d) In case of Bids/Applications under power of attorney or by limited companies, corporate, trust
etc., relevant documents not being submitted along with the Bid cum application
form/Application Form;

(e) Bids/Applications by persons prohibited from buying, selling or dealing in the shares directly
or indirectly by SEBI or any other regulatory authority;

223
 (f) Bids/Applications by persons in the United States;

(g) Bids/Applications by any person outside India if not in compliance with applicable foreign
and Indian laws;

(h) PAN not mentioned in the Bid cum Application Form/Application Form, except for
Bids/Applications by or on behalf of the Central or State Government and officials appointed
by the court and by the investors residing in the State of Sikkim, provided such claims have
been verified by the Depository Participant;

(i) In case no corresponding record is available with the Depositories that matches the DP ID, the
Client ID and the PAN;

(j) Bids/Applications for lower number of Equity Shares than the minimum specified for that
category of investors;

(k) Bids/Applications at a price less than the Floor Price and Bids/Applications at a price more
than the Cap Price;
(l) Bids/Applications at Cut-off Price by NIIs and QIBs;

(m) The amounts mentioned in the Bid cum Application Form/Application Form does not tally
with the amount payable for the value of the Equity Shares Bid/Applied for;

(n) Bids/Applications for amounts greater than the maximum permissible amounts prescribed by
the regulations;

(o) Submission of more than five Bid cum Application Forms/Application Form as through a
single ASBA Account;

(p) Bids/Applications for number of Equity Shares which are not in multiples Equity Shares
which are not in multiples as specified in the RHP;

(q) Multiple Bids/Applications as defined in this GID and the RHP/Prospectus;

(r) Bid cum Application Forms/Application Forms are not delivered by the Bidders/Applicants
within the time prescribed as per the Bid cum Application Forms/Application Form,
Bid/Offer Opening Date advertisement and as per the instructions in the RHP and the Bid cum
Application Forms;
(s) Inadequate funds in the bank account to block the Bid/Application Amount specified in the
Bid cum Application Form/Application Form at the time of blocking such Bid/Application
Amount in the bank account;

(t) In case of Anchor Investors, Bids/Applications where sufficient funds are not available in
Escrow Accounts as per final certificate from the Escrow Collection Banks;

(u) Where no confirmation is received from SCSB for blocking of funds;

(v) Bids/Applications by Bidders (other than Anchor Investors) not submitted through ASBA
process;
(w) Bids/Applications submitted to a BRLM at locations other than the Specified Cities and Bid
cum Application Forms/Application Forms, under the ASBA process, submitted to the Escrow
Collecting Banks (assuming that such bank is not a SCSB where the ASBA Account is
maintained), to the issuer or the Registrar to the Offer;

(x) Bids/Applications not uploaded on the terminals of the Stock Exchanges; and

(y) Bids/Applications by SCSBs wherein a separate account in its own name held with any other
SCSB is not mentioned as the ASBA Account in the Bid cum Application Form/Application
Form.

5.6 BASIS OF ALLOCATION

(a) The SEBI ICDR Regulations, 2009 specify the allocation or Allotment that may be made to various
categories of Bidders/Applicants in an Offer depending on compliance with the eligibility conditions.
Certain details pertaining to the percentage of Offer size available for allocation to each category is

224
 disclosed overleaf of the Bid cum Application Form and in the RHP/Prospectus. For details in relation
to allocation, the Bidder/Applicant may refer to the RHP/Prospectus.

(b) Under-subscription in any category (except QIB Category) is allowed to be met with spill over from
any other category or combination of categories at the discretion of the Issuer and in consultation with
the BRLM and the Designated Stock Exchange and in accordance with the SEBI ICDR Regulations,
2009. Unsubscribed portion in QIB Category is not available for subscription to other categories.

(c) In case of under subscription in the Offer, spill-over to the extent of such under-subscription may be
permitted from the Reserved Portion if any to the Offer. For allocation in the event of an under-
subscription applicable to the Issuer, Bidders/Applicants may refer to the RHP.

(d) Illustration of the Book Building and Price Discovery Process Bidders should note that this example is
solely for illustrative purposes and is not specific to the Offer; it also excludes Bidding by Anchor
Investors.

Bidders can bid at any price within the price band. For instance, assume a price band of ` 20 to ` 24 per share,
offer size of 3,000 equity shares and receipt of five bids from bidders, details of which are shown in the table
below. A graphical representation of the consolidated demand and price would be made available at bidding.

Bid Quantity Bid Price Cumulative Quantity Subscription (%)

500 24 500 16.7
1,000 23 1,500 50.0
1,500 22 3,000 100.0
2,000 21 5,000 166.7
2,500 20 7,500 250.0

The price discovery is a function of demand at various prices. The highest price at which the issuer is able to
issue the desired number of equity shares is the price at which the book cuts off, i.e., ` 22 in the above
example. The issuer and the Selling Shareholders, in consultation with the Book Running Lead Manager will
finalise the issue price at or below such cut-off price, i.e., at or below ` 22. All bids at or above this issue price
and cut-off bids are valid bids and are considered for allocation in the respective categories.

e) Alternate Method of Book Building

In case of FPOs, Issuers may opt for an alternate method of Book Building in which only the Floor
Price is specified for the purposes of Bidding (“Alternate Book Building Process”). The Issuer may
specify the Floor Price in the RHP or advertise the Floor Price at least one Working Day prior to the
Bid/Offer Opening Date. QIBs may Bid at a price higher than the Floor Price and the Allotment to the
QIBs is made on a price priority basis. The Bidder with the highest Bid Amount is allotted the number
of Equity Shares Bid for and then the second highest Bidder is Allotted Equity Shares and this process
continues until all the Equity Shares have been allotted. RIIs, NIIs and Employees are Allotted Equity
Shares at the Floor Price and Allotment to these categories of Bidders is made proportionately. If the
number of Equity Shares Bid for at a price is more than available quantity then the Allotment may be
done on a proportionate basis. Further, the Issuer may place a cap either in terms of number of
specified securities or percentage of issued capital of the Issuer that may be Allotted to a single
Bidder, decide whether a Bidder be allowed to revise the bid upwards or downwards in terms of price
and/or quantity and also decide whether a Bidder be allowed single or multiple bids.

SECTION 6: ISSUE PROCEDURE IN FIXED PRICE ISSUE

Applicants may note that there is no Bid cum Application Form in a Fixed Price Offer:. As the Offer
Price is mentioned in the Fixed Price Offer therefore on filing of the Prospectus with the RoC, the Application
so submitted is considered as the application form. Applicants may only use the specified Application Form for
the purpose of making an Application in terms of the Prospectus which may be submitted through the
Designated Intermediary.

Applicants may submit an Application Form either in physical form to the any of the Designated
Intermediaries or in the electronic form to the SCSB or the Designated Branches of the SCSBs authorising
blocking of funds that are available in the bank account specified in the Application Form only (“ASBA
Account”). The Application Form is also made available on the websites of the Stock Exchanges at least one
day prior to the Bid/Offer Opening Date.

225
In a fixed price Offer, allocation in the net offer to the public category is made as follows: minimum fifty Per
cent to Retail Individual Investors; and remaining to (i) individual investors other than Retail Individual
Investors; and (ii) other Applicants including corporate bodies or institutions, irrespective of the number of
specified securities applied for. The unsubscribed portion in either of the categories specified above may be
allocated to the Applicants in the other category.

For details of instructions in relation to the Application Form, Bidders/Applicants may refer to the relevant
section of the GID.

SECTION 7: ALLOTMENT PROCEDURE AND BASIS OF ALLOTMENT

The Allotment of Equity Shares to Bidders/Applicants other than Retail Individual Investors and Anchor
Investors may be on proportionate basis. For Basis of Allotment to Anchor Investors, Bidders/Applicants may
refer to RHP/Prospectus. No Retail Individual Investor will be Allotted less than the minimum Bid Lot subject
to availability of shares in Retail Individual Investor Category and the remaining available shares, if any will be
Allotted on a proportionate basis. The Issuer is required to receive a minimum subscription of 90% of the Offer
(excluding any Offer for Sale of specified securities). However, in case the Offer is in the nature of Offer for
Sale only, then minimum subscription may not be applicable.

7.1 ALLOTMENT TO RIIs

Bids received from the RIIs at or above the Offer Price may be grouped together to determine the total
demand under this category. If the aggregate demand in this category is less than or equal to the Retail
Portion at or above the Offer Price, full Allotment may be made to the RIIs to the extent of the valid
Bids. If the aggregate demand in this category is greater than the allocation to in the Retail Portion at or
above the Offer Price, then the maximum number of RIIs who can be Allotted the minimum Bid Lot
will be computed by dividing the total number of Equity Shares available for Allotment to RIIs by the
minimum Bid Lot (“Maximum RII Allottees”). The Allotment to the RIIs will then be made in the
following manner:

(a) In the event the number of RIIs who have submitted valid Bids in the Offer is equal to or less
than Maximum RII Allottees, (i) all such RIIs shall be Allotted the minimum Bid Lot; and (ii)
the balance available Equity Shares, if any, remaining in the Retail Portion shall be Allotted
on a proportionate basis to the RIIs who have received Allotment as per (i) above for the
balance demand of the Equity Shares Bid by them (i.e. who have Bid for more than the
minimum Bid Lot).

(b) In the event the number of RIIs who have submitted valid Bids in the Offer is more than
Maximum RII Allottees, the RIIs (in that category) who will then be Allotted minimum Bid
Lot shall be determined on the basis of draw of lots.

7.2 ALLOTMENT TO NIIs

Bids received from NIIs at or above the Offer Price may be grouped together to determine the total
demand under this category. The Allotment to all successful NIIs may be made at or above the Offer
Price. If the aggregate demand in this category is less than or equal to the Non-Institutional Category at
or above the Offer Price, full Allotment may be made to NIIs to the extent of their demand. In case the
aggregate demand in this category is greater than the Non-Institutional Category at or above the Offer
Price, Allotment may be made on a proportionate basis up to a minimum of the Non-Institutional
Category.

7.3 ALLOTMENT TO QIBs

For the Basis of Allotment to Anchor Investors, Bidders/Applicants may refer to the SEBI ICDR
Regulations, 2009 or RHP/Prospectus. Bids received from QIBs Bidding in the QIB Category (net of
Anchor Portion) at or above the Offer Price may be grouped together to determine the total demand
under this category. The QIB Category may be available for Allotment to QIBs who have Bid at a price
that is equal to or greater than the Offer Price. Allotment may be undertaken in the following manner:

(a) In the first instance allocation to Mutual Funds for up to 5% of the QIB Category may be
determined as follows: (i) In the event that Bids by Mutual Fund exceeds 5% of the QIB
Category, allocation to Mutual Funds may be done on a proportionate basis for up to 5% of
the QIB Category; (ii) In the event that the aggregate demand from Mutual Funds is less than

226
 5% of the QIB Category then all Mutual Funds may get full Allotment to the extent of valid
Bids received above the Offer Price; and (iii) Equity Shares remaining unsubscribed, if any
and not allocated to Mutual Funds may be available for Allotment to all QIBs as set out at
paragraph 7.4(b) below;

(b) In the second instance, Allotment to all QIBs may be determined as follows: (i) In the event of
oversubscription in the QIB Category, all QIBs who have submitted Bids above the Offer
Price may be Allotted Equity Shares on a proportionate basis for up to 95% of the QIB
Category; (ii) Mutual Funds, who have received allocation as per (a) above, for less than the
number of Equity Shares Bid for by them, are eligible to receive Equity Shares on a
proportionate basis along with other QIBs; and (iii) Under-subscription below 5% of the QIB
Category, if any, from Mutual Funds, may be included for allocation to the remaining QIBs on
a proportionate basis.

7.4 ALLOTMENT TO ANCHOR INVESTOR (IF APPLICABLE)

i. Allocation of Equity Shares to Anchor Investors at the Anchor Investor Offer Price will be at
the discretion of the issuer in consultation with the Investor Selling Shareholder and the
BRLM, subject to compliance with the following requirements: i. not more than 60% of the
QIB Category will be allocated to Anchor Investors;

ii. one-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject
to valid Bids being received from domestic Mutual Funds at or above the price at which
allocation is being done to other Anchor Investors; and

iii. allocation to Anchor Investors shall be on a discretionary basis and subject to:

(i) Maximum of 2 such investors shall be permitted for allocation upto `10 crore;
(ii) Minimum of 2 and maximum of 15 such investors shall be permitted for allocation above
Rs, 10 crore and upto `250 crore, subject to minimum allotment of `5 crore per such investor;
(iii) in case of allocation above Rs.250 crore; a minimum of 5 such investors and a maximum
of 15 such investors for allocation upto Rs.250 crore and an additional 10 such investors for
every additional Rs.250 crore or part thereof, shall be permitted, subject to a minimum
allotment of Rs.5 crore per such investor.

iv. A physical book is prepared by the Registrar on the basis of the Anchor Investor Application
Forms received from Anchor Investors. Based on the physical book and at the discretion of the
issuer in consultation with the BRLM, selected Anchor Investors will be sent a CAN and if
required, a revised CAN.

v. In the event that the Offer Price is higher than the Anchor Investor Offer Price: Anchor
Investors will be sent a revised CAN within one day of the Pricing Date indicating the number
of Equity Shares allocated to such Anchor Investor and the pay-in date for payment of the
balance amount. Anchor Investors are then required to pay any additional amounts, being the
difference between the Offer Price and the Anchor Investor Offer Price, as indicated in the
revised CAN within the pay-in date referred to in the revised CAN. Thereafter, the Allotment
Advice will be issued to such Anchor Investors.

vi. In the event the Offer Price is lower than the Anchor Investor Offer Price: Anchor
Investors who have been Allotted Equity Shares will directly receive Allotment Advice.

7.5 BASIS OF ALLOTMENT FOR QIBs (OTHER THAN ANCHOR INVESTORS), NIIs AND
RESERVED CATEGORY, IF ANY, IN CASE OF OVER-SUBSCRIBED ISSUE

In the event of the Offer being over-subscribed, the Issuer may finalise the Basis of Allotment in
consultation with the Designated Stock Exchange in accordance with the SEBI ICDR Regulations,
2009.

The allocation may be made in marketable lots, on a proportionate basis as explained below:

(a) Bidders may be categorized according to the number of Equity Shares applied for;

227
 (b) The total number of Equity Shares to be Allotted to each category as a whole may be arrived
at on a proportionate basis, which is the total number of Equity Shares applied for in that
category (number of Bidders in the category multiplied by the number of Equity Shares
applied for) multiplied by the inverse of the over-subscription ratio;

(c) The number of Equity Shares to be Allotted to the successful Bidders may be arrived at on a
proportionate basis, which is total number of Equity Shares applied for by each Bidder in that
category multiplied by the inverse of the over-subscription ratio;

(d) In all Bids where the proportionate Allotment is less than the minimum Bid Lot decided per
Bidder, the Allotment may be made as follows: the successful Bidders out of the total Bidders
for a category may be determined by a draw of lots in a manner such that the total number of
Equity Shares Allotted in that category is equal to the number of Equity Shares calculated in
accordance with (b) above; and each successful Bidder may be Allotted a minimum of such
Equity Shares equal to the minimum Bid Lot finalised by the Issuer;

(e) If the proportionate Allotment to a Bidder is a number that is more than the minimum Bid lot
but is not a multiple of one (which is the marketable lot), the decimal may be rounded off to
the higher whole number if that decimal is 0.5 or higher. If that number is lower than 0.5 it
may be rounded off to the lower whole number. Allotment to all Bidders in such categories
may be arrived at after such rounding off; and

(f) If the Equity Shares allocated on a proportionate basis to any category are more than the
Equity Shares Allotted to the Bidders in that category, the remaining Equity Shares available
for Allotment may be first adjusted against any other category, where the Allotted Equity
Shares are not sufficient for proportionate Allotment to the successful Bidders in that
category. The balance Equity Shares, if any, remaining after such adjustment may be added to
the category comprising Bidders applying for minimum number of Equity Shares.

7.6 DESIGNATED DATE AND ALLOTMENT OF EQUITY SHARES

(a) Designated Date: On the Designated Date, the Escrow Collection Banks shall transfer the
funds represented by allocation of Equity Shares to Anchor Investors from the Escrow
Account, as per the terms of the Escrow Agreement, into the Public Issue Account with the
Bankers to the Offer. The balance amount after transfer to the Public Issue Account shall be
transferred to the Refund Account. Payments of refund to the Bidders applying in the Anchor
Investor Portion shall be made from the Refund Account as per the terms of the Escrow
Agreement and the RHP. On the Designated Date, the Registrar to the Issue shall instruct the
SCSBs to transfer funds represented by allocation of Equity Shares from ASBA Accounts into
the Public Issue Account.

(b) Issuance of Allotment Advice: Upon approval of the Basis of Allotment by the Designated
Stock Exchange, the Registrar shall upload the same on its website. On the basis of the
approved Basis of Allotment, the Issuer shall pass necessary corporate action to facilitate the
Allotment and credit of Equity Shares. Bidders/Applicants are advised to instruct their
Depository Participant to accept the Equity Shares that may be allotted to them pursuant to the
Offer.

Pursuant to confirmation of such corporate actions, the Registrar will dispatch Allotment
Advice to the Bidders/Applicants who have been Allotted Equity Shares in the Offer.

(c) The dispatch of Allotment Advice shall be deemed a valid, binding and irrevocable contract.

(d) Issuer will ensure that: (i) the Allotment of Equity Shares; and

(e) credit of shares to the successful Bidders/Applicants Depository Account will be completed
within six Working Days of the Bid/Offer Closing Date. The Issuer also ensures the credit of
shares to the successful Applicant’s depository account is completed within five Working
Days from the Bid/Issue Close Date.

SECTION 8: INTEREST AND REFUNDS

8.1 COMPLETION OF FORMALITIES FOR LISTING & COMMENCEMENT OF TRADING

228
 The Issuer may ensure that all steps for the completion of the necessary formalities for listing and
commencement of trading at all the Stock Exchanges are taken within six Working Days of the
Bid/Offer Closing Date. The Registrar to the Offer may give instructions for credit to Equity Shares the
beneficiary account with CDPs, and dispatch the Allotment Advice within six Working Days of the
Bid/Offer Closing Date.

8.2 GROUNDS FOR REFUND

8.2.1 NON RECEIPT OF LISTING PERMISSION

An Issuer makes an application to the Stock Exchange(s) for permission to deal in/list and for an
official quotation of the Equity Shares. All the Stock Exchanges from where such permission is sought
are disclosed in RHP/Prospectus. The Designated Stock Exchange may be as disclosed in the
RHP/Prospectus with which the Basis of Allotment may be finalised. If the Issuer fails to make
application to the Stock Exchange(s) or obtain permission for listing of the Equity Shares, in
accordance with the provisions of Section 40 of the Companies Act, 2013, the Issuer shall be
punishable with a fine which shall not be less than ₹5 lacs but which may extend to ₹50 lacs and every
officer of the Issuer who is in default shall be punishable with imprisonment for a term which may
extend to one year or with fine which shall not be less than ₹50,000 but which may extend to ₹3 lacs,
or with both.

If the permissions to deal in and for an official quotation of the Equity Shares are not granted by any of
the Stock Exchange(s), the Issuer may forthwith take steps to refund, without interest, all moneys
received from Bidders/Applicants.

If such money is not refunded to the Bidders within the prescribed time after the Issuer becomes liable
to repay it, then the Issuer and every director of the Issuer who is an officer in default may, on and from
such expiry of such period, be liable to repay the money, with interest at such rate, as disclosed in the
RHP/Prospectus.

8.2.2 NON RECEIPT OF MINIMUM SUBSCRIPTION

If the Issuer does not receive a minimum subscription of 90% of the Net Offer (excluding any offer for
sale of specified securities), including devolvement to the Underwriters, the Issuer may forthwith, take
steps to unblock the entire subscription amount received within six Working Days of the Bid/Offer
Closing Date and repay, without interest, all moneys received from Anchor Investors. In case the Offer
is in the nature of Offer for Sale only, then minimum subscription may not be applicable. In case of
under-subscription in the Offer, the Equity Shares in the Fresh Issue will be issued prior to the sale of
Equity Shares in the Offer for Sale.

If there is a delay beyond the prescribed time after the Issuer becomes liable to pay or unblock the
amount received from Bidders, then the Issuer and every director of the Issuer who is an officer in
default may on and from expiry of 15 Working Days, be jointly and severally liable to repay the
money, with interest at the rate of 15% per annum in accordance with the Companies (Prospectus and
Allotment of Securities) Rules, 2014, as amended.

8.2.3 MINIMUM NUMBER OF ALLOTTEES

The Issuer may ensure that the number of prospective Allottees to whom Equity Shares may be allotted
may not be less than 1,000 failing which the entire application monies may be refunded forthwith.

8.2.4 IN CASE OF ISSUES MADE UNDER COMPULSORY BOOK BUILDING

In case an Issuer not eligible under Regulation 26(1) of the SEBI ICDR Regulations, 2009 comes for
an Offer under Regulation 26(2) of SEBI (ICDR) Regulations, 2009 but fails to Allot not less than 75%
of the Net Offer to QIBs, in such case full subscription money is to be refunded.

8.3 MODE OF REFUND

(a) In case of Bids/Applications (other than Anchor Investors): Within six Working Days of
the Bid/Offer Closing Date, the Registrar to the Offer may give instructions to SCSBs for
unblocking the amount in ASBA Account on unsuccessful Bid/Application and also for any
excess amount blocked on Bidding/Application.

(b) In case of Anchor Investors: Within six Working Days of the Bid/Offer Closing Date, the
Registrar to the Offer may dispatch the refund orders for all amounts payable to unsuccessful
Anchor Investors.

229
 (c) In case of Anchor Investors, the Registrar to the Offer may obtain from the depositories, the
Bidders/Applicants’ bank account details, including the MICR code, on the basis of the DP
ID, Client ID and PAN provided by the Anchor Investors in their Anchor Investor Application
Forms for refunds. Accordingly, Anchor Investors are advised to immediately update their
details as appearing on the records of their depositories. Failure to do so may result in delays
in dispatch of refund orders or refunds through electronic transfer of funds, as applicable, and
any such delay may be at the Anchor Investors’ sole risk and neither the Issuer, the Registrar
to the Offer, the Escrow Collection Banks, or the Syndicate, may be liable to compensate the
Anchor Investors for any losses caused to them due to any such delay, or liable to pay any
interest for such delay. Please note that refunds shall be credited only to the bank account
from which the Bid Amount was remitted to the Escrow Bank.

8.3.1 Electronic mode of making refunds for Anchor Investors

The payment of refund, if any, may be done through various electronic modes as mentioned below:

(a) NEFT—Payment of refund may be undertaken through NEFT wherever the branch of the
Anchor Investors’ bank is NEFT enabled and has been assigned the Indian Financial System
Code (“IFSC”), which can be linked to the MICR of that particular branch. The IFSC Code
may be obtained from the website of RBI as at a date prior to the date of payment of refund,
duly mapped with MICR numbers. Wherever the Anchor Investors have registered their nine
digit MICR number and their bank account number while opening and operating the demat
account, the same may be duly mapped with the IFSC Code of that particular bank branch and
the payment of refund may be made to the Anchor Investors through this method. In the event
NEFT is not operationally feasible, the payment of refunds may be made through any one of
the other modes as discussed in this section;

(b) Direct Credit—Anchor Investors having their bank account with the Refund Banker may be
eligible to receive refunds, if any, through direct credit to such bank account;

(c) RTGS—Anchor Investors having a bank account at any of the centres notified by SEBI where
clearing houses are managed by the RBI, may have the option to receive refunds, if any,
through RTGS; and

Please note that refunds through the abovementioned modes shall be credited only to the bank
account from which the Bid Amount was remitted to the Escrow Bank.

For details of levy of charges, if any, for any of the above methods, Bank charges, if any, for
cashing such cheques, pay orders or demand drafts at other centres, etc. Anchor Investors may
refer to RHP/Prospectus.

8.4 INTEREST IN CASE OF DELAY IN ALLOTMENT OR REFUND

The Issuer may pay interest at the rate of 15% per annum where the refund or portion thereof is made
in electronic manner, the refund instructions have not been given to the clearing system in the disclosed
manner and/or demat credits are not made to Bidders/Applicants or instructions for unblocking of
funds in the ASBA Account are not dispatched within the six Working days of the Bid/Offer Closing
Date. The Issuer may pay interest at 15% per annum for any delay beyond 15 days from the Bid/Offer
Closing Date, if Allotment is not made.

SECTION 9: GLOSSARY AND ABBREVIATIONS

Unless the context otherwise indicates or implies, certain definitions and abbreviations used in this document
may have the meaning as provided below. References to any legislation, act or regulation may be to such
legislation, act or regulation as amended from time to time.

Term Description
Allotment/Allot/Allotted The allotment of Equity Shares pursuant to the Offer to successful
Bidders/Applicants
Allotment Advice Note or advice or intimation of Allotment sent to the Bidders/Applicants who have
been Allotted Equity Shares after the Basis of Allotment has been approved by the
designated Stock Exchanges
Allottees An Bidder/Applicant to whom the Equity Shares are Allotted

230
 Term Description
Anchor Investor A Qualified Institutional Buyer, applying under the Anchor Investor Portion in
accordance with the requirements specified in SEBI ICDR Regulations, 2009 and the
Red Herring Prospectus.
Anchor Investor The form used by an Anchor Investor to make a Bid in the Anchor Investor Portion
Application Form and which will be considered as an application for Allotment in terms of the Red
Herring Prospectus and Prospectus
Anchor Investor Portion Up to 60% of the QIB Category which may be allocated by the Issuer in consultation
with the BRLM, to Anchor Investors on a discretionary basis. One-third of the
Anchor Investor Portion is reserved for domestic Mutual Funds, subject to valid Bids
being received from domestic Mutual Funds at or above the price at which allocation
is being done to Anchor Investors
Application Form The form in terms of which the Applicant should make an application for Allotment
in case of issues other than Book Built Issues, includes Fixed Price Issue
Application Supported An application, whether physical or electronic, used by Bidders/Applicants, other
by Blocked Amount / than Anchor Investors, to make a Bid and authorising an SCSB to block the Bid
ASBA Amount in the specified bank account maintained with such SCSB
ASBA Account Account maintained with an SCSB which may be blocked by such SCSB to the
extent of the Bid Amount of the Bidder/Applicant
Banker(s) to the The banks which are clearing members and registered with SEBI as Banker to the
Offer/Escrow Collection Offer with whom the Escrow Account(s) for Anchor Investors may be opened, and
Bank(s)/Collecting as disclosed in the RHP/Prospectus and Bid cum Application Form of the Issuer
Banker
Basis of Allotment The basis on which the Equity Shares may be Allotted to successful
Bidders/Applicants under the Offer
Bid An indication to make an offer during the Bid/Offer Period by a prospective Bidder
pursuant to submission of Bid cum Application Form or during the Anchor Investor
Bid/Offer Period by the Anchor Investors, to subscribe for or purchase the Equity
Shares of the Issuer at a price within the Price Band, including all revisions and
modifications thereto. In case of issues undertaken through the fixed price process,
all references to a Bid should be construed to mean an Application
Bid Amount The highest value of the optional Bids indicated in the Bid cum Application Form
and payable by the Bidder/Applicant upon submission of the Bid (except for Anchor
Investors), less discounts (if applicable). In case of issues undertaken through the
fixed price process, all references to the Bid Amount should be construed to mean
the Application Amount
Bid/Offer Closing Date Except in the case of Anchor Investors (if applicable), the date after which the
Designated Intermediaries may not accept any Bids for the Offer, which may be
notified in an English national daily, a Hindi national daily and a regional language
newspaper at the place where the registered office of the Issuer is situated, each with
wide circulation. Applicants/Bidders may refer to the RHP/Prospectus for the
Bid/Offer Closing Date
Bid/Offer Opening Date The date on which the Designated Intermediaries may start accepting Bids for the
Offer, which may be the date notified in an English national daily, a Hindi national
daily and a regional language newspaper at the place where the registered office of
the Issuer is situated, each with wide circulation. Applicants/Bidders may refer to the
RHP/Prospectus for the Bid/Offer Opening Date
Bid/Offer Period Except in the case of Anchor Investors (if applicable), the period between the
Bid/Offer Opening Date and the Bid/Offer Closing Date inclusive of both days and
during which prospective Bidders/Applicants (other than Anchor Investors) can
submit their Bids, inclusive of any revisions thereof. The Issuer may consider
closing the Bid/Offer Period for QIBs one working day prior to the Bid/Offer
Closing Date in accordance with the SEBI ICDR Regulations, 2009.
Applicants/Bidders may refer to the RHP/Prospectus for the Bid/Offer Period
Bid cum Application An application form, whether physical or electronic, used by Bidders, other than
Form Anchor Investors, to make a Bid and which will be considered as the application for
Allotment in terms of the Red Herring Prospectus and the Prospectus
Bidder/Applicant Any prospective investor who makes a Bid pursuant to the terms of the
RHP/Prospectus and the Bid cum Application Form. In case of issues undertaken
through the fixed price process, all references to a Bidder/Applicant should be
construed to mean an Bidder/Applicant
Book Built Process/ The book building process as provided under SEBI ICDR Regulations, 2009, in

231
 Term Description
Book Building Process/ terms of which the Offer is being made
Book Building Method
Broker Centres Broker centres notified by the Stock Exchanges, where Bidders/Applicants can
submit the Bid cum Application Forms to a Registered Broker. The details of such
broker centres, along with the names and contact details of the Registered Brokers
are available on the websites of the Stock Exchanges.
BRLM(s)/ Book The Book Running Lead Manager to the Offer as disclosed in the RHP/Prospectus
Running Lead and the Bid cum Application Form of the Issuer. In case of issues undertaken
Manager(s)/ Lead through the fixed price process, all references to the Book Running Lead Manager
Manager/LM should be construed to mean the Lead Manager or LM
Business Day Monday to Saturday (except 2nd and 4th Saturday of a month and public holidays)
CAN/Confirmation of The note or advice or intimation sent to each successful Bidder/Applicant indicating
Allotment Note the Equity Shares which may be Allotted, after approval of Basis of Allotment by
the Designated Stock Exchange
Cap Price The higher end of the Price Band, above which the Offer Price and the Anchor
Investor Offer Price may not be finalised and above which no Bids may be accepted
Client ID Client Identification Number maintained with one of the Depositories in relation to
demat account
Collecting Depository A depository participant as defined under the Depositories Act, 1996, registered with
Participant or CDPs SEBI and who is eligible to procure Bids at the Designated CDP Locations in terms
of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued
by SEBI
Cut-off Price Offer Price, finalised by the Issuer in consultation with the Book Running Lead
Manager(s), which can be any price within the Price Band. Only RIIs, Retail
Individual Shareholders and employees are entitled to Bid at the Cut-off Price. No
other category of Bidders/Applicants are entitled to Bid at the Cut-off Price
DP Depository Participant
DP ID Depository Participant’s Identification Number
Depositories National Securities Depository Limited and Central Depository Services (India)
Limited
Demographic Details Details of the Bidders/Applicants including the Bidder/Applicant’s address, name of
the Applicant’s father/husband, investor status, occupation and bank account details
Designated Branches Such branches of the SCSBs which may collect the Bid cum Application Forms used
by Bidders/Applicants (excluding Anchor Investors) and a list of which is available
on http://www.sebi.gov.in/cms/sebi_data/attachdocs/1316087201341.html
Designated CDP Such locations of the CDPs where Bidders can submit the Bid cum Application
Locations Forms to Collecting Depository Participants.

The details of such Designated CDP Locations, along with names and contact details
of the Collecting Depository Participants eligible to accept Bid cum Application
Forms are available on the respective websites of the Stock Exchanges
(www.bseindia.com and www.nseindia.com)
Designated Date The date on which funds are transferred by the Escrow Collection Bank(s) from the
Escrow Account and the amounts blocked by the SCSBs are transferred from the
ASBA Accounts, as the case may be, to the Public Issue Account or the Refund
Account, as appropriate, after the Prospectus is filed with the RoC, following which
the board of directors may Allot Equity Shares to successful Bidders/Applicants in
the Fresh Issue may give delivery instructions for the transfer of the Equity Shares
constituting the Offer for Sale
Designated Syndicate Members, Sub-Syndicate/Agents, SCSBs, Registered Brokers, Brokers,
Intermediaries the CDPs and RTAs, who are authorized to collect Bid cum Application Forms from
Collecting Agent the Bidders, in relation to the Offer
Designated RTA Such locations of the RTAs where Bidders can submit the Bid cum Application
Locations Forms to RTAs.

The details of such Designated RTA Locations, along with names and contact details
of the RTAs eligible to accept Bid cum Application Forms are available on the
respective websites of the Stock Exchanges (www.bseindia.com and
www.nseindia.com)
Designated Stock The designated stock exchange as disclosed in the RHP/Prospectus of the Issuer
Exchange

232
 Term Description
Discount Discount to the Offer Price that may be provided to Bidders/Applicants in
accordance with the SEBI ICDR Regulations, 2009.
Draft Prospectus The draft prospectus filed with SEBI in case of Fixed Price Issues and which may
mention a price or a Price Band
Employees Employees of an Issuer as defined under SEBI ICDR Regulations, 2009 and
including, in case of a new company, persons in the permanent and full time
employment of the promoting companies excluding the promoters and immediate
relatives of the promoters. For further details, Bidder/Applicant may refer to the
RHP/Prospectus
Equity Shares Equity Shares of the Issuer
Eligible NRI(s) NRI(s) from jurisdictions outside India where it is not unlawful to make an offer
or invitation under the Offer and in relation to whom the Bid cum Application
Form and the Red Herring Prospectus will constitute an invitation to purchase the
Equity Shares
Escrow Account Account opened with the Escrow Collection Bank(s) and in whose favour the
Anchor Investors may issue cheques or demand drafts or transfer money through
NEFT or RTGS in respect of the Bid Amount when submitting a Bid
Escrow Agreement Agreement to be entered into among the Issuer, the Registrar to the Offer, the Book
Running Lead Manager(s), the Syndicate Member(s), the Escrow Collection Bank(s)
and the Refund Bank(s) for collection of the Bid Amounts from Anchor Investors
and where applicable, remitting refunds of the amounts collected to the Anchor
Investors on the terms and conditions thereof
Escrow Collection Refer to definition of Banker(s) to the Offer
Bank(s)
First Bidder/Applicant The Bidder/Applicant whose name appears first in the Bid cum Application Form or
Revision Form
Fixed Price Issue/Fixed The Fixed Price process as provided under SEBI ICDR Regulations, 2009, in terms
Price Process/Fixed of which the Offer is being made
Price Method
Floor Price The lower end of the Price Band, at or above which the Offer Price and the Anchor
Investor Offer Price may be finalised and below which no Bids may be accepted,
subject to any revision thereto
Foreign Venture Capital Foreign Venture Capital Investors as defined and registered with SEBI under the
Investors or FVCIs SEBI (Foreign Venture Capital Investors) Regulations, 2000
IPO Initial public offering
Issuer/Company The Issuer proposing the initial public offering/further public offering as applicable
Maximum RII Allottees The maximum number of RIIs who can be Allotted the minimum Bid Lot. This is
computed by dividing the total number of Equity Shares available for Allotment to
RIIs by the minimum Bid Lot.
MICR Magnetic Ink Character Recognition - nine-digit code as appearing on a cheque leaf
Mutual Fund A mutual fund registered with SEBI under the SEBI (Mutual Funds) Regulations,
1996
Mutual Funds Portion 5% of the QIB Category (excluding the Anchor Investor Portion) available for
allocation to Mutual Funds only, being such number of equity shares as disclosed in
the RHP/Prospectus and Bid cum Application Form
NEFT National Electronic Fund Transfer
Net Offer The Offer less reservation portion
Non-Institutional All Bidders/Applicants, including sub accounts of FIIs registered with SEBI which
Investors or NIIs are foreign corporates or foreign individuals and FPIs which are Category III foreign
portfolio investors, that are not QIBs or RIBs and who have Bid for Equity Shares
for an amount of more than ₹200,000 (but not including NRIs other than Eligible
NRIs)
Non-Institutional The portion of the Offer being such number of Equity Shares available for allocation
Category to NIIs on a proportionate basis and as disclosed in the RHP/Prospectus and the Bid
cum Application Form
Non-Resident A person resident outside India, as defined under the FEMA and includes an NRI,
FPIs registered with SEBI and FVCIs registered with SEBI
OCB/Overseas A company, partnership, society or other corporate body owned directly or indirectly
Corporate Body to the extent of at least 60% by NRIs including overseas trusts, in which not less
than 60% of beneficial interest is irrevocably held by NRIs directly or indirectly and

233
 Term Description
which was in existence on October 3, 2003 and immediately before such date had
taken benefits under the general permission granted to OCBs under FEMA
Offer Public issue of Equity Shares of the Issuer including the Offer for Sale if applicable
Offer for Sale Public offer of such number of Equity Shares as disclosed in the RHP/Prospectus
through an offer for sale by the Selling Shareholder
Other Investors Investors other than Retail Individual Investors in a Fixed Price Issue. These include
individual applicants other than retail individual investors and Other Investors
including corporate bodies or institutions irrespective of the number of specified
securities applied for
Offer Price The final price, less discount (if applicable) at which the Equity Shares may be
Allotted to Bidders other than Anchor Investors, in terms of the Prospectus. Equity
Shares will be Allotted to Anchor Investors at the Anchor Investor Offer Price The
Offer Price may be decided by the Issuer in consultation with the Book Running
Lead Manager(s)
PAN Permanent Account Number allotted under the Income Tax Act, 1961
Price Band Price Band with a minimum price, being the Floor Price and the maximum price,
being the Cap Price and includes revisions thereof. The Price Band and the minimum
Bid lot size for the Offer may be decided by the Issuer in consultation with the Book
Running Lead Manager(s) and advertised, at least five working days in case of an
IPO and one working day in case of FPO, prior to the Bid/Offer Opening Date, in
English national daily, Hindi national daily and regional language at the place where
the registered office of the Issuer is situated, newspaper each with wide circulation
Pricing Date The date on which the Issuer in consultation with the Book Running Lead
Manager(s), finalise the Offer Price
Prospectus The prospectus to be filed with the RoC in accordance with Section 26 of the
Companies Act, 2013 after the Pricing Date, containing the Offer Price, the size of
the Offer and certain other information
Public Issue Account An account opened with the Banker to the Offer to receive monies from the Escrow
Account and from the ASBA Accounts on the Designated Date
QIB Category The portion of the Offer being such number of Equity Shares to be Allotted to QIBs
on a proportionate basis
Qualified Institutional As defined under SEBI ICDR Regulations, 2009
Buyers or QIBs
RTGS Real Time Gross Settlement
Red Herring The red herring prospectus issued in accordance with Section 32 of the Companies
Prospectus/RHP Act, 2013, which does not have complete particulars of the price at which the Equity
Shares are offered and the size of the Offer. The RHP may be filed with the RoC at
least three days before the Bid/Offer Opening Date and may become a Prospectus
upon filing with the RoC after the Pricing Date. In case of issues undertaken through
the fixed price process, all references to the RHP should be construed to mean the
Prospectus
Refund Account(s) The account opened with Refund Bank(s), from which refunds to Anchor Investors,
if any, of the whole or part of the Bid Amount may be made
Refund Bank(s) Refund bank(s) as disclosed in the RHP/Prospectus and Bid cum Application Form
of the Issuer
Refunds through Refunds through Direct Credit, NEFT, RTGS or ASBA, as applicable
electronic transfer of
funds
Registrar and Share Registrar and share transfer agents registered with SEBI and eligible to procure Bids
Transfer Agents or at the Designated RTA Locations in terms of circular no.
RTAs CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI
Registered Broker Stock Brokers registered with the Stock Exchanges having nationwide terminals,
other than the members of the Syndicate
Registrar to the Offer/ The Registrar to the Offer as disclosed in the RHP/Prospectus and Bid cum
RTO Application Form
Reserved Category/ Categories of persons eligible for making application/Bidding under reservation
Categories portion, if any
Reservation Portion The portion of the Offer reserved for such category of eligible Bidders/Applicants as
provided under the SEBI ICDR Regulations, 2009
Retail Individual Investors who applies or bids for a value of not more than ₹200,000 (including

234
 Term Description
Investors/(RIIs) HUFs applying through their karta and eligible NRIs and does not include NRIs
other than Eligible NRIs.
Retail Individual Shareholders of a listed Issuer who applies or bids for a value of not more than
Shareholders ₹200,000.
Retail Portion The portion of the Offer being such number of Equity Shares available for allocation
to RIIs which shall not be less than the minimum Bid Lot, subject to availability in
RII category and the remaining shares to be Allotted on proportionate basis.
Revision Form The form used by the Bidders, including ASBA Bidders, in an issue through Book
Building Process to modify the quantity of Equity Shares and/or bid price indicated
therein in any of their Bid cum Application Forms or any previous Revision Form(s)
RoC The Registrar of Companies
SEBI The Securities and Exchange Board of India constituted under the Securities and
Exchange Board of India Act, 1992
SEBI ICDR The Securities and Exchange Board of India (Issue of Capital and Disclosure
Regulations, 2009 Requirements) Regulations, 2009
Self Certified Syndicate A bank registered with SEBI, which offers the facility of ASBA and a list of which
Bank(s) or SCSB(s) is available on
http://www.sebi.gov.in/cms/sebi_data/attachdocs/1316087201341.html
Specified Locations Bidding centres where the Syndicate shall accept Bid cum Application Forms, a list
of which is available on the website of SEBI at
www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries and
updated from time to time
Stock Exchanges/SE The stock exchanges as disclosed in the RHP/Prospectus of the Issuer where the
Equity Shares Allotted pursuant to the Offer are proposed to be listed
Syndicate The Book Running Lead Manager(s) and the Syndicate Member
Syndicate Agreement The agreement to be entered into among the Issuer, and the Syndicate in relation to
collection of Bid cum Application Forms by Syndicate Members
Syndicate Member(s)/ The Syndicate Member(s) as disclosed in the RHP/Prospectus
SM
Underwriters The Book Running Lead Manager(s) and the Syndicate Member(s)
Underwriting The agreement amongst the Issuer, and the Underwriters to be entered into on or
Agreement after the Pricing Date
Working Day Any day, other than 2nd and 4th Saturday of the month, Sundays or public holidays,
on which commercial banks in Mumbai and Chennai are open for business, provided
however, with reference to (a) announcement of Price Band; and (b) Bid/Offer
Period, “Working Days” shall mean all days, excluding Saturdays, Sundays and
public holidays, which are working days for commercial banks in India.

235
 RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991 of the Government of
India and FEMA. While the Industrial Policy, 1991 prescribes the limits and the conditions subject to which
foreign investment can be made in different sectors of the Indian economy, FEMA regulates the precise manner
in which such investment may be made. Under the Industrial Policy, unless specifically restricted, foreign
investment is freely permitted in all sectors of Indian economy up to any extent and without any prior approvals,
but the foreign investor is required to follow certain prescribed procedures for making such investment. The
government bodies responsible for granting foreign investment approvals are FIPB and the RBI.

The Government has from time to time made policy pronouncements on FDI through press notes and press
releases. The Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government
of India (“DIPP”), issued Consolidated FDI Policy Circular of 2016, which with effect from June 7, 2016,
consolidates and supersedes all previous press notes, press releases and clarifications on FDI issued by the DIPP
that were in force and effect as on June 7, 2016. The Government proposes to update the consolidated circular
on FDI Policy once every year and therefore, Consolidated FDI Policy Circular of 2016 will be valid until the
DIPP issues an updated circular.

The transfer of shares between an Indian resident and a non-resident does not require the prior approval of the
FIPB or the RBI, provided that (i) the activities of the investee company are under the automatic route under the
foreign direct investment (“FDI”) Policy and transfer does not attract the provisions of the Takeovers
Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI policy; and (iii) the
pricing is in accordance with the guidelines prescribed by the SEBI/RBI.

As per the existing policy of the Government of India, OCBs cannot participate in this Offer.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities
laws in the United States and may not be offered or sold within the United States or to, or for the account or
benefit of, U.S. persons (as defined in Regulation S) except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws in the
United States.

Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in
compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where
those offers and sales occur.

The above information is given for the benefit of the Bidders. Our Company, the Selling Shareholders and the
BRLM are not liable for any amendments or modification or changes in applicable laws or regulations, which
may occur after the date of this Draft Red Herring Prospectus. Bidders are advised to make their independent
investigations and that the number of Equity Shares Bid for do not exceed the applicable limits under laws or
regulations.

236
 SECTION VIII: MAIN PROVISIONS OF THE ARTICLES OF THE ASSOCIATION

Set forth below is certain information relating to our share capital, voting rights, dividend, lien, forfeiture,
restrictions on transfer and transmission of Equity Shares or debentures and/ or on their consolidation/ splitting
and other important terms of Articles of Association of our Company. Please note that each provision herein
below is numbered as per the corresponding article number in the Articles of Association and capitalized/
defined terms herein have the same meaning given to them in the Articles of Association.

Capitalized terms used in this section have the meaning that has been given to such terms in the Articles of
Association of our Company. Pursuant to Schedule I of the Companies Act, 2013 and the SEBI ICDR
Regulations, the main provisions of the Articles of Association of our Company are detailed below:

TABLE ‘F’ EXCLUDED

1.(i) The regulations contained in the Table marked ‘F’ in Schedule I to the Companies Act, 2013 shall not
apply to the Company, except in so far as the same are repeated contained or expressly made applicable
in these Articles or by the said Act.

(ii) The regulations for the management of the Company and for the observance by the members thereto
and their representatives, shall, subject to any exercise of the statutory powers of the Company with
reference to the deletion or alteration of or addition to its regulations by resolution as prescribed or
permitted by the Companies Act, 2013, be such as are contained in these Articles.

Share capital and variation of rights

2. (a) The Authorised Share Capital of the Company shall be such amount and be divided into such shares
as may from time to time, be provided in clause V of Memorandum of Association. with power to
Board of Directors to reclassify, subdivide, consolidate and increase and with power from time to
time, to issue any shares of the original capital or any new capital with and subject to any
preferential, qualified or special rights, privileges, or conditions may be, thought fit and upon the
sub-division of shares to apportion the right to participate in profits, in any manner as between the
shares resulting from sub-division.

(b) If and whenever the capital of the Company is divided into shares of different classes, the tights of
any such class may be varied, modified, affected, extended, abrogated or surrendered as provided
by the said Act or by Articles of Association or by the terms of issue, but not further or otherwise.

(c) Subject to the provisions of the Act and these Articles, the shares in the capital of the Company
shall be under the control of the Board who may issue, allot or otherwise dispose of the same or any
of them to such persons, in such proportion and on such terms and conditions and either at a
premium or at par and at such time as they may from time to time think fit.

4. Subject to the provisions of the Act and these Articles, the Board may issue and allot shares in the
capital of the Company on payment or part payment for any property or assets of any kind whatsoever
sold or transferred, goods or machinery supplied or for services rendered to the Company in the
conduct of its business and any shares which may be so allotted may be issued as fully paid-up or
partly paid-up otherwise than for cash, and if so issued, shall be deemed to be fully paid-up or partly
paid-up shares, as the case may be.

5. 1. The Company may issue the following kinds of shares in accordance with these Articles, the
Act, the Rules and other applicable laws:
(a) Equity share capital:

(i) with voting rights; and / or

(ii) with differential rights as to dividend, voting or otherwise in accordance

with the Rules; and

(b) Preference share capital.

2. To raise money in such manner as the Company shall think fit, and in particular by the issue
of fresh shares or equity or equivalent in India or abroad that would result in listing in stock
exchanges in the respective places of issue of such equity or equivalent.

6. 1. Every person whose name is entered as a member in the register of members shall be

237
 entitled to receive within two months after allotment or within one month from the date of
receipt by the Company of the application for the registration of transfer or transmission or
within such other period as the conditions of issue shall provide

(a) one certificate for all his shares without payment of any charges; or
(b) several certificates, each for one or more of his shares, upon payment of such charges
as may be fixed by the Board for each certificate after the first.

2. Every certificate shall be under the seal and shall specify the shares to which it relates and the
amount paid-up thereon.

3. In respect of any share or shares held jointly by several persons, the Company shall not be
bound to issue more than one certificate, and delivery of a certificate for a share to one of
several joint holders shall be sufficient delivery to all such holders.

4. A person subscribing to shares offered by the Company shall have the option either to receive
certificates for such shares or hold the shares in a dematerialised state with a depository.
Where a person opts to hold any share with the depository, the Company shall intimate such
depository the details of allotment of the share to enable the depository to enter in its records
the name of such person as the beneficial owner of that share.

5. If any share certificate be worn out, defaced, mutilated or torn or if there be no further space
on the back for endorsement of transfer, then upon production and surrender thereof to the
Company, a new certificate may be issued in lieu thereof, and if any certificate is lost or
destroyed then upon proof thereof to the satisfaction of the Company and on execution of such
indemnity as the Board deems adequate, a new certificate in lieu thereof shall be given. Every
certificate under this Article shall be issued on payment of fees for each certificate as may be
fixed by the Board.

6. The provisions of the foregoing Articles relating to issue of certificates shall mutatis mutandis
apply to issue of certificates for any other securities including debentures (except where the
Act otherwise requires) of the Company.

7. 1. The Company may exercise the powers of paying commissions conferred by the Act,
to any person in connection with the subscription to its securities, provided that the rate per
cent or the amount of the commission paid or agreed to be paid shall be disclosed in the
manner required by the Act and the Rules.

2. The rate or amount of the commission shall not exceed the rate or amount prescribed in the
Rules.

3. The commission may be satisfied by the payment of cash or the allotment of fully or partly
paid shares or partly in the one way and partly in the other.

8. 1. If at any time the share capital is divided into different classes of shares, the rights attached to
any class (unless otherwise provided by the terms of issue of the shares of that class) may,
subject to the provisions of the Act, and whether or not the Company is being wound up, be
varied with the consent in writing, of such number of the holders of the issued shares of that
class, or with the sanction of a resolution passed at a separate meeting of the holders of the
shares of that class, as prescribed by the Act.

2. To every such separate meeting, the provisions of these Articles relating to general meetings
shall mutatis mutandis apply.

9. The rights conferred upon the holders of the shares of any class issued with preferred or other rights
shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be
deemed to be varied by the creation or issue of further shares ranking pari passu therewith.

10. Subject to the provisions of the Act, the Board shall have the power to issue or re-issue preference
shares of one or more classes which are liable to be redeemed, or converted to equity shares, on such
terms and conditions and in such manner as determined by the Board in accordance with the Act.

11. (1) The Board or the Company, as the case may be, may, in accordance with the Act and the
Rules, issue further shares to –

238
 (a) persons who, at the date of offer, are holders of equity shares of the Company; such
offer shall be deemed to include a right exercisable by the person concerned to
renounce the shares offered to him or any of them in favour of any other person; or

(b) employees under any scheme of employees’ stock option; or

(c) any persons, whether or not those persons include the persons referred to in clause (a)
or clause (b) above.

(2) A further issue of shares may be made in any manner whatsoever as the Board may determine
including by way of preferential offer or private placement, subject to and in accordance with
the Act and the Rules.

12. 1. Except as provided by the Act, the Company shall not, except by reduction of capital
under the provision of Sections 66 or Section 242 of the said Act, buy its own shares nor give,
whether directly or indirectly, and whether by means of a loan, guarantee, provision of
security or otherwise any financial assistance for the purpose of or in connection with a
purchase or subscription made or to be made by any person of or for any shares in the
Company or in its holding company. Provided that nothing in this Article shall be taken to
prohibit:

i. the provision of money in accordance with any scheme approved by the Company
through Special Resolution and in accordance with the requirements specified in the
relevant Rules, for the purchase of, or subscription for, fully paid up Shares in the
Company, if the purchase of, or the subscription for the Shares held by trustees for
the benefit of the employees or such Shares held by the employee of the Company;

ii. the giving of loans by the Company to persons in the employment of the Company
other than its Directors or Key Managerial Personnel, for an amount not exceeding
their salary or wages for a period of six months with a view to enabling them to
purchase or subscribe for fully paid up Shares in the Company to be held by them by
way of beneficial ownership. Nothing in this clause shall affect the right of the
Company to redeem any shares issued under Section 55.

2. Notwithstanding what is stated in Articles 12.1 above, in the event it is permitted by the Law
and subject to such conditions, approvals or consents as may be laid down for the purpose, the
Company shall have the power to buy-back its own shares, whether or not there is any
consequent reduction of Capital. If and to the extent permitted by Law, the Company shall
also have the power to re-issue the shares so bought back

13. The Company shall have power to issue Securities at a premium and shall duly comply with the
provision of Sections 52 of the said Act.

14. 1. Subject to the provisions of Section 55 of the said Act, whenever any preference shares are
issued which are or at the option of the Company are to be liable to be redeemed, thefollowing
provisions shall take effect

i. No such shares shall be redeemed except out of the profits of the Company which
would otherwise be available for dividend or out of the proceeds of a fresh issue of
shares made for the purposes of the redemption.
ii. No such shares shall be redeemed unless are fully paid.
iii. The premium, if any payable on redemption must be provided for out of the profits of
the Company or out of the Company’s Securities Premium Account before the shares
are redeemed.
iv. Where any such shares are redeemed otherwise than out of the proceeds of a fresh
issue there shall, out of profits which would otherwise have been available for
dividend be transferred to the Capital Redemption Reserve Account, a sum equal to
the nominal amount of the share redeemed.
2. Subject to the provisions of Section 55 of the Act and these Articles the redemption of
preference shares hereunder may be effected in accordance with the terms and conditions of
their issue and in the absence of any such terms and conditions in such manner as the
Directors may think fit.

239
 3. The redemption of preference shares under this provision by the Company shall not be taken
as reducing the amount of its authorised share capital.

4. Where the Company has redeemed or is about to redeem any preference shares, it shall never
have power to issue shares up to the nominal amount of the shares redeemed or to be
redeemed as if those shares had never been issued; and accordingly the share capital of the
Company shall not, for the purpose of calculating the fees payable under Section 385 of the
said Act, be deemed to be increased by the issue of shares in pursuance of this Article.
Provided that, where new shares are issued before the redemption of the old shares, the new
shares shall not so far as related to stamp duty, be deemed to have been issued in pursuance of
this Article unless the old shares are redeemed within one month after the issue of the new
shares.

5. The Capital Redemption Reserve Account may, notwithstanding anything in this Article, be
applied by the Company, in paying up unissued shares of the Company to be issued to
members of the Company as fully paid bonus shares.

Lien
15. 1. The Company shall have a first and paramount lien –

(a) on every share (not being a fully paid share), for all monies (whether presently
payable or not) called, or payable at a fixed time, in respect of that share; and

(b) on all shares (not being fully paid shares) standing registered in the name of a
member, for all monies presently payable by him or his estate to the Company:
Provided that the Board may at any time declare any share to be wholly or in part
exempt from the provisions of this clause.

2. The Company’s lien, if any, on a share shall extend to all dividends or interest, as the case
may be, payable and bonuses declared from time to time in respect of such shares for any
money owing to the Company.

3. Unless otherwise agreed by the Board, the registration of a transfer of shares shall operate as a
waiver of the Company’s lien. * The fully paid up shares shall be free from all lien and that in
case of partly paid shares, the Company’s lien shall be restricted to money called or payable at
a fixed price in respect of such shares

* Clause 15 (1)(3) has been amended vide Special resolution passed in the Annual
General Meeting held on April 27, 2016

16. The Company may sell, in such manner as the Board thinks fit, any shares on which the Company has a
lien: Provided that no sale shall be made—

(a) unless a sum in respect of which the lien exists is presently payable; or
(b) until the expiration of fourteen days after a notice in writing stating and demanding payment
of such part of the amount in respect of which the lien exists as is presently payable, has been
given to the registered holder for the time being of the share or to the person entitled thereto
by reason of his death or insolvency or otherwise.

17. 1. To give effect to any such sale, the Board may authorise some person to transfer the shares
sold to the purchaser thereof.

2. The purchaser shall be registered as the holder of the shares comprised in any such transfer.

3. The receipt of the Company for the consideration (if any) given for the share on the sale
thereof shall (subject, if necessary, to execution of an instrument of transfer or a transfer by
relevant system, as the case may be) constitute a good title to the share and the purchaser shall
be registered as the holder of the share.
4. The purchaser shall not be bound to see to the application of the purchase money, nor shall his
title to the shares be affected by any irregularity or invalidity in the proceedings with reference
to the sale.

18. 1. The proceeds of the sale shall be received by the Company and applied in payment of such
part of the amount in respect of which the lien exists as is presently payable.

2. The residue, if any, shall, subject to a like lien for sums not presently payable as existed upon

240
 the shares before the sale, be paid to the person entitled to the shares at the date of the sale.

19. In exercising its lien, the Company shall be entitled to treat the registered holder of any share as the
absolute owner thereof and accordingly shall not (except as ordered by a court of competent
jurisdiction or unless required by any statute) be bound to recognise any equitable or other claim to, or
interest in, such share on the part of any other person, whether a creditor of the registered holder or
otherwise. The Company’s lien shall prevail notwithstanding that it has received notice of any such
claim.

20. The provisions of these Articles relating to lien shall mutatis mutandis apply to any other securities
including debentures of the Company.

Calls on shares

21. 1. The Board may, from time to time, make calls upon the members in respect of any monies
unpaid on their shares (whether on account of the nominal value of the shares or by way of
premium) and not by the conditions of allotment thereof made payable at fixed times. *
Provided that the Board shall not give the option or right to call on shares to any person except
with the sanction of the Company in the General Meeting

* Clause 21(1) has been amended vide Special resolution passed in the Annual General
Meeting held on April 27, 2016

2. Each member shall, subject to receiving at least fourteen days’ notice specifying the time or
times and place of payment, pay to the Company, at the time or times and place so specified,
the amount called on his shares.

3. The Board may, from time to time, at its discretion, extend the time fixed for the payment of
any call in respect of one or more members as the Board may deem appropriate in any
circumstances.

4. A call may be revoked or postponed at the discretion of the Board.

22. A call shall be deemed to have been made at the time when the resolution of the Board authorising the
call was passed and may be required to be paid by instalments.

23. The joint holders of a share shall be jointly and severally liable to pay all calls in respect
thereof.

24. 1. If a sum called in respect of a share is not paid before or on the day appointed for
payment thereof (the “due date”), the person from whom the sum is due shall pay interest
thereon from the due date to the time of actual payment at such rate as may be fixed by the
Board.

2. The Board shall be at liberty to waive payment of any such interest wholly or in part.

25. 1. Any sum which by the terms of issue of a share becomes payable on allotment or at any fixed
date, whether on account of the nominal value of the share or by way of premium, shall, for
the purposes of these Articles, be deemed to be a call duly made and payable on the date on
which by the terms of issue such sum becomes payable.

2. In case of non-payment of such sum, all the relevant provisions of these Articles as to
payment of interest and expenses, forfeiture or otherwise shall apply as if such sum had
become payable by virtue of a call duly made and notified.

26. The Board –

a. may, if it thinks fit, receive from any member willing to advance the same, all or any part of
the monies uncalled and unpaid upon any shares held by him; and

b. upon all or any of the monies so advanced, may (until the same would, but for such advance,

241
 become presently payable) pay interest at such rate as may be fixed by the Board. Nothing
contained in this clause shall confer on the member (a) any right to participate in profits or
dividends or (b) any voting rights in respect of the moneys so paid by him until the same
would, but for such payment, become presently payable by him.

27. If by the conditions of allotment of any shares, the whole or part of the amount of issue price thereof
shall be payable by instalments, then every such instalment shall, when due, be paid to the Company by
the person who, for the time being and from time to time, is or shall be the registered holder of the
share or the legal representative of a deceased registered holder.

28. All calls shall be made on a uniform basis on all shares falling under the same class.

Explanation: Shares of the same nominal value on which different amounts have been paid-up shall not
be deemed to fall under the same class.

29. Neither a judgment nor a decree in favour of the Company for calls or other moneys due in respect of
any shares nor any part payment or satisfaction thereof nor the receipt by the Company of a portion of
any money which shall from time to time be due from any member in respect of any shares either by
way of principal or interest nor any indulgence granted by the Company in respect of payment of any
such money shall preclude the forfeiture of such shares as herein provided.

30. The provisions of these Articles relating to calls shall mutatis mutandis apply to any other securities
including debentures of the Company.

Transfer of Shares

31. 1. The instrument of transfer of any share in the Company shall be duly executed by or on behalf
of both the transferor and transferee.

2. The transferor shall be deemed to remain a holder of the share until the name of the transferee
is entered in the register of members in respect thereof.

32. The Board may, subject to the right of appeal conferred by the Act decline to register -

(a) the transfer of a share, not being a fully paid share, to a person of whom they do not approve;
or

(b) any transfer of shares on which the Company has a lien.

33. In case of shares held in physical form, the Board may decline to recognise any instrument of transfer
unless –

(a) the instrument of transfer is duly executed and is in the form as prescribed in the Rules made
under the Act;
(b) the instrument of transfer is accompanied by the certificate of the shares to which it relates,
and such other evidence as the Board may reasonably require to show the right of the
transferor to make the transfer; and
(c) the instrument of transfer is in respect of only one class of shares.
*(d) There shall be a common form of transfer in accordance with the Act and Rules.

* Clause 33(d) has been inserted vide Special resolution passed in the Annual General Meeting
held on April 27, 2016

34. On giving of previous notice of at least seven days or such lesser period in accordance with the Act and
Rules made there under, the registration of transfers may be suspended at such times and for such
periods as the Board may from time to time determine:

Provided that such registration shall not be suspended for more than thirty days at any one time or for
more than forty five days in the aggregate in any year.

242
35. The provisions of these Articles relating to transfer of shares shall mutatis mutandis apply to any other
securities including debentures of the Company.

Transmission of Shares

36. 1. On the death of a member, the survivor or survivors where the member was a joint holder,
and his nominee or nominees or legal representatives where he was a sole holder, shall be the
only persons recognised by the Company as having any title to his interest in the shares.

2. Nothing in clause (1) shall release the estate of a deceased joint holder from any liability in
respect of any share which had been jointly held by him with other persons.

37. 1. Any person becoming entitled to a share in consequence of the death or insolvency of a
member may, upon such evidence being produced as may from time to time properly be
required by the Board and subject as hereinafter provided, elect, either -

a. to be registered himself as holder of the share; or

b. to make such transfer of the share as the deceased or insolvent member could have
made.

2 The Board shall, in either case, have the same right to decline or suspend registration as it
would have had, if the deceased or insolvent member had transferred the share before his
death or insolvency.
3. The Company shall be fully indemnified by such person from all liability, if any, by actions
taken by the Board to give effect to such registration or transfer.

38. 1. If the person so becoming entitled shall elect to be registered as holder of the share himself, he
shall deliver or send to the Company a notice in writing signed by him stating that he so
elects.

2. If the person aforesaid shall elect to transfer the share, he shall testify his election by
executing a transfer of the share.

3. All the limitations, restrictions and provisions of these regulations relating to the right to
transfer and the registration of transfers of shares shall be applicable to any such notice or
transfer as aforesaid as if the death or insolvency of the member had not occurred and the
notice or transfer were a transfer signed by that member.
39. A person becoming entitled to a share by reason of the death or insolvency of the holder shall be
entitled to the same dividends and other advantages to which he would be entitled if he were the
registered holder of the share, except that he shall not, before being registered as a member in respect
of the share, be entitled in respect of it to exercise any right conferred by membership in relation to
meetings of the Company: Provided that the Board may, at any time, give notice requiring any such
person to elect either to be registered himself or to transfer the share, and if the notice is not complied
with within ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other
monies payable in respect of the share, until the requirements of the notice have been complied with.
40. The provisions of these Articles relating to transmission by operation of law shall mutatis mutandis
apply to any other securities including debentures of the Company.

Forfeiture of Shares

41. If a member fails to pay any call, or instalment of a call or any money due in respect of any share, on
the day appointed for payment thereof, the Board may, at any time thereafter during such time as any
part of the call or instalment remains unpaid or a judgement or decree in respect thereof remains
unsatisfied in whole or in part, serve a notice on him requiring payment of so much of the call or
instalment or other money as is unpaid, together with any interest which may have accrued and all
expenses that may have been incurred by the Company by reason of non-payment.

42. The notice aforesaid shall:

a. Name a further day (not being earlier than the expiry of fourteen days from the date of service
of the notice) on or before which the payment required by the notice is to be made; and

243
 b. State that, in the event of non-payment on or before the day so named, the shares in respect of
which the call was made shall be liable to be forfeited.

43. If the requirements of any such notice as aforesaid are not complied with, any share in respect of which
the notice has been given may, at any time thereafter, before the payment required by the notice has
been made, be forfeited by a resolution of the Board to that effect.

44. Neither the receipt by the Company for a portion of any money which may from time to time be due
from any member in respect of his shares, nor any indulgence that may be granted by the Company in
respect of payment of any such money, shall preclude the Company from thereafter proceeding to
enforce a forfeiture in respect of such shares as herein provided. Such forfeiture shall include all
dividends declared or any other moneys payable in respect of the forfeited shares and not actually paid
before the forfeiture. * There shall be no forfeiture of unclaimed Dividends before the claim becomes
barred by Law.

* Clause 44 has been amended vide Special resolution passed in the Annual General Meeting held on
April 27, 2016

45. When any share shall have been so forfeited, notice of the forfeiture shall be given to the defaulting
member and an entry of the forfeiture with the date thereof, shall forthwith be made in the register of
members but no forfeiture shall be invalidated by any omission or neglect or any failure to give such
notice or make such entry as aforesaid.

46. The forfeiture of a share shall involve extinction at the time of forfeiture, of all interest in and all claims
and demands against the Company, in respect of the share and all other rights incidental to the share.

47. 1. A forfeited share shall be deemed to be the property of the Company and may be sold
or re-allotted or otherwise disposed of either to the person who was before such forfeiture the
holder thereof or entitled thereto or to any other person on such terms and in such manner as
the Board thinks fit.

2. At any time before a sale, re-allotment or disposal as aforesaid, the Board may cancel the
forfeiture on such terms as it thinks fit.

48. 1. A person whose shares have been forfeited shall cease to be a member in respect of the
Forfeited shares, but shall, notwithstanding the forfeiture, remain liable to pay, and shall pay,
to the Company all monies which, at the date of forfeiture, were presently payable by him to
the Company in respect of the shares.

2. All such monies payable shall be paid together with interest thereon at such rate as the Board
may determine, from the time of forfeiture until payment or realisation. The Board may, if it
thinks fit, but without being under any obligation to do so, enforce the payment of the whole
or any portion of the monies due, without any allowance for the value of the shares at the time
of forfeiture or waive payment in whole or in part.

3. The liability of such person shall cease if and when the Company shall have received payment
in full of all such monies in respect of the shares.

49. 1. A duly verified declaration in writing that the declarant is a director, the manager or the
secretary of the Company, and that a share in the Company has been duly forfeited on a date
stated in the declaration, shall be conclusive evidence of the facts therein stated as against all
persons claiming to be entitled to the share;

2. The Company may receive the consideration, if any, given for the share on any sale, re
allotment or disposal thereof and may execute a transfer of the share in favour of the person to
whom the share is sold or disposed of;

3. The transferee shall thereupon be registered as the holder of the share; and

244
 4. The transferee shall not be bound to see to the application of the purchase money, if any, nor
shall his title to the share be affected by any irregularity or invalidity in the proceedings in
reference to the forfeiture, sale, re-allotment or disposal of the share.

50. Upon any sale after forfeiture or for enforcing a lien in exercise of the powers hereinabove given, the
Board may, if necessary, appoint some person to execute an instrument for transfer of the shares sold
and cause the purchaser’s name to be entered in the register of members in respect of the shares sold
and after his name has been entered in the register of members in respect of such shares the validity of
the sale shall not be impeached by any person.

51. Upon any sale, re-allotment or other disposal under the provisions of the preceding Articles, the
certificate(s), if any, originally issued in respect of the relative shares shall (unless the same shall on
demand by the Company has been previously surrendered to it by the defaulting member) stand
cancelled and become null and void and be of no effect, and the Board shall be entitled to issue a
duplicate certificate(s) in respect of the said shares to the person(s) entitled thereto.

52. The Board may, subject to the provisions of the Act, accept a surrender of any share from or by any
member desirous of surrendering them on such terms as they think fit.

53. The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum
which, by the terms of issue of a share, becomes payable at a fixed time, whether on account of the
nominal value of the share or by way of premium, as if the same had been payable by virtue of a call
duly made and notified.

54. The provisions of these Articles relating to forfeiture of shares shall mutatis mutandis apply to any
other securities including debentures of the Company.

Alteration of capital

55. Subject to the provisions of the Act, the Company may, by ordinary resolution -

a. Increase the share capital by such sum, to be divided into shares of such amount as it thinks
expedient;

b. Consolidate and divide all or any of its share capital into shares of larger amount than its
existing shares:

Provided that any consolidation and division which results in changes in the voting percentage
of members shall require applicable approvals under the Act;
c. Convert all or any of its fully paid-up shares into stock, and reconvert that stock into fully
paid-up shares of any denomination;

d. Sub-divide its existing shares or any of them into shares of smaller amount than is fixed by the
memorandum;
e. Cancel any shares which, at the date of the passing of the resolution, have not been taken or
agreed to be taken by any person.
56. Where shares are converted into stock:

a. The holders of stock may transfer the same or any part thereof in the same manner as, and
subject to the same Articles under which, the shares from which the stock arose might before
the conversion have been transferred, or as near thereto as circumstances admit:
Provided that the Board may, from time to time, fix the minimum amount of stock
transferable, so, however, that such minimum shall not exceed the nominal amount of the
shares from which the stock arose;

b. The holders of stock shall, according to the amount of stock held by them, have the same
rights, privileges and advantages as regards dividends, voting at meetings of the Company,
and other matters, as if they held the shares from which the stock arose; but no such privilege

245
 or advantage (except participation in the dividends and profits of the Company and in the
assets on winding up) shall be conferred by an amount of stock which would not, if existing in
shares, have conferred that privilege or advantage;

c. Such of these Articles of the Company as are applicable to paid-up shares shall apply to stock
and the words “share” and “shareholder”/“member” shall include “stock” and “stock-holder”
respectively.

57. The Company may, by resolution as prescribed by the Act, reduce in any manner and in accordance
with the provisions of the Act and the Rules:

a. Its share capital; and/or

b. Any capital redemption reserve account; and/or
c. Any securities premium account; and/or
d. Any other reserve in the nature of share capital.

Joint Holders

58. Where two or more persons are registered as joint holders (not more than three) of any share, they shall
be deemed (so far as the Company is concerned) to hold the same as joint tenants with benefits of
survivor ship , subject to the following and other provisions contained in these Articles :
a. The joint -holders of any share shall be liable severally as well as jointly for and in respect of
all calls or installments and other payments which ought to be made in respect of such share.
b. On the death of any one or more of such joint -holders, the survivor or survivors shall be the
only person or persons recognized by the Company as having any title to the share but the
Directors may require such evidence of death as they may deem At, and nothing herein
contained shall be taken to release the estate of a deceased joint -holder from any liability on
shares held by him jointly with any other person.

c. Any one of such joint holders may give effectual receipts of any dividends, interests or other
moneys payable in respect of such share.

d. Only the person whose name stands first in the register of members as one of the joint -holders
of any share shall been titled to the delivery of certificate, if any, relating to such share or to
receive notice (which term shall be deemed to include all relevant documents) and any notice
served on or sent to such person shall be deemed service on all the joint -holders.

e i. Anyone of two or more joint -holders may vote at any meeting either personally or
by attorney or by proxy in respect of such shares as if he were solely entitled thereto
and if more than one of such joint - holders be present at any meeting personally or
by proxy or by attorney then that one of such persons so present whose name stands
first or higher (as the case may be) on the register in respect of such shares shall
alone be entitled to vote in respect thereof.
ii. Several executors or administrators of a deceased member in whose (deceased
member) sole name any share stands, shall for the purpose of this clause be deemed
joint -holders.

f. The provisions of these Articles relating to joint holders of shares shall mutatis mutandis apply
to any other securities including debentures of the Company registered in joint names.

Capitalization of profits
59. 1. The Company by ordinary resolution in general meeting may, upon the recommendation of
the Board, resolve

a. That it is desirable to capitalize any part of the amount for the time being standing to
the credit of any of the Company’s reserve accounts, or to the credit of the profit and
loss account, or otherwise available for distribution; and

b. That such sum be accordingly set free for distribution in the manner specified in
clause (2) below amongst the members who would have been entitled thereto, if
distributed by way of dividend and in the same proportions.

2. The sum aforesaid shall not be paid in cash but shall be applied, subject to the provision
contained in clause (3) below, either in or towards:

246
 A. Paying up any amounts for the time being unpaid on any shares held by such
members respectively;

B. Paying up in full, unissued shares or other securities of the Company to be allotted

and distributed, credited as fully paid-up, to and amongst such members in the
proportions aforesaid;
C. Partly in the way specified in sub-clause (A) and partly in that specified in sub-clause
(B).

3. A securities premium account and a capital redemption reserve account or any other
permissible reserve account may, for the purposes of this Article, be applied in the paying up
of unissued shares to be issued to members of the Company as fully paid bonus shares;

4. The Board shall give effect to the resolution passed by the Company in pursuance of
this Article.

60. 1. Whenever such a resolution as aforesaid shall have been passed, the Board shall -
a. Make all appropriations and applications of the amounts resolved to be capitalized
thereby, and all allotments and issues of fully paid shares or other securities, if any;
and

b. Generally do all acts and things required to give effect thereto.

2. The Board shall have power—

a. To make such provisions, by the issue of fractional certificates/coupons or by

payment in cash or otherwise as it thinks fit, for the case of shares or other securities
becoming distributable infractions; and

b. To authorize any person to enter, on behalf of all the members entitled thereto, into
an agreement with the Company providing for the allotment to them respectively,
credited as fully paid-up, of any further shares or other securities to which they may
be entitled upon such capitalization, or as the case may require, for the payment by
the Company on their behalf, by the application thereto of their respective
proportions of profits resolved to be capitalized, of the amount or any part of the
amounts remaining unpaid on their existing shares.

3. Any agreement made under such authority shall be effective and binding on such members.

Buy-back of shares
61. Notwithstanding anything contained in these Articles but subject to all applicable provisions of the Act
or any other law for the time being in force, the Company may purchase its own shares or other
specified securities.

General meetings
62. All general meetings other than annual general meeting shall be called extraordinary general meeting.

63. The Board may, whenever it thinks fit, call an extraordinary general meeting.

Proceedings at general meetings

64. 1. No business shall be transacted at any general meeting unless a quorum of members is
present at the time when the meeting proceeds to business.
2. No business shall be discussed or transacted at any general meeting except election of
Chairperson whilst the chair is vacant.
3. The quorum for a general meeting shall be as provided in the Act.

65. The Chairperson of the Company shall preside as Chairperson at every general meeting of the
Company.

66. If there is no such Chairperson, or if he is not present within fifteen minutes after the time appointed for
holding the meeting, or is unwilling to act as chairperson of the meeting, the directors present shall
elect one of their members to be Chairperson of the meeting.

247
67. If at any meeting no director is willing to act as Chairperson or if no director is present within fifteen
minutes after the time appointed for holding the meeting, the members present shall, by poll or
electronically, choose one of their members to be Chairperson of the meeting.

68. On any business at any general meeting, in case of an equality of votes, whether on a show of hands or
electronically or on a poll, the Chairperson shall have a second or casting vote.

69. 1. The Company shall cause minutes of the proceedings of every general meeting of any
class of members or creditors and every resolution passed by postal ballot to be prepared and
signed in such manner as may be prescribed by the Rules and kept by making within thirty
days of the conclusion of every such meeting concerned or passing of resolution by postal
ballot entries thereof in books kept for that purpose with their pages consecutively numbered.

2. There shall not be included in the minutes any matter which, in the opinion of the Chairperson
of the meeting -

a. Is, or could reasonably be regarded, as defamatory of any person; or

b. is irrelevant or immaterial to the proceedings; or
c. is detrimental to the interests of the Company.

3. The Chairperson shall exercise an absolute discretion in regard to the inclusion or non-
inclusion of any matter in the minutes on the grounds specified in the aforesaid clause.

4. The minutes of the meeting kept in accordance with the provisions of the Act shall be
evidence of the proceedings recorded therein.

70. 1. The books containing the minutes of the proceedings of any general meeting of the Company
or a resolution passed by postal ballot shall: (a) be kept at the registered office of the
Company; and (b) be open to inspection of any member without charge, during 11.00 a.m. to
1.00 p.m. on all working days other than Saturdays.

2. Any member shall be entitled to be furnished, within the time prescribed by the Act, after he
has made a request in writing in that behalf to the Company and on payment of such fees as
may be fixed by the Board, with a copy of any minutes referred to in clause (1) above:
Provided that a member who has made a request for provision of a soft copy of the minutes of
any previous general meeting held during the period immediately preceding three financial
years, shall be entitled to be furnished with the same free of cost.

71. The Board, and also any person(s) authorised by it, may take any action before the commencement of
any general meeting, or any meeting of a class of members in the Company, which they may think fit
to ensure the security of the meeting, the safety of people attending the meeting, and the future orderly
conduct of the meeting. Any decision made in good faith under this Article shall be final, and rights to
attend and participate in the meeting concerned shall be subject to such decision.

72. 1. The Chairperson may, suo motu, adjourn the meeting from time to time and from place to
place,

2. No business shall be transacted at any adjourned meeting other than the business left
unfinished at the meeting from which the adjournment took place. Business at adjourned
meeting,
3. When a meeting is adjourned for thirty days or more, notice of the adjourned meeting shall be
given as in the case of an original meeting.
4. Save as aforesaid, and save as provided in the Act, it shall not be necessary to give any notice
of an adjournment or of the business to be transacted at an adjourned meeting
Voting Rights

73. Subject to any rights or restrictions for the time being attached to any class or classes of shares -

a. on a show of hands, every member present in person shall have one vote; and
b. on a poll, the voting rights of members shall be in proportion to his share in the paid-up equity
share capital of the company.

74. A member may exercise his vote at a meeting by electronic means in accordance with the Act and shall
vote only once.

248
75. 1. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by
proxy, shall be accepted to the exclusion of the votes of the other joint holders.

2. For this purpose, seniority shall be determined by the order in which the names stand in the
register of members.

76. A member of unsound mind, or in respect of whom an order has been made by any court having
jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by his committee or other
legal guardian, and any such committee or guardian may, on a poll, vote by proxy. If any member be a
minor, the vote in respect of his share or shares shall be by his guardian or any one of his guardians.

77. Subject to the provisions of the Act and other provisions of these Articles, any person entitled under the
Transmission Clause to any shares may vote at any general meeting in respect thereof as if he was the
registered holder of such shares, provided that at least 48 (forty eight) hours before the time of holding
the meeting or adjourned meeting, as the case may be, at which he proposes to vote, he shall duly satisfy
the Board of his right to such shares unless the Board shall have previously admitted his right to vote at
such meeting in respect thereof.

78. Any business other than that upon which a poll has been demanded may be proceeded with, pending the
taking of the poll.

79. No member shall be entitled to vote at any general meeting unless all calls or other sums presently
payable by him in respect of shares in the Company have been paid or in regard to which the Company
has exercised any right of lien.

80. A member is not prohibited from exercising his voting on the ground that he has not held his share or
other interest in the Company for any specified period preceding the date on which the vote is taken, or
on any other ground not being a ground set out in the preceding Article.

81. Any member whose name is entered in the register of members of the Company shall enjoy the same
rights and be subject to the same liabilities as all other members of the same class.

Proxy

82. 1. Any member entitled to attend and vote at a general meeting may do so either personally or
through his constituted attorney or through another person as a proxy on his behalf, for that
meeting.

2. The instrument appointing a proxy and the power-of- attorney or other authority, if any, under
which it is signed or a notarised copy of that power or authority, shall be deposited at the
registered office of the Company not less than 48 hours before the time for holding the meeting
or adjourned meeting at which the person named in the instrument proposes to vote, and in
default the instrument of proxy shall not be treated as valid.

83. An instrument appointing a proxy shall be in the form as prescribed in the Rules.

84. A vote given in accordance with the terms of an instrument of proxy shall be valid, notwithstanding the
previous death or insanity of the principal or the revocation of the proxy or of the authority under which
the proxy was executed, or the transfer of the shares in respect of which the proxy is given:

Provided that no intimation in writing of such death, insanity, revocation or transfer shall have been
received by the Company at its office before the commencement of the meeting or adjourned meeting at
which the proxy is used.

Board of Directors

85. Unless otherwise determined by the Company in general meeting, the number of directors shall not be
less than 3 (three) and shall not be more than 14 (fourteen). The Company shall have the power to
increase the number of Directors beyond 15 after passing a Special Resolution.

86. 1. The Board shall have the power to determine the directors whose period of office is or is not
liable to determination by retirement of directors by rotation.

249
 2. The same individual may, at the same time, be appointed as the Chairperson of the Company
as well as the Managing Director or Chief Executive Officer of the Company.

3. No director of the company be required to hold any qualification shares.

87. 1. The remuneration of the directors shall, in so far as it consists of a monthly payment, be
deemed to accrue from day-to-day.

2. The remuneration payable to the directors, including any managing or whole-time director or
manager, if any, shall be determined in accordance with and subject to the provisions of the
Act by an ordinary resolution passed by the Company in general meeting.

3. Any one or more of the Directors shall be paid such additional remuneration as may be fixed
by the Directors for services rendered by him or them and any one or more of the Directors
shall be paid further remuneration if any as the Company in General Meeting or the Board of
Directors shall from time to time determine. Such remuneration and/or additional remuneration
may be paid by way of salary or commission on net profits or turnover or by participation in
profits or by way of perquisites or in any other manner or by any or all of those modes

4. A Director may receive remuneration by way of fee not exceeding such amount as may be
permissible under the Rules for attending each meetings of the Board or Committee thereof; or
of any other purpose whatsoever as may be decided by the Board. In addition to the
remuneration payable to them in pursuance of the Act, the directors may be paid all travelling,
hotel and other expenses properly incurred by them—

a. in attending and returning from meetings of the Board of Directors or any committee
thereof or general meetings of the Company; or
b. in connection with the business of the Company.

88. All cheques, promissory notes, drafts, hundis , bills of exchange and other negotiable instruments, and
all receipts for monies paid to the Company, shall be signed, drawn, accepted, endorsed, or otherwise
executed, as the case may be, by such person and in such manner as the Board shall from time to time
by resolution determine.

89. 1. Subject to the provisions of the Act, the Board shall have power at any time, and from time to
time, to appoint a person as an additional director, provided the number of the directors and
additional directors together shall not at any time exceed the maximum strength fixed for the
Board by the Articles.

2. Such person shall hold office only up to the date of the next annual general meeting of the
Company but shall be eligible for appointment by the Company as a director at that meeting
subject to the provisions of the Act.

90. 1. The Board may appoint an alternate director to act for a director (hereinafter in this Article
Called “the Original Director”) during his absence for a period of not less than three months
from India. No person shall be appointed as an alternate director for an independent director
unless he is qualified to be appointed as an independent director under the provisions of the
Act.

2. An alternate director shall not hold office for a period longer than that permissible to the
Original Director in whose place he has been appointed and shall vacate the office if and when
the Original Director returns to India.

3. If the term of office of the Original Director is determined before he returns to India the
automatic reappointment of retiring directors in default of another appointment shall apply to
the Original Director and not to the alternate director.

91. 1. If the office of any director appointed by the Company in general meeting is vacated before his
term of office expires in the normal course, the resulting casual vacancy may, be filled by the
Board of Directors at a meeting of the Board.

2. The director so appointed shall hold office only upto the date upto which the director in whose
place he is appointed would have held office if it had not been vacated.

250
Powers of Board

92. The management of the business of the Company shall be vested in the Board and the Board may
exercise all such powers, and do all such acts and things, as the Company is by the memorandum of
association or otherwise authorized to exercise and do, and, not hereby or by the statute or otherwise
directed or required to be exercised or done by the Company in general meeting but subject nevertheless
to the provisions of the Act and other laws and of the memorandum of association and these Articles
and to any regulations, not being inconsistent with the memorandum of association and these Articles or
the Act, from time to time made by the Company in general meeting provided that no such regulation
shall invalidate any prior act of the Board which would have been valid if such regulation had not been
made.

Proceedings of the Board

93. 1. The Board of Directors may meet for the conduct of business, adjourn and otherwise regulate
its meetings, as it thinks fit. A meeting of the Board shall be called by giving not less than
seven days’ notice in writing to every director at his address registered with the company and
such notice shall be sent by hand delivery or by post or by electronic means: Provided that a
meeting of the Board may be called at shorter notice to transact urgent business subject to the
condition that at least one independent director, if any, shall be present at the meeting:
Provided further that in case of absence of independent directors from such a meeting of the
Board, decisions taken at such a meeting shall be circulated to all the directors and shall be
final only on ratification thereof by at least one independent director, if any.

2. The Chairperson or any one Director with the previous consent of the Chairperson may, or the
company secretary on the direction of the Chairperson shall, at any time, summon a meeting
of the Board.

3. The quorum for a Board meeting shall be as provided in the Act.

4. The participation of directors in a meeting of the Board may be either in person or through
video conferencing or audio visual means or teleconferencing, as may be prescribed by the
Rules or permitted under law.

94. 1. Save as otherwise expressly provided in the Act, questions arising at any meeting of the Board
shall be decided by a majority of votes.

2. In case of an equality of votes, the Chairperson of the Board, if any, shall have a second or
casting vote.

95. The continuing directors may act notwithstanding any vacancy in the Board; but, if and so long as their
number is reduced below the quorum fixed by the Act for a meeting of the Board, the continuing
directors or director may act for the purpose of increasing the number of directors to that fixed for the
quorum, or of summoning a general meeting of the Company, but for no other purpose.

96. 1. The Chairperson of the Company shall be the Chairperson at meetings of the Board. In his
absence, the Board may elect a Chairperson of its meetings and determine the period for which
he is to hold office.

2. If no such Chairperson is elected, or if at any meeting the Chairperson is not present within
fifteen minutes after the time appointed for holding the meeting, the directors present may
choose one of their number to be Chairperson of the meeting.

97. 1. The Board may, subject to the provisions of the Act, delegate any of its powers to Committees
consisting of such member or members of its body as it thinks fit.

251
 2. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any
regulations that may be imposed on it by the Board.

3. The participation of directors in a meeting of the Committee may be either in person or

through video conferencing or audio visual means or teleconferencing, as may be prescribed
by the Rules or permitted under law.

98. 1. A Committee may elect a Chairperson of its meetings unless the Board, while constituting a
Committee, has appointed a Chairperson of such Committee.

2. If no such Chairperson is elected, or if at any meeting the Chairperson is not present within fif-
teen minutes after the time appointed for holding the meeting, the members present may choose
one of their members to be Chairperson of the meeting.

99. 1. A Committee may meet and adjourn as it thinks fit.

2. Questions arising at any meeting of a Committee shall be determined by a majority of votes of

the members present.

3. In case of an equality of votes, the Chairperson of the Committee shall have a second or
casting vote.

100. All acts done in any meeting of the Board or of a Committee thereof or by any person acting as a
director, shall, notwithstanding that it may be afterwards discovered that there was some defect in the
appointment of any one or more of such directors or of any person acting as aforesaid, or that they or
any of them were disqualified or that his or their appointment had terminated, be as valid as if every
such director or such person had been duly appointed and was qualified to be a director.

101. Save as otherwise expressly provided in the Act, a resolution in writing, signed, whether manually or by
secure electronic mode, by a majority of the members of the Board or of a Committee thereof, for the
time being entitled to receive notice of a meeting of the Board or Committee, shall be valid and
effective as if it had been passed at a meeting of the Board or Committee, duly convened and held.

Chief Executive Officer, Manager, Company Secretary and Chief Financial Officer

102. a. Subject to the provisions of the Act,—

A chief executive officer, manager, company secretary and chief financial officer may be
appointed by the Board for such term, at such remuneration and upon such conditions as it may
think fit; and any chief executive officer, manager, company secretary and chief financial officer
so appointed may be removed by means of a resolution of the Board; the Board may appoint one
or more chief executive officers for its multiple businesses.

b. A director may be appointed as chief executive officer, manager, company secretary or chief
financial officer.

Registers

103. The Company shall keep and maintain at its registered office all statutory registers namely, register of
charges, register of members, register of debenture holders, register of any other security holders, the
register and index of beneficial owners and annual return, register of loans, guarantees, security and
acquisitions, register of investments not held in its own name and register of contracts and arrangements
for such duration as the Board may, unless otherwise prescribed, decide, and in such manner and
containing such particulars as prescribed by the Act and the Rules. The registers and copies of annual
return shall be open for inspection during 11.00 a.m. to 1.00 p.m. on all working days, other than
Saturdays, at the registered office of the Company by the persons entitled thereto on payment, where
required, of such fees as may be fixed by the Board but not exceeding the limits prescribed by the
Rules.

252
104. a. The Company may exercise the powers conferred on it by the Act with regard to the keeping of
a foreign register; and the Board may (subject to the provisions of the Act) make and vary such
regulations as it may think fit respecting the keeping of any such register.

b. The foreign register shall be open for inspection and may be closed, and extracts may be taken
therefrom and copies thereof may be required, in the same manner, mutatis mutandis, as is
applicable to the register of members.

The Seal

105. 1. The Board shall provide for the safe custody of the seal.

2. The seal of the Company shall not be affixed to any instrument except by the authority of a
resolution of the Board or of a Committee of the Board authorised by it in that behalf, and
except in the presence of at least one director or the manager, if any, or of the secretary or such
other person as the Board may appoint for the purpose; and such director or manager or the
secretary or other person aforesaid shall sign every instrument to which the seal of the Company
is so affixed in their presence.

Dividends and Reserve

106. The Company in general meeting may declare dividends, but no dividend shall exceed the amount
recommended by the Board but the Company in general meeting may declare a lesser dividend.

107. Subject to the provisions of the Act, the Board may from time to time pay to the members such interim
dividends of such amount on such class of shares and at such times as it may think fit.

108. 1. The Board may, before recommending any dividend, set aside out of the profits of the Company
such sums as it thinks fit as a reserve or reserves which shall, at the discretion of the Board, be
applied for any purpose to which the profits of the Company may be properly applied, including
provision for meeting contingencies or for equalising dividends; and pending such application,
may, at the like discretion, either be employed in the business of the Company or be invested in
such investments (other than shares of the Company) as the Board may, from time to time, think
fit.

2. The Board may also carry forward any profits which it may consider necessary not to divide,
without setting them aside as a reserve.

109. 1. Subject to the rights of persons, if any, entitled to shares with special rights as to dividends, all
dividends shall be declared and paid according to the amounts paid or credited as paid on the
shares in respect whereof the dividend is paid, but if and so long as nothing is paid upon any of
the shares in the Company, dividends may be declared and paid according to the amounts of the
shares.

2. No amount paid or credited as paid on a share in advance of calls shall be treated for the purposes
of this Article as paid on the share.

3. All dividends shall be apportioned and paid proportionately to the amounts paid or credited as
paid on the shares during any portion or portions of the period in respect of which the dividend is
paid; but if any share is issued on terms providing that it shall rank for dividend as from a
particular date such share shall rank for dividend accordingly.

110. 1. The Board may deduct from any dividend payable to any member all sums of money, if any,
presently payable by him to the Company on account of calls or otherwise in relation to the
shares of the Company.

2. The Board may retain dividends payable upon shares in respect of which any person is, under the
Transmission Clause hereinbefore contained, entitled to become a member, until such person
shall become a member in respect of such shares.

253
111. 1. Any dividend, interest or other monies payable in cash in respect of shares may be paid by
electronic mode or by cheque or warrant sent through the post directed to the registered address
of the holder or, in the case of joint holders, to the registered address of that one of the joint
holders who is first named on the register of members, or to such person and to such address as
the holder or joint holders may in writing direct.

2. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.

3. Payment in any way whatsoever shall be made at the risk of the person entitled to the money paid
or to be paid. The Company will not be responsible for a payment which is lost or delayed. The
Company will be deemed to having made a payment and received a good discharge for it if a
payment using any of the foregoing permissible means is made.

112. Any one of two or more joint holders of a share may give effective receipts for any dividends, bonuses
or other monies payable in respect of such share.

113. No dividend shall bear interest against the Company.

114. The waiver in whole or in part of any dividend on any share by any document (whether or not under
seal) shall be effective only if such document is signed by the member (or the person entitled to the
share in consequence of the death or bankruptcy of the holder) and delivered to the Company and if or
to the extent that the same is accepted as such or acted upon by the Board.

Accounts

115. 1. The books of account and books and papers of the Company, or any of them, shall be open to the
inspection of directors in accordance with the applicable provisions of the Act and the Rules.

2. No member (not being a director) shall have any right of inspecting any books of account or
books and papers or document of the Company except as conferred by law or authorised by the
Board.

Winding up

116. Subject to the applicable provisions of the Act and the Rules made thereunder

a. If the Company shall be wound up, the liquidator may, with the sanction of a special resolution of
the Company and any other sanction required by the Act, divide amongst the members, in specie
or kind, the whole or any part of the assets of the Company, whether they shall consist of
property of the same kind or not.

b. For the purpose aforesaid, the liquidator may set such value as he deems fair upon any property
to be divided as aforesaid and may determine how such division shall be carried out as between
the members or different classes of members.

c. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees
upon such trusts for the benefit of the contributories if he considers necessary, but so that no
member shall be compelled to accept any shares or other securities where on there is any liability.

Indemnity and Insurance

117. a. Subject to the provisions of the Act, every director, managing director, whole-time director,
manager, company secretary and other officer of the Company shall be indemnified by the
Company out of the funds of the Company, to pay all costs, losses and expenses (including
traveling expense) which such director, manager, company secretary and officer may incur or
become liable for by reason of any contract entered into or act or deed done by him in his
capacity as such director, manager, company secretary or officer or in any way in the discharge
of his duties in such capacity including expenses.

254
 b. Subject as aforesaid, every director, managing director, manager, company secretary or other
officer of the Company shall be indemnified against any liability incurred by him in defending
any proceedings, whether civil or criminal in which judgement is given in his favour or in which
he is acquitted or discharged or in connection with any application under applicable provisions of
the Act in which relief is given to him by the Court.

c. The Company may take and maintain any insurance as the Board may think fit on behalf of its
present and/or former directors and key managerial personnel for indemnifying all or any of them
against any liability for any acts in relation to the Company for which they may be liable but
have acted honestly and reasonably.

General Power

118. Wherever in the Act, it has been provided that the Company shall have any right, privilege or authority
or that the Company could carry out any transaction only if the Company is so authorized by its articles,
then and in that case this Article authorizes and empowers the Company to have such rights, privileges
or authorities and to carry out such transactions as have been permitted by the Act, without there being
any specific Article in that behalf herein provided.

255
 SECTION IX: OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The following contracts (not being contracts entered into in the ordinary course of business carried on by our
Company or contracts entered into more than two years before the date of this Draft Red Herring Prospectus)
which are or may be deemed material have been entered or to be entered into by our Company. These contracts,
copies of which will be attached to the copy of the Draft Red Herring Prospectus, have been delivered to the
RoC for registration and also the documents for inspection referred to hereunder, was available for inspection at
the Registered Office of our Company from 10.00 am to 4.00 pm on Working Days (Monday to Friday) from
the date of the Draft Red Herring Prospectus until the Bid/ Offer Closing Date.

a. Material Contracts to the Offer

1. Offer Agreement entered into between our Company, the Selling Shareholders and the BRLM dated
June 16, 2016 and Amendment to Offer Agreement dated June 29, 2016 .
2. Agreement entered into between our Company, the Selling Shareholders and the Registrar to the Offer
dated May 27, 2016 and Amendment to Agreement dated June 29, 2016.
3. Escrow Agreement dated [•] between our Company, the Selling Shareholders, the BRLM, the Bankers
to the Offer and the Registrar to the Offer.
4. Syndicate Agreement dated [•], 2016 between our Company, the Selling Shareholders, the BRLM and
the Syndicate Member.
5. Share Escrow Agreement dated [•], 2016 between our Company, the Selling Shareholders, the BRLM
and the Demat Escrow Agent.
6. Underwriting Agreement dated [•] 2016 between our Company, the Selling Shareholders, the BRLM
and the Syndicate Member.

b. Material Documents

1. Certified copies of the updated Memorandum and Articles of Association of our Company as amended
from time to time.
2. Certified copies of our certificate of incorporation dated November 21, 2005.
3. Certificate dated April 21, 2016 issued by the RoC Chennai for change in Name of the Company and
Certificate dated May 12, for conversion of private company to public Company.
4. Certified copy of the Board Resolution authorising the Offer dated May 23, 2016 and copy of Board
resolution dated July 4, 2016, 2016 approving the Draft Red Herring Prospectus.

5. Letters from Selling Shareholders approving the Offer for Sale and consenting to include up to
1,45,79,560 Equity Shares held by them, as part of the Offer for Sale.
6. The examination reports of the Statutory Auditors, on our Company’s Restated Financial Information
dated July 2, 2016, included in this Draft Red Herring Prospectus.
7. Statement of Tax Benefits and report dated July 2, 2016 from, M/s. RAJ AND RAVI , Chartered
Accountants.
8. Annual Reports of the Company for fiscal years 2011-2012, 2012-2013, 2013-2014, 2014-2015 and
2015-2016.
9. Consent of the Directors, Promoters, the BRLM, the Syndicate member, CFO, Legal Counsel to
Offer, Selling Shareholders, Registrar to the Offer, named in this Draft Red Herring Prospectus,
Escrow Collection Banks, Bankers to the Offer, Bankers/ Lenders to our Company, IRR Advisory
Services Pvt Ltd, Company Secretary and Compliance Officer as referred to in their specific
capacities.
10. Due Diligence Certificate dated July 4, 20166 addressed to SEBI from the BRLM.
11. In-principle listing approvals dated [•], 2016 and [•], 2016 issued by the BSE and the NSE respectively.
12. Tripartite Agreement between NSDL, our Company and the Registrar to the Offer dated May 12, 2016,
2016.
13. Tripartite Agreement between CDSL, our Company and the Registrar to the Offer dated May 4, 2016.
Any of the contracts or documents mentioned in this Draft Red Herring Prospectus may be amended or
modified at any time if so required in the interest of our Company or if required by the other parties,
without reference to the shareholders subject to compliance of the provisions contained in the
Companies Act, 2013 and other relevant statutes.

256
 DECLARATION

I , P. Sundaraparipooranan, hereby declare and certify that all statements made, and undertakings provided, in
this Draft Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in
the Offer are true and correct. I assume no responsibility for any of the statements made, or undertakings
provided by the Company or any other Selling Shareholder or any expert or any other persons in this Draft Red
Herring Prospectus.

Signed By P. Sundaraparipooranan

Date: July 4, 2016

Place: Chennai

257
 DECLARATION

I , P Murali, hereby declare and certify that all statements made, and undertakings provided, in this Draft Red
Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer are true
and correct. I assume no responsibility for any of the statements made, or undertakings provided by the
Company or any other Selling Shareholder or any expert or any other persons in this Draft Red Herring
Prospectus.

Signed by Dr. P. Murali

Date: July 4, 2016

Place: Chennai

258
 DECLARATION

I , V. A. Deepa, authorised representative of Avon Cycles Limited, , hereby declare and certify that all
statements made, and undertakings provided, in this Draft Red Herring Prospectus about or in relation to Avon
Cycles Limited and the Equity Shares being offered by it in the Offer are true and correct. Avon Cycles Limited
assume no responsibility for any of the statements made, or undertakings provided by the Company or any other
Selling Shareholder or any expert or any other persons in this Draft Red Herring Prospectus.

Signed by V.A. Deepa

On behalf of Avon Cycles Limited

Date: July 4, 2016

Place: Chennai

259
 DECLARATION

I , R. Srinivasan, hereby declare and certify that all statements made, and undertakings provided, in this Draft
Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer
are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the
Company or any other Selling Shareholder or any expert or any other persons in this Draft Red Herring
Prospectus.

Signed By R. Srinivasan,

Date: July 4, 2016

Place: Chennai

260
 DECLARATION

I, Mallika Murali, hereby declare and certify that all statements made, and undertakings provided, in this Draft
Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer
are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the
Company or any other Selling Shareholder or any expert or any other persons in this Draft Red Herring
Prospectus.

Signed by Mallika Murali

Date: July 4, 2016

Place: Chennai

261
 DECLARATION

We, the Directors, hereby declare and certify that all relevant provisions of the Companies Act (including the
rules made thereunder) and the rules, regulations, and guidelines issued by the Government of India or the
SEBI, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus
is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act or rules, regulations,
and guidelines made thereunder, as the case may be. We further certify that all the statements and disclosures in
this Draft Red Herring Prospectus are true and correct.

Mr. N. Gopalaswami
Chairman

Dr. P. Murali
Managing Director

Mr. E. S. Chandrasekaran
Executive Director

Dr. P. Perumalsamy
Non- Executive Independent Director

Mrs. Lakshmi V Iyer

Non- Executive Independent Director

Signed by Chief Financial Officer

Mr. E. Mullaivalavan

Date: July 4, 2016

Place: Chennai

262